Page last updated: 2024-12-05

ethinyl estradiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5991
CHEMBL ID691
CHEBI ID4903
SCHEMBL ID4071
MeSH IDM0007862

Synonyms (430)

Synonym
AC-2169
BIDD:ER0162
smr000058319
MLS000028479 ,
17alpha-ethynylestra-1,3,5(10)-triene-3,17beta-diol
CHEBI:4903 ,
17alpha-ethynylestradiol
(17beta)-17-ethynylestra-1(10),2,4-triene-3,17-diol
17a-ethynylestradiol
SGCUT00127
17alpha-ethinyl-estra-1,3,5(10)-triene-3,17beta-diol
LMST02010036
anovlar
17.alpha.-ethinyl-3,3,5)-estratriene
17-ethinyl-3,17-oestradiol
ee
ylestrol
chee-o-gen
17-ethynylestradiol
17.alpha.-ethynyl-1,5-estratriene-3,17.beta.-diol
17.alpha.-ethynyloestradiol
orestralyn
17.alpha.-ethynyl-1,5-oestratriene-3,17.beta.-diol
estorals
17-ethynyloestra-1,5(10)-triene-3,17.beta.-diol
17.alpha.-ethynylestradiol
diogyn e
estoral [orion]
component of ortrel
17.beta.-estradiol, 17-ethynyl-
inestra
diognat-e
component of demulen
lynoral
perovex
estigyn
feminone
primogyn c
17.alpha.-ethynyloestra-1,5(10)-triene-3,17.beta.-diol
19-norpregna-1,5(10)-trien-20-yne-3,17-diol, (17.alpha.)-
wln: l e5 b666ttt&j e1 fq f1uu1 oq
novestrol
ginestrene
progynon c
neo-estrone
oradiol
nogest-s
19-nor-17.alpha.-pregna-1,5(10)-trien-2-yne-3,17-diol
eticyclol
chee-o-genf
17-ethynyloestradiol
component of oracon
estra-1,5[10]-triene-3,17.beta.-diol, 17-ethynyl-
17.alpha.-ethinyloestra-1,5(10)-triene-3,17.beta.-diol
17.alpha.-ethinyl-3,3,5)oestratriene
primogyn
17.alpha.-ethynylestra-1,5(10)-triene-3,17.beta.-diol
eticyclin
amenoron
diogyn-e
ethidol
estoral
estoral (orion)
ethynylestradiol
nsc10973
dyloform
ertonyl
orestrayln
component of ovral
nsc-10973
etistradiol
menolyn
estinyl
17.alpha.-ethinylestra-1,5(10)-triene-3,17.beta.-diol
17.alpha.-ethinyl-.delta.(sup1,5(10))oestratriene-3,17-.beta.-diol
19-nor-17.alpha.-pregna-1,5[10]-trien-20-yne-3,17-diol
estra-1,5(10)-triene-3,17.beta.-diol, 17.alpha.-ethynyl-
eticylol
17.alpha.-ethynylestradiol-l7.beta.
19-nor-17.alpha.-pregna-1,5(10)-trien-20-yne-3,17-diol
ethinyloestradiol
linoral
eston-e
spanestrin
etinoestryl
17-ethinyl-3,17-estradiol
esteed
17.alpha.-ethynyloestradiol-17.beta.
palonyl
17.alpha.-ethynyl-17.beta.-oestradiol
ethinoral
follicoral
estradiol, 17-ethynyl-
etinestrol
17-ethinylestradiol
primogyn m
17.alpha.-ethinyl-17.beta.-estradiol
17.alpha.-ethinylestradiol
17-ethynyl-3-17-dihydroxy-1,5-oestratriene
estra-1,5(10)-triene-3,17.beta.-diol, 17-ethynyl-
etinestryl
NCGC00091533-01
17alpha-ethinyl-3,17-dihydroxy-delta(sup1,3,5)-estratriene
einecs 200-342-2
3,17-beta-dihydroxy-17-alpha-ethynyl-1,3,5(10)-estratriene
microfollin
ethinyloestradiol [steroidal oestrogens]
3,17beta-dihydroxy-17alpha-ethynyl-1,3,5(10)-oestratriene
17-alpha-ethynyl-17-beta-oestradiol
(17-alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17,diol
diprol
19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-
17alpha-ethinyl-3,17-dihydroxy-delta(sup1,3,5)oestratriene
estopherol
estra-1,3,5(10)-triene-3,17beta-diol, 17alpha-ethynyl-
17-alpha-ethinyloestra-1,3,5(10)-triene-3,17-beta-diol
ethinylestradiol [inn:ban:jan]
17alpha-ethinyloestra-1,3,5(10)-triene-3,17beta-diol
brn 2419975
17-alpha-ethinyl-17-beta-estradiol
17alpha-ethinylestra-1,3,5(10)-triene-3,17beta-diol
19-nor-17-alpha-pregna-1,3,5(10)-triene-20-yne-3,17-diol
ethinyl e2
etinilestradiolo [dcit]
aethinyloestradiolum
ai3-52941
EE2 ,
17-alpha-ethinyl-3,17-dihydroxy-delta(sup 1,3,5)-estratriene
ee(sub 2)
17-alpha-ethynylestradiol
17alpha-ethynyloestradiol
17-alpha-ethynylestradiol-17-beta
ethynyloestradiol
19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol
ethinyl estradiol [usp]
etinilestradiol [inn-spanish]
ethinyl-oestranol
aethinyoestradiol [german]
hsdb 3587
19-nor-17alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol
17-alpha-ethinylestra-1,3,5(10)-triene-3,17-beta-diol
ethinylestradiolum [inn-latin]
17-alpha-ethynyl-1,3,5(10)-oestratriene-3,17-beta-diol
17alpha-ethinylestradiol-17beta
17-alpha-ethynyl-1,3,5-oestratriene-3,17-beta-diol
3,17-beta-dihydroxy-17-alpha-ethynyl-1,3,5(10)-oestratriene
estra-1,3,5(10)-triene-3,17-beta-diol, 17-alpha-ethynyl-
3,17beta-dihydroxy-17alpha-ethynyl-1,3,5(10)-estratriene
17-alpha-ethynyl-1,3,5(10)-estratriene-3,17-beta-diol
17alpha-ethinylestradiol
17alpha-ethinyl-delta(sup1,3,5(10))oestratriene-3,17-beta -diol
17alpha-ethynyloestradiol-17beta; 17beta-estradiol, 17-ethynyl-
ccris 286
estoral (van)
17-alpha-ethinyl-delta(sup 1,3,5(10))oestratriene-3,17-beta-diol
C07534
ethynyl estradiol
ethinylestradiol
ethinyl estradiol
57-63-6
17alpha-ethinyl estradiol
17alpha-ethynylestradiol, >=98%
TO_000048
MLS000758274
DB00977
NCGC00091533-04
ethinyl estradiol (usp)
estinyl (tn)
D00554
ethinylestradiol (jp17/inn)
NCGC00091533-05
ovulen-21
norinyl
ovulen-28
NCI60_000234
estradiol, ethinyl
17-alpha-ethynyl estradiol
17 alpha-ethinyestradiol
HMS2051I19
bdbm50187243
ethinylestradiolum
CHEMBL691 ,
(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol
NCGC00091533-08
NCGC00091533-09
NCGC00091533-07
tox21_300413
NCGC00254514-01
tox21_201291
NCGC00258843-01
MLS001424011
tox21_111147
dtxsid5020576 ,
cas-57-63-6
dtxcid70576
HMS2235J09
CCG-100819
prosexol
progynon m
etivex
(17alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
unii-423d2t571u
etinilestradiol
aethinyoestradiol
etinilestradiolo
423d2t571u ,
17alpha-ethinyl-1,3,5(10)-estratriene-3,17-diol
certostat
17alpha-ethinyl-17beta-estradiol
17-ethynylestra-1,3,5(10)-triene-3,17beta-diol
levora component ethinyl estradiol
quartette component ethinyl estradiol
ethinyl estradiol component of aranelle
ethinyl estradiol component of previfem
levlite component ethinyl estradiol
ethinyl estradiol component of femcon fe
aviane component ethinyl estradiol
ethinyl estradiol component of quasense
ethinyl estradiol component of ovral
taytulla component ethinyl estradiol
enskyce component ethinyl estradiol
ethinyl estradiol component of altavera
ethinyl estradiol component of cryselle
cryselle component ethinyl estradiol
ethinyl estradiol [usp-rs]
previfem component ethinyl estradiol
kurvelo component ethinyl estradiol
femcon fe component ethinyl estradiol
elifemme component ethinyl estradiol
orsythia component ethinyl estradiol
ethinyl estradiol component of norquest fe
setlakin component ethinyl estradiol
beyaz component ethinyl estradiol
altavera component ethinyl estradiol
introvale component ethinyl estradiol
ethinyl estradiol [ema epar]
ethinyl estradiol component of ortho tri-cyclen
kelnor component ethinyl estradiol
lo loestrin fe component ethinyl estradiol
levonest component ethinyl estradiol
ethinyl estradiol component of tri-previfem
velivet component ethinyl estradiol
bekyree component ethinyl estradiol
lessina component ethinyl estradiol
ethinyl estradiol component of kelnor
seasonique component ethinyl estradiol
cyclessa component ethinyl estradiol
ethinylestradiol [inci]
xulane component ethinyl estradiol
marlissa component ethinyl estradiol
tri lo sprintec component ethinyl estradiol
lybrel component ethinyl estradiol
nordette component ethinyl estradiol
ethinyl estradiol component of nuvaring
desogen component ethinyl estradiol
portia component ethinyl estradiol
nuvaring component ethinyl estradiol
volnea component ethinyl estradiol
pimtrea component ethinyl estradiol
ethinyl estradiol component of cyclessa
ethinyl estradiol component of levonest
vyfemla component ethinyl estradiol
ethinyl estradiol component of annovera
19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17.alpha.)-
ethinyl estradiol component of safyral
trivora component ethinyl estradiol
norquest fe component ethinyl estradiol
annovera component ethinyl estradiol
ethinylestradiol [jan]
yasmin component ethinyl estradiol
brevicon component ethinyl estradiol
minastrin 24 fe component ethinyl estradiol
ethinyl estradiol component of estrostep fe
ethinylestradiolum [who-ip latin]
triphasil component ethinyl estradiol
ethinylestradiol [ep monograph]
yaz component ethinyl estradiol
ethinyl estradiol [mi]
ethinyl estradiol component of beyaz
ethinyl estradiol component of sprintec
mircette component ethinyl estradiol
seasonale component ethinyl estradiol
isibloom component ethinyl estradiol
ethinyl estradiol component of yasmin
ethinyl estradiol component of alesse
enpresse component ethinyl estradiol
ethinyl estradiol component of introvale
ethinyl estradiol component of twirla
zovia component ethinyl estradiol
ethinylestradiol [mart.]
ethinyl estradiol component of levlite
ethinylestradiol [who-ip]
estrostep fe component ethinyl estradiol
ethinyl estradiol component of tri-legest fe
ethinyl estradiol [usp monograph]
vienva component ethinyl estradiol
ortho-cept component ethinyl estradiol
ethinyl estradiol component of ortho-cept
ethinyl estradiol component of lo loestrin fe
viorele component ethinyl estradiol
twirla component ethinyl estradiol
ethinyl estradiol component of tri lo sprintec
ethinyl estradiol [orange book]
kariva component ethinyl estradiol
ethinyl estradiol component of seasonique
ethinyl estradiol [hsdb]
preven component ethinyl estradiol
ovral component ethinyl estradiol
ortho tri-cyclen component ethinyl estradiol
femhrt component ethinyl estradiol
aranelle component ethinyl estradiol
ethinyl estradiol component of yaz
tri-previfem component ethinyl estradiol
ethinyl estradiol component of setlakin
ethinyl estradiol [vandf]
ethinyl estradiol component of loseasonique
alesse component ethinyl estradiol
ethinyl estradiol component of kariva
quasense component ethinyl estradiol
ethinyl estradiol component of tri-sprintec
ethinyl estradiol component of lybrel
loseasonique component ethinyl estradiol
tri-sprintec component ethinyl estradiol
sprintec component ethinyl estradiol
ethinyl estradiol component of preven
lo minastrin fe component ethinyl estradiol
ethinylestradiol [inn]
ethinylestradiol [who-dd]
safyral component ethinyl estradiol
tri-legest fe component ethinyl estradiol
ethinyl estradiol component of desogen
norinyl component ethinyl estradiol
ethinyl estradiol component of seasonale
ethinyl estradiol component of velivet
ethinyl estradiol component of femhrt
ethinyl estradiol component of mircette
S1625
AKOS015894925
gtpl7071
HY-B0216
NC00069
SCHEMBL4071
tox21_111147_1
NCGC00091533-10
KS-5257
AB00441335-11
Q-201076
17.alpha.-ethinylestra-1,3,5(10)-triene-3,17.beta.-diol
seasonale (salt/mix)
17.alpha.-ethynyl-1,3,5(10)-estratriene-3,17.beta.-diol
estra-1,3,5(10)-triene-3,17.beta.-diol, 17.alpha.-ethynyl-
anovlar (salt/mix)
ylestol
17.alpha.-ethinyl-3,17-dihydroxy-.delta.(sup1,3,5)oestratriene
estopherol (salt/mix)
17-ethynyloestra-1,3,5(10)-triene-3,17.beta.-diol
17.alpha.-ethynylestra-1,3,5(10)-triene-3,17.beta.-diol
oracon (salt/mix)
3,17.beta.-dihydroxy-17.alpha.-ethynyl-1,3,5(10)-oestratriene
19-nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17.beta.-diol
17.alpha.-ethinyloestra-1,3,5(10)-triene-3,17.beta.-diol
nordette (salt/mix)
triphasil (salt/mix)
ortrel (salt/mix)
desogen (salt/mix)
tri-levlen (salt/mix)
19-nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17-diol
17.alpha.-ethinyl-3,17-dihydroxy-.delta.(sup1,3,5)-estratriene
17.alpha.-ethynyloestra-1,3,5(10)-triene-3,17.beta.-diol
17.alpha.-ethinyl-1,3,5(10)-estratriene-3,17-diol
17-ethynyl-3-17-dihydroxy-1,3,5-oestratriene
ortho evra (salt/mix)
17.alpha.-ethinyl-.delta.(sup1,3,5(10))oestratriene-3,17-.beta. -diol
ortho-cyclen (salt/mix)
levlen (salt/mix)
17.alpha.-ethynyl-1,3,5(10)-oestratriene-3,17.beta.-diol
19-nor-17.alpha.-pregna-1,3,5(10)-trien-20-yn-3,17-diol
seasonique (salt/mix)
3,17.beta.-dihydroxy-17.alpha.-ethynyl-1,3,5(10)-estratriene
secrovin (salt/mix)
3wf ,
(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthrene-3,17-diol
OPERA_ID_1808
AB00441335_12
17alpha-ethynyl-1,3,5(10)-estratriene-3,17beta-diol
mfcd00003690
SR-01000721903-3
sr-01000721903
ethinyl estradiol, united states pharmacopeia (usp) reference standard
17alpha-ethynylestradiol, >=98.0% (hplc)
17alpha-ethynylestradiol, vetranal(tm), analytical standard
ethinylestradiol, european pharmacopoeia (ep) reference standard
17a-ethinyl-17b-estradiol
17-ethynylestradiol ram
17a-ethynyl-17b-oestradiol
17a-ethynyloestradiol-17b
17a-ethynylestradiol-l7b
estoral {[orion]}
17a-ethynyloestradiol
ethinyl estradiol, pharmaceutical secondary standard; certified reference material
ethinylestradiol for system suitability, european pharmacopoeia (ep) reference standard
17a-ethinylestradiol
17a-ethinylestradiol 100 microg/ml in acetonitrile
HMS3715J09
(9beta,13alpha,14beta,17alpha)-17-ethynylestra-1(10),2,4-triene-3,17-diol
17 alpha ethynylestradiol
17|a-ethynylestradiol;ethynylestradiol
17alpha-ethynylestradiol (ee2)
Q415563
Z1521553721
1050678-65-3
BRD-K48195008-001-19-9
ethinyl-estradiol
H11762
19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17a)-
17-ethynylestradiol;ethynylestradiol
(1r,3as,3br,9bs,11as)-1-ethynyl-11a-methyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-1,7-diol
EN300-119516
CS-0694931
HY-B0216R
ethinylestradiol (standard)
ethinylestradiolum (inn-latin)
ethinyl estradiol (usp-rs)
etinilestradiol (inn-spanish)
ethinylestradiol (mart.)
primogyn c(or m)
ethinyl estradiol (usp monograph)
roldiol
ethinylestradiol (ep monograph)
estroals

Research Excerpts

Overview

Ethinyl estradiol sulfate is a potent drug for improving heart performance, which also dramatically reduces damage by apoptosis, proinflammatory activity, and NO production. 17α-ethinyl Estradiol (EE2) is a synthetic compound widely used in the generation of contraceptive pills.

ExcerptReferenceRelevance
"Ethinyl estradiol (EE2) is a synthetic environmental estrogen with considerable estrogenic activity. "( Transcriptome analysis of changes in M. aeruginosa growth and microcystin production under low concentrations of ethinyl estradiol.
An, L; Dai, R; Li, Z; Ma, Y; Shen, W; Tang, T; Yan, F, 2023
)
2.56
"Ethinyl estradiol sulfate is a potent drug for improving heart performance, which also dramatically reduces damage by apoptosis, proinflammatory activity, and NO production, validating that EES can blunt multiple harmful outcomes arising from hypoxia and hypovolemia. "( Ethinyl estradiol sulfate acts without fluid resuscitation through estrogen receptors to rapidly protect the cardiovascular system from severe hemorrhage.
Chaudry, IH; Hubbard, WJ; Yang, S, 2021
)
3.51
"17α-ethinyl estradiol (EE2) is a synthetic compound widely used in the generation of contraceptive pills. "( Exposure to 17α-ethinyl estradiol during early pregnancy affects fetal growth and survival in mice.
Meyer, N; Müller, JE; Rodriguez, HA; Santamaria, CG; Schumacher, A; Zenclussen, AC, 2019
)
1.42
"Ethinyl estradiol (EE2) is a synthetic estrogen used in contraceptive pills, whereas zearalenone (ZEA) is a natural mycoestrogen found with increasing prevalence in various cereal crops."( Xenoestrogens Ethinyl Estradiol and Zearalenone Cause Precocious Puberty in Female Rats via Central Kisspeptin Signaling.
Ferenczi, S; Hrabovszky, E; Kalló, I; Kovács, KJ; Kriszt, R; Kuti, D; Molnár, C; Polyák, Á; Szőke, Z; Winkler, Z, 2015
)
1.5
"Ethinyl estradiol is a potent synthetic estrogen that is widely prescribed in oral contraceptives and is also used in the treatment of breast and prostate cancer. "( Multigenerational reproductive toxicology study of ethinyl estradiol (CAS No. 57-63-6) in Sprague-Dawley rats.
, 2010
)
2.06
"Ethinyl estradiol is a potent synthetic estrogen that is widely prescribed in oral contraceptives and is also used in the treatment of breast and prostate cancer. "( Toxicology and carcinogenesis study of ethinyl estradiol (CAS No. 57-63-6) in Sprague-Dawley rats (feed study).
, 2010
)
2.07
"Ethinyl estradiol is a potent endocrine disrupting compound in fish and ubiquitously present in the aquatic environment. "( 17α-Ethinyl estradiol affects anxiety and shoaling behavior in adult male zebra fish (Danio rerio).
Bollner, T; Hallgren, S; Hällström, IP; Olsén, H; Olsson, PE; Reyhanian, N; Volkova, K, 2011
)
2.37
"Ethinyl estradiol is a semisynthetic estrogen compound found in birth control pills, and its chemical structure allows this compound to retain activity when given orally."( Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system.
Matejuk, A; Offner, H; Subramanian, S; Vandenbark, AA; Zamora, A, 2003
)
1.37
"Ethinyl estradiol (EE) is a strong promoter and weak hepatocarcinogen in rats. "( Enhanced mitochondrial gene transcript, ATP, bcl-2 protein levels, and altered glutathione distribution in ethinyl estradiol-treated cultured female rat hepatocytes.
Chen, J; Delannoy, M; He, P; Odwin, S; Trush, MA; Yager, JD, 2003
)
1.97
"Ethinyl estradiol (EE2) is an extremely potent synthetic estrogen and a common component in oral contraceptives. "( Trace analysis of ethinyl estradiol in casein diet using gas chromatography with electron capture detection.
Billedeau, SM; Evans, RL; Holder, CL; Rushing, LG; Siitonen, PH, 2005
)
2.1
"Ethinyl estradiol (EE) is a strong promoter of hepatocarcinogenesis in female rats. "( Growth stimulation followed by growth inhibition in livers of female rats treated with ethinyl estradiol.
He, H; Lucier, GW; Sewall, CH; Yager, JD; Zurlo, J, 1994
)
1.95
"Ethinyl estradiol (EE) is a strong hepatic promoter and weak complete hepatocarcinogen. "( Enhanced levels of several mitochondrial mRNA transcripts and mitochondrial superoxide production during ethinyl estradiol-induced hepatocarcinogenesis and after estrogen treatment of HepG2 cells.
Chen, J; Gokhale, M; Li, Y; Trush, MA; Yager, JD, 1998
)
1.96
"Ethinyl estradiol (EE) is a strong promoter of hepatocarcinogenesis. "( Increased mitochondrial superoxide production in rat liver mitochondria, rat hepatocytes, and HepG2 cells following ethinyl estradiol treatment.
Chen, J; Lavigne, JA; Li, Y; Trush, MA; Yager, JD, 1999
)
1.96
"Ethinyl estradiol (EE) is a strong promoter of hepatocarcinogenesis in the rat. "( Inhibition of TGF-beta-induced apoptosis by ethinyl estradiol in cultured, precision cut rat liver slices and hepatocytes.
Chen, J; Gokhale, M; Odwin, S; Schofield, B; Yager, JD, 2000
)
2.01
"Ethinyl estradiol is a well documented, predictable cholestatic agent. "( Effects of ethinyl estradiol on substrate uptake and efflux by isolated rat hepatocytes.
Stacey, NH, 1986
)
2.1

Effects

Ethinyl estradiol(EE2)therapy has been reported to be an effective endocrine therapy for postmenopausal hormone receptor-positive advanced breast cancer, especially in the supposed acquired resistance state. Ethinyl Estradiol has been administered orally, 100 micrograms per day during three days.

ExcerptReferenceRelevance
"Ethinyl estradiol(EE2)therapy has been reported to be an effective endocrine therapy for postmenopausal hormone receptor-positive advanced breast cancer, especially in the supposed acquired resistance state. "( [Ethinyl Estradiol Therapy for Postmenopausal Women with Heavily Pre-Treated Endocrine-Responsive Metastatic Breast Cancer].
Hattori, A; Hirano, A; Inoue, H; Kamimura, M; Kodera, A; Matsuoka, A; Naritaka, Y; Ogura, K; Sakaguchi, S; Tanaka, N; Yukawa, H, 2019
)
2.87
"Ethinyl estradiol has been administered orally, 100 micrograms per day during three days, to enhance the growth hormone (GH) response to usual pharmacological stimuli. "( [Responses of somatotropin to stimuli after brief administration of estradiol in short children].
Canlorbe, P; Garnier, P; Job, JC; Roger, M,
)
1.57

Actions

Ethinyl estradiol was used to suppress elevated serum follicle stimulating hormone (FSH) levels, thus theoretically allowing restoration of down-regulated FSH receptors and response to endogenous gonadotropins. Ethinyl Estradiol Cmax was 21% lower with no change in AUC.

ExcerptReferenceRelevance
"Ethinyl estradiol Cmax was 21% lower with no change in AUC."( The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent.
Buraglio, M; Crean, CS; Tompson, DJ, 2013
)
1.11
"Ethinyl estradiol was used to lower follicle stimulation hormone (FSH) and restore sensitivity of follicles to mild FSH stimulation."( In vitro fertilization (IVF) outcome in women in overt menopause attempting to induce follicular maturation by follicle stimulating hormone (FSH) receptor down-regulation.
Check, JH; DiAntonio, A; DiAntonio, G; Wilson, C, 2016
)
1.16
"Ethinyl estradiol causes an increase in triglycerides and HDL cholesterol, while progestins tend to increase total cholesterol and decrease HDL cholesterol."( [Metabolic risks of oral contraception].
Monier, L, 1988
)
0.9
"Ethinyl estradiol caused an increase in palmitic and a decrease in stearic acid in the 1-position of serum lecithin while estradiol valerate did not influence these fatty acids at all."( Effects induced by two different estrogens on serum individual phospholipids and serum lecithin fatty acid composition.
Gustafson, A; Johnson, P; Samsice, G; Silfverstolpe, G; Svanborg, A, 1981
)
0.98
"Ethinyl estradiol was used to suppress elevated serum follicle stimulating hormone (FSH) levels, thus theoretically allowing restoration of down-regulated FSH receptors and response to endogenous gonadotropins."( Successful pregnancy in a 42-year-old woman with imminent ovarian failure following ovulation induction with ethinyl estradiol without gonadotropins and in vitro fertilization.
Berger, GS; Check, JH; Check, ML; Choe, JK, 2002
)
1.97

Treatment

Ethinyl estradiol treatment to female rats resulted in increased levels of serum alkaline phosphatase, but was not associated with any other manifestation of toxicity such as increased serum transaminases or toxic lesions. Treatment with ethinyl Estradiol reduced total cholesterol and apolipoprotein A-I concentrations in the serum of female and male animals.

ExcerptReferenceRelevance
"In ethinyl estradiol-treated rats only the A-IV transport rate increased due to lipid infusion."( Mesenteric lymph apolipoproteins in control and ethinyl estradiol-treated rats: a model for studying apolipoproteins of intestinal origin.
Castle, CK; Krause, BR; Roheim, PS; Sloop, CH, 1981
)
1.03
"Ethinyl estradiol treatment to female rats resulted in increased levels of serum alkaline phosphatase, but was not associated with any other manifestation of toxicity such as increased serum transaminases or toxic lesions. "( Serum alkaline phosphatase elevation in female rats treated with ethinyl estradiol.
Gopinath, C; Rombout, PJ; Van Versendaal, RG, 1978
)
1.94
"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid."( Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.
Davis, RA; Jensen, RT; Kern, F, 1977
)
1.21
"Pretreatment with ethinyl estradiol attenuated this effect."( Pentagastrin-induced hemoconcentration in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol.
Bellavance, F; Granger, R; Jahandar, F; Lara, N; Le Melledo, JM; McManus, K; Morrow, J; Perez-Parada, J; Tait, G, 2011
)
0.9
"Treatment with ethinyl estradiol resulted in a three-fold increase in 3H-CLE-LDL uptake by the liver."( Metabolic fate of low density lipoprotein and high density lipoprotein labeled with an ether analogue of cholesteryl ester.
Coetzee, GA; Stein, O; Stein, Y; Van der Westhuyzen, DR, 1984
)
0.61
"Treatment with ethinyl estradiol is known to impair bile formation, bile acid transport and Na,K-ATPase activity, to alter receptor-mediated endocytosis and transcytosis of IgA and asialoorosomucoid and to affect membrane lipid composition and fluidity. "( Ethinyl estradiol decreases acidification of rat liver endocytic vesicles.
Root, KV; Van Dyke, RW, 1993
)
2.08
"Treatment with ethinyl estradiol reduced total cholesterol and apolipoprotein A-I concentrations in the serum of female and male animals."( Effects of high-dose ethinyl estradiol on serum concentrations and hepatic secretion of the very-low-density lipoprotein, triacylglycerol, cholesterol, and apolipoprotein A-I in the rat.
Heimberg, M; Weinstein, I; Wilcox, HG, 1986
)
0.93
"Treatment with ethinyl estradiol and norethisteron resulted in significant (p less than 0.01) mean increases in serum cholesterol, triglycerides, HDL-C, and LDL-C of 20.6%, 95.5%, 23.6%, and 22.2% above pretreatment values, respectively."( Increase of serum lipids and serum lipoproteins in girls under therapy with estrogen and norethisteron for height reduction.
Frisch, H; Schober, E; Strobl, W; Weninger, M; Widhalm, K, 1987
)
0.61
"Treatment with ethinyl estradiol or norethindrone reduces the bone-turnover rate and plasma calcium levels in normal postmenopausal women, without affecting the secretion of calcium-regulating hormones. "( Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.
Peacock, M; Selby, PL, 1986
)
2.07

Toxicity

Overnight soaking of the ring before first use has the potential to reduce the side effect of transient nausea. However, a higher incidence of minor adverse effects such as breast tenderness and nausea were demonstrated when compared to oral contraceptive containing with ethinyl estradiol (EE) 30 microg and levonorgestrel 150 microg.

ExcerptReferenceRelevance
" Also examined was the probability that a side effect would occur in the 2nd or 3rd cycle if the user had not experienced such an effect in the 1st cycle."( The probability of side effects with ovral, norinyl 1/50 and norlestrin.
Berger, GS; Edelman, DA; Talwar, PP, 1979
)
0.26
" The study medication demonstrated no adverse effects on cervical cytology, blood pressure, body weight or laboratory variables, while pre-existing benign breast disease generally improved."( A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol.
Walling, M, 1992
)
0.49
" The study medication demonstrated no adverse effects on cervical cytology, blood pressure, body weight or laboratory variables, while pre-existing benign breast disease generally improved."( A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol.
Walling, M, 1992
)
0.49
" The cardiovascular side effect at this dose are considerable (29%) but comparable rates are reported in some studies following placebo treatment of patients with prostatic carcinoma."( Oestrogen in the treatment of prostatic carcinoma. What is the safe and effective dose of ethinyloestradiol?
Jonas, U; Langeveld, JW; Lycklama à Nijeholt, AA, 1989
)
0.28
" The most common side effect was inter-menstrual bleeding with the 35-microgram pill."( Side effects and compliance with low- and conventional-dose oral contraceptives among adolescents.
Jay, MS; Litt, IF; Neel, EU, 1987
)
0.27
" The side effect profile was favourable."( Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Coelingh Bennink, HJ; Dieben, TO; op ten Berg, MT, 1994
)
0.29
" These findings show that the new OC has very good cycle control and a agreeable side effect profile."( Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Coelingh Bennink, HJ; Dieben, TO; op ten Berg, MT, 1994
)
0.29
" Adverse drug reactions (ADR) are not accepted nor acceptable from a population of young women free of disease who expect from their mode of contraception to be fully efficient and devoid from side effects."( [Side effects of third generation progestins].
Sitruk-Ware, R, 1993
)
0.29
" Our results indicate that the tested new biphasic OC combination is reliable, well tolerated, safe and effective against hyperandrogenism."( Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel.
Angioni, S; Deiana, P; Genazzani, AR; Grasso, A; Mauri, A; Silferi, M; Volpe, A, 1994
)
0.29
"To compare two oral contraceptive pills, both containing 150 micrograms desogestrel, but with either 20 micrograms (Mercilon) or 30 micrograms (Marvelon/Desolett) ethinyl oestradiol (EE), regarding reliability, cycle control and side effect profile."( Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund, M; Røde, A; Westergaard, J, 1993
)
0.29
" Although higher proportions of women in the vitamin B-6 group reported decreases in OC-related side effect severity between admission and the 30-day follow-up visit, these differences were appreciable only for headache and dizziness and none was statistically significant."( Effect of vitamin B6 on the side effects of a low-dose combined oral contraceptive.
Grubb, GS; Juárez-Perez, MA; Ponce de León, R; Villegas-Salas, E, 1997
)
0.3
" Overnight soaking of the ring before first use has the potential to reduce the side effect of transient nausea, presumed attributable to the accumulation of ethinyl estradiol on the ring surface during storage."( Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
Fraser, IS; Jackanicz, T; Lacarra, M; Mishell, DR; Weisberg, E, 1997
)
0.49
" There were no serious adverse events related to treatment, and most adverse events were those commonly observed in clinical trials with oral contraceptives."( A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
Albring, M; Bannemerschult, R; Brill, K; Fox, P; Hanker, JP; Wünsch, C, 1997
)
0.49
"4% of women discontinued OC use due to adverse events."( A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
Albring, M; Bannemerschult, R; Brill, K; Fox, P; Hanker, JP; Wünsch, C, 1997
)
0.49
" Sixty-two serious adverse events (SAE) occurred in 59 of 1655 women."( Efficacy and safety of the new antiandrogenic oral contraceptive Belara.
Andreas, JO; Goldberg, J; Zahradnik, HP, 1998
)
0.3
" Of the 62 serious adverse events reported by 59 women, only the 2 cases of deep venous thrombosis could be linked to Belara use."( Efficacy and safety of the new antiandrogenic oral contraceptive Belara.
Andreas, JO; Goldberg, J; Zahradnik, HP, 1998
)
0.3
"No serious adverse effects were observed in either group."( A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety.
Ledger, WJ; Saxena, BB; Singh, M; Singh, R; Thomas, D, 1996
)
0.29
"6% of all subjects reported one or more adverse events, and a total of 43."( An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
, 1998
)
0.3
"The study confirmed that Mircette is a safe and efficacious oral contraceptive that is well tolerated and acceptable to women who have previously used oral contraceptives, as well as first-time users."( An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
, 1998
)
0.3
" There were no serious adverse effects."( Safety and effectiveness of hormonal postcoital contraception: a prospective study.
Armengol, J; Aura, M; Calaf, J; Cuberas, N; Espinós, JJ; Senosiain, R; Vanrell, C, 1999
)
0.3
"The combination of ethinylestradiol and levonorgestrel in low doses is an effective and safe method of postcoital contraception."( Safety and effectiveness of hormonal postcoital contraception: a prospective study.
Armengol, J; Aura, M; Calaf, J; Cuberas, N; Espinós, JJ; Senosiain, R; Vanrell, C, 1999
)
0.3
" This study indicates that use of a single CVR releasing EE and NET-Ac over a period of 12 months constitutes an acceptable, safe and effective contraceptive method."( Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
Alvarez, F; Brache, V; Fraser, IS; Lacarra, M; Mishell, DR; Nash, HA; Weisberg, E, 1999
)
0.3
" The 2 most common adverse events cited as reasons for discontinuation were headache (2% of subjects) and metrorrhagia (2%)."( Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).
Archer, DF; DelConte, A; Maheux, R; O'Brien, FB, 1999
)
0.51
" This analysis revealed that the OC exhibited a side effect profile that was similar, in many cases, to that of placebo."( Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence.
Godwin, AJ; Lippman, JS; Olson, W; Redmond, G, 1999
)
0.3
" The adverse events reported in both treatment groups are consistent with those expected with the use of combined hormonal contraceptives."( Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lu
Cromie, MA; Garceau, RJ; Kaunitz, AM, 1999
)
0.49
" The incidence of other adverse events was similar among treatment groups, an observation that supports the safety of both formulations."( Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.
Kaunitz, AM, 2000
)
0.53
" In order to evaluate sublethal toxic effects of environmentally relevant concentrations of NP, juvenile Common carp (Cyprinus carpio) were exposed to NP concentrations ranging from 1 to 15 microg NP/l over a 70-day period."( Chronic toxicity of nonylphenol and ethinylestradiol: haematological and histopathological effects in juvenile Common carp (Cyprinus carpio).
Bauer, C; Ferling, H; Kalbfus, W; Mallow, U; Negele, RD; Schwaiger, J; Spieser, OH, 2000
)
0.31
" The occurrence of adverse events was recorded at each visit."( Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials.
Coney, P; DiGiovanna, JJ; Harrison, DD; Langley, RG; Washenik, K, 2001
)
0.31
" Adverse events were typical of hormonal contraception, and most were mild-to-moderate in severity and not treatment limiting."( Efficacy and safety of a transdermal contraceptive system.
Creasy, GW; Fisher, AC; Lenihan, JP; Meador, ML; Shangold, GA; Smallwood, GH, 2001
)
0.31
"2%) participants experienced a serious adverse event classified as possibly, probably, or likely related to the patch."( A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra).
Creasy, GW; Fisher, AC; Meador, ML; Odlind, V; Shangold, GA; Sibai, BM, 2002
)
0.31
"Overall, the contraceptive patch is well tolerated and has a side effect profile similar to an established oral contraceptive."( A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra).
Creasy, GW; Fisher, AC; Meador, ML; Odlind, V; Shangold, GA; Sibai, BM, 2002
)
0.31
" These results suggested that THA at biologically active choleretic dose had low toxicity, it might be safe for further development as a therapeutic agent for a short period of treatment in cholestasis."( Evaluation of the acute and subacute toxicity of a choleretic phloracetophenone in experimental animals.
Chuncharunee, A; Komaratat, P; Piyachaturawat, P; Suksamrarn, A; Tubtim, C, 2002
)
0.31
" The highest dose of BPA was decreased to 600 mg/kg per day from the second week of administration because a male rat given 1000 mg/kg BPA had died within 1 week with toxic clinical signs."( Subacute oral toxicity study of ethynylestradiol and bisphenol A, based on the draft protocol for the "Enhanced OECD Test Guideline no. 407".
Imatanaka, N; Noda, S; Sawaki, M; Takatsuki, M; Yamasaki, K, 2002
)
0.31
" Using the contraceptive pill administered by vaginal route is a safe method with fewer side effects and more acceptability when compared with the oral route."( Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route.
Faghihzadeh, S; Lamyian, M; Rajaei, L; Ziaei, S, 2002
)
0.31
" The highest dose of BPA was reduced to 600 mg/kg per day from the second week of the study onwards because a male rat given 1000 mg/kg per day of BPA died within the first week, showing toxic clinical signs."( Changes of serum alpha 2u-globulin in the subacute oral toxicity study of ethynyl estradiol and bisphenol A based on the draft protocol for the 'Enhanced OECD Test Guideline No. 407'.
Noda, S; Takatsuki, M; Takeyoshi, M; Yamasaki, K, 2002
)
0.31
" Progestins with androgenic properties have been incriminated in unexpected vascular events because of their adverse effect on the lipid profile."( [Side effects of third generation progestagens].
Sitruk-ware, R, 1993
)
0.29
" The most common adverse events in both treatment groups were nausea, vomiting, dizziness, and chloasma."( A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 microg ethinylestradio1/75 microg gestodene (Meliane) and 30 microg ethinylestradio1/75 microg gestodene (Gynera).
Jaisamrarn, U; Kriengsinyot, R; Taneepanichskul, S, 2002
)
0.31
"These data suggest that both therapies were similarly effective and safe in the treatment of hirsutism."( Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism.
Başogul, O; Inal, M; Ispahi, C; Karanfil, C; Onoglu, A; Taner, C; Tinar, S, 2002
)
0.31
" Results showed that the dosage regimen could damage the epididymal sperms and onset of antifertility within 6 weeks in male rats, and prevent the incidence of the side effect of irreversible azoospermia."( [A beam of dawn light of study on gossypol as a safe, effective, and reversible male antifertility contraceptive--evaluation of the studies by using low dose gossypol combined with steroid hormone for male contraception].
Xue, S, 2000
)
0.31
" The most frequent adverse events were headache (reported in 35% of subjects), absence of bleeding (16%), flu-like syndrome (15%), pharyngitis (15%) and abdominal pain (15%)."( The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg.
, 1999
)
0.3
" Ten women discontinued because of adverse events and one undesired pregnancy occurred during treatment."( Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
Baracat, EC; Barbosa, IC; Faggion, D; Filho, CI, 2006
)
0.33
"evaluation of the frequency of adverse events during the therapy with a transdermal contraceptive system (TCS) in comparison to an oral contraceptive."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
" Safety evaluation was based on the frequency of adverse effects, changes in physical and gynecological examinations."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
"The incidence of most adverse effects was similar between the transdermal and oral contraceptive therapies, except of a higher incidence of breast pain, dysmenorrhoea and application site reactions in the patch group."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
"The study suggests that a transdermal contraceptive system is a safe and well tolerated therapy."( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
Radowicki, S; Skórzewska, K; Szlendak, K, 2005
)
0.33
"The analysis of adverse events revealed two crucial points for acceptability, compliance and continuation: poor cycle control and disturbance of sexual intercourse due to vaginal dryness and loss of desire."( Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives.
Cagiano, R; Sabatini, R, 2006
)
0.33
" Overall, the study drug was well tolerated and adverse events experienced were typical of hormonal contraceptive use."( Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg.
Alincic, S; Cibula, D; Karck, U; Kunz, J; Marr, J; Weidenhammer, HG, 2006
)
0.33
" Safety was primarily assessed by monitoring the occurrence of adverse events."( Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara, over three medication cycles.
Binder, N; Feichtinger, W; Höschen, K; Spona, J, 2008
)
0.35
" EE/ CMA was well tolerated, with few adverse events reported; most were typically cycle-related and included headache, breast discomfort, nausea and vomiting."( Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara, over three medication cycles.
Binder, N; Feichtinger, W; Höschen, K; Spona, J, 2008
)
0.35
"Genotoxicity biomarkers are widely measured in ecotoxicology as molecular toxic endpoints of major environmental pollutants."( Investigating the relationship between embryotoxic and genotoxic effects of benzo[a]pyrene, 17alpha-ethinylestradiol and endosulfan on Crassostrea gigas embryos.
Akcha, F; Caisey, X; Quiniou, F; Rousseau, S; Wessel, N, 2007
)
0.34
" However, a higher incidence of minor adverse effects such as breast tenderness and nausea were demonstrated when compared to oral contraceptive containing with ethinyl estradiol (EE) 30 microg and levonorgestrel 150 microg."( Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years.
Boonyarangkul, A; Taneepanichskul, S, 2007
)
0.54
"96% women presented one or more adverse effects during the follow-up; 33."( Long-term safety and tolerability of flutamide for the treatment of hirsutism.
Balasch, J; Castelo-Branco, C; Gómez, O; Moyano, D, 2009
)
0.35
"Flutamide is very effective for hirsutism treatment; however, adverse effects are very frequent and associated with low long-term compliance."( Long-term safety and tolerability of flutamide for the treatment of hirsutism.
Balasch, J; Castelo-Branco, C; Gómez, O; Moyano, D, 2009
)
0.35
" The most frequent adverse events were consistent with OC treatment, and no unexpected events occurred."( Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-
Hanjalic-Beck, A; Zahradnik, HP, 2008
)
0.56
" tentans, indicating that adverse effects are not expected, and that environmental exposure to EE2 likely poses a low risk to benthic invertebrates."( Chronic toxicity of the synthetic hormone 17alpha-ethinylestradiol to Chironomus tentans and Hyalella azteca.
Balakrishnan, VK; Dussault, EB; Sibley, PK; Solomon, KR, 2008
)
0.35
"This low-dose, 28-day OC incorporating 7 days of 10 mcg EE during the hormone free interval is effective and safe for the prevention of pregnancy and is well-tolerated by women."( Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo.
Hait, H; Poindexter, A; Reape, KZ, 2008
)
0.35
" Safety assessments included physical examinations, laboratory evaluations and adverse event records."( Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
Archer, DF; Ballagh, SA; Grubb, GS; Kovalevsky, G, 2009
)
0.6
" Pearl index, adverse event (AE) incidence and bleeding profiles were assessed."( Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
Apter, D; Constantine, GD; Emerich, J; Greven, K; Grubb, GS; Klasa-Mazurkiewicz, D; Melis, GB; Spaczynski, M; Spielmann, D; Teichmann, A, 2009
)
0.63
"Continuous LNG 90 mcg/EE 20 mcg was shown to be a safe and effective OC in this direct comparison to a cyclic OC."( Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
Apter, D; Constantine, GD; Emerich, J; Greven, K; Grubb, GS; Klasa-Mazurkiewicz, D; Melis, GB; Spaczynski, M; Spielmann, D; Teichmann, A, 2009
)
0.63
" Cycle control and adverse events reported with this regimen were similar to those reported with other low-dose OCs."( The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
Kroll, R; Margolis, M; Reape, KZ, 2010
)
0.58
" In addition, the regimen was well tolerated and incidence of adverse events were consistent with what has been reported with other low-dose OCs."( The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
Kroll, R; Margolis, M; Reape, KZ, 2010
)
0.58
"Oral contraceptive pills (OCPs) are one of the most effective reversible and accessible contraceptives, and patient acceptance for their use depends partly on the unfavorable adverse effects."( A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran.
Kashanian, M; Shahpourian, F; Zare, O, 2010
)
0.62
" The most common "at least possibly related" adverse events were headache, breast discomfort and nausea."( Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
Binder, N; Brucker, C; Christoph, A; Hedon, B; Höschen, K; The, HS, 2010
)
0.36
" In light of these changes in regimens, clinicians may be seeking evidence that the new regimens are safe and will not result in unexpected adverse events."( A look at the long-term safety of an extended-regimen OC.
Davis, MG; Hait, H; Reape, KZ, 2010
)
0.36
" We evaluated incidence of reported adverse events (AEs), rates of study discontinuation, and reported bleeding patterns."( A look at the long-term safety of an extended-regimen OC.
Davis, MG; Hait, H; Reape, KZ, 2010
)
0.36
"This study demonstrated that the AE profile of the 91-day extended-regimen OC over 4 years was similar to that seen in the 1-year clinical trials, with no unexpected adverse events."( A look at the long-term safety of an extended-regimen OC.
Davis, MG; Hait, H; Reape, KZ, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Treatment-related adverse events (AEs) were reported by 22 (37%) of 59 subjects and were reported most commonly in Cycle 1, decreasing continuously thereafter."( Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
Hartschuh, E; Höschen, K; König, S; Rabe, T; Wahlstrom, T, 2010
)
0.36
" Primary end points included bleeding profile and adverse events."( Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.
Constantine, GD; Fortier, MP; Grubb, GS; Mirkin, S; Reid, RL; Smith, L, 2010
)
0.6
" Adverse events were comparable to cyclic OC regimens, except unscheduled vaginal bleeding."( Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.
Constantine, GD; Fortier, MP; Grubb, GS; Mirkin, S; Reid, RL; Smith, L, 2010
)
0.6
"03 mg/CMA 2 mg by evaluating the incidence and severity of adverse drug reactions (ADRs) and cycle control over 13 treatment cycles."( Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.
Albers, D; Höschen, K; Nowack, C; Pushparajah, DS; Röhm, P, 2011
)
0.37
" Data were documented on volunteer diaries, and adverse events (AEs) were reported during five visits."( Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy.
Kuhl, H; Lange, E; Manthey, T; Mellinger, U; Mittmann, K; Palombo-Kinne, E; Sänger, N; Stahlberg, S; Wiegratz, I, 2011
)
0.37
" Inappropriate movement responses due to toxic effects of contaminants may ultimately impact important ecological variables."( Rapid-behaviour responses as a reliable indicator of estrogenic chemical toxicity in zebrafish juveniles.
Castro, LF; Monteiro, NM; Santos, MM; Sárria, MP; Soares, J; Vieira, MN, 2011
)
0.37
" In the investigational group, the most frequently reported adverse events were acne (16."( Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.
Bahamondes, L; Darney, P; Kaunitz, AM; Korver, T; Sommer, W; Verhoeven, C; Westhoff, C, 2012
)
0.38
" Most treatment-emergent adverse events were mild, and all resolved by study end."( Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.
Bush, M; Lewis, E; Scott, R; Watanalumlerd, P; Zhi, H, 2012
)
0.38
"02 mg EE is a safe and significantly effective treatment for moderate truncal acne."( A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
Kimball, AB; Lima, XT; Palli, MB; Reyes-Habito, CM, 2013
)
0.6
" It is important to identify any secondary toxic mechanisms that can be used to prevent or treat the toxicity."( Molecular mechanism of 17α-ethinylestradiol cytotoxicity in isolated rat hepatocytes.
O'Brien, P; Wan, L, 2014
)
0.4
" Efficacy was measured using the Pearl Index and the life-table method; safety and tolerability were assessed through reported adverse events (AEs)."( Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
Howard, B; Hsieh, J; Kaunitz, AM; Portman, DJ; Ricciotti, N; Weiss, H, 2014
)
0.63
" We conclude that specific concentrations of estrogens can confer resistance against cytotoxicity in Caco-2 cells, due in part to positive modulation of ABC transporters involved in extrusion of their toxic substrates."( Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
Arias, A; Catania, VA; Luquita, MG; Mottino, AD; Perdomo, VG; Rigalli, JP; Ruiz, ML; Villanueva, SS; Vore, M, 2014
)
0.4
" The most frequent adverse events were headache (9."( Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
Bassol, S; Mellinger, U; Merz, M; Weisberg, E; Wiegratz, I, 2014
)
0.4
" The safety variables were adverse events (AE), lab examinations, physical and gynecological examinations, vital signs and body weights and questionnaires."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Baihua, D; Caiyan, W; Hongyu, W; Huan, S; Liangdan, T; Meiqing, X; Mulan, R; Qinping, L; Shulan, Z; Wen, D; Xiaomao, L; Xiaoyan, X; Youdi, X; Yufeng, L; Zheng'ai, X; Zhisong, M; Zirong, H; Ziyan, H, 2014
)
0.4
"YAZ is highly effective, acceptable and safe for Chinese women."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Baihua, D; Caiyan, W; Hongyu, W; Huan, S; Liangdan, T; Meiqing, X; Mulan, R; Qinping, L; Shulan, Z; Wen, D; Xiaomao, L; Xiaoyan, X; Youdi, X; Yufeng, L; Zheng'ai, X; Zhisong, M; Zirong, H; Ziyan, H, 2014
)
0.4
"Treatment-emergent adverse events of 2% or greater in the LNG/EE contraceptive patch were nasopharyngitis (5."( Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015
)
0.42
"The LNG/EE contraceptive patch and combination oral contraceptives were well tolerated and associated with similar treatment-emergent adverse event incidences in obese and nonobese women."( Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015
)
0.42
"We previously reported that neonatal exposure to 17α-ethynylestradiol (EE) led to delayed adverse effects in which age-related anovulation after sexual maturation was accelerated."( Early indicators of delayed adverse effects in female reproductive organs in rats receiving neonatal exposure to 17alpha-ethynylestradiol.
Hayashi, S; Inoue, K; Matsuo, S; Morikawa, T; Takahashi, M; Tamura, K; Taya, K; Watanabe, G; Yoshida, M, 2014
)
0.4
" The main adverse effects of YAZ included intermenstrual bleeding [13% (12/93) versus 3% (3/94)], menorrhagia [9% (8/93) versus 1% (1/94)], nausea [5% (5/93) versus 4% (4/94)] and skin rash [4% (4/93) versus 2% (2/94)]."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Cheng, W; Fu, Y; Li, L; Mi, W; Sun, L; Wang, J; Xie, S; Zhang, H; Zhang, J, 2014
)
0.4
" The most common adverse effects are intermenstrual bleeding, menorrhagia, nausea and rash."( [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Cheng, W; Fu, Y; Li, L; Mi, W; Sun, L; Wang, J; Xie, S; Zhang, H; Zhang, J, 2014
)
0.4
" In summary, these findings suggest that OP has adverse effects on fat metabolism in pregnant rats and inhibits fat deposition via regulating lipogenic genes in the liver and adipose tissue."( The adverse effect of 4-tert-octylphenol on fat metabolism in pregnant rats via regulation of lipogenic proteins.
An, BS; Hwang, DY; Jeung, EB; Kang, EJ; Kim, J; Kim, JE; Kim, SC; Lee, GS; Park, MN, 2015
)
0.42
"PubMed and the Cochrane Library databases were searched for all articles in all languages published between inception and September 2014 relevant to dyslipidemia, CHC use and serious adverse events (MI, stroke, VTE or pancreatitis)."( Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.
Curtis, KM; Dragoman, M; Gaffield, ME, 2016
)
0.43
" Safety and tolerability were assessed primarily through reported adverse events (AEs)."( Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
Ackerman, R; Feldman, R; Howard, B; Hsieh, J; Kroll, R; Ricciotti, N; Weiss, H, 2016
)
0.66
"Progestins and estroprogestins are safe drugs to use in the long term."( Safety of medical treatments for endometriosis.
Berlanda, N; Somigliana, E; Vercellini, P; Viganò, P, 2016
)
0.43
"3% (fingers-only) of subjects reported at least 1 treatment-related adverse event (AE); all were mild."( Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study.
Feldman, R; Fox, MC; Frenkl, TL; Wang, Y; Yacik, C, 2016
)
0.43
"Once-monthly NuvaRing is efficacious and safe for use in Chinese women."( Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
Chang, Q; Di, W; Fan, GS; Korver, T; Marintcheva-Petrova, M; McCrary Sisk, C; Qin, Y; Ren, M; Su, P; Wang, G; Wu, S; Yacik, C, 2016
)
0.43
"To review and evaluate the potential adverse effects of these oral contraceptives (OCP) to overweight women."( Pills-related severe adverse events: A case report in Taiwan.
Chang, HY; Chen, CH; Chen, HH; Chin, HY; Liu, WM, 2016
)
0.43
"Surface water concentrations of the synthetic estrogen 17α-ethinylestradiol (EE2) as low as 1ng/L can cause adverse reproductive effects in fish under acute and chronic exposure conditions, whereas higher concentrations (> 5ng/L) in acute studies are necessary to elicit adverse effects in freshwater mussels."( Extending the toxicity-testing paradigm for freshwater mussels: Assessing chronic reproductive effects of the synthetic estrogen 17α-ethinylestradiol on the unionid mussel Elliptio complanata.
Barnhart, MC; Bringolf, RB; Cope, WG; Hammer, EJ; Leonard, JA, 2017
)
0.46
" The aim of this study was to evaluate the incidence of TE using the Japanese Adverse Drug Event Report (JADER) database."( Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
Abe, J; Fukuda, A; Hane, Y; Hasegawa, S; Hatahira, H; Hirade, K; Kinosada, Y; Matsui, T; Motooka, Y; Naganuma, M; Nakamura, M; Sasaoka, S; Takahashi, Y, 2017
)
0.46
" There were no incident pregnancies, serious adverse events, serious social harms, or early discontinuations for safety reasons."( A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use.
Agaba, S; Buyze, J; Crucitti, T; De Baetselier, I; Delvaux, T; Jespers, V; Kestelyn, E; Mwambarangwe, L; Ndagijimana, JC; Umulisa, MM; Uwineza, M; van de Wijgert, JHHM; Van Nuil, JI, 2018
)
0.48
"Intermittent and continuous NuvaRing® use were safe in Rwandan women and improved Nugent scores over time."( A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use.
Agaba, S; Buyze, J; Crucitti, T; De Baetselier, I; Delvaux, T; Jespers, V; Kestelyn, E; Mwambarangwe, L; Ndagijimana, JC; Umulisa, MM; Uwineza, M; van de Wijgert, JHHM; Van Nuil, JI, 2018
)
0.48
"9% reported adverse drug reactions."( Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study.
Di, W; Gu, X; He, Y; Qian, F; Sun, X, 2020
)
0.81
" After 3 months of treatment, anthropometric assessments along with variations in sex hormones related index, glucolipid metabolic index, changes in bilateral ovarian volume, as well as adverse effect of the combination were evaluated."( Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study.
Chen, Z; Huang, L; Ke, H; Li, L; Li, TT; Li, X; Peng, X; Tan, Q; Yang, Y; Zeng, J; Zhang, H; Zhang, R, 2020
)
0.81
" It was seen that 81 patients reported no adverse reactions."( Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study.
Chen, Z; Huang, L; Ke, H; Li, L; Li, TT; Li, X; Peng, X; Tan, Q; Yang, Y; Zeng, J; Zhang, H; Zhang, R, 2020
)
0.81
" Large phase 4 studies will be needed to confirm if this combination is associated with an improved adverse event profile or lower thrombosis risk."( Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Achilles, SL; Archer, DF; Bouchard, C; Chen, MJ; Creinin, MD; Foidart, JM; Jensen, JT; Kaunitz, AM; Westhoff, CL, 2021
)
0.62
" Other than bleeding complaints and mood disturbance, no adverse event resulted in E4/DRSP discontinuation at rates >1%."( Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.
Achilles, SL; Apolikhina, I; Archer, DF; Bouchard, C; Chen, MJ; Creinin, M; Foidart, JM; Jensen, JT; Jost, M; Kaunitz, AM; Piltonen, T; Suturina, L; Weyers, S; Zatik, J, 2022
)
0.72
"75 mg/L, no observed adverse effect level derived from its reproductive toxicity) and SMX (0."( Co-contaminants of ethinylestradiol and sulfamethoxazole in groundwater exacerbate ecotoxicity and ecological risk and compromise the energy budget of C. elegans.
Chang, CH; How, CM; Huang, CW; Kuo, YH; Liao, VH; Yen, PL; Yu, CW, 2023
)
0.91

Pharmacokinetics

Study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15. Compared with a combination oral contraceptive (COC) containing EE 35 mcg and norgestimate 250 mcg.

ExcerptReferenceRelevance
" During the 4-10 hours following administration, carbon-14-CA in plasma disappeared with a half-life of 3 + or -1."( Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 micrograms ethinyloestradiol to 6 young women.
Dogs, G; Hümpel, M; Schulze, PE; Speck, U; Weiss, C; Wendt, H, 1977
)
0.26
" At the end of treatment cycles one and three, the terminal half-life of LNG was in the range of 24-26 h, while a mean value of 20 h was observed following single dose administration."( Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
al-Yacoub, G; Fuhrmeister, A; Kuhnz, W, 1992
)
0.28
"Serum concentration profiles and pharmacokinetic parameters (cmax, tmax, AUC24, AUC0-00, MRT) of ethinylestradiol (EE2) and levonorgestrel (LNG) were obtained following administration of two combined oral contraceptives."( Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Brandstädt, A; Carol, W; Jäger, R; Kasch, R; Klinger, G, 1992
)
0.28
"Serum concentration profiles and pharmacokinetic parameters of ethinyl estradiol (EE2) and levonorgestrel (LNG) were obtained after administration of 2 combined oral contraceptives (OCs)."( Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Brandstädt, A; Carol, W; Jäger, R; Kasch, R; Klinger, G, 1992
)
0.52
" This increase was due to an increased dose of LNG according to the triphasic dose regimen, a concomitantly ethinylestradiol-induced increase in SHBG and due to pharmacokinetic accumulation, since LNG had a terminal half-life of approximately 28."( Pharmacokinetics of levonorgestrel in 18 women after 1 month of treatment with a triphasic oral contraceptive.
al-Yacoub, G; Kuhnz, W, 1991
)
0.28
" Goethe University in Frankfurt am Main, Germany, compared serum data on 34 20-39 year old women who used either the oral contraceptive Marvelon (30 mcg ethinyl estradiol [EE] and 150 mcg desogestrel [DG] or Lovelle (20 mcg EE and 150 mcg DG) to observe their pharmacokinetics and some pharmacodynamic parameters."( Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Fitzner, M; Jung-Hoffmann, C; Kuhl, H, 1991
)
0.48
"Ethinyl estradiol is part of almost every combined oral contraceptive, and its pharmacokinetic characteristics have been thoroughly investigated in numerous studies."( Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
Gansau, C; Kuhnz, W; Louton, T; Mahler, M; Sostarek, D, 1991
)
1.94
"Researchers at the research laboratories of Schering, AG pharmaceutical company in Berlin, Germany compared basic pharmacokinetic parameters of ethinyl estradiol and free and total testosterone in 10 women after single dose administration of a triphasic oral contraceptive (OC) containing ."( Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
Gansau, C; Kuhnz, W; Louton, T; Mahler, M; Sostarek, D, 1991
)
0.7
" Blood samples were collected at the end of each treatment month, assayed for EE and the half-life of elimination (Tel) and bioavailability (area under the serum concentration-time curve, AUC) calculated."( Intrasubject variability in the pharmacokinetics of ethynyloestradiol.
Fotherby, K, 1991
)
0.28
" Wide variations were observed between the women in the calculated pharmacokinetic parameters, while there was a relatively close correspondence between the intra-individually obtained values, except for one case."( [Inter- and intra-individual variability of pharmacokinetic parameters for contraceptive steroids].
Carol, W; Jäger, R; Kasch, R; Klinger, G; Michels, W, 1991
)
0.28
" The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1."( Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol.
Chiang, ST; Lobo, RA; Stanczyk, FZ; Woutersz, TB, 1990
)
0.28
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: (1) maximum serum concentration, (2) time to maximum serum concentration, (3) total area under the serum concentration versus time curve, and (4) serum half-life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.28
" The pharmacokinetic properties of desogestrel were characterized by the following parameters: maximum serum concentration, time to maximum serum concentration, total area under the serum concentration vs time curve, and serum 1/2 life of elimination."( Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Assendorp, R; Bergink, W; Kloosterboer, L; Qvist, I; van Lier, W; Voortman, G, 1990
)
0.28
" The pharmacokinetic differences of EE whether caused by dietary, ethnic, or other factors are not merely differences in gastric absorption or renal excretion."( Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications.
Goldzieher, JW, 1990
)
0.28
"The pharmacokinetic and protein-binding properties of gestodene and ethinyl estradiol have been investigated after single and multiple dosing in several studies in 83 healthy, young women."( Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive.
Hümpel, M; Kuhnz, W; Täuber, U, 1990
)
0.79
" Our studies show that this idea is untenable because the half-life of the sulfates is not long enough for such an effect."( Pharmacokinetics of ethinyl estradiol and mestranol.
Brody, SA; Goldzieher, JW, 1990
)
0.6
"A pharmacodynamic and pharmacokinetic study of the Chinese No."( A pharmacodynamic and pharmacokinetic study of the Chinese No. 1 pill.
Chen, JK; Fan, SB; Fotherby, K; Gui, YL; He, ML; Li, LM; Song, S; Yang, PJ, 1990
)
0.28
" Pharmacokinetic data showed pronounced interindividual variations."( [Pharmacokinetics of ethinyl estradiol following the administration of combination contraceptive preparations].
Carol, W; Jäger, R; Kasch, R; Klinger, G, 1990
)
0.6
"We have examined the pharmacokinetic parameters derived from the analysis of plasma ethinyl estradiol (EE) and norethindrone levels after administration of a single dose of three bioequivalent norethindrone-1mg/mestranol (ME)-50 micrograms formulations (Ortho-NovumR 1/50, NorinylR 1/50 and Norcept-MR 1/50) and three norethindrone-1mg/ethinyl estradiol-35 micrograms formulations (Ortho-Novum 1/35R, NorinylR 1/35, Norcept-ER 1/35) in a randomized crossover design involving 24 women for the 35 micrograms and 27 women for the 50 micrograms agents."( Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are "low-dose" pills really lower?
Brody, SA; Goldzieher, JW; Turkes, A, 1989
)
0.72
"Plasma concentration profiles and pharmacokinetic parameters have been obtained following single dose administration of three commonly used oral contraceptive steroid preparations, Ovral, Nordette and Norminest to Egyptian women."( Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
Back, DJ; el-Raghy, I; Fathalla, M; Makeram, M; Orme, ML; Osman, F; Salem, H, 1986
)
0.27
" The volume of distribution was not significantly different in patients and controls; thus there was a tendency (nonsignificant) for the elimination half-life and area under curve after the intravenous dose to be less in the women with cystic fibrosis."( Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
Back, DJ; Batten, JC; Grimmer, SF; Hodson, ME; Orme, ML; Rogers, SM; Stead, RJ, 1987
)
0.27
"6 ml/hr/kg and the half-life was 19."( Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking.
D'Ambrosio, R; Gardner, MJ; Jusko, WJ; Kanarkowski, R; Tornatore, KM, 1988
)
0.53
" The clearance of levonorgestrel was significantly lower in chronic OC users (mean elimination half-life of 30 hours) than in single-dose subjects (mean elimination half-life of 23 hours)."( Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking.
D'Ambrosio, R; Gardner, MJ; Jusko, WJ; Kanarkowski, R; Tornatore, KM, 1988
)
0.53
" The time to peak (tmax) was significantly longer and the peak concentration (Cmax) significantly reduced following vaginal administration."( Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration.
Back, DJ; Grimmer, SF; Orme, ML; Rogers, S; Stevenson, PJ, 1987
)
0.27
" The analysis of the plasma concentrations obtained after administration of EE-3 and EE-17 indicates significant differences in their pharmacokinetic profiles."( Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate.
Dorantes, A; Goldzieher, JW; Mileikowsky, G; Newburger, J; Stavchansky, SA,
)
0.13
" This evidence of a pharmacodynamic interaction between contraceptive steroids and ethanol in rats is consistent with a recent clinical report of significant contraceptive steroid-related improvement in tolerance to ethanol with no apparent effect on the pharmacokinetics of ethanol."( Kinetics of drug action in disease states. XXII. Effects of contraceptive steroids on the pharmacodynamics of ethanol in rats.
Levy, G; Wanwimolruk, S, 1987
)
0.27
" It appears that during the first 3-9 months of low dose oral contraceptive treatment, these steroids do not alter the pharmacokinetic behaviour of theophylline in adolescent females."( Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives.
Chin, TF; Correia, J; Koren, G; MacLeod, SM; Tesoro, A, 1985
)
0.27
" The problems in quantitating various pharmacokinetic parameters and the techniques for their evaluation, as well as methods for the determination of the requisite sampling times and frequencies are discussed, and best estimates for the various parameters, as derived from the literature, are provided."( Pharmacokinetics of ethynyl estradiol: a current view.
Goldzieher, JW; Newburger, J, 1985
)
0.27
" had any significant effect on plasma concentrations of EE2 or levonorgestrel or on any pharmacokinetic parameter determined."( Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine.
Back, DJ; Breckenridge, AM; Grimmer, SF; Orme, ML; Purba, HS, 1984
)
0.27
" Neither drug given 1 hour before the OC had any significant effect on pharmacokinetic concentrations of EE2 or levonorgestrel or on any pharmacokinetic parameter determined."( Pharmacokinetics of oral contraceptive steroids following the administration of the antimalarial drugs primaquine and chloroquine.
Back, DJ; Breckenridge, AM; Grimmer, SF; Orme, ML; Purba, HS, 1984
)
0.27
" time curve (AUC), and (e) plasma half-life (t1/2)."( Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women.
Goebelsmann, U; Henzl, M; Ling, T; Miyakawa, I; Mroszczak, EJ; Runkel, R; Stanczyk, FZ, 1983
)
0.27
" Pharmacokinetic studies carried out indicate that sulphate acts as a reservoir or slow release form for unconjugated and biologically active EE."( Pharmacokinetics of ethynyloestradiol in humans.
Fotherby, K, 1982
)
0.26
" There was no significant difference in a number of pharmacokinetic parameters between the two times of administration, suggesting that morning or evening administration of the contraceptive are equally effective."( Pharmacokinetics of oral contraceptive steroids after morning or evening administration.
Fotherby, K; Kiriwat, O, 1983
)
0.27
" There were no significant differences between morning and evening administration of the OC for any of the pharmacokinetic parameters of EE."( Pharmacokinetics of oral contraceptive steroids after morning or evening administration.
Fotherby, K; Kiriwat, O, 1983
)
0.27
" Extremely wide variations were observed between women in the various calculated pharmacokinetic parameters."( Variability of pharmacokinetic parameters for contraceptive steroids.
Fotherby, K, 1983
)
0.27
" Absorption phase half-life ranged from 14-22 minutes, distribution phase varied from 1-3 hours, and the elimination half life ranged from 6-14 hours."( Plasma levels and pharmacokinetics of ethynyl estrogens in various populations. I. Ethynylestradiol.
de la Pena, A; Dozier, TS; Goldzieher, JW, 1980
)
0.26
" After this event, an apparently terminal monoexponential decline was eventually established with a half-life of 13."( The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women.
Back, DJ; Bolt, HM; Breckenridge, AM; Crawford, FE; Orme, ML; Rowe, PH; Schindler, AE, 1980
)
0.26
" Once the EHC had begun, a monoexponential decline was established for EE with a half-life of about 13."( The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women.
Back, DJ; Bolt, HM; Breckenridge, AM; Crawford, FE; Orme, ML; Rowe, PH; Schindler, AE, 1980
)
0.26
" The mean maximum plasma levonorgestrel concentrations (Cmax), time to Cmax (tmax) and area under the plasma time-concentration curves (AUC(0,t)) did not differ between subjects given tenidap or placebo."( An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates, PE; Mesure, R, 1995
)
0.29
" There was no appreciable difference in mean maximum plasma levonorgestrel concentrations (Cmax), time to Cmax (tmax), and area under the plasma time-concentration curves (AUC[0,t]) between the tenidap group and the placebo group."( An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates, PE; Mesure, R, 1995
)
0.29
" Pharmacokinetic assessments of ethinyl estradiol and gestodene were performed on day 14 of both cycles."( Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.
Banfield, CR; Colucci, RD; Glue, P; Haring, P; Lin, CC; Meehan, JW; Nomeir, A; Radwanski, E; Reidenberg, P; Saano, V, 1995
)
0.57
" Following single dose administration, a mean terminal half-life of 22 h was observed for LNG."( Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels i
Jütting, G; Kuhnz, W; Staks, T, 1994
)
0.29
" The mean terminal half-life for LNG was 22 hours."( Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels i
Jütting, G; Kuhnz, W; Staks, T, 1994
)
0.29
" At the end of treatment cycle three, the terminal half-life of CPA had increased to a mean value of 78."( Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
Jütting, G; Kuhnz, W; Staks, T, 1993
)
0.29
" The terminal half-life of CPA was higher at the end of treatment cycle 3 than after a single dose (78."( Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
Jütting, G; Kuhnz, W; Staks, T, 1993
)
0.29
"To demonstrate that pharmacokinetic measurements were made at steady state."( Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer, DF; Lammers, P; Timmer, CJ, 1994
)
0.52
" The statistical analysis on Cmax, AUC, Css,min, and Tmax indicated that the pharmacokinetics of ethinyl E2 on days 7, 14, and 21 were not statistically significantly different, indicating dose equivalency."( Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer, DF; Lammers, P; Timmer, CJ, 1994
)
0.52
" Following single dose administration, a mean terminal half-life of 18 h was observed for GEST."( Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the
Baumann, A; Dibbelt, L; Jütting, G; Knuppen, R; Kuhnz, W; Staks, T, 1993
)
0.29
" The mean terminal half-life for gestodene after receiving the single dose was 18 hours."( Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the
Baumann, A; Dibbelt, L; Jütting, G; Knuppen, R; Kuhnz, W; Staks, T, 1993
)
0.29
" Respective changes were seen with regard to the area under the EE2 serum concentration curve up to 4 and 24 hours (AUC0-4 and AUC0-24), cmax and tmax of serum EE2."( Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Schindler, AE; Simon, A; Ward, S; Winkler, UH, 1993
)
0.5
" No significant differences were seen in serum EE2 levels including the rise in mean EE2 on days 1-10, or the smaller rise between days 10-21, or the pharmacokinetic parameters Cmax, tmax, area under the curve (AUC) at 0-4 hours, or AUC at 0-24 hours."( Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Schindler, AE; Simon, A; Ward, S; Winkler, UH, 1993
)
0.5
"Our purpose was to compare the pharmacokinetic parameters of oral administration of a 35 micrograms ethinyl estradiol, 1 mg norethindrone pill in peritoneal dialysis patients and normal women."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.5
" Pharmacokinetic parameters were calculated by noncompartmental analysis and statistical analysis performed with Mann-Whitney U testing."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.29
"There is no difference in the pharmacokinetic parameters for norethindrone in peritoneal dialysis patients compared with normal women."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.29
"In a single-dose and multiple-dose study, gynecologists from California, North Carolina, and Texas, compared pharmacokinetic parameters of the low dose oral contraceptive (OC), Ortho-Novum 1/35, (35 mcg ethinyl estradiol and 1 mg norethindrone) in premenopausal women with renal failure on peritoneal analysis and in age and weight matched controls."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.47
" Pharmacokinetic evaluation was carried out with TOPFIT and parameters were evaluated for differences with the t-test."( A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive.
Heger-Mahn, D; Heuner, A; Hümpel, M; Kuhnz, W; Richert, K, 1995
)
0.29
"It was the aim of the study to compare the pharmacokinetic properties of the two new estrogens, ZK 136295 and ZK 115194, with those of ethinylestradiol (EE2) after single intravenous (60 micrograms) and oral (120 and 240 micrograms) administration in 54 postmenopausal women."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
"7 hours); and EE2 had a mean terminal half-life of 26."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" In the present paper, a study about amoxicillin-ethinylestradiol (EE2) pharmacokinetic potential interaction was studied."( Study of the pharmacokinetic interaction between ethinylestradiol and amoxicillin in rabbits.
Diez, MJ; Fernández, N; García, JJ; Pereda, P; Sierra, M; Terán, T, 1997
)
0.3
" None of the norethindrone pharmacokinetic parameters changed significantly in the presence of topiramate."( Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Doose, DR; Nayak, RK; Rosenfeld, WE; Walker, SA, 1997
)
0.51
"The purpose of the present report is to summarize the most important pharmacokinetic features of the new progestogens."( Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism.
Stanczyk, FZ, 1997
)
0.3
" In the present study, the compartmental and noncompartmental pharmacokinetic parameters of ethinylestradiol (EE) in rabbits after oral administration were determined."( Influence of two commercial fibers in the pharmacokinetics of ethinylestradiol in rabbits.
Calle, AP; Diez, MJ; Fernández, N; García, JJ; Sierra, M; Terán, MT, 1998
)
0.3
" Mean Cmax and AUC values for norgestrel decreased by 12% and 10%, respectively, when administered with ABT-761."( Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers.
Awni, WM; Dube, LM; O'Dea, RF; Wong, SL, 1998
)
0.52
"Statistically significant decreases in ethinyl oestradiol mean Cmax (-32%) and mean AUC (-41%), and a statistically significant increase in the mean terminal elimination rate constant (+31%) were observed during concomitant ritonavir."( Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
Cavanaugh, JH; Eason, CJ; Granneman, GR; Hsu, A; Leonard, JM; Locke, CS; Ouellet, D; Qian, J, 1998
)
0.3
" After administration of a single dose of OC, serum ethinyl estradiol concentrations peaked at 4 hours and declined thereafter, with a typical half-life of 17 hours."( Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
Cavanaugh, JH; Eason, CJ; Granneman, GR; Hsu, A; Leonard, JM; Locke, CS; Ouellet, D; Qian, J, 1998
)
0.55
" No changes were observed for other pharmacokinetic parameters assessed for either ethinyl estradiol or norethindrone."( Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.
Abernethy, DR; Collins, JM; Donahue, SR; Flockhart, DA; Thacker, D; Trapnell, CB, 1998
)
0.78
" Furthermore, no changes were seen for other pharmacokinetic parameters assessed for thalidomide between days 1 and 21."( Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.
Abernethy, DR; Collins, JM; Donahue, SR; Flockhart, DA; Thacker, D; Trapnell, CB, 1998
)
0.55
" Pharmacokinetic profiles of EE and NE were determined on day 21 of the second and third cycles."( Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.
Knowlton, P; Koup, JR; Loi, CM; Sedman, AJ; Stern, R; Vassos, AB, 1999
)
0.3
" The pharmacokinetic profiles of plasma concentrations of thalidomide were evaluated with both noncompartmental and compartmental methods, whereas those of ethinyl estradiol and norethindrone were calculated with noncompartmental methods."( Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Colburn, W; Kook, KA; Scheffler, MR; Thomas, SD, 1999
)
0.5
" There were no significant differences between pharmacokinetic parameters for thalidomide after 1 dose and those after 18 consecutive doses."( Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Colburn, W; Kook, KA; Scheffler, MR; Thomas, SD, 1999
)
0.3
" These were assayed for ethinyloestradiol and levonorgestrel and the resulting data used to derive pharmacokinetic data for these steroids."( Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000
)
0.31
"The mean AUC(0,24 h), Cmax and tmax for ethinyloestradiol and the mean AUC(0, 24 h) and Cmax for levonorgestrel during ziprasidone co-administration were not statistically significantly different from corresponding values occurring during placebo co-administration."( Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000
)
0.31
"The findings of this study suggest that, based on pharmacokinetic and tolerability data, ziprasidone may be co-administered with ethinyloestradiol and levonorgestrel without loss of contraceptive efficacy or increased risk of adverse events."( Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000
)
0.31
" Lack of pharmacokinetic effect was prospectively defined as 90% CI for the point estimate (PE) of the ratio (RSG + OC):(P + OC) contained within a 20% equivalence range for both ethinylestradiol and norethindrone (analyzed by ANOVA)."( Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
Culkin, KT; Finnerty, D; Freed, MI; Inglis, AM; Jorkasky, DK; Miller, AK; Patterson, SD, 2001
)
0.31
" Pharmacokinetic assessments were performed on day 14 based on plasma levels of ethinyl estradiol and levonorgestrel up to 24 hours after dosing and serum tolterodine levels at 1 to 3 hours after dosing."( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
Landgren, BM; Olsson, B, 2001
)
0.75
" There was no evidence of a pharmacokinetic interaction between tolterodine and the steroid hormones in the oral contraceptive used, nor did the oral contraceptive show any relevant pharmacokinetic interaction with tolterodine."( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
Landgren, BM; Olsson, B, 2001
)
0.52
" Pharmacokinetic profiles for ethinyl estradiol and for a single oral dose of triazolam (0."( Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.
Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2002
)
0.86
" The half-life of triazolam was also decreased, but the half-life of ethinyl estradiol did not appear to be affected by treatment with modafinil."( Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.
Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2002
)
0.81
" This overview summarizes the relevant pharmacokinetic data for the contraceptive patch."( Pharmacokinetic overview of Ortho Evra/Evra.
Abrams, LS; Natarajan, J; Skee, D; Wong, FA, 2002
)
0.31
"The contraceptive patch exhibits an excellent pharmacokinetic profile, maintaining efficacious serum hormone concentrations under varying conditions."( Pharmacokinetic overview of Ortho Evra/Evra.
Abrams, LS; Natarajan, J; Skee, D; Wong, FA, 2002
)
0.31
"To determine the pharmacokinetic profile of norelgestromin (NGMN) and ethinyloestradiol (EE) following application of the contraceptive patch, Evra/Ortho Evra, at each of four anatomic sites (abdomen, buttock, arm, and torso)."( Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.
Abrams, LS; Anderson, GD; Natarajan, J; Skee, DM; Wong, FA, 2002
)
0.31
"Concomitant administration of NVP at steady state with EE/NET resulted in a significant (29%) median reduction in the area under the plasma concentration time curve (AUC(infinity)) and a significant reduction in mean residence time (MRT) and half-life (t(1/2)) of EE."( Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.
Hutman, HW; Lamson, M; Marshak, A; McDonough, M; Mildvan, D; Robinson, P; Yarrish, R, 2002
)
0.57
"The plasma concentration-time curves and pharmacokinetic parameters of ethinyl estradiol and levonorgestrel were not statistically different during concomitant treatment with either levetiracetam or placebo."( Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.
Janik, F; Levy, RH; Ragueneau-Majlessi, I, 2002
)
0.55
" The clearance and volume of distribution of LNG decreased and the terminal half-life increased after repeated daily administration, compared with single administration."( A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
Blode, H; Endrikat, J; Gerlinger, C; Kuhnz, W; Rosenbaum, P, 2002
)
0.31
"To study the pharmacokinetics of a combination oral contraceptive (OC) containing norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure."( Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.
Bialer, M; Doose, DR; Jacobs, D; Padmanabhan, M; Schwabe, S; Wang, SS, 2003
)
0.74
"5 mg/kg body weight and pharmacokinetic parameters were determined using model-independent analysis."( Determination using liquid-chromatography-electrospray tandem mass spectroscopy of ethinylestradiol serum pharmacokinetics in adult Sprague-Dawley rats.
Churchwell, MI; Delclos, KB; Doerge, DR; Newbold, RR; Twaddle, NC, 2003
)
0.32
"To compare the pharmacokinetic parameters and safety of the progestagen, Org 30659, (17alpha)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one), and ethinyl estradiol (EE) in Caucasian and Japanese women after single and multiple doses."( Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE).
Cohen, AF; de Visser, SJ; Fukazawa, I; Machielsen, CS; Uchida, E; Uchida, N; van den Heuvel, MW; van Doorn, MB; van Vliet-Daskalopoulou, E, 2003
)
0.52
"The peak concentration and extent of exposure of Org 30659, and to a lesser extent of EE, in Japanese women are higher than in Caucasian women."( Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE).
Cohen, AF; de Visser, SJ; Fukazawa, I; Machielsen, CS; Uchida, E; Uchida, N; van den Heuvel, MW; van Doorn, MB; van Vliet-Daskalopoulou, E, 2003
)
0.32
"The mean values of the pharmacokinetic parameters AUC and Cmax of ethinylestradiol and levonorgestrel after multiple-dose treatment with losigamone or placebo were quite similar and met the criteria for bioequivalence."( Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers.
Dienel, A; Klement, S; Müller, F, 2004
)
0.32
" Although isotretinoin and estradiol are metabolized largely by cytochrome P450 (CYP) 3A4 and glucuronidation, the potential for clinical drug interaction, with subsequent pharmacodynamic impact, has not been evaluated."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.55
" The pharmacokinetics of ethinyl estradiol and norethindrone (INN, norethisterone) (the components of Ortho Novum 7/7/7; Ortho-McNeil Pharmaceutical, Inc, Raritan, NJ) and pharmacodynamic assessments of oral contraceptive effectiveness (concentrations of serum progesterone, luteinizing hormone, and follicle-stimulating hormone) were determined on days 6 and 20 of 2 separate oral contraceptive cycles, before and during isotretinoin treatment."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.86
" Isotretinoin did not cause any statistically significant increases in pharmacodynamic markers, although a majority of women had increases in these measures."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.55
"The small reduction in ethinyl estradiol and norethindrone levels associated with isotretinoin was not associated with any pharmacodynamic changes in our study."( The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Guidos, A; Hendrix, CW; Jackson, KA; Khoo, KC; Kretzer, R; Liss, CM; McLane, J; Shah, LP; Trapnell, CB; Whitmore, E, 2004
)
0.86
"Two separate open-label, parallel-group, single-centre, pharmacokinetic and pharmacodynamic interaction studies."( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004
)
0.32
" Pharmacokinetic parameters of plasma norethindrone and ethinylestradiol were compared before and after tazarotene administration (cycle day 6 of the second and third cycles, respectively)."( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004
)
0.32
"1 mg), the area under the plasma concentration-time curve from zero to 24 hours (AUC24) and the peak concentration in plasma (Cmax) for tazarotenic acid were 121 +/- 27 microg."( Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Tang-Liu, DD; Walker, PS; Yu, D; Yu, Z, 2004
)
0.32
" This study assessed the effect of alosetron co-administration on pharmacodynamic markers of contraceptive efficacy, on the pharmacokinetics of estrogen and progesterone OC components, and on the activity of biochemical markers for the risk of thrombosis."( Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).
Ameen, VZ; Baidoo, CA; Campanella, C; Kersey, KE; Koch, K; Manzo, JA, 2004
)
0.32
" Comparable systemic exposure of EE and 17-DNE in the presence and absence of dexloxiglumide suggests that dexloxiglumide treatment is unlikely to interfere with the safety and efficacy of oral contraceptives based on the analysis of the resulting pharmacokinetic profile."( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005
)
0.33
"The disposition kinetics of [3H]taurocholate ([3H]TC) in perfused normal and cholestatic rat livers were studied using the multiple indicator dilution technique and several physiologically based pharmacokinetic models."( Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.
Chang, P; Hung, DY; Roberts, MS; Siebert, GA, 2005
)
0.33
"Several antiepileptic drugs have clinically significant pharmacokinetic interactions with oral contraceptives (OCs) that may result in contraceptive failure."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.55
"035 mg and norethindrone [NOR] 1 mg) and on pharmacodynamic variables that may be increased in the event of reduced contraceptive efficacy (concentrations of serum luteinizing hormone [LH], follicle-stimulating hormone [FSH], and progesterone)."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.55
" There was no pharmacodynamic evidence that zonisamide is likely to reduce the contraceptive effectiveness of OCs containing EE and NOR."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.55
"Two pharmacokinetic studies were performed to investigate whether there is any interaction between etonogestrel or ethinylestradiol released from the combined contraceptive vaginal ring NuvaRing and concomitant treatment with orally administered amoxicillin or doxycycline."( Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
Dogterom, P; Thomsen, T; van den Heuvel, MW, 2005
)
0.33
" Calculation of etonogestrel and ethinylestradiol interaction/control ratios confirmed the absence of pharmacokinetic interactions."( Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
Dogterom, P; Thomsen, T; van den Heuvel, MW, 2005
)
0.33
"The results from these studies demonstrate the absence of pharmacokinetic interactions between etonogestrel and ethinylestradiol released from NuvaRing and the oral antibiotics amoxicillin and doxycycline, suggesting that contraceptive efficacy would also be unaffected."( Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
Dogterom, P; Thomsen, T; van den Heuvel, MW, 2005
)
0.33
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
"The aim of this study was to evaluate the effect of solifenacin on the pharmacokinetic (PK) parameters of an oral contraceptive (OC) containing ethinyl estradiol (EE) and levonorgestrel (LNG)."( Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
Krauwinkel, WJ; Kuipers, ME; Smulders, RA; Swart, PJ; Taekema-Roelvink, ME; Visser, N, 2005
)
0.76
"To assess the pharmacokinetic and pharmacodynamic effects of co-administration of a combined oral contraceptive (ethinyloestradiol plus levonorgestrel) and lamotrigine."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.33
"Of the 22 enrolled subjects, 16 had evaluable pharmacokinetic data."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.33
"A clinically relevant pharmacokinetic interaction was observed during co-administration of a combined oral contraceptive and lamotrigine."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.33
" In view of the vast clinical applications and interactions of steroidal oral contraceptives with commonly used therapeutic agents, the interaction potential of certain concomitantly administered therapeutic agents was investigated in terms of postcoital contraceptive efficacy (pharmacological) and the pharmacokinetic profile of centchroman in female Sprague-Dawley rats."( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats.
Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006
)
0.33
" Pharmacokinetic interaction was studied in normal female rats with or without coadministered drugs."( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats.
Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006
)
0.33
" In pharmacokinetic interaction studies, most of the therapeutic agents affected the rate and extent of absorption of centchroman."( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats.
Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006
)
0.33
"Published data on pharmacokinetic parameters for chlormadinone acetate (CMA) are in part contradictory, especially with regard to terminal half-life (t(1/2,z))."( Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Göhler, K; Kneip, C; Terlinden, R; Uragg, H, 2006
)
0.33
" Single-dose and steady-state pharmacokinetic parameters were calculated."( Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Göhler, K; Kneip, C; Terlinden, R; Uragg, H, 2006
)
0.33
"Using an optimized pharmacokinetic design, this study indicated men exhibit significantly higher zidovudine-monophosphate and zidovudine-triphosphate exposure following zidovudine oral administration, having implications for drug toxicity and overall tolerance of zidovudine therapy."( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.
Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006
)
0.33
" Consequently, there are numerous reports in the literature describing EE-containing OC formulations as perpetrators of pharmacokinetic drug interactions."( Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Balimane, P; Cui, D; Han, YH; Rodrigues, AD; Sinz, M; Wang, B; Yang, Z; Zhang, H, 2007
)
0.34
" Plasma concentration-time profiles and pharmacokinetic parameters were characterized for EE and 2 major metabolites of norgestimate, norgestrel (NG) and 17-deacetyl norgestimate (17-DNGM)."( Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
Bettenhausen, DK; Connolly, M; Forbes, WP; Pentikis, H; Trapnell, CB, 2007
)
0.58
" No differences in pharmacokinetic parameters were observed for EE, NG, or 17-DNGM when a single dose of the OC was administered alone or with rifaximin."( Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
Bettenhausen, DK; Connolly, M; Forbes, WP; Pentikis, H; Trapnell, CB, 2007
)
0.58
" The clinical significance of the differences in pharmacokinetic and pharmacodynamic profiles between the patch and oral contraceptive is not fully known."( Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
Devineni, D; Janssens, L; LaGuardia, KD; Leung, AT; Massarella, J; Skee, D; Vaccaro, N, 2007
)
0.34
" The geometric mean ratios for the difference between EE alone and following rifalazil for EE Cmax, AUC(0-24) and Cmin were 105."( Lack of effect of rifalazil on ethinyl estradiol pharmacokinetics in healthy postmenopausal women.
Cabana, B; Chen, YX; Gilman, S; Kivel, N; Michaelis, A; Pieniaszek, H, 2007
)
0.63
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic assessments were performed on day 14 for each session."( Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
De Pauw, M; Felicione, E; Guzman, SS; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T, 2008
)
0.62
"The pharmacokinetic interaction observed here is considered to be clinically relevant as EE concentrations are considerably reduced when DRV/r is co-administered with EE and NE."( Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
De Pauw, M; Felicione, E; Guzman, SS; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Vangeneugden, T, 2008
)
0.62
"5, 2, 3, 4, 6, 8, 12, and 24 hours postdose on day 21 of each cycle for determination of AUC0-24 h and Cmax of ethinyl estradiol and norelgestromin."( Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Dunbar, S; Johnson-Levonas, AO; Lasseter, KC; Li, S; Miller, DL; Rosko, K; Schwartz, JI; Wagner, JA; Yuan, J, 2009
)
0.77
" Pharmacokinetic data (AUC, C(max), t(max)) were determined the day before (reference) and after (test) a 14-day period of Ze 117 intake (250 mg twice daily)."( St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.
Bauer, S; Brattström, A; Kunter, U; Roots, I; Will-Shahab, L, 2009
)
0.35
" The method has been successfully applied to a pharmacokinetic study of the ORTHO EVRA patch in rabbits."( Determination of norelgestromin in rabbit plasma by LC-MS/MS and its application to the pharmacokinetic study of ORTHO EVRA.
Ding, C; Ge, Q; Liu, X; Zhi, X; Zhou, Z, 2009
)
0.35
" Etravirine 200 mg bid was coadministered on Day 1 to Day 15 of Cycle 3, with pharmacokinetic assessments of ethinylestradiol, norethindrone and etravirine on Day 15."( Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.
Aharchi, F; Hoetelmans, RM; Kakuda, TN; Peeters, M; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, B, 2009
)
0.35
" The LNG half-life was significantly longer in the obese group (52."( Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.
Cameron, JL; Carlson, NE; Cherala, G; Edelman, AB; Jensen, JT; Munar, MY; Stanczyk, FZ; Stouffer, RL, 2009
)
0.35
"Thirty-day, open-label, fixed-sequence, pharmacokinetic drug-drug interaction study."( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney, BP; Mathias, A, 2009
)
0.35
" Geometric mean ratios (90% confidence intervals) for the pharmacokinetic parameters for deacetyl norgestimate and ethinyl estradiol were estimated by using analysis of variance and compared with the no-effect criterion for bioequivalence."( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney, BP; Mathias, A, 2009
)
0.56
" Comparability would be declared if the 90% confidence intervals for the geometric mean ratio of AUC0-24hr and Cmax in the absence and presence of laropiprant were within predefined bounds (0."( Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Gutierrez, MJ; Johnson-Levonas, AO; Lai, E; Liu, F; Pramanik, B; Schwartz, JI; Wagner, JA; Wang, YH,
)
0.13
" Pharmacokinetic (PK) monitoring was conducted on Days 1, 21, 84 and 91."( Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti, CE; Hendy, CH; Margolis, MB; O'Leary, CM; Waters, DH, 2011
)
0.37
" Pharmacokinetic parameters over the 24-h dosing period were similar at all time points measured after achieving steady-state plasma concentrations."( Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti, CE; Hendy, CH; Margolis, MB; O'Leary, CM; Waters, DH, 2011
)
0.37
" We sought to assess the pharmacodynamic effects of CBZ on breakthrough bleeding and ovulation during oral contraceptive (OC) use."( Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding.
Davis, AR; Stanczyk, FZ; Westhoff, CL, 2011
)
0.37
" Pharmacokinetic parameters were evaluated on cycle day 21, and endogenous hormones assayed on cycle days 1, 7, 14 and 21."( Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers.
Butler, K; Teng, R, 2011
)
0.37
" The pharmacokinetic parameters measured were maximum steady-state plasma concentration during a dosage interval (C(max,ss)), time to reach maximum plasma concentration following administration at steady state (t(max,ss)) and area under the plasma concentration-time curve during a dosage interval (τ) at steady state (AUC(τ,ss))."( Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich, C; Giessmann, T; Graefe-Mody, U; Iovino, M; Port, A; Ring, A; Woerle, HJ, 2011
)
0.37
" Pharmacokinetic parameters, including AUC(0-24), C(max), and C(min), were calculated using noncompartmental methods, and drug interactions were evaluated using an ANOVA model by treatment group."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
" Twenty-one subjects completed the study and were included in the pharmacokinetic analysis; 4 discontinued for reasons unrelated to study drug and 2 discontinued because of adverse events."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
"This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15, a transdermal contraceptive delivery system, compared with a combination oral contraceptive (COC) containing EE 35 mcg and norgestimate 250 mcg."( Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2012
)
2.13
" Single- (Day 8) and multiple-dose (Day 22) pharmacokinetic profiles were assessed for each treatment period."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
" Single-dose oral contraceptive administration 30 minutes after exenatide resulted in mean (90% CI) Cmax reductions of 46% (42-51%) and 41% (35-47%) for EE and LV, respectively."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"The observed reduction in Cmax is likely of limited importance given the unaltered oral contraceptive bioavailability and trough concentrations; however, for oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before exenatide injection."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
" The co- administration of EE had no relevant effect on the pharmacokinetic parameters of 3 mg DRSP."( Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women.
Blode, H; Kowal, K; Reif, S; Roth, K, 2012
)
0.38
" The effect of vismodegib on rosiglitazone and OC pharmacokinetic parameters (primary objective) was evaluated through pharmacokinetic sampling over a 24-h period (Days 1 and 8)."( Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
Colburn, D; Colevas, AD; Graham, RA; LoRusso, PM; Low, JA; Malhi, V; Mita, M; Piha-Paul, SA; Yin, M, 2013
)
0.39
"This study compares the pharmacokinetic profile, adhesion and safety of the AG200-15 Agile Patch (AP), a novel contraceptive patch releasing low-dose ethinyl estradiol (EE) and levonorgestrel (LNG), during wear under external conditions of heat, humidity and exercise versus normal activities."( Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.59
" Blood samples were collected for pharmacokinetic evaluations."( Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.39
" This study determined whether application of the AP to three different anatomical sites (lower abdomen, buttock and upper torso) influences the pharmacokinetic profile of EE and levonorgestrel (LNG)."( Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.39
" For plasma LNG levels, median Tmax (72-120 h) and mean Cmax (1436-1589 pg/mL) were similar across application sites."( Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013
)
0.39
" Three open-label phase 1 studies were conducted in healthy human participants to investigate potential pharmacokinetic (PK) and/or pharmacodynamic (PD) interactions between albiglutide and medications that may be used concomitantly."( Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.
Bush, M; Lewis, E; Scott, R; Watanalumlerd, P; Zhi, H, 2012
)
0.38
" The pharmacokinetic parameters of area under the concentration-time curve (AUC), maximum steady-state plasma drug concentration (Cmax ), and time to maximum concentration (tmax ) were measured for the OC components and lacosamide."( Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello, W; Rosenkranz, B; Schmid, B; Wierich, W, 2013
)
0.39
" In each of the 31 volunteers who completed the trial (through cycle 3), pharmacodynamic assessment showed progesterone serum concentration was <5."( Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello, W; Rosenkranz, B; Schmid, B; Wierich, W, 2013
)
0.39
" There were no relevant changes in the time to reach peak levels (t (max,ss)) or terminal elimination half-life (t (½,ss)) of EE and LNG between test and reference treatments."( Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2013
)
0.39
" Thus, we herein report the pharmacokinetic changes of doxorubicin with respect to the changes in its biliary excretion and hepatic metabolism in EEC rats."( Effects of 17α-ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin.
Choi, YH; Lee, MG; Lee, YK, 2013
)
0.39
" Ethinyl estradiol Cmax was 21% lower with no change in AUC."( The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent.
Buraglio, M; Crean, CS; Tompson, DJ, 2013
)
1.3
"Rilpivirine coadministration had no effect on (least square mean ratio, 90% confidence interval) ethinylestradiol Cmin (1."( Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Buelens, A; Crauwels, HM; Hoetelmans, RM; Stevens, M; van Heeswijk, RP, 2014
)
0.4
"Two open-label, randomized, two-period, crossover studies were performed to determine the safety, delivery rates, and pharmacokinetic properties of a combination estradiol (E2)/levonorgestrel (LNG) transdermal delivery system (TDS)."( Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Bourg, D; Bourg, L; Harrison, LI; Karara, AH; Melikian, AP; Morrison, D; Poola, N; Zurth, C, 2014
)
0.4
" A population pharmacokinetic (PK) model for EE was developed using nonlinear mixed-effects modeling to characterize the PK profile of EE administered in Quartette and other extended-regimen LNG/EE COCs."( A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
Bond, M; Darwish, M; Fiedler-Kelly, J; Grasela, T; Hsieh, J; Ricciotti, N, 2014
)
0.4
" This was a 112-day, open-label, fixed-sequence pharmacokinetic (PK) study in healthy female subjects that included a lead-in cycle (OC only; N = 21), cycle 1 (OC only; N = 15), cycle 2 (OC + sofosbuvir; N = 15), and cycle 3 (OC + ledipasvir; N = 15)."( Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
German, P; Mathias, A; Moorehead, L; Pang, P; Vimal, M, 2014
)
0.6
"To determine if increasing the hormone dose or eliminating the hormone-free interval improves key pharmacokinetic (PK) alterations caused by obesity during oral contraceptive (OC) use."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.4
" Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2."( Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Elgadi, M; Huang, F; Lang, B; Sabo, JP, 2015
)
0.42
"We evaluated the potential pharmacokinetic interaction between pradigastat, a potent and selective diacylglycerol acyltransferase 1 inhibitor, and Levora-28®, a combination oral contraceptive (COC) containing 30 μg ethinylestradiol (EE) and 150 μg levonorgestrel (LVG)."( Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects.
Bhansali, S; Chen, J; Majumdar, T; Meyers, C; Neelakantham, S; Rebello, S; Sunkara, G; Trusley, C, 2015
)
0.42
" Plasma concentrations of EE and LNG were measured up to 72 hours post administration, and the PK parameters Cmax and AUClast were estimated using noncompartmental methods."( Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Chakraborty, A; Jakab, A; Legangneux, E; Mensinga, T; Neelakantham, S; Rouzade-Dominguez, ML; Sivasubramanian, R; Ufer, M; Woessner, R, 2015
)
0.62
"In conclusion, EE PK was unchanged, whereas Cmax and AUClast of LNG were 19% and 32% lower, respectively, when given with mavoglurant Further investigation regarding the impact on contraceptive efficacy is warranted."( Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Chakraborty, A; Jakab, A; Legangneux, E; Mensinga, T; Neelakantham, S; Rouzade-Dominguez, ML; Sivasubramanian, R; Ufer, M; Woessner, R, 2015
)
0.62
" This study was aimed to describe the pharmacokinetic characteristics of this new combination contraceptive tablet in female Chinese volunteers."( Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers.
Ding, L; Geng, T; Liu, X; Sun, C; Wu, Y; Xin, X, 2016
)
0.67
" Blood samples for pharmacokinetic analysis were taken until 168 hours postdose."( Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Dutta, S; Foulds, P; King, A; Korb, S; Patel, G; Sumeray, M; Wade, JR, 2016
)
0.67
"A moderate pharmacokinetic drug-drug interaction between DRSP and KTZ was demonstrated in this study."( Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.
Berse, M; Gschwend, S; Höchel, J; Klein, S; Schütt, B; Wiesinger, H; Zollmann, FS, 2015
)
0.42
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016
)
0.63
" Thirty-one women completed the study; 23 yielded evaluable pharmacokinetic data."( Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study.
Casjens, M; Ludwig, M; Schuett, B; Waellnitz, K; Zurth, C, 2015
)
0.66
" Mean half-life was similar in the presence and absence of tofacitinib: 13."( Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
Alvey, CW; Krishnaswami, S; Menon, S; Petit, W; Riese, R; Shi, H; Wang, R, 2016
)
0.43
" Confusing in some of the literature is that a few studies have reported erroneously calculated pharmacokinetic parameters after multiple dosing of oral contraceptives."( Clarification of contraceptive drug pharmacokinetics in obesity.
Jusko, WJ, 2017
)
0.46
" These studies evaluated the safety and pharmacokinetic interactions between elbasvir (EBR) and grazoprevir (GZR) and ethinyl estradiol/levonorgestrel (EE/LNG)."( No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Butterton, JR; Caro, L; Feng, HP; Guo, Z; Huang, X; Ma, J; Mangin, E; Marshall, WL; O'Reilly, TE; Panebianco, D; Talaty, J; Yeh, WW, 2017
)
0.86
" The aim of this study was to explore the pharmacokinetic characteristics of baicalin in rats with 17α-ethynylestradiol (EE)-induced intrahepatic cholestasis (IC) based on its choleretic effects."( Pharmacokinetic Characteristics of Baicalin in Rats with 17α-ethynyl-estradiol-induced Intrahepatic Cholestasis.
Lei, K; Liu, D; Xiang, D; Xu, YJ; Yang, JY; Zhang, CL, 2018
)
0.48
" Blood samples for pharmacokinetic profiling of laquinimod, EE and LNG were collected on day 21 and day 22 of Cycles 1 and 3 pre-dose and multiple times post-dose."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.51
"The combination of COC and laquinimod treatment was found to be safe, tolerable, and devoid of any noticeable pharmacokinetic interaction."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.51
" The harmonic mean terminal half-life for ethinylestradiol (7."( The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
Feng, T; Friedman, A; Mohamed, MF; Othman, AA; Trueman, S, 2019
)
0.51
" Serial blood samples were collected for pharmacokinetic analysis."( Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive.
Christmann, R; Naik, H; Tidemann-Miller, B; Versavel, M; Zhao, Y, 2020
)
0.56
"The SPRM VPR interfered with the pharmacodynamic effects of the COC."( The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive-A randomized controlled trial.
Casjens, M; Draeger, C; Loewen, S; Rohde, B; Schultze-Mosgau, MH; Schütt, B; Zimmermann, T, 2021
)
0.62
" Pharmacokinetic data from 15 patients were analysed."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
0.72
"This study employed population pharmacokinetic (popPK) models to predict levonorgestrel (LNG) and ethinyl estradiol (EE) exposure after dosing with the transdermal contraceptive TWIRLA® (LNG/EE TDS) as a 12-week extended regimen in a healthy female population."( Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model.
Archer, DF; Korner, P; Lohmer, LRL; Pirone, J; Previtera, M; Stanczyk, FZ, 2022
)
1.21
"The study enrolled 25 participants, with pharmacokinetic data assessed for 20 participants."( Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants.
Bertz, RJ; Bhardwaj, R; Croop, RS; Morris, B; Stringfellow, JC, 2023
)
1.13

Compound-Compound Interactions

The metabolic effects of cyproterone acetate (2 mg) combined with a new dose level of ethinyl estradiol (35 micrograms) were studied over a one-year period in 31 patients presenting moderate clinical hyperandrogenism. The effects of androgenic properties of progestins combined with ethinyl Estradiol on endothelial function, lipids and free radical production in such women were investigated.

ExcerptReferenceRelevance
" We have characterized PCN or macrolides induced cytochromes P-450 by their specific ability to interact with macrolide derivatives and, using the cytochrome P-450 spectral binding assays, we have shown that some compounds, implicated in drug interaction with macrolides, interact preferentially with the same cytochromes."( Specific drug binding to rat liver cytochrome P-450 isozymes induced by pregnenolone-16 alpha-carbonitrile and macrolide antibiotics. Implications for drug interactions.
Delaforge, M; Sartori, E, 1990
)
0.28
"The metabolic effects of cyproterone acetate (2 mg) combined with a new dose level of ethinyl estradiol (35 micrograms) were studied over a one-year period in 31 patients presenting moderate clinical hyperandrogenism."( Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients.
Cathelineau, G; Fiet, J; Hardy, N; Martineau, I; Vexiau, P; Vexiau-Robert, D; Villette, JM, 1990
)
0.73
" In 60 healthy, randomly allocated women, the effects of ethinyl estradiol, 30 micrograms, combined with gestodene, 75 micrograms, and desogestrel, 150 micrograms, on blood coagulation, fibrinolysis, and platelet function were compared."( Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
Bonnar, J; Daly, L, 1990
)
0.8
" We investigated the effect of this new sexual hormone alone and in combination with ethynylestradiol on the elimination of both testdrugs."( [Effect of a new gestagen--dienogest--and its combination with ethinyl estradiol on the activity of biotransformation reactions].
Balogh, A; Hoffmann, A; Klinger, G; Liewald, S; Liewald, T; Schröder, S; Splinter, FC, 1990
)
0.52
"Oral contraceptives (OCs) should be used with additional caution in combination with other drugs in certain disease states."( Drug interactions with oral contraceptive preparations.
Shenfield, GM, 1986
)
0.27
" Thirty-one male-to-female transsexuals, treated at least 3 months either with 100 mg CA alone or in combination with 50 micrograms ethinyloestradiol (EO)/day, were studied."( The effect of cyproterone acetate alone and in combination with ethinylestradiol on the hypothalamic pituitary adrenal axis, prolactin and growth hormone release in male-to-female transsexuals.
de Vries, CP; Gooren, LJ; van der Veen, EA, 1986
)
0.27
" A multicenter study was therefore done, in which two preparations containing CA in combination with ethinylestradiol (EE) were compared with a marketed combined oral contraceptive pill."( Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.
Carlborg, L, 1986
)
0.52
"The effects of serum lipids and lipoproteins of 2 mg cyproterone acetate (CPA) given alone and in combination with 35 or 50 micrograms ethinyl estradiol (EE) were studied in 21 oophorectomized women in a study with a cross-over design."( Effects of cyproterone acetate (CPA) on serum lipoproteins when administered alone and in combination with ethinyl estradiol (EE).
Crona, N; Enk, L; Lindberg, UB; Samsioe, G; Silfverstolpe, G, 1987
)
0.69
" In combination with EE, however, DG seems to counteract the effects of EE to a lesser extent than NORG, as judged particularly from the effects on TG and PL in serum and VLDL."( The effects of two gonane progestins alone and in combination with ethinyl estradiol on serum lipoproteins.
Crona, N; Samsioe, G; Silfverstolpe, G, 1985
)
0.51
"Serum concentrations of growth hormone (GH) and somatomedin C were monitored in 14 women during post-menopausal replacement therapy with oestrogen alone and in combination with a specific antioestrogen."( Growth hormone and somatomedin C during post-menopausal replacement therapy with oestrogen alone and in combination with an antioestrogen.
Fröhlander, N; von Schoultz, B, 1988
)
0.27
" In the experiments performed in rats, under effect of ethinyl estradiol and norethisteron acetate, and especially at their combination with benactyzine, the first signs of overmaturation are revealed in oocytes situating in the follicular cavity."( [Effect of an estrogen-progestin preparation alone and in combination with amizil on the structure and electrophoretic parameters of oocytes and early rat embryos].
Kitaev, EM; Lupanova, GE; Makusheva, VP; Snetkova, MG, 1987
)
0.52
" In combination with EE, however, DG seems to be less "anti-oestrogenic" than NORG, as judged from the higher apo-AI and SHBG values after the combination DG + EE compared to those after NORG + EE."( Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona, N; Samsioe, G; Silfverstolpe, G, 1984
)
0.46
" In combination with EE, however, DG seems to be less antiestrogenic than NORG, as judged from the higher apo-AI and SHBG values after the combination of DG EE compared to those after NORG & EE."( Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona, N; Samsioe, G; Silfverstolpe, G, 1984
)
0.46
"The study purpose was to obtain additional clinical experience with 200 mcg of ethinyl estradiol combined with 2 mg dl-norgestrel as an emergency postcoital contraceptive."( A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent.
Rademaker, AW; Smith, RP; Yuzpe, AA, 1982
)
0.75
"125 mg Ng (norgestimate) combined with ."( Effects of norgestimate in combination with ethinyl estradiol on cervical mucus.
Borin, K; Moghissi, KS; Mohsenian, M, 1981
)
0.52
"The pharmacokinetics and pharmacodynamics of 150 micrograms desogestrel (DG) or 150 micrograms 3-keto-desogestrel (KDG) in combination with 30 micrograms ethinylestradiol (EE) were compared in a cross-over study."( Prodrug versus drug effects of 150 micrograms desogestrel or 3-keto-desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3-keto-desogestrel.
Fitzner, M; Jung-Hoffmann, C; Kuhl, H, 1995
)
0.29
" This study was undertaken to compare safety and efficacy of a low dose of flutamide (125 mg twice daily) alone and in combination with a triphasic oral contraceptive (OC) in women with idiopathic hirsutism."( Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
Cédrin, I; Dodin, S; Faure, N; Guy, J; Lemay, A; Méchain, C; Turcot-Lemay, L, 1995
)
0.29
" Nevertheless, at 6 months post-treatment this decrease was still significant only in the group who took flutamide in combination with an oral contraceptive."( Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
Cédrin, I; Dodin, S; Faure, N; Guy, J; Lemay, A; Méchain, C; Turcot-Lemay, L, 1995
)
0.29
"The effect of gestodene 75 micrograms (GTD) versus desogestrel 150 micrograms (DSG) combined with 30 micrograms of ethinylestradiol (EE) on acne lesions and plasma androstenedione (A), total testosterone (T), sex hormone binding globulin (SHBG) and "free androgen index" (FAI) was evaluated in an open study on 19 patients aged 18-35 years affected with postpubertal or persistent non-severe acne vulgaris."( Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango, D; Manna, P; Miggiano, GA; Ricci, S; Serra, GB, 1996
)
0.29
" They aimed to evaluate the effect of GTD and DSG combined with low doses of EE on acne lesions and on hormone levels."( Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango, D; Manna, P; Miggiano, GA; Ricci, S; Serra, GB, 1996
)
0.29
"3), were included in a single-center, non-comparative study to investigate the effect on inhibition of ovulation of an oral contraceptive containing 20 micrograms ethinylestradiol in combination with 100 micrograms levonorgestrel."( Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol.
Brill, K; Feichtinger, W; Kindermann, C; Spona, J; Wünsch, C, 1996
)
0.29
" Subsequently, all patients received GH 18 IU/m2/week in combination with oxandrolone (Ox) (0."( Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height.
Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T, 1996
)
0.29
"Many adverse drug-drug interactions are attributable to pharmacokinetic problems and can be understood in terms of alterations of P450-catalyzed reactions."( Role of cytochrome P450 enzymes in drug-drug interactions.
Guengerich, FP, 1997
)
0.3
"The objective of this study was to provide evidence of the validity of pig hepatocytes as a model to study the regulation of human CYP3A4 with special emphasis on drug-drug interactions."( Pig hepatocytes as an in vitro model to study the regulation of human CYP3A4: prediction of drug-drug interactions with 17 alpha-ethynylestradiol.
Friis, C; Hansen, KT; Olsen, AK, 1997
)
0.3
" In combination with ethinyloestradiol, it has been shown to be of clinical benefit to women displaying signs of androgenization, such as acne, seborrhoea and hirsutism."( [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].
Albring, M; Brill, K; Gollnick, H, 1999
)
0.3
"To investigate ovulation inhibition with drospirenone, a novel progestogen that has a profile similar to natural progesterone, when given alone or in combination with ethinylestradiol."( Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol.
Freundl, F; Grillo, M; Heithecker, R; Helmerhorst, FM; Rosenbaum, P; Rossmanith, W; Schmidt, W; Thomas, K; Wolf, A; Wuttke, W, 2000
)
0.31
"Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS)."( The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
de Vries, CS; Farmer, RD; Seaman, HE, 2003
)
0.82
" The combination with drospirenone had less impact on blood pressure than the combination with desogestrel."( A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Buicu, C; Endrikat, J; Gaspard, U; Gerlinger, C; Heithecker, R; Lefebvre, P; Scheen, A, 2003
)
0.32
"d-1) combined with steroid hormones (methyltestosterone 20 mg."( [A beam of dawn light of study on gossypol as a safe, effective, and reversible male antifertility contraceptive--evaluation of the studies by using low dose gossypol combined with steroid hormone for male contraception].
Xue, S, 2000
)
0.31
"To explore the risk of liver disorders associated with cyproterone acetate combined with ethinyloestradiol (CPA/EE)."( The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD.
de Vries, CS; Farmer, RD; Seaman, HE,
)
0.13
"To derive risk estimates for venous thromboembolism (VTE) in women prescribed cyproterone acetate combined with ethinyloestradiol (CPA/EE), a drug licensed in the UK for the treatment of women with acne or hirsutism."( Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.
de Vries, CS; Farmer, RD; Seaman, HE, 2004
)
0.32
"The authors examined the changes in the haemostasis during the use of the oral contraceptive combination with 20 microg ethynil estradiol/150 microg desogestrel at 35 women, a basic group, who used the oral contraceptive in the duration of 12 months and a control group (n=35), who do not use the pills."( [Effect of the monophase oral contraceptive combination with 20 ug ethinyl estradiol/150 ug desogestrel on haemostasis].
Markova, D; Milchev, N; Terzhumanov, R; Uchikova, E, 2004
)
0.56
"Three milligrams of DRSP, a progestogen with antimineralocorticoid activity, was combined with either 30 or 20 microg ethinyl estradiol (EE) (DRSP/30EE; DRSP/20EE) and compared with a preparation containing 150 microg desogestrel (DSG) and 30 microg ethinyl estradiol (DSG/30EE)."( A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Endrikat, J; Gerlinger, C; Heithecker, R; Kluft, C; Mulder, SM, 2006
)
0.74
" An effort is made to relate this information to known clinical drug-drug interactions."( Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Balimane, P; Cui, D; Han, YH; Rodrigues, AD; Sinz, M; Wang, B; Yang, Z; Zhang, H, 2007
)
0.34
"To compare the effects of 3 therapeutic regimens widely used in practice--OHC alone and in combination with metformin or rosiglitazone on body weight and anthropometric proportions, hormonal and metabolic alterations."( [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Atanasova, I; Genchev, G; Kamenov, Z; Khristov, V; Kolarov, G; Milcheva, B; Orbetsova, M; Shigarminova, R; Zakharieva, S, 2006
)
0.33
" Mean plasma concentration-time profiles for atazanavir, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), darunavir (DRV, administered with ritonavir [RTV]), and drospirenone/ethinylestradiol were similar following co-administration of GSK2248761."( Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ, 2012
)
0.38
" The exposure of ethinylestradiol and levonorgestrel was similar when Microgynon® 30 was administered with or without dalcetrapib; for ethinylestradiol the geometric mean ratio %, (90% confidence interval (CI)) for AUC0-24 and Cmax were 92 (86 - 98) and 105 (95 - 115) and for levonorgestrel 92 (88 - 96) and 93 (87 - 99), respectively."( No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Anzures-Cabrera, J; Derks, M; Young, A, 2012
)
0.38
" Thus, the primary objective of this study was to assess the effects on arterial function and structure of an OC containing chlormadinone acetate (2 mg) and ethinylestradiol (30 mcg), alone or combined with spironolactone (OC+SPL), in patients with PCOS."( The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
de Sá, MF; dos Reis, RM; Fernandes, JB; Ferriani, RA; Martins, WP; Soares, GM; Vieira, CS, 2012
)
0.38
"The objective of this study was to evaluate the effect of three contraceptive pills containing ethinylestradiol (EE) (20 or 30 mcg) in combination with drospirenone (DRSP) and levonorgestrel (LNG) on plasma concentration of adhesion molecules vascular cell adhesion molecule -1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin."( Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study.
Franceschini, SA; Fumagalli, HF; Martinez, EZ; Marzocchi-Machado, CM; Stocco, B; Toloi, MR, 2012
)
0.38
"A cross-sectional study was conducted with 72 participants (18-30 years old) distributed into three groups that used oral contraceptives containing EE 20 or 30 mcg combined with DRSP 3 mg or EE 30 mcg/LNG 150 mcg for at least 6 months."( Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study.
Franceschini, SA; Fumagalli, HF; Martinez, EZ; Marzocchi-Machado, CM; Stocco, B; Toloi, MR, 2012
)
0.38
"The aim of this study was to investigate the effects of treatment with drospirenone/ethinyl oestradiol (E/E) alone or in combination with metformin on the elastic properties of the aorta in women with PCOS."( The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Akpek, M; Calapkorur, B; Celik, A; Karaca, Z; Kaya, MG; Kelestimur, F; Unluhizarci, K; Yildirim, S, 2012
)
0.38
" To assess whether the efficacy of a combined oral contraceptive (OC) could be compromised during fingolimod therapy, a steady-state, drug-drug interaction study of fingolimod with ethinylestradiol/levonorgestrel was performed in healthy female volunteers."( Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
David, OJ; den Daas, I; Emotte, C; Jakab, A; Meiser, K; Ocwieja, M; Schmouder, R; Wemer, J, 2012
)
0.38
" Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI study with oral contraceptives (OCs)."( Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
Colburn, D; Colevas, AD; Graham, RA; LoRusso, PM; Low, JA; Malhi, V; Mita, M; Piha-Paul, SA; Yin, M, 2013
)
0.39
"The objective of the study was to evaluate whether treatment with metformin (M) or M combined with oral contraceptive pills (OCPs) resulted in a more advantageous body composition than treatment with OCP alone."( Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Altinok, ML; Andersen, M; Glintborg, D; Hermann, AP; Mumm, H; Ravn, P, 2014
)
0.4
"M treatment alone or in combination with OCP was associated with weight loss and improved body composition compared with OCP, whereas free T levels decreased during M+OCP or OCP."( Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Altinok, ML; Andersen, M; Glintborg, D; Hermann, AP; Mumm, H; Ravn, P, 2014
)
0.4
" Based on these results, a series of clinical drug-drug interaction (DDI) studies were conducted to evaluate the effect of ivacaftor on sensitive substrates of CYP2C8 (rosiglitazone), CYP3A (midazolam), CYP2D6 (desipramine), and P-gp (digoxin)."( Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.
Chavan, AB; Dubey, N; Gilmartin, GS; Higgins, M; Li, C; Luo, X; Mahnke, L; Robertson, SM, 2015
)
0.42
" These are of particular interest since anti-androgenic biological activity has been identified in the aquatic environment and is potentially implicated in sexual disruption alone and in combination with steroid oestrogens."( Environmental concentrations of anti-androgenic pharmaceuticals do not impact sexual disruption in fish alone or in combination with steroid oestrogens.
Brian, J; Green, C; Jobling, S; Kanda, R; Scholze, M; Williams, R, 2015
)
0.42
"The present study was conducted to investigate the influence of the strong CYP3A4 inhibitor ketoconazole (KTZ) on the pharmacokinetics of drospirenone (DRSP) administered in combination with ethinylestradiol (EE) or estradiol (E2)."( Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.
Berse, M; Gschwend, S; Höchel, J; Klein, S; Schütt, B; Wiesinger, H; Zollmann, FS, 2015
)
0.42
"A moderate pharmacokinetic drug-drug interaction between DRSP and KTZ was demonstrated in this study."( Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.
Berse, M; Gschwend, S; Höchel, J; Klein, S; Schütt, B; Wiesinger, H; Zollmann, FS, 2015
)
0.42
"The aim of the study was to evaluate the efficacy of different dosages of estetrol (E4) combined with one of two progestins in suppressing the pituitary-ovarian axis and ovulation in healthy premenopausal women."( Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Appels, N; Coelingh Bennink, HJ; Duijkers, IJ; Foidart, JM; Jost, M; Klipping, C; Maillard, C; Mawet, M; Zimmerman, Y, 2015
)
0.42
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016
)
0.63
" This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg)."( Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.
Kam, J; Leahy, M; Meka, V; Nestorov, I; Sheikh, SI; Zhao, G; Zhu, B, 2017
)
0.85
"This was an open-label, randomized, crossover, drug-drug interaction study conducted over three menstrual cycles in healthy women with regular menses."( Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.
Alami, M; Creasy, G; Han, L; Hoskin, E; Kumar, N; Merkatz, R; Plagianos, M; Roberts, K; Simmons, KB; Variano, B, 2018
)
0.69
"To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance."( Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018
)
0.48
"Diane-35 in combination with orlistat or metformin is more effective in reducing androgen than Diane-35 alone."( Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018
)
0.48
" Migraine predominately affects women of childbearing age; thus, it is important to determine potential drug-drug interactions between a common oral contraceptive and drugs used to treat migraine."( A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
Eisele, O; Gabriel, K; Lee, E; Mikol, DD; Vutikullird, A; Wang, Y; Xu, Y; Zhou, Y, 2019
)
0.51
"We sought to evaluate potential drug-drug interactions between erenumab and a common oral contraceptive."( A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
Eisele, O; Gabriel, K; Lee, E; Mikol, DD; Vutikullird, A; Wang, Y; Xu, Y; Zhou, Y, 2019
)
0.51
"This was a Phase I, open-label, two cohort (n=18/cohort), fixed-sequence study in healthy females that evaluated the drug-drug interaction (DDI) between multiple-dose ATV+COBI or DRV+COBI and single-dose drospirenone/ethinyl estradiol (EE)."( Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Das, M; Kearney, BP; Ling, KH; Majeed, SR; West, S, 2019
)
0.7
"To evaluate the effects of Chinese medicine Dingkun Pill () alone or in combination with Diane-35 on patients with polycystic ovary syndrome (PCOS)."( Is There An Advantage of Using Dingkun Pill () alone or in Combination with Diane-35 for Management of Polycystic Ovary Syndrome? A Randomized Controlled Trial.
Deng, Y; Ma, RL; Ma, X; Sun, AJ; Wang, YF; Xue, W; Zhu, SY, 2020
)
0.56
"To compare the efficacy and the tolerability of letrozole combined with oral contraceptives versus oral contraceptives alone in treating endometriosis-related pain."( Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study.
Luan, X; Wang, Y; Zhao, Y, 2021
)
0.62
" A drug-drug interaction study to evaluate the potential effect of FIL on the pharmacokinetics (PK) of the oral contraceptive levonorgestrel (LEVO)/ethinyl estradiol (EE) was conducted."( Lack of Drug-Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
Ampaw, L; Anderson, K; Begley, R; Kearney, BP; Mathias, A; Qin, A; Watkins, TR; Weng, W, 2021
)
1.03
" Due to its widespread use and CYP3A4-mediated metabolism, there is concern regarding drug-drug interactions (DDIs), particularly a suboptimal LNG exposure when co-administered with CYP3A4 inducers, potentially leading to unintended pregnancies."( Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H, 2021
)
0.62
" We investigated the effects of androgenic properties of progestins combined with ethinyl estradiol (EE) on endothelial function, lipids and free radical production in such women."( Effects of androgenic properties of progestin combined with ethinyl estradiol on vascular endothelial reactivity, plasma lipids and free radical production in women with endometriosis.
Matsushita, H; Noguchi, Y; Sakurada, T; Shinohara, K; Wakatsuki, A; Watanabe, K, 2021
)
1.09
" As women of childbearing potential may be prescribed insomnia drugs, a drug-drug interaction study was conducted."( Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.
Aluri, J; Dayal, S; Filippov, G; Hall, N; Landry, I; Moline, M; Reyderman, L, 2021
)
0.62
"It is widely acknowledged that drug-drug interactions (DDIs) involving estrogen (17α-ethinylestradiol (EE))-containing oral contraceptives (OCs) are important."( Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition.
Rodrigues, AD, 2022
)
0.72
"This was an open-label, two-period, fixed-sequence, drug-drug interaction study."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
0.72
"Hormonal contraceptives are among the most effective forms of reversible contraception, but many other compounds, including some antiretrovirals, have clinically meaningful drug-drug interactions (DDIs) with hormonal contraceptives."( A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
Ankrom, W; Brimhall, D; Fillgrove, KL; Gravesande, KN; Iwamoto, MN; Jackson Rudd, D; Matthews, RP; Stoch, SA; Zhang, S, 2021
)
0.83
"The results of this trial support the use of LNG/EE contraceptives in combination with islatravir without dose adjustment."( A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
Ankrom, W; Brimhall, D; Fillgrove, KL; Gravesande, KN; Iwamoto, MN; Jackson Rudd, D; Matthews, RP; Stoch, SA; Zhang, S, 2021
)
0.83
" It is metabolized via cytochrome P450 (CYP) 3A, but little is known about the drug-drug interactions of JNJ-56136379 when combined with drugs that inhibit or are metabolized by CYP3A."( Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Biermer, M; Biewenga, J; Hillewaert, V; Kakuda, TN; Nangosyah, J; Palmer, M; Rasschaert, F; Snoeys, J; Talloen, W; Vandenbossche, J; Yogaratnam, J, 2022
)
0.72
" Understanding drug-drug interactions (DDIs) is important in individuals taking fostemsavir with hormonal contraceptives or menopausal or gender-affirming hormonal therapies."( Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration.
Ackerman, P; Clark, A; Mageau, AS; Magee, M; Mannino, F; Moore, K; Nwokolo, N; Post, E; Shah, R, 2023
)
1.26
" Therefore, for an investigational drug intended to be used in women with reproductive potential, evaluating its effects on the pharmacokinetics of COCs is important to determine if additional labeling is necessary for managing drug-drug interactions (DDIs) between the concomitant product and the COCs."( Combined Oral Contraceptives As Victims of Drug Interactions.
Li, L; Lu, Y; Seo, SK; Tran, D; Yang, X, 2023
)
0.91

Bioavailability

Lyophilized nanosuspension of poorly soluble Ethinyl estradiol (EE) was fabricated to enhance its solubility and bioavailability using a quality-by-design (QbD) approach. The bioavailability of ethinyl Estradiol was significantly greater in women with cystic fibrosis.

ExcerptReferenceRelevance
" Comparison of the results of the intravenous and oral administration of the steroid suggested that its oral bioavailability is 42%."( An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay.
Back, DJ; Breckenridge, AM; Crawford, FE; MacIver, M; Orme, ML; Rowe, PH; Watts, MJ, 1979
)
0.26
" In addition, the bioavailability of EE, by comparison of its pharmacokinetics after intravenous and oral ingestion, was determined."( An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay.
Back, DJ; Breckenridge, AM; Crawford, FE; MacIver, M; Orme, ML; Rowe, PH; Watts, MJ, 1979
)
0.26
"The bioavailability and pharmokinetics of cyproterone acetate (CA) were studied in 6 healthy young women."( Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 micrograms ethinyloestradiol to 6 young women.
Dogs, G; Hümpel, M; Schulze, PE; Speck, U; Weiss, C; Wendt, H, 1977
)
0.26
" Orally administered NETO was highly bioavailable (84."( Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey.
Hümpel, M; Li, QG,
)
0.13
" The results indicate that OCBZ, like most antiepileptic drugs (AEDs), decreases the bioavailability of EE and LNG, perhaps by affecting metabolism or protein binding."( Possible interaction between oxcarbazepine and an oral contraceptive.
Haring, P; Klosterskov Jensen, P; Menge, GP; Saano, V; Svenstrup, B,
)
0.13
" In both cases, the in vitro mucosal conjugation rose while the in vivo bioavailability fell (4."( The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease.
Back, DJ; Ellis, A; Gilmore, IT; Grimmer, SF; Orme, ML; Tjia, JF, 1992
)
0.28
" Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59."( The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
Back, DJ; Green, S; Orme, M; Ward, S, 1991
)
0.28
"Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2) but different progestins (gestodene and desogestrel, respectively), were compared with respect to the relative bioavailability of EE2."( Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design.
Back, D; Kuhnz, W; Louton, T; Power, J; Schütt, B, 1991
)
0.86
" Blood samples were collected at the end of each treatment month, assayed for EE and the half-life of elimination (Tel) and bioavailability (area under the serum concentration-time curve, AUC) calculated."( Intrasubject variability in the pharmacokinetics of ethynyloestradiol.
Fotherby, K, 1991
)
0.28
" It is concluded that the combination of ethinylestradiol with cholesterol forming an eutectic mixture, when administered orally to normal women, modulates the absorption and the bioavailability of the EE."( Absorption of oral ethinylestradiol is delayed by its eutectic mixture with cholesterol.
Antúnez, O; Boeck, L; Díaz-Sánchez, V; Noguera, M; Vargas, L, 1991
)
0.28
"Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2) but different progestins (gestodene and desogestrel, respectively), were compared with respect to the relative bioavailability of EE2."( Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design.
Gansau, C; Hümpel, M; Kuhnz, W; Louton, T; Schütt, B; Steinberg, B, 1990
)
0.81
" Ethinyl estradiol (mean systemic bioavailability 40% to 50%) is extensively metabolized, principally to a sulfate conjugate."( Gastrointestinal metabolism of contraceptive steroids.
Back, DJ; Madden, S; Orme, ML, 1990
)
1.19
" Studies on kinetics and bioavailability showed that after oral administration of EE 3-sulfate only about 20% appeared as free EE in the blood, while EE 17-sulfate produced about half this amount."( Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications.
Goldzieher, JW, 1990
)
0.28
"The bioavailability of 17 alpha-ethinyloestradiol was determined after intravenous, nasal, and intraduodenal, administration in the rat."( Nasal absorption of 17 alpha-ethinyloestradiol in the rat.
Bawarshi-Nassar, RN; Crooks, PA; Hussain, A, 1989
)
0.28
"The influence of three diets (olestra, triglyceride oil, and water) on the bioavailability of a single dose of propranolol, diazepam, norethindrone, and ethinyl estradiol was evaluated."( Influence of absorbable and nonabsorbable lipids and lipidlike substances on drug bioavailability.
Leff, RD; Roberts, RJ, 1989
)
0.48
" Bioavailability ranged between 40."( Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
Back, DJ; Grimmer, SF; Orme, ML; Shenoy, N, 1987
)
0.27
" Bioavailability was calculated as the ratio of area under the plasma concentration time curve of the oral to the area under the curve of the iv dose."( Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
Back, DJ; Grimmer, SF; Orme, ML; Shenoy, N, 1987
)
0.27
"The bioavailability of ethinyloestradiol and levonorgestrel has been studied in 5 young women with an ileostomy following surgery for ulcerative colitis and compared to that in 5 control subjects."( The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy.
Back, DJ; Cowie, A; Gilmore, I; Grimmer, SF; Orme, ML; Tjia, J, 1986
)
0.27
"The bioavailability of contraceptive steroids was studied in 12 women who were given an antacid and a contraceptive pill simultaneously."( Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
Joshi, JV; Joshi, UM; Sankolli, GM; Shah, RS, 1986
)
0.27
" Apparently, self-dosing with this antacid will not affect bioavailability of oral contraceptive steroids."( Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
Joshi, JV; Joshi, UM; Sankolli, GM; Shah, RS, 1986
)
0.27
"The relative bioavailability of levonorgestrel (LNG) and ethinyl estradiol (EE) administered concomitantly both as an oral tablet and as a solution was assessed in a randomized two-period crossover study in 24 healthy women."( The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive.
Chiang, S; Goebelsmann, U; Hoffman, D; Woutersz, T, 1986
)
0.77
"The relative bioavailability of levonorgestrel (LNG) and ethinyl estradiol (EE) administered concomitantly both as an oral tablet and as a solution was assessed in a randomized 2-period crossover study in 24 healthy women."( The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive.
Chiang, S; Goebelsmann, U; Hoffman, D; Woutersz, T, 1986
)
0.77
" In addition, the oral bioavailability of ethinyloestradiol was greater in women with cystic fibrosis than in controls (76."( Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
Back, DJ; Batten, JC; Grimmer, SF; Hodson, ME; Orme, ML; Rogers, SM; Stead, RJ, 1987
)
0.27
" The bioavailability of ethinyl estradiol was significantly greater in women with cystic fibrosis (76."( Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
Back, DJ; Batten, JC; Grimmer, SF; Hodson, ME; Orme, ML; Rogers, SM; Stead, RJ, 1987
)
0.58
"The relative bioavailability of levonorgestrel (LNG) and ethinylestradiol (EE2) administered as a conventional tablet (150/30) or capsule has been assessed in a randomized two-period crossover study in 9 healthy volunteer women."( The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form.
Back, DJ; Cohen, M; Elstein, M; Killick, SR; Shenoy, N; Stevenson, PJ, 1987
)
0.27
"9 female volunteers, aged 18-38 years participated in this study contrasting the bioavailability of levonorgestrel (LNG) and ethinylestradiol (EE2)."( The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form.
Back, DJ; Cohen, M; Elstein, M; Killick, SR; Shenoy, N; Stevenson, PJ, 1987
)
0.27
"This study assessed the bioavailability of vaginally administered ethinyl estradiol (EE) and determined the effects of 2 different doses of oral and vaginal EE of comparable bioavialability on serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations as well as on corticosteroid-binding globulin binding capacity (CBG-BC), sex hormone-binding globulin capacity (SHBG-BC), high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol, and triglycerides."( Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
Goebelsmann, U; Mashchak, CA; Mishell, DR, 1985
)
0.74
" Thus the distribution of synthetic steroids between various protein bound and nonprotein bound components in serum may influence their bioavailability at different target tissues."( Distribution and percentages of non-protein bound contraceptive steroids in human serum.
Hammond, GL; Lähteenmäki, P; Lähteenmäki, PL; Luukkainen, T, 1982
)
0.26
" Also it appears that individual differences in CPA bioavailability do not satisfactorily explain the lack of therapeutic response in about 30% of the cases."( Antiandrogens in the treatment of acne and hirsutism.
Hammerstein, J; Moltz, L; Schwartz, U, 1983
)
0.27
" The pharmacokinetics and bioavailability of NET remain unchanged during early pregnancy."( Norethisterone acetate and ethinylestradiol in early human pregnancy.
Düsterberg, B; Hasan, H; Kivikoski, A; Laajoki, V; Pulkkinen, MO, 1984
)
0.27
" The absorption rate constant (ka) and peripheral to central compartment transfer rate constant (k21) were similar for NET and EE2, but statistically significant differences were observed with respect to the distribution rate constant (alpha), the central to peripheral transfer rate constant (k12), the overall elimination rate constant (ke1), and volume of distribution (V1/F)."( Plasma levels and pharmacokinetics of norethindrone and ethinylestradiol administered in solution and as tablets to women.
Goebelsmann, U; Henzl, M; Ling, T; Miyakawa, I; Mroszczak, EJ; Runkel, R; Stanczyk, FZ, 1983
)
0.27
" Chronic treatment with dapsone does not appear to reduce the bioavailability of NET or EE."( Norethisterone and ethinyl estradiol kinetics during dapsone therapy.
Bhatki, S; Joshi, JV; Joshi, UM; Maitra, A; Sankolli, G, 1984
)
0.6
" Wide variations such as the 10-fold variation in bioavailability and elimination rate may have important consequences, particularly with the reduction during the past few years in the daily dose of OCs."( Pharmacokinetics of ethynyloestradiol in humans.
Fotherby, K, 1982
)
0.26
" Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose."( The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette.
Back, DJ; Bates, M; Breckenridge, AM; Hall, JM; MacIver, M; Orme, ML; Park, BK; Rowe, PH, 1981
)
0.26
" With reference to the present efforts to reduce the hormone content of the pill, 3 factors which influence the bioavailability of these substances are of great importance."( [Oral contraceptives. Clinical pharmacology, pharmacokinetics and drug interactions (author's transl)].
Staiger, C, 1982
)
0.26
" Increased bioavailability may help in devising future formulations with a lesser amount of progestogen while still maintaining similar efficacy."( The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
Elstein, M; Fahmy, DR; Nuttall, ID, 1982
)
0.53
" The bioavailability of orally administered EE2 was about 60%, confirming the presence of a substantial first-pass effect."( The pharmacokinetics and metabolism of ethinyl estradiol and its three sulfates in the baboon.
Castracane, VD; Goldzieher, JW; Moore, PH; Newburger, J; Williams, MC, 1983
)
0.54
" Its oral bioavailability is about 33% after administration of 30 or 100 micrograms to healthy volunteers and slightly lower than that of ethynyl estradiol (50%) due to a "first-pass effect"."( Pharmacokinetics and metabolism of moxestrol in humans.
Coussediere, D; Cousty, C; Raynaud, JP; Salmon, J, 1983
)
0.27
" The bioavailability of norethisterone and ethinyl estradiol (EE) is incomplete when drugs are given orally as opposed to intravenously."( The third S.K. & F. Prize lecture, University of London, December 1981. The clinical pharmacology of oral contraceptive steroids.
Orme, ML, 1982
)
0.53
" Vaginal administration apparently increases the bioavailability of EE; it does not facilitate a selective reduction of estrogenic effects upon the liver."( Vaginal administration of ethinylestradiol: effects on ovulation and hepatic transcortin synthesis.
Hammerstein, J; Moltz, L; Schneller, E; Schwartz, U, 1982
)
0.26
" The data indicate, that intestinal absorption of ethinylestradiol involves several superimposed kinetics and that glucuronidation in the gut may result in a decreased bioavailability of the compound."( First pass biotransformation of ethinylestradiol in rat small intestine in situ.
del Pino, VL; Remmer, H; Schiemenz, C; Schwenk, M, 1982
)
0.26
" However, use of standard equations to predict the oral bioavailability of drugs known to be metabolized by hepatic first pass resulted in significantly higher values than those obtained experimentally."( First-pass metabolism of ethinyl estradiol in dogs and rats.
Haddadin, M; Hirai, S; Hussain, A; Smith, RB, 1981
)
0.57
" Bioavailability as measured by the area under the serum ethynyloestradiol concentration-time curve also showed more than a ten-fold variation."( Pharmacokinetics of ethynyloestradiol in women for different populations.
Abdel-Rahman, HA; Akpoviroro, J; Brenner, PF; Chan, T; Coutinho, EM; de Souza, JC; Dozier, TS; Fotherby, K; Goldzieher, JW; Gomez-Rogers, C; Gopalan, S; Grech, ES; Gual, C; Hickey, MV; Kim, SW; Koetsawang, S; Kwon, E; Landgren, BM; Lichtenberg, R; Mapa, MK; Molina, R; Nukulkarn, P; Plunkett, ER; Ratnam, SS; Shearman, RP; Sheth, UK; Toppozada, HK, 1981
)
0.26
" Basic pharmacokinetic parameters of levonorgestrel were calculated and from the ratio of the AUC values obtained after both administrations, the bioavailability of norgestimate-derived levonorgestrel was calculated."( Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women.
Blode, H; Kuhnz, W; Mahler, M, 1994
)
0.29
"Our purpose was to determine the relationship between bioavailability of contraceptive steroids and bleeding patterns."( A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
Bell, WK; Burkman, RT; Kimball, AW; Kwiterovich, P; Saleh, WA; Zacur, HA, 1993
)
0.29
" Bioavailability of both contraceptive steroids as measured by baseline values and 1-hour slopes did not correlate with bleeding patterns at 3, 6, and 9 months of use."( A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels.
Bell, WK; Burkman, RT; Kimball, AW; Kwiterovich, P; Saleh, WA; Zacur, HA, 1993
)
0.29
"Oral therapy with natural or synthetic estrogens, like ethinylestradiol, suffers from low, suboptimally defined bioavailability and excess hepatic estrogen actions."( Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application.
Elger, W; Hedden, A; Reddersen, G; Schneider, B; Schwarz, S, 1995
)
0.29
"The effects of grapefruit juice on the bioavailability of 17 alpha-ethinylestradiol (EE2) after a single oral administration of 50 micrograms EE2 have been investigated."( Can grapefruit juice influence ethinylestradiol bioavailability?
Balogh, A; Börner, A; Jäger, R; Klinger, G; Matthey, K; Vollanth, R; Weber, A, 1996
)
0.29
" In particular, our objective was to examine whether one or both compounds were characterized by an improved oral bioavailability with less inter-subject variability than EE2."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" Specifically, they examined whether one or both of the new estrogens improved bioavailability with less inter-subject variability than EE2."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" After compartmental (two-compartment open model) and noncompartmental analyses of plasma concentrations, statistical analysis revealed that the presence of fiber (both A and B) decreased between 29% and 35% the extent of EE absorbed (represented by the pharmacokinetic parameters area under the curve and the maximum plasma concentration) without affecting the rate of the absorption process (represented by the time to reach maximum concentration and the absorption rate constant)."( Influence of two commercial fibers in the pharmacokinetics of ethinylestradiol in rabbits.
Calle, AP; Diez, MJ; Fernández, N; García, JJ; Sierra, M; Terán, MT, 1998
)
0.3
" With the use of the highly accurate and specific technique of IDMS it can now be unequivocally established that the different progestins in the tested oral contraceptives have no influence on the bioavailability of EE2 (area under EE2 serum concentration curves, as usually defined in pharmacokinetics)."( Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives--results of isotope dilution mass spectrometry measurements.
Albring, M; Bidlingmaier, F; Brill, K; Siekmann, A; Siekmann, L, 1998
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"Stimulated nitric oxide bioavailability remained unaffected in a group of premenopausal women receiving oral contraceptives."( Effects of oral contraceptives on vascular endothelium in premenopausal women.
Delles, C; Jacobi, J; John, S; Schlaich, MP; Schmieder, RE, 2000
)
0.31
" In comparison with the DSG/EE COC, the absolute bioavailability for NuvaRing was higher for etonogestrel (102."( Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
Mulders, TM; Timmer, CJ, 2000
)
0.31
" When psyllium was administered, the extent of EE absorbed increased slightly and the rate of absorption was slower."( Influence of two dietary fibers in the oral bioavailability and other pharmacokinetic parameters of ethinyloestradiol.
Alonso, ML; Calle, AP; Diez, MJ; Fernández, N; García, JJ; González, A; Prieto, C; Sahagún, A; Sierra, M, 2000
)
0.31
" Differences between therapeutically equivalent and brand-name, low-dose oral contraceptives, with respect to the bioavailability of hormones, may interfere with contraceptive efficacy and increase breakthrough bleeding."( Low-dose oral contraceptives: health consequences of discontinuation.
Ansbacher, R, 2000
)
0.31
"Using steady-state conditions we aimed to test if administration of oral activated charcoal affects the bioavailability of norethisterone acetate (NET Ac) and gestodene (GEST) by inhibiting their enterohepatic recirculation."( The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
Elomaa, K; Lähteenmäki, P; Ranta, S; Tuominen, J, 2001
)
0.31
" Nevertheless, it is argued that this technique for determining ethinyl estradiol in human plasma will be a valuable tool for comparing bioavailability of different oral contraceptive drugs."( Monitoring of the oral contraceptive 17-alpha-ethinyloestradiol-17 beta in human plasma by isotopic-dilution mass spectrometry.
Breuer, H; Siekmann, A; Siekmann, L, 1978
)
0.5
" The nasal and sublingual modes of administration rapidly convert estradiol into estrone, while the absorption rate through the cutaneous mode is even quicker, and subcutaneous implantation guarantees constant plasmatic levels for about 6 months."( [What happens in our patients' bodies to the steroid hormones we prescribe? Pt. 1. Estrogens].
Rozenbaum, H, 1981
)
0.26
"As part of the development of a combination product containing norethindrone acetate and low-dose ethinyl estradiol for continuous hormone replacement therapy in postmenopausal women, a study was conducted to determine the effect of a high-fat meal on the bioavailability of norethindrone and ethinyl estradiol from tablets containing 1 mg norethindrone acetate/10 micrograms ethinyl estradiol."( The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy.
Boyd, RA; Eldon, MA; Zegarac, EA, 2003
)
0.78
" Because ENG bioavailability was higher following vaginal administration, the systemic progestogen exposures were comparable with the two contraceptives."( Complete and robust ovulation inhibition with NuvaRing.
Killick, S, 2002
)
0.31
"Contraception is recommended for female patients during ursodeoxycholic acid (UDCA) treatment for the potential teratogenic effect of this bile acid, and the aim of our study was to determine whether this treatment affects the bioavailability of ethinylestradiol (EE2)."( Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.
Baisini, O; Benini, F; Brunetti, G; Kuhnz, W; Lanzini, A; Marschall, HU; Petraglia, F; Scalia, S; Tauschel, HD, 2004
)
0.32
"Co-administration with UDCA does not affect the bioavailability of EE2 in healthy volunteers, indicating that contraceptive efficacy is not affected."( Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.
Baisini, O; Benini, F; Brunetti, G; Kuhnz, W; Lanzini, A; Marschall, HU; Petraglia, F; Scalia, S; Tauschel, HD, 2004
)
0.32
"To the beneficial properties of dietary fiber in human health, several disadvantages can be added as the possible modification of the bioavailability of other drugs when administered by the oral route."( Effect of glucomannan and the dosage form on ethinylestradiol oral absorption in rabbits.
Castro, LJ; Diez, MJ; Fernández, N; García, JJ; González, A; Sahagún, A; Sierra, M, 2004
)
0.32
"The impact of intestinal conjugative metabolism on oral bioavailability was assessed by sequential and simultaneous analyses of the reported data in humans."( Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans.
Hayashi, M; Kawashima, K; Mizuma, T; Sakaguchi, S; Sakai, S, 2005
)
0.33
"Separate crossover studies compared the bioavailability of oral vs."( Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration.
Hahn, PM; Kives, S; Reid, RL; Stanczyk, FZ; White, E, 2005
)
0.33
"05), suggesting that EE2 bioavailability to the fish was likely greater under less-turbid water conditions."( Effects of eutrophication on vitellogenin gene expression in male fathead minnows (Pimephales promelas) exposed to 17alpha-ethynylestradiol in field mesocosms.
Campbell, S; deNoyelles, F; Gordon, DA; Graham, DW; Knapp, CW; Lattier, DL; Lazorchak, JM; Reddy, TV; Toth, GP, 2006
)
0.33
"3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), the 7alpha-fluorine analog of hyodeoxycholic acid (HDCA), was synthesized to improve bioavailability and stability of ursodeoxycholic acid (UDCA)."( 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
Asciutti, S; Baldoni, M; Camaioni, E; Castellani, D; Clementi, M; Clerici, C; Fiorucci, S; Giuliano, V; Mazzocchi, A; Morelli, A; Morelli, O; Nardi, E; O'Connell, NC; Orlandi, S; Pellicciari, R; Renga, B; Sabatino, G; Sadeghpour, B; Setchell, KD, 2006
)
0.33
"This study aimed to develop ultraflexible liposomes as an alternative to the oral route, which would enhance the bioavailability and reduce the toxicity of ethinylestradiol."( Ethinylestradiol-loaded ultraflexible liposomes: pharmacokinetics and pharmacodynamics.
Agashe, H; Garg, M; Jain, NK; Mishra, D, 2006
)
0.33
" In other pharmacokinetic parameters, clearance (CL) remained unchanged; however, there was decrease in bioavailability (F) and volume of distribution (V(d)) in some situations."( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats.
Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006
)
0.33
" In addition, the 90% CI for the bioavailability contrasts (OC alone vs OC with rifaximin) for the maximum plasma concentration, area under the plasma concentration-time curve from zero to the last measurable plasma concentration or to infinity for EE, NG, and 17-DNGM all ranged from 86-118%."( Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
Bettenhausen, DK; Connolly, M; Forbes, WP; Pentikis, H; Trapnell, CB, 2007
)
0.58
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" The study was conducted to investigate the relative bioavailability and pharmacokinetic parameters of EE and drsp after oral administration of EE-betadex clathrate/drsp."( Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Benda, N; Blode, H; Schürmann, R, 2008
)
0.83
"The relative bioavailability of EE and drsp after EE-betadex clathrate/drsp tablet administration was comparable with that achieved with the EE/drsp tablet (107% and 101%, respectively)."( Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Benda, N; Blode, H; Schürmann, R, 2008
)
0.83
"The betadex clathrate formulation of EE, when combined with DRSP, does not affect the pharmacokinetics and relative bioavailability of either EE or drsp."( Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
Benda, N; Blode, H; Schürmann, R, 2008
)
0.83
" Furthermore, serum and the interstitial peritendinous tissue concentrations of insulin-like growth factor I (IGF-I) and IGF-binding proteins showed a reduced bioavailability in HE-OC compared with results in LE-NOC."( Ethinyl oestradiol administration in women suppresses synthesis of collagen in tendon in response to exercise.
Doessing, S; Flyvbjerg, A; Frystyk, J; Hansen, M; Kjaer, M; Koskinen, SO; Langberg, H; Magnusson, SP; Petersen, SG; Westh, E, 2008
)
0.35
"1 mL g(-1)) this apparently did not control estrogen bioavailability since it showed no effects on hormone mineralization."( Factors controlling the biodegradation of 17beta-estradiol, estrone and 17alpha-ethinylestradiol in different natural soils.
Marschner, B; Stumpe, B, 2009
)
0.35
" Because ENG bioavailability was higher following vaginal administration, the systemic progestogen exposures were comparable with the oral contraceptives."( [NuvaRing-combined contraceptive vaginal ring: state of art in 2008. Expert Board of Polish Gynecological Society].
Debski, R; Kotarski, J; Paszkowski, T; Pawelczyk, L; Skrzypulec, V; Tomaszewski, J, 2008
)
0.35
"The bioavailability and bioequivalence of two different film coated tablets containing ethinylestradiol (CAS 57-63-6) and chlormadinone acetate (CAS 302-22-7) (Bellissima as test and the respective preparation from the originator as reference) were investigated in 20 healthy female volunteers after oral single-dose administration."( Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
Barkworth, M; Bonn, M; Eydeler, U; Rovati, LC, 2009
)
0.35
"We studied whether in young nonobese women with PCOS (15 subjects, EE30+CMA-PCOS group) a six-cycle treatment with EE30+CMA can reduce androgen levels, androgen bioavailability and the score of hirsutism and acne, and modify glucose-insulin metabolism evaluated by the oral glucose tolerance test and the body composition evaluated by bio-impedenziometry."( Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
Etzi, R; Guerriero, S; Lello, S; Marotto, MF; Melis, GB; Orrù, M; Pani, F; Paoletti, AM; Pilloni, M; Sorge, R; Uras, R; Zedda, P, 2010
)
0.36
" Our goal was to evaluate the association of a model contaminant [17α-ethinylestradiol (EE2)] with nC(60) and determine bioavailability of EE2 after accumulation by a filter feeding organism [Brine shrimp (BS) Artemia sp."( No bioavailability of 17α-ethinylestradiol when associated with nC60 aggregates during dietary exposure in adult male zebrafish (Danio rerio).
Compton, RN; Henry, TB; Menn, FM; Park, JW; Sayler, G, 2010
)
0.36
"Manufactured nanoparticles (NPs) released into surface waters will associate with other substances and these interactions may affect environmental fate and bioavailability of NPs and the associated substances."( The association between nC60 and 17α-ethinylestradiol (EE2) decreases EE2 bioavailability in zebrafish and alters nanoaggregate characteristics.
Ard, S; Compton, RN; Henry, TB; Menn, FM; Park, JW; Sayler, GS, 2011
)
0.37
" No clinically relevant reduction in bioavailability of ethinyl estradiol/levonorgestrel occurred."( Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Hindsberger, C; Jacobsen, LV; Vouis, J; Zdravkovic, M, 2011
)
0.83
" The pharmacolokinetic and pharmacodynamic properties of these estrogens are compared to those of EE (absorption, metabolization, bioavailability etc."( Pharmacological profile of estrogens in oral contraception.
Bitzer, J, 2011
)
0.37
" Moreover, the area under the curve of EE and MPA revealed an increase in bioavailability after transdermal administration as compared to oral route."( Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats.
Agrawal, SS; Pruthi, JK, 2011
)
0.37
"Consistent with its effect on gastric emptying, exenatide, an injectable treatment for type 2 diabetes, may slow the absorption rate of concomitantly administered oral drugs resulting in a decrease in maximum concentration (Cmax)."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"Exenatide did not alter the bioavailability nor decrease daily trough concentrations for either oral contraceptive component."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"The observed reduction in Cmax is likely of limited importance given the unaltered oral contraceptive bioavailability and trough concentrations; however, for oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before exenatide injection."( Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
Kothare, PA; Linnebjerg, H; Mace, K; Mitchell, MI; Northrup, J; Seger, ME, 2012
)
0.38
"The bioavailability of EE and drospirenone was similar after administration of EE/drospirenone/levomefolate calcium and EE/drospirenone."( Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
Blode, H; Diefenbach, K; Eydeler, U; Richard, F; Rohde, B; Trummer, D; Wiesinger, H, 2012
)
0.38
" For further improvement of the in vitro to in vivo predictive value of in vitro assays, the relevance of other kinetic characteristics should be studied, including binding to carrier proteins, oral bioavailability and the formation of estrogenic metabolites."( Effect of combining in vitro estrogenicity data with kinetic characteristics of estrogenic compounds on the in vivo predictive value.
Brand, W; Heringa, MB; Murk, AJ; Punt, A; Schriks, M; van Wezel, AP, 2013
)
0.39
" This study evaluated the relative bioavailability of EE and GSD after application of this patch to three different sites."( Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
Höchel, J; Ludwig, M; Schuett, B; Zurth, C, 2014
)
0.61
" The primary objective was to investigate the relative bioavailability of transdermally administered EE and GSD between test and comparator sites using the primary variable area under the concentration- time curve (AUC(0-168)) during week 4 of each period."( Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
Höchel, J; Ludwig, M; Schuett, B; Zurth, C, 2014
)
0.61
" The sorption-limited bioavailability of EE2, which is inherently resistant to biodegradation due to chemical structure, as MAX and Freundlich sorption coefficients (Kf) were negatively correlated."( 17 β-estradiol and 17 α-ethinylestradiol mineralization in sewage sludge and biosolids.
Ascef, B; Claeys, A; Farenhorst, A; Rose, KP, 2014
)
0.4
"To determine the relative bioavailability of ethinyl estradiol (EE) and gestodene (GSD) after application of a novel transdermal contraceptive patch vs."( Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.
Hofmann, B; Merz, M; Reinecke, I; Schuett, B; Zurth, C, 2014
)
0.96
"The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D), on the bioavailability of a combined oral contraceptive was investigated."( Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
Flint, A; Hartvig, H; Jensen, CB; Jensen, L; Kapitza, C; Nosek, L, 2015
)
0.42
" The very poor solubility and wettability of these drugs, along with their high potency (adsorption issues), give rise to difficulties in designing intravenous (IV) formulations to assess absolute bioavailability of products containing both drugs."( Norelgestromin/ethinyl estradiol intravenous infusion formulation optimization, stability and compatibility testing: A case study to overcome polysorbate 80 interference in chromatographic analysis.
Abdallah, IA; Hammell, DC; Hassan, HE; Stinchcomb, AL, 2016
)
0.79
"Coadministration of SYM-1219 and EE2/NET, either on the same day or 1 day apart, had no clinically relevant effects on the bioavailability of EE2 or NET."( Lack of a Pharmacokinetic Interaction Between SYM-1219 Granules Containing 2 Grams of Secnidazole and a Combined Oral Contraceptive in a Phase 1, Randomized, Open-Label Study in Healthy Female Volunteers.
Adetoro, N; Braun, CJ; Pentikis, HS, 2017
)
0.46
" The effects of photobleaching on the composition, photosensitizing property and bioavailability of HA were investigated here along with the subsequent influence on its photochemical and biological reactivity in mediating 17α-ethynylestradiol (EE2) degradation."( Photobleaching alters the photochemical and biological reactivity of humic acid towards 17α-ethynylestradiol.
Chen, F; Dionysiou, DD; Huang, B; Pan, X; Ren, D; Yang, B, 2017
)
0.46
" The objective of this study was to examine the bioavailability and bioactivity of ethinyl estradiol (EE2) sorbed onto SWCNTs in a fish gastrointestinal (GI) tract."( Influence of the Gastrointestinal Environment on the Bioavailability of Ethinyl Estradiol Sorbed to Single-Walled Carbon Nanotubes.
Bisesi, JH; Castillo, B; Crosby, H; Das, D; Denslow, ND; Ferguson, PL; Lavelle, CM; Liu, K; Ngo, T; Plazas-Tuttle, J; Robinson, SE; Sabo-Attwood, T; Saleh, NB, 2017
)
0.91
" The general aim of this study was to evaluate the effects of biosolid application on EE2 and TCS adsorption and bioavailability in soils through testing with wheat plants."( Effects of applying biosolids to soils on the adsorption and bioavailability of 17α-ethinylestradiol and triclosan in wheat plants.
Ahumada, I; Ascar, L; Brown, S; Cantarero, R; Richter, P, 2017
)
0.46
" We measured the bioavailability of nitric oxide (NO), a main mediator of vascular homeostasis in a cohort of young female subjects (n=114) and compared the results in users or not of CPs containing ethinyl estradiol and synthetic progestogens."( Heme-nitrosylated hemoglobin and oxidative stress in women consuming combined contraceptives. Clinical application of the EPR spectroscopy.
Balligand, JL; Beauloye, C; Dei Zotti, F; Lobysheva, II; Pothen, L; Rifahi, A; van Eeckhoudt, S, 2017
)
0.64
" EC508 might offer significant advantages in indications like fertility control and HRT based on its high oral bioavailability and lack of hepatic estrogenicity."( A prodrug design for improved oral absorption and reduced hepatic interaction.
Ahmed, G; Elger, W; Meece, F; Nair, HB; Nickisch, K; Schneider, B; Wyrwa, R, 2017
)
0.46
" Although the marketed product of CMA as oral tablets under the trade name Belara® has been highly successful, there is still room for further improvements in oral bioavailability and a reduction in the clinical dose to decrease related adverse effects."( Enhanced Oral Bioavailability of Chlormadinone Acetate through a Self-Microemulsifying Drug Delivery System for a Potential Dose Reduction.
Cao, Y; Chen, J; Chen, L; Huang, T; Zeng, J; Zheng, W, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Doses were scaled from human doses to account for differences in bioavailability and body weight, and OCs were administered daily via oral gavage for 4 rat estrous cycles (20 days)."( The Effect of Oral Contraceptive Hormones on Anterior Cruciate Ligament Strength.
Chang, W; Dragoo, JL; Hsue, L; Konopka, JA; Thio, T, 2020
)
0.56
"Lyophilized nanosuspension of poorly soluble Ethinyl estradiol (EE) was fabricated to enhance its solubility and bioavailability using a quality-by-design (QbD) approach."( QbD Based Approach to Enhance the In-Vivo Bioavailability of Ethinyl Estradiol in Sprague-Dawley Rats.
Hajare, AA; Powar, TA, 2020
)
1.06
" As a competitor of SHBG-androgen binding, EE2 could bind with SHBG and increase the bioavailability of androgen."( Dietary Intake of 17α-Ethinylestradiol Promotes HCC Progression in Humanized Male Mice Expressing Sex Hormone-Binding Globulin.
Heo, JH; Hong, EJ; Jeong, SH; Jo, SL; Ko, JW; Kwun, HJ; Lee, SR, 2021
)
0.62

Dosage Studied

Ethinyl estradiol (EE), at a dosage of 5 mg/day for 5 consecutive days (5 mg EE) has generally been used for interception. Tenofovir DF did not affect the steady-state pharmacokinetics of norgestimate or ethinyl Estradiol, including the concentration at the end of the dosing interval.

ExcerptRelevanceReference
"The type of distribution of low dosage drugs that occurs in batches of commercially available tablets has been examined."( Content uniformity of potent drugs in tablets.
Orr, NA; Sallam, EA, 1978
)
0.26
"The effects of two differing dosage schedules of ethinyloestradiol and levonorgestrel, taken cyclically as oral contraceptives, on blood pressure, body mass, blood glucose and serum triglycerides were measured."( The effect of cyclical administration of levonorgestrel and ethinyloestradiol on blood pressure, body mass, blood glucose and serum triglycerides.
Bloch, B, 1979
)
0.26
" Levels of the 3 parameters were unaffected by dosage of the new progestin."( Effect of oral contraceptive containing a new progestin (ORG 2969) on plasma renin activity, growth hormone and immunoreactive insulin.
Erkkola, R; Lammintausta, R; Liukko, P, 1979
)
0.26
" Type and dosage of estrogen were unrelated to endometrial malignancy."( Estrogens, progestogens and endometrial cancer.
Gambrell, RD, 1977
)
0.26
" Requisites of such therapy are a through history to establish a real need, a complete gynecologic examination with a Pap smear before therapy begins and annually afterward, use of the smallest daily dose of estrogen that gives the desired effect, and periodic attempts to reduce the dosage or stop the hormone."( Estrogens for the menopause. Maximizing benefits, minimizing risks.
Seller, JC, 1977
)
0.26
" Over the dosage range studied, the effects of the two kinds of estrogen were indistinguishable."( Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Chenault, CB; de la Peña, A; Dozier, TS; Goldzieher, JW; Kraemer, DC, 1978
)
0.26
" Effects of the 2 kinds of estrogens were indistinguishable over the dosage range studied."( Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Chenault, CB; de la Peña, A; Dozier, TS; Goldzieher, JW; Kraemer, DC, 1978
)
0.26
" The two oral contraceptive dosage forms studied produced qualitatively and quantitatively similar metabolic changes."( Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
Cornish, EJ; Hain, R; Nash, AL, 1979
)
0.26
" In both studies, the 2 oral contraceptive dosage forms had similar metabolic quantitative and qualitative changes: both resulted in an increase in serum concentration of triglycerides (30 to 33%), B-lipoproteins (27 to 29%), and ceruloplasmin (75 to 90%), and a decrease in serum levels of antithrombin 3 (22 to 29%) and ascorbic acid (30 to 42%)."( Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
Cornish, EJ; Hain, R; Nash, AL, 1979
)
0.26
" Each dosage increase improved cycle control and lessened bleeding irregularities."( Low-dose combination oral contraceptives: a controlled clinical study of three different norgestrel-ethinyl estradiol ratios.
Arnt, IC; Ferrari, A; Sartoretto, JN; Woutersz, TB, 1977
)
0.47
" A total of 1,991 patients were studied for more than two years while they were receiving various dosage combinations of these steroids."( Optimum dosage of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol.
Lawson, JS; Osterman, JJ; Pasquale, SA; Yuliano, SE, 1979
)
0.47
"Ethinylestradiol sulphate (J 96) is a depot estrogen which in a dosage of 2 mg per week has clearly antigonadotropic effects and evokes a suppression of the free testosterone in bilaterally orchiectomized patients with carcinoma of the prostate."( [Initial experience with ethinyl estradiol sulfonate (J 96) in the therapy of prostate carcinoma].
Dörner, G; Guddat, HM; Rohde, W; Schnorr, D; Stahl, F, 1979
)
0.56
" The occurrence of a secondary peak in plasma at around 12 hours after dosing gave strong evidence that EE undergoes enterohepatic circulation in women; an event that may have considerable clinical significance."( An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay.
Back, DJ; Breckenridge, AM; Crawford, FE; MacIver, M; Orme, ML; Rowe, PH; Watts, MJ, 1979
)
0.26
" This dosage schedule called for 4 tablets over 12 hours, and the clinician claims that this schedule avoids some of the semantic difficulties associated with the usual treatment of 50-60 tablets of estrogen over 5 days."( An alternative to the use of high-dose estrogens for postcoital contraception.
Schilling, LH, 1979
)
0.26
"This study determined whether a reduction in ethinyl estradiol (EE) dosage from 50-30 mcg was associated with any change in biological features of estrogenic effects in the genital tract (karyopyknotic index, ferning, spinnbarkeit, volume, and clarity of cervical mucus) or biochemical effects (ceruloplasmin and sex hormone binding globulin)."( Some estrogenic effects of two oral contraceptives consisting of norgestrel and two different doses of ethynylestradiol.
Bye, PG; Elstein, M; Fotherby, K; Miller, JF, 1979
)
0.52
" About 75% of dosed radioactivity was excreted in feces largely via bile and more than 20% in urine within 72 hr after administration."( [Absorption, distribution, excretion and metabolism of SC-11800EE, a combined steroid preparation of SC-11800 (ethynodiol diacetate) and ethinyl estradiol in rats and mice (author's transl)].
Furukawa, H; Hashimoto, M; Miyazaki, H; Suzuki, H, 1977
)
0.46
" Because of the low dosage of active ingredients the authors consider Ovoresta M a welcome supplement to the existing oral contraceptives."( [Clinical aspects of a new, very low dose combination contraceptive].
Grcić, R; Kapor, M; Mladenović, D; Pestelek, B, 1978
)
0.26
" Because of the low dosage of active ingredients the authors consider Ovoresta M a welcome supplement to existing oral contraceptives."( [Clinical aspects of a new, very low dose combination contraceptive].
Grcić, R; Kapor, M; Mladenović, D; Pestelek, B, 1978
)
0.26
"A high-pressure liquid chromatographic method is described for the analysis of estrogens in pharmaceutical tablet and injectable dosage forms."( High-pressure liquid chromatographic analysis of estrogens in pharmaceuticals by measurement of their dansyl derivatives.
Roos, RW, 1978
)
0.26
" Each patient received one substance over 5 days doubling the dose every consecutive day, and switching to another estrogen after a treatment free interval of 2 days, rising the dosage of the second preparation twofold every consecutive day over another 5 days."( [Comparative high rising dose study of oral 17-alpha-ethinylestradiol (EE2), estriol (E3), and parenteral 16-alpha-17-beta-estrioldihemisuccinate (E3-suc) in their effects on serum levels of glutamate transaminase (GOT), pyruvate transaminase (GPT), leuci
Kohler, P; Leis, D; Zach, H, 1978
)
0.26
" Each of 3 preparations (estriol (E), 17 alpha-ethinyl estradiol (17AEE), and estriol dihemisucconate (ED)) was administered for 5 days of 3 consecutive weeks, with the dosage of the preparation being doubled daily."( [Comparative high rising dose study of oral 17-alpha-ethinylestradiol (EE2), estriol (E3), and parenteral 16-alpha-17-beta-estrioldihemisuccinate (E3-suc) in their effects on serum levels of glutamate transaminase (GOT), pyruvate transaminase (GPT), leuci
Kohler, P; Leis, D; Zach, H, 1978
)
0.51
" The potency and dosage is correlated with the pathogenic effects observed."( Effects of contraceptive pills and intrauterine devices on urinary bladder.
Fayad, M; Kamel, M; Mooro, H; Osman, MI; Youssef, AF; Zahran, MM, 1976
)
0.26
" En 1974 nous avons proposé une méthode de dosage radio-immunologique homologue (A."( [Dosage of prolactin in normal and pathological subjects (author's transl)].
Colin, C; Dourcy, C; Franchimont, P; Gaspard, U; Legros, JJ; Remacle, P; Reuter, A; van Cauwenberge, JR; Vrindts-Gevaert, Y,
)
0.13
" The serum levels of d-norgestrel were related to the dosage of dl-norgestrel ingested."( Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner, PF; Goebelsmann, U; Mishell, DR; Stanczyk, FZ, 1977
)
0.26
"48 women, aged 17-41, were treated with weekly dosages of 1 mg ethinylestradiolsulfonate (EES) and a 10 mg dosage of norethisterone acetate (NEA) or a ."( [Changes of the endometrium during oral hormonal contraception with ethinyl estradiol sulfonate and norethisterone acetate or d-noregestrel].
Büttner, HH; Göretzlehner, G; Rudolf, K, 1976
)
0.49
"A trial was carried out in 3 clinics to test the efficacy of and cycle control obtained with a very low dosage oral contraceptive combination of lynesternol (0."( Clinical investigation of a very low dosage oral contraceptive combination: 0-75 mg lynestrenol and 0-0375 mg ethinyl oestradiol.
Altkemper, R; Prinz, W; Soergel, W, 1976
)
0.26
" This decrease varied with the type of progestogen used in continuous low dosage therapy."( The effect of combination and low dose progestogen oral contraceptives on serum lipids.
Donde, UM; Virkar, K, 1975
)
0.25
"It is possible to reduce side effects of oral contraceptives by individualizing the dosage and type of pill on the basis of such factors as length and regularity of normal cycle and sensitivity to endogenous progesterone, as demonstrated by premenstrual tension and depression."( Letter: Side effects of oral contraceptives.
Carey, HM, 1975
)
0.25
" In the intermediate dosage range, both factors contributed to the decreased ratio."( Effect of 17alpha-ethinylestradiol on biliary excretion of bile acids.
Watanabe, H, 1975
)
0.25
"05 mg ethinyl estradiol per tablet), is given to young female rats at 50 x the human dosage for an extended period, plasma vitamin A levels are elevated about 50%."( Effect of Ovral, a combination type oral contraceptive agent, on vitamin A metabolism in rats.
Olson, JA; Supopark, W, 1975
)
0.74
" The results indicate that at a dosage of 3-4."( The effects of medroxyprogesterone acetate and ethinylestradiol on hemogram, prostate, testes, and semen quality in normal dogs.
Bamberg-Thalén, B; Linde-Forsberg, C, 1992
)
0.28
" This study shows that estrogen/progestogen treatment in standard contraceptive dosage usually leads to only moderate and non-progressive stimulation of pituitary activity in women with hyperprolactinemic amenorrhea, but occasional excessive growth of a prolactinoma can occur and treatment needs to be monitored."( The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea.
Fahy, UM; Foster, PA; Hartog, M; Hull, MG; Torode, HW, 1992
)
0.28
" The issues to be resolved include the age at which treatment should be begun, the preparation, route of administration, and dosage to be given, the effect on concurrent growth hormone administration, the rate of dose increase during treatment, the timing and nature of progestin administration, and the total duration of treatment."( Estrogen therapy in Turner's syndrome.
Cutler, GB; Ross, JL, 1992
)
0.28
"The objective of the study was to investigate patient compliance with two different dosage regimens."( Dosage frequency and drug-compliance behaviour--a comparative study on compliance with a medication to be taken twice or four times daily.
Eggert-Kruse, W; Kruse, W; Rampmaier, J; Runnebaum, B; Weber, E, 1991
)
0.28
" The following difference was found: Women using the lower dosed preparation showed significantly less suppressed FSH values compared to women using Marvelon."( [Clinical experience with Mercilon and Marvelon with special reference to ovarian function].
Huber, PR; Mall-Haefeli, M; Werner-Zodrow, I, 1991
)
0.28
" However, the observed increase in area under the curve was within the range of pharmacokinetic accumulation, to be expected on the basis of dosing interval and terminal half-life."( Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
Gansau, C; Kuhnz, W; Louton, T; Mahler, M; Sostarek, D, 1991
)
0.5
"0 hours after dosing with their OCS on days 5, 6, 7 and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH and LH by radioimmunoassay."( The lack of interaction between temafloxacin and combined oral contraceptive steroids.
Back, DJ; Mant, T; Martin, C; Millar, E; Morrison, P; Orme, M; Tjia, J, 1991
)
0.28
"0 hours after dosing with OCs on days 5, 6, 7, and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH, and LH by radioimmunoassay."( The lack of interaction between temafloxacin and combined oral contraceptive steroids.
Back, DJ; Mant, T; Martin, C; Millar, E; Morrison, P; Orme, M; Tjia, J, 1991
)
0.28
"One of the critical issues in risk assessment for chemical carcinogens is the evaluation of dose-response relationships for tumor promoters."( Dose-response relationships in promotion of rat hepatocarcinogenesis by 17 alpha-ethinylestradiol.
Campen, D; Lucier, G; Maronpot, R, 1990
)
0.28
" However, due to the low dosage of steroids, it is of utmost importance to avoid errors in its use."( Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China.
Qian, LJ; Sang, GW; Weng, LJ; Xu, D; Zhang, JY; Zheng, HZ, 1991
)
0.28
" Tumors of other reproductive tissues (mammary gland, ovary, oviduct, cervix, or uterus) demonstrated no discernible DES dose-response relationship."( Carcinogenicity of diethylstilbestrol in the Wistar rat: effect of postnatal oral contraceptive steroids.
Baggs, RB; Miller, RK; Odoroff, CL, 1991
)
0.28
" As combinations with low EE doses and a sufficiently effective progestogen component do not differ from higher dosed oral contraceptives in their contraceptive safety and cycle control, there are no indications for pills containing 50 micrograms EE, except the normophasic sequential preparations for women with sustained irregular bleedings when taking low dose combinations."( [Ovulation inhibitors: the significance of estrogen dose].
Kuhl, H, 1990
)
0.28
" These results indicate that these changes are related to the dosage and estrogen-progestogen ratio of the preparation."( A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
Holck, S; Loke, DF; Ng, CS; Ratnam, SS; Samsioe, G, 1990
)
0.5
" Evidence of the vascular complications of oral contraceptives suggests that venous thromboembolism correlates with estrogen dosage and arterial complications with both estrogen and progestogen components."( Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
Bonnar, J; Daly, L, 1990
)
0.55
" A dose-response relationship was seen in the endocrine and clinical performance of the CVR."( Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol.
Alapiessa, U; Apter, D; Assendorp, R; Cacciatore, B; Stenman, UH, 1990
)
0.28
"A comparative clinical trial of two combined oral contraceptives differing only in estrogen type and dosage was conducted at the Centro de Investigaciones Hideyo Noguchi in Merida, Yucatan, Mexico."( A comparative clinical trial of Norinyl 1 + 35 versus Norinyl 1 + 50 in Merida, Yucatan, Mexico.
de Cetina, TC; Dunson, TR; Gamboa, LV; Reyes, LP; Rowan, AJ; Waszak, CS; Weaver, MB, 1990
)
0.28
"The pharmacokinetic and protein-binding properties of gestodene and ethinyl estradiol have been investigated after single and multiple dosing in several studies in 83 healthy, young women."( Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive.
Hümpel, M; Kuhnz, W; Täuber, U, 1990
)
0.79
" This wide variability confounds efforts to establish tight dose-response relationships, a point rarely considered in clinical or epidemiologic studies of these compounds."( Pharmacokinetics of ethinyl estradiol and mestranol.
Brody, SA; Goldzieher, JW, 1990
)
0.6
" Within further studies, a simpler dosage regimen should also be taken into account."( Compliance with short-term high-dose ethinyl oestradiol in young patients with primary infertility. New insights from the use of electronic devices.
Eggert-Kruse, W; Kruse, W; Rampmaier, J; Runnebaum, B; Weber, E, 1990
)
0.28
" Contraceptive agents with reduced dosage of steroid components (rigevidon or triquilar) produced less pronounced increase in systolic or diastolic blood pressure (less than by 2-3 mm Hg)."( [Changes in arterial blood pressure of women using hormonal contraceptives in relation to their cardiovascular history].
Dubnitskaia, LV; Korsakov, SG; Manuilova, IA, 1989
)
0.28
"In a study of low-dose oral contraceptives, it was found that the low dosage caused insignificant effects on glucose and lipid metabolism."( Metabolic effects of three new low-dose pills: a six-month experience.
Bertolotto, A; Fioretti, P; Fruzzetti, F; Giampietro, O; Melis, G; Miccoli, R; Navalesi, R; Orlandi, MC; Ricci, C, 1989
)
0.28
" This permits a very low dosage in oral contraceptives in which 75 mcg of Gestoden are combined with 30 mcg of ethinylestradiol."( [Oral contraception with low-dose progestagen].
Heinzl, S, 1989
)
0.28
" Since the amount of norethindrone in the two dosage groups was the same, this difference in the pharmacokinetics between the 35 micrograms EE and the 50 micrograms ME formulations remains unexplained."( Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are "low-dose" pills really lower?
Brody, SA; Goldzieher, JW; Turkes, A, 1989
)
0.49
" Pretreatment with EE shifted the EGF dose-response curve, causing a dramatic enhancement of the response to EGF beginning at 2 ng EGF/ml."( Effects of the liver tumor promoter ethinyl estradiol on epidermal growth factor-induced DNA synthesis and epidermal growth factor receptor levels in cultured rat hepatocytes.
Shi, YE; Yager, JD, 1989
)
0.55
" The recommended dosage is 2 tablets taken 12 hours apart, preferably within 12-24 hours, and no later that 72 hours, after intercourse."( Ovral as a "morning-after" contraceptive.
, 1989
)
0.28
" Morphometric determinations of the testes indicated that the number of Leydig cells in a unit area (mm2) in the interstitial tissue showed a dose-response relationship to ethinyl estradiol in the normal testes."( Leydig cell hyperplasia in fetal mice treated transplacentally with ethinyl estradiol.
Konishi, H; Tanimura, T; Yasuda, Y, 1986
)
0.7
"Efforts to minimize oral contraceptive side effects have focused on the use of new dosage schemes and the synthesis of new steroids that can be used in safer, low-dose formulations."( Pharmacological and endocrine profiles of gestodene.
Huber, J; Spona, J, 1987
)
0.27
" Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne."( On therapeutic approaches to some special types of acne.
Rajka, G, 1985
)
0.27
" The individual AUCs for 3-keto-desogestrel after dosing with desogestrel (plus EE) or 3-keto-desogestrel (plus EE) show a similar degree of variation."( Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel.
Bosch, AM; Hasenack, HG; Käär, K, 1986
)
0.27
" Studies of the oral contraceptives in current use show that the coagulation effects depend on the dosage of estrogen and the type of progestogen used in combination."( Coagulation effects of oral contraception.
Bonnar, J, 1987
)
0.27
" The weekly dosage of 2 mg Turisteron led to a decrease of the biologically active, free testosterone to less than 2% compared with the initial value."( [Conservative therapy of prostate cancer using Turisteron].
Dörner, G; Guddat, HM; Rohde, W; Schnorr, D; Stahl, F, 1987
)
0.27
"Oral contraceptives were initially very high in estrogen and progestogen and had a uniform dosage schedule throughout the entire cycle."( Phasic approach to oral contraceptives.
Hale, RW, 1987
)
0.27
"Oral contraceptives were initially very high in estrogen and progestogen and had a uniform dosage schedule throughout the entire cycle."( Phasic approach to oral contraceptives.
Hale, RW, 1987
)
0.27
"5 micrograms daily dosage significantly increased uterine weights by as much as 10% to 46% after 2 to 4 weeks."( Antimammary carcinogenic activity of 17-alpha-ethinyl estriol.
Lemon, HM, 1987
)
0.27
" This is the first dosing study of contraceptive steroids in a murine model of lupus."( Suppression of reproductive function in autoimmune NZB/W mice: effective doses of four contraceptive steroids.
Keisler, LW; Walker, SE, 1987
)
0.27
"45 patients with prostatic cancer were treated conservatively with Turisteron at a dosage of 2 mg per week."( [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
Dörner, G; Guddat, HM; Rohde, W; Schnorr, D; Stahl, F, 1987
)
0.48
" As a result the use of Cytonal at least in the dosage hitherto used is no longer worth being advocated."( [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
Fiedler, R; Klebingat, KJ; Lorenz, G; Panzig, E; Steinhauser, I, 1987
)
0.27
"The effects of two cyclically administered, triphasic, combined low dosage oestrogen and progestogen oral contraceptives on haemostasis have been compared in a longitudinal study, over 6 months, in 26 healthy females aged 16-30 years."( A comparison of the effects of two triphasic oral contraceptives on haemostasis.
Cohen, H; Gillmer, MD; Machin, SJ; Mackie, IJ; Walshe, K, 1988
)
0.27
" With a dosage of 2 mg per week it shows a distinct antigonadotropic and antiandrogenic effect."( [Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].
Dörner, G; Guddat, HM; Rhode, W; Schnorr, D; Stahl, F, 1987
)
0.6
" One should, however, be aware that Diane contains only 2 mg cyproterone acetate (CPA) and a better effect would most probably have been obtained using a higher dosage of CPA."( A comparative study of Aldactone and Diane in the treatment of hirsutism.
Djøseland, O; Lunde, O, 1987
)
0.27
" In summary, we found evidence of an induction of myocardial ischaemia during treatment with exogenous oestrogens at low dosage in patients with prostatic cancer."( Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer.
Edhag, O; Henriksson, P; Linde, B, 1987
)
0.27
"Ethinylestradiol (EE), at a dosage of 5 mg/day for 5 consecutive days (5 mg EE), has generally been used for interception."( A comparison of high-dose estrogens versus low-dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women.
Haspels, AA; Van Santen, MR, 1985
)
0.27
"Ethinyl estradiol (EE), at a dosage of 5 mg/day for 5 consecutive days (5 mg EE) has generally been used for interception."( A comparison of high-dose estrogens versus low-dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women.
Haspels, AA; Van Santen, MR, 1985
)
1.71
" These changes are considered as a regulative phenomenon, without consequences for the application of the high dosage therapy with these steroid hormones in the treatment of excessive growth."( Effects of high doses of oestrogens and androgens on lipoproteins: observations in the treatment of excessive growth with sexual hormones.
Hanefeld, M; Hinkel, GK; Jaross, W; Leonhardt, W; Trübsbach, A, 1985
)
0.27
" Once inhibition of ovulation was established, the dosage was gradually reduced to 3, 2, and 1 pellet without decreased suppression of ovulation."( Estradiol pellet implantation for contraception.
Bohler, CS; Greenblatt, RB; Hernandez-Ayup, S, 1974
)
0.25
"Eighty-six women of proved fertility used an incremental dosage regimen of a combined oral contraceptive for a total of 570 cycles over one year."( Assessment of incremental dosage regimen of combined oestrogen-progestogen oral contraceptive.
Brosens, IA; Robertson, WB; Van Assche, FA, 1974
)
0.25
" Serum percentage of iodine uptake, total thyroxine, free thoraxine, and weight changes in 38 women taking combination oral contraceptives and 27 taking low dosage progestagens were studied."( Thyroid functions of women taking oral contraceptives.
Barsivala, V; Virkar, K, 1974
)
0.25
" Patients had been treated with 4 different dosage combinations of estrogen and progestins over periods varying from 3 months to 24 months."( Progestational agents and blood coagulation. VI. Relationship of ABO blood types to changes induced by oral contraceptives.
Lillie, MA; Mink, IB, 1974
)
0.25
" None of the dystrophy cases exhibited an anabolic response to any dosage of HGH tested."( Metabolic effects of human growth hormone and of estrogens in boys with Duchenne muscular dystrophy.
Barlow, J; Chyatte, SB; Gerron, GG; Jordan, A; O'Beirne, I; Patterson, JH; Rudman, D; Shavin, JS, 1972
)
0.25
"A clinical series in a private gynecological practice with 50 patients aged 19-43 years who were seen between January 1966 and July 1968 were given a daily dosage of ."( Family planning with norgestrel-ethinyl oestradiol in a private gynaecological practice.
Croxford, VA, 1969
)
0.25
" 60 lactating rats were treated, beginning on day of delivery and continuing for 21 days, with one of 9 different dosage schedules."( The effects of norgestrel, ethinyl estradiol, and their combination, Ovral, on lactation and the offspring of rats treated during lactation.
Clancy, DA; Edgren, RA,
)
0.43
" In support of this hypothesis, both cytochrome P-450 concentrations and the rate of catalysis of the D-homoannulation pathway by this enzyme were significantly decreased in hepatic microsomes from rhesus monkeys which had been administered mestranol and/or ethynerone (17 alpha-ethynylated steroids) at dosage levels mimicking human exposure to oral contraceptive agents."( Cytochrome P-450-dependent oxidation of the 17 alpha-ethynyl group of synthetic steroids. D-homoannulation or enzyme inactivation.
Au, WY; Hill, DE; Kadlubar, FF; Schmid, SE; Slikker, W,
)
0.13
" Ethynerone/mestranol (20:1), anagestone/mestranol (10:1), or vehicle was administered by gavage over a 10-year period on a cycling schedule of 21 days of dosing followed by 7 days without."( Changes in estrogen metabolism after chronic oral contraceptive administration in the rhesus monkey.
Bailey, JR; Lipe, GW; Slikker, W; Sziszak, TJ,
)
0.13
" Thus it appears that CA has no untoward effect upon glucocorticoid secretion when given in high dosage for prolonged periods to hirsute women."( Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism.
Croxson, MS; Evans, MC; France, J; Holdaway, IM; Ibbertson, HK; Sheehan, A; Wilson, T, 1983
)
0.27
" The medium-dose regimen (total dosage per cycle: 192 mg of CPA) is more effective than the low-dose regimen (42 mg of CPA per cycle) in the treatment of patients with moderate hyperandrogenism who do not require the high-dose oral standard antiandrogen therapy (1000 mg of CP A per cycle)."( [Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study].
Kaiser, E; Moltz, L, 1984
)
0.27
" Desogestrel at a dose level used in oral contraceptives did not inhibit the EE-induced increase in SHBG capacity while its influence on this parameter at twice the clinical dosage (0."( Short-term effects of desogestrel and ethinyloestradiol on serum proteins in women.
Käär, K; Rhen, K; Tarkkila, T, 1984
)
0.27
"To determine which dosage of estrogen might provide physiologic replacement while minimizing adverse effects, 20 postmenopausal women were studied before and after oral administration of ethinyl estradiol."( Biologic effects of various doses of ethinyl estradiol in postmenopausal women.
Eggena, P; Geola, FL; Hershman, JM; Judd, HL; Lu, JK; Mandel, FP; Sambhi, MP, 1982
)
0.73
" Each dosage of each formulation was ingested by three women."( Comparison of pharmacodynamic properties of various estrogen formulations.
Brenner, PF; Dozono-Takano, R; Eggena, P; Lobo, RA; Mashchak, CA; Mishell, DR; Nakamura, RM, 1982
)
0.26
" Forty-two climacteric women were studied before and after treatment with various drugs at different doses (patients receiving identical compounds served as their own controls for the evaluation of dosage effects; duration of medication: 14 days at each dose)."( Effects of various replacement oestrogens on hepatic transcortin synthesis in climacteric women.
Hammerstein, J; Moltz, L; Schneller, E; Schwartz, U; Volger, H, 1983
)
0.27
" A high dosage "reverse sequential" therapy of 100 mg CPA on the 5th-14th days of the menstrual cycle and 40 mcg ethinyl estradiol (EE) on the 5th-25th days is used in severe cases."( [Clinical use of antiandrogens in the female].
Hammerstein, J; Moltz, L; Schwartz, U, 1980
)
0.47
" With the same contraceptive reliability its cycle stability is very much better than the monophase preparations, which are 40% high dosed in the progestin proportion (levonorgestrel and desogestrel)."( [Progress in oral contraception. Advantages of a levonorgestrel-containing 3-stage preparation over low-dose levonorgestrel and desogestrel containing monophasic combination preparations].
Lachnit-Fixson, U, 1984
)
0.27
" It is very difficult to show a correlation of ambiguous side effects such as depression and mood changes and the dosage level."( Advances in oral contraception. An international review of levonorgestrel and ethinyl estradiol.
Goldzieher, JW, 1983
)
0.49
"In the present study the Authors consider whether estroprogestins at low dosage may influence the basal levels of plasma Prolactin in a group of patients subdivided on the basis of their different ways of life."( Prolactin plasma levels and oral contraceptives at low dosage.
Dessole, S; Firinu, C; Milia, S; Piras, G, 1983
)
0.27
"In this study, the authors considered whether estroprogestins at low dosage may influence the basal levels of plasma prolactin (PRL) in a group of patients subdivided on the basis of different lifestyle."( Prolactin plasma levels and oral contraceptives at low dosage.
Dessole, S; Firinu, C; Milia, S; Piras, G, 1983
)
0.27
" Low dosage and strong affinity for target cell receptors are important in the selection of the appropriate agent."( Prescribing an oral contraceptive for the individual woman.
Chick, P, 1980
)
0.26
" A dose-response experiment carried out in healthy women indicated that 10 mg of norethisterone (NET) with 1 mg of ethinylestradiol (EE2) when given by intramuscular injection maintained NET serum levels above 1 ng/ml for at least 25 days."( Development of a low-dose monthly injectable contraceptive system: I. Choice of compounds, dose and administration route.
Diaz-Sanchez, V; Garza-Flores, J; Jimenez-Thomas, S; Rudel, HW, 1984
)
0.27
" A dose-response experiment carried out in healthy women indicated that intramuscular injection of 10 mg of NET with 1 mg of EE2 maintained NET serum levels above 1 ng/ml for at least 25 days."( Development of a low-dose monthly injectable contraceptive system: I. Choice of compounds, dose and administration route.
Diaz-Sanchez, V; Garza-Flores, J; Jimenez-Thomas, S; Rudel, HW, 1984
)
0.27
" After a 6 to 8 weeks treatment at a dosage of one milligram weekly a DEI of 7,27 (+/- 0,74) was attainable."( [Effect of ethinyl estradiol sulfonate on the urethral epithelium after bilateral oophorectomy].
Kindt, J; Retzke, U; Scheunert, EU, 1984
)
0.66
" The effectiveness of Stediril may be compromised by failure to follow the dosage schedule: 1 pill daily for 21 days followed by a pill-free interval of 7 days when withdrawal bleeding occurs."( [Stediril].
Csech, J; Gervais, C, 1984
)
0.27
" The dose-response curve for suppression by dexamethasone of urinary cortisol during estrogen treatment was indistinguishable from that during the control period."( Estrogens and the hypothalamo-pituitary-adrenal axis in man: evidence for normal feedback regulation by corticosteroids.
Baumann, G, 1983
)
0.27
" Thus, the effects of CPA containing drug on the endometrium depend essentially on their type, dosage and mode of administration."( Effects of cyproterone acetate and ethinylestradiol on endometrial histology.
Klebe, U; Moltz, L; Pickartz, H, 1983
)
0.27
" Low concentrations of E3 (10(-10) M) stimulate growth of MCF-7 cells in vitro and dose-response curves show E3 to be only slightly less effective than E2."( Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo.
Katzenellenbogen, BS, 1984
)
0.27
"During the past 25 years over 50 million women have used oral contraceptives (OCs) and have been exposed to the actions of ethinyl estradiol (EE) or its 3-methylether, mestranol, usually at the dosage of 50 mcg/day."( Pharmacokinetics of ethynyloestradiol in humans.
Fotherby, K, 1982
)
0.47
" Due to the fact that menstrual cycles in a given woman may vary in length and that it takes patients several days on intermediate or long-acting insulin to achieve a steady state with regard to any dosage adjustment, it is difficult to design an insulin regimen that maintains euglycemia throughout the menstrual cycle in these labile patients."( Oral contraceptives abolish luteal phase exacerbation of hyperglycemia in type I diabetes.
Bleicher, SJ; Sacerdote, A,
)
0.13
" The results indicate that hormonal contraception of the low dosage type may be administered to women with previously impaired glucose tolerance in pregnancy without any deterioration of the glucose metabolism post partum."( Low dosage oral contraception in women with previous gestational diabetes.
Kühl, C; Mølsted-Pedersen, L; Skouby, SO, 1982
)
0.26
"Scanning electron microscopy and a capillary tube sperm penetration test were used to study the cervical mucus of women using a triphasic oral contraceptive supplying a varying dosage of estrogen and gestagen during the cycle."( Ultrastructure of cervical mucus and sperm penetration during use of a triphasic oral contraceptive.
Myklebust, RU; Ulstein, M, 1982
)
0.26
" After oral dosage administration, the 3-glucuronide and, in some cases, the 3,17-diglucuronide also become important."( The pharmacokinetics and metabolism of ethinyl estradiol and its three sulfates in the baboon.
Castracane, VD; Goldzieher, JW; Moore, PH; Newburger, J; Williams, MC, 1983
)
0.54
" It is consequently concluded that the abnormal biopsies observed in the beginning of the cycle in some treated patients is due only to a transitory estrogenic effect and that the early administration of progestagen in the normophasic dosage scheme not only counteracts this effect but could play a protective role against hyperplasia."( Combined clinical, histological and stereomorphometric studies with a new oral contraceptive of normophasic type: Fysioquens.
Dombrowicz, N; Van de Walle, J, 1980
)
0.26
" The dose-response curve obtained with the assay procedure (12 replicate samples) compared well on all points with a standard radioimmunoassay."( Enzyme immunoassay for specific determination of the synthetic estrogen, ethynyl estradiol, in plasma.
Dyas, J; Read, GF; Riad-Fahmy, D; Turkes, A, 1981
)
0.26
" Half the dosage was administered immediately upon entry into the study and the remainder 12 hours later."( A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent.
Rademaker, AW; Smith, RP; Yuzpe, AA, 1982
)
0.52
" Conversely, evidence of lupus exacerbation did not develop in any of 11 patients who received pure progestogen oral contraceptive therapy with either continuous low-dose norsteroids (6 patients) or discontinuous progestogens at normal dosage (5 patients)."( Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus.
Bach, JF; Dougados, M; Jungers, P; Kuttenn, F; Lesavre, P; Pélissier, C; Tron, F, 1982
)
0.26
" These findings indicate that estrogen replacement therapy, in a dosage recommended for treatment of the menopause, stimulated a sustained rise in serum prolactin over 24 hours."( Circadian pattern of prolactin secretion in postmenopausal women receiving estrogen with or without progestin.
Carlson, HE; Chang, RJ; Davidson, BJ; Judd, HL, 1982
)
0.26
" In contrast, of 16 patients receiving pure progestogen contraceptive therapy with either discontinuous normal dosage progestogens (9 cases) or continuous low-dose norsteroids (7 cases), only one developed clinical or immunological evidence of lupus exacerbation within 3 months of hormonal therapy."( [Effect of hormonal contraception on the course of lupus nephropathy].
Bach, JF; Dougados, M; Jungers, P; Kuttenn, F; Pélissier, C; Pertuiset, N; Tron, F, 1982
)
0.26
" In contrast, of 16 patients receiving pure progestogen contraceptive therapy with either discontinuous normal dosage progestogens (9 cases) or continuous low-dose norsteroids (7 cases), only 1 developed clinical or immunological evidence of lupus exacerbation within 3 months of hormonal therapy."( [Effect of hormonal contraception on the course of lupus nephropathy].
Bach, JF; Dougados, M; Jungers, P; Kuttenn, F; Pélissier, C; Pertuiset, N; Tron, F, 1982
)
0.26
" Norlestrin, a combination of norethindrone acetate and ethinylestradiol (50:1) was given orally on a continuous cyclic regimen of 21 d of dosing followed by 7 d without treatment."( Ten-year oral toxicity study with Norlestrin in rhesus monkeys.
de la Iglesia, F; Fitzgerald, J; Goldenthal, EI, 1982
)
0.26
" A lethal effect on fetuses of both groups with single and continuous exposure to ethinyl estradiol was observed in a dose-response relationship."( Effect of ethinyl estradiol on development of mouse fetuses.
Kihara, T; Nishimura, H; Yasuda, Y, 1981
)
0.89
" Concentrations of plasma cholesteryl ester decreased with increasing dosage of ethynyl estradiol, as a result of decreases in HDL cholesteryl ester."( Alterations of plasma HDL lipids and apolipoproteins in female rats treated with ethynyl estradiol.
Heimberg, M; Kenagy, R; Weinstein, I; Wilcox, HG, 1981
)
0.26
"To test the effects of Progynon M, a postcoital contraceptive used in Tubingen where these studies were carried out, 6 female volunteers, aged 20-30 years, with no previous use of this or other hormonal medication and in good health, were dosed with 3 mg of EE (ethinyl estradiol) on Day 25 of menstrual cycle."( The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women.
Back, DJ; Bolt, HM; Breckenridge, AM; Crawford, FE; Orme, ML; Rowe, PH; Schindler, AE, 1980
)
0.44
" During the second part of the study (Phase II), a 10-day pre-treatment with the same dosage of non-radioactive compound preceded the administration of the radioactive steroid."( Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. The distribution and excretion of radioactivity after an oral dose of the labelled drug.
Hasenack, HG; Nieuwenhuyse, H; Vihko, R; Viinikka, L; Ylikorkala, O, 1980
)
0.26
" Four women in each group were taking either a low dosage progestogen compound like norethisterone (NET) 350 micrograms or d-norgestrel (d-Ng) 50 micrograms alone or low dosage combination pills containing NET 1 mg or d-Ng 150 micrograms with 30 micrograms ethinyl estradiol (EE2) or a biodegradable implant containing 25 mg NET or d-Ng."( Release of 19-nor-testosterone type of contraceptive steroids through different drug delivery systems into serum and breast milk of lactating women.
Mehta, S; Saxena, BN; Toddywalla, VS; Virkar, KD, 1980
)
0.44
"Albino rats were fed ethynylestradio to the diet for 2 yr at dosage levels (0."( Studies of the components of an oral contraceptive agent in albino rats. I. Estrogenic component.
Schardein, JL, 1980
)
0.26
"01) suggest that a hypercoagulable state persists in low dosage OC users."( Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives.
Donnez, J; Grandjean, P; Lavenne, E; Schlit, AF, 1995
)
0.29
" Even though the low dosage of ethinyl estradiol (20 mcg) may have contributed to the prevention of bone mass loss, it could not achieve the peak bone mass."( Bone mass and long-term monophasic oral contraceptive treatment in young women.
Filippa, N; Gallina, D; Nappi, RE; Perotti, F; Polatti, F, 1995
)
0.57
"To extend and confirm previous data, we examined the effects of raloxifene on the proximal tibia of ovariectomized rats, aged 6 months, longitudinally and cross-sectionally by computed tomography (pQCT) and then compared the effects to those of orally dosed estrogen."( Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
Bryant, HU; Kim, J; Sato, M; Short, LL; Slemenda, CW, 1995
)
0.29
"To evaluate the clinical and hormonal response of the antiandrogen flutamide (Eulexin, Schering Plough, Milan, SA, Italy) associated with a low dosage oral contraceptive (OC) in a group of hirsute women who were unresponsive to OC treatment."( Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994
)
0.29
"After 8 months treatment with flutamide and low dosage OC, the Ferriman-Gallwey score improved in all patients, mean values decreasing from 25."( Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994
)
0.29
"Flutamide, associated with low dosage OC, favorably influence the hirsutism in PCOD women who are unresponsive to OC treatment alone."( Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994
)
0.29
" We conclude that exogenous EE, in the dosage used in this study, does not overcome CC-induced alterations in endometrial thickness."( Exogenous estrogen therapy concurrent with clomiphene citrate--lack of effect on serum sex hormone levels and endometrial thickness.
Battino, S; Ben-Ami, M; Geslevich, Y; Matilsky, M; Shalev, E; Weiner, E, 1994
)
0.29
" An ethinyl estradiol dose-response effect was evident on hemostasis in all OC groups, but the changes in coagulation factors at higher doses were more pronounced in smokers than in nonsmokers."( Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.
Fioretti, P; Fruzzetti, F; Ricci, C, 1994
)
0.8
" The serum concentrations of KDG and gestodene during multiple dosing cannot be predicted on the basis of single dose pharmacokinetics."( Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Power, J; Schindler, AE; Simon, A; Winkler, U, 1993
)
0.29
" The dosage schedule was 7/7/7, that is, a different dose for each 7-day period."( Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer, DF; Lammers, P; Timmer, CJ, 1994
)
0.52
"The dosage of ethinylestradiol used in emergency contraception is very shortlived and this study shows no effect on clotting factors."( Clotting factors after emergency contraception.
Taberner, D; Webb, A, 1993
)
0.29
" Two parameters were evaluated: percentage of prescribed doses taken (administration compliance) and adherence to the prescribed dose schedule (regimen compliance, number of days with two or four dosing events recorded)."( Compliance and adverse drug reactions: a prospective study with ethinylestradiol using continuous compliance monitoring.
Eggert-Kruse, W; Kruse, W; Rampmaier, J; Runnebaum, B; Weber, E, 1993
)
0.29
" A dose-response curve was always consistently obtained using estradiol-17 beta (E2), with a mid point at around 100 nM E2 and a maximum response at around 1000 nM."( Vitellogenin synthesis in cultured hepatocytes; an in vitro test for the estrogenic potency of chemicals.
Bennetau, B; Dunoguès, J; Flouriot, G; Foucher, JL; Le Gac, F; Pelissero, C; Sumpter, JP, 1993
)
0.29
" During multiple dosing an increased area under the concentration curve and decreased apparent oral clearance was observed for ethinyl estradiol in peritoneal dialysis patients compared with normal women."( Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
Carr, BR; Droegemueller, W; Dupuis, RE; Lobo, RA; Price, TM; Stanczyk, FZ, 1993
)
0.49
" Thus, under dosing conditions commonly used to assess uterotrophic activity, these "antiestrogens" are complete, albeit less potent, estrogen agonists in the luminal epithelium and, unlike estrogens, induce hypertrophy in the glandular epithelium."( Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens.
Branham, WS; Sheehan, DM; Zehr, DR, 1993
)
0.29
" The combination oral contraceptive contained 75 microgram gestodene (GSD) and 20 microgram ethinyl estradiol (EE2) per dosage unit."( A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive.
Heger-Mahn, D; Heuner, A; Hümpel, M; Kuhnz, W; Richert, K, 1995
)
0.51
" The use of the lowest efficacious dosage could reduce costs."( Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
Cédrin, I; Dodin, S; Faure, N; Guy, J; Lemay, A; Méchain, C; Turcot-Lemay, L, 1995
)
0.29
" In the present investigation, female MRL lpr/lpr mice have been dosed po daily for 7 months with the selective estrogen receptor modulator (SERM) LY139478 (4 mg/kg) or 17alpha-ethinylestradiol (EE2, 1 mg/kg) and compared to vehicle control animals."( The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.
Apelgren, LD; Bailey, DL; Bryan, N; Bumol, TF; Evans, GF; Fouts, RL; Glasebrook, A; Sandusky, GE; Short, L; Zuckerman, SH, 1996
)
0.29
" The NA-EE2 treatment groups had a significant linear dose-response trend for increasing BMD."( The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial.
Genant, H; Rowan, J; Speroff, L; Symons, J; Wilborn, W, 1996
)
0.29
" The dosage included single intravenous (60 mcg) and oral (120 and 240 mcg) administration."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" In order to determine whether CLO has tissue selective actions, we performed a dose-response study in adult (6-month-old) ovariectomized (OVX'd) rats."( Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats.
Bryant, HU; Jimenez, MA; Magee, DE; Turner, RT, 1997
)
0.3
"GH is known to improve height velocity in girls with Turner syndrome (TS) but the optimal dosage regimen has yet to be defined."( Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome. (Dutch Working Group on Growth Hormone).
de Muinck Keizer-Schrama, S; Delemarre-van de Waal, H; Drop, S; Gerver, WJ; Jansen, M; Reeser, H; Stijnen, T; van Teunenbroek, A; Vulsma, T; Waelkens, J; Wit, JM, 1997
)
0.3
" It indicates that the role of PGs in the effects of COCs is significant and their design may in addition to reduction of oestrogen dosage be important in reducing haemostatic complications."( Effect of oral contraceptives on haemostasis variables.
Kluft, C; Lansink, M, 1997
)
0.3
" Up to date a drastic dosage reduction of both steroid hormones has been accomplished ameliorating the side effects on the one hand, and being active compounds as contraceptives, in the other."( [Endometrial interference of synthetic estrogens in fertility regulation.Is it necessary to interfere with the antiovulatory mechanism at the central nervous system level in order to obtain contraception?].
Cortés-Gallegos, V; Rojas, T; Sojo Aranda, QI, 1997
)
0.3
" It is reasonable to choose a preparation with the lowest estrogen and gestagen dose and to change the dosage only after 3-4 months of use at the earliest if side effects such as bleeding irregularities occur."( [Rationale for prescribing oral contraceptives].
Teichmann, AT, 1998
)
0.3
" Dose-response curves for the induction of AlkPhos activity by the different estrogenic compounds were generated with EST/ISH and control pcDNA/ISH cells."( Regulation of estrogen activity by sulfation in human Ishikawa endometrial adenocarcinoma cells.
Falany, CN; Falany, JL; Kotov, A; Wang, J, 1999
)
0.3
" Dose-response studies established that the potency and efficacy of both estrogens in the uterus were the same for all four hormone-regulated genes."( Synthetic estrogen 17alpha-ethinyl estradiol induces pattern of uterine gene expression similar to endogenous estrogen 17beta-estradiol.
Chiappetta, C; Hyder, SM; Stancel, GM, 1999
)
0.6
" EE was orally given to adult male rats at a daily dosage of 10 mg/kg for 3 and 5 d, and at daily dosages of I and 10 mg/kg for 1, 2, 3, and 4 weeks."( Epididymal sperm motion as a parameter of male reproductive toxicity: sperm motion, fertility, and histopathology in ethinylestradiol-treated rats.
Hishikawa, A; Kanamori, S; Kaneto, M; Kishi, K,
)
0.13
" The findings of this study indicate that there is little potential for dosages as high as 30 mg/day, the maximum recommended dosing schedule, of rizatriptan to alter the plasma concentrations of oral contraceptives."( A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers.
Goldberg, MR; Liu, G; Shadle, CR, 2000
)
0.31
" After discontinuation of GH treatment, the dosage of oestrogens was further increased to adult supplementation levels."( A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial.
Asarfi, A; De Muinck Keizer-Schrama, SM; Drop, SL; Sass, TC; Stijnen, T; Van Leeuwen, WJ; Van Rijn, RR; Van Teunenbroek, A, 2000
)
0.31
"Among new forms of hormonal contraception, three interesting exemples are described with a high level of effectiveness and low dosage regimen that allow improved safety and tolerance: a very low-dose estrogen-progestogen combination of ethinylestradiol and gestodene for 24-day cyclical administration; a progestogen-alone subcutaneous implant containing etonogestrel; and a levonorgestrel-releasing intrauterine system."( [New forms of hormonal contraception].
Buicu, C; Gaspard, U; van den Brûle, F, 2000
)
0.31
" It has been postulated that a threshold dosage of CPA has mutagenic effects, but in the same way data have been published documenting that a continuous low dosage of cyproterone acetate leads to a reduction of mutagenic episodes."( [Long-term side-effects following cyproterone acetate containing therapy in gynecology].
Regidor, M; Regidor, PA; Schindler, EM; Speer, K, 2000
)
0.31
" These findings suggest that similar to the pill containing 30 microg EE2, the lower dosage of the EE2 pill (20 microg) is also capable of reducing bone resorption."( Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
Ajossa, S; Floris, S; Guerriero, S; Mannias, M; Melis, GB; Orrù, M; Paoletti, AM; Vacca, AM, 2000
)
0.31
" These findings suggest that similar to the pill containing 30 mcg EE2, the lower dosage of the EE2 pill (20 mcg) is also capable of reducing bone resorption."( Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
Ajossa, S; Floris, S; Guerriero, S; Mannias, M; Melis, GB; Orrù, M; Paoletti, AM; Vacca, AM, 2000
)
0.31
" Low dosage ethinyloestradiol before planned induction of puberty was not beneficial."( A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis.
Barnes, N; Betts, P; Buckler, JM; Butler, GE; Dunger, D; Johnston, DI; Swift, PG, 2001
)
0.31
"Nine untrained women using low dosage monophasic oral contraceptives (OC) performed an intermittent treadmill test on two different occasions within one pill-cycle to determine the effect of OC on performance and some commonly used metabolic markers."( Low dosage monophasic oral contraceptive use and intermittent exercise performance and metabolism in humans.
De Vito, G; Lynch, NJ; Nimmo, MA, 2001
)
0.31
" The number of egg-ropes produced by the first generation females varied between treatments but no dose-response pattern was evident."( Chronic exposure to 17 alpha-ethinylestradiol and bisphenol A-effects on development and reproduction in the freshwater invertebrate Chironomus riparius (Diptera: Chironomidae).
Carroll, K; Pascoe, D; Watts, MM, 2001
)
0.31
" Steroids were delivered by silicone elastomer implants placed subdermally except for oral dosing in 1 experiment."( The roles of estrogen and progestin in producing deciduosarcoma and other lesions in the rabbit.
Didolkar, AK; Jänne, OA; Nash, HA; Sundaram, K; Zook, BC,
)
0.13
"The effects on procoagulants, anticoagulants, pro-fibrinolytics and antifibrinolytics and fibrin turnover were evaluated after treatment for six consecutive cycles, the impact of reduction of ethinyl estradiol dosage on these effects being assessed."( Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira, AC; Franceschini, SA; Montes, MB; Toloi, MR,
)
0.56
" The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 microg/EE 35 microg, significantly decreased mean maximum follicular diameter following a 3-day intentional delayed dosing phase when compared with oral levonorgestrel (LNG) 50/75/125 microg/EE 30/40/30 micorg and oral LNG 100 microg/EE 20 microg, and was as effective as oral LNG 50/75/125 microg/EE 30/40/30 microg and oral desogestrel 150 microg/EE 20 microg in altering cervical mucus composition (i."( Transdermal contraception.
Abrams, LS; Creasy, GW; Fisher, AC, 2001
)
0.31
" Pharmacokinetic assessments were performed on day 14 based on plasma levels of ethinyl estradiol and levonorgestrel up to 24 hours after dosing and serum tolterodine levels at 1 to 3 hours after dosing."( The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.
Landgren, BM; Olsson, B, 2001
)
0.75
" As with Ortho-Cyclen, patch regimens included 21 dosing days (3 consecutive 7-day patches) followed by 1 dose-free week."( Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study.
Creasy, GW; Dittrich, R; Fisher, AC; Parker, L; Rosen, JB; Shangold, G, 2002
)
0.55
"The patch regimens demonstrated a dose-response for ovulation suppression and cycle control."( Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study.
Creasy, GW; Dittrich, R; Fisher, AC; Parker, L; Rosen, JB; Shangold, G, 2002
)
0.55
" Eighty-five women who met study criteria, made minimal dosing errors, and underwent at least three ultrasonographic examinations were analyzed."( Predicting risk of ovulation in new start oral contraceptive users.
Creinin, MD; Pymar, HC; Reid, L; Schwartz, JL, 2002
)
0.31
" A major advantage of this method compared to oral contraceptives is a nearly 90% perfect adherence to the dosing schedule across all age groups."( The transdermal contraceptive patch: a new approach to hormonal contraception.
Burkman, RT,
)
0.13
" In this study, dose-response and time course relationships for Vtg induction were determined in male western fence lizards (Sceloporus occidentalis) given intraperitoneal injections of 17alpha-ethinylestradiol (EE2)."( Dose-response and time course relationships for vitellogenin induction in male western fence lizards (Sceloporus occidentalis) exposed to ethinylestradiol.
Brasfield, SM; Janz, DM; Talent, LG; Weber, LP, 2002
)
0.31
" After generating complete dose-response curves for each chemical, ternary mixtures were then tested in a full factorial design (4 concentrations per chemical, 64 treatment groups)."( An approach for assessing estrogen receptor-mediated interactions in mixtures of three chemicals: a pilot study.
Carney, EW; Charles, GD; Gennings, C; Gollapudi, BB; Zacharewski, TR, 2002
)
0.31
" Therefore, the facile dansyl derivatization coupled with tandem mass spectral analysis allowed the development of a highly sensitive and specific method for quantitation of trace levels of EE in the plasma of rhesus monkeys dosed orally and intravenously with EE."( Derivatization of ethinylestradiol with dansyl chloride to enhance electrospray ionization: application in trace analysis of ethinylestradiol in rhesus monkey plasma.
Anari, MR; Bakhtiar, R; Evans, DC; Franklin, RB; Huskey, S; Zhu, B, 2002
)
0.31
" An antithromboembolic effects was suggested with an increasing combined dosage of norethisterone acetate."( Thromboembolic disease and the steroidal content of oral contraceptives.
Swyer, GI, 1970
)
0.25
"The observation that estrogens in sufficient dosage given postcoitally may prevent implantation of the ovum have led to studies regarding practical clinical application."( Post-coital oral contraception.
Morris, JM; Van Wagenen, G, 1966
)
0.24
" The pill blocks the normal hypothalamo-hypophyseal secretions and prevents ovulation; high dosage pills are completely effective in doing this; minipills less effective."( [The pill].
Dellenbach, P; Schick, R,
)
0.13
" The dosage was either 5 mg of stilboestrol 5 times daily for 5 days, or 1 mg of ethinyloestradiol twice daily for 5 days."( The "morning-after pill"--a preliminary report.
Haspels, AA, 1969
)
0.25
" This is attributed to the lack of androgenicity of desogestrel in the clinical dosage used in this study."( Desogestrel and ethinyloestradiol.
Haspels, AA; Weyers, WJ, 1983
)
0.27
" However, for Wyeth's Triphasil and Berlex's Tri-Levlen the phase 1 dosage of progestin and ethinyl estradiol is much lower than for monophasics."( How effective are low-dose triphasics when pills are missed?
, 1988
)
0.49
" Moderately dosed combined OCs elevate triglycerides but their effects on total cholesterol and HDL are moderate."( [Metabolic risks of oral contraception].
Monier, L, 1988
)
0.27
"The effect on liver functions of oral contraceptives (OCs) was studied by measuring the effect low dosage (Primovlar and Ovulen) OCs on serum pseudocholine esterase, a hepatic enzyme."( Effect of low dosage contraceptive pills on serum pseudocholine esterase level.
El Khodary, M; Mikaty, N; Nagui, AR; Shaarawy, M; Shalaby, M, 1976
)
0.26
" These variations depend on the different methods of dosage and on individual variations among patients."( [What happens in our patients' bodies to the steroid hormones we prescribe? Pt. 1. Estrogens].
Rozenbaum, H, 1981
)
0.26
" Since the levels of HDL between the OC I and OC II groups did not differ significantly, there is no advantage to a reduced dosage of estrogen and progestogen."( The influence of high- and low-dose hormonal contraceptives on HDL and total cholesterol levels.
Novacan Hudnik, S; Pretnar Darovec, A,
)
0.13
" Incomplete ovarian inhibition poses risks over the short and long terms of functional ovarian cysts and loss of the protective effects of higher dosed pills against ovarian and endometrial cancers and benign breast disease."( [Oral contraception: disadvantages of estrogen reduction].
Denis, C, 1993
)
0.29
" Dosage is increased only when break through bleeding occurs."( Newer synthetic progestins for the treatment of endometriosis.
Kistner, RW, 1970
)
0.25
" The optimum dosage of oral contraceptives to attain this condition has yet to be determined, and the dosage of estrogen in particular may be significantly reduced."( Tricycle pill regime.
Loudon, NB, 1978
)
0.26
" In general, the lowest effective dose of any drug, including contraceptives, is the best practice, but as the dosage is decreased from 50 mcg, cycle control is less effective though side effects are minimized; therefore, reliance on bleeding patterns is necessary for deciding an individual's dosage schedule."( The choice of the dose of oestrogen in a combined oral contraceptive.
Smith, M, 1978
)
0.26
" Administration and dosage of the various agents is to be specified by a doctor according to the particular method, and to the state of health of the patient."( [Pharmacological aspects of oral contraceptives (author's transl)].
Simon, P; Soubrie, C; Weil-levy, C, 1980
)
0.26
" Results with hirsutism were satisfactory in 9 of 11 cases but the improvement was slow and often incomplete due to the weak dosage of cyproterone acetate."( [Clinical use of ethinyl estradiol in combination with cyproterone acetate. Study based on 50 cases (author's transl)].
Henrion, R; Laveissiere, MN, 1982
)
0.6
" RT-PCR was used as a semiquantitative technique to record gene expression in adult male zebrafish, which were exposed to 17alpha-ethinylestradiol in time-and dose-response experiments."( Effects of 17a-ethinylestradiol on the expression of three estrogen-responsive genes and cellular ultrastructure of liver and testes in male zebrafish.
Braunbeck, T; Islinger, M; Völkl, A; Willimski, D, 2003
)
0.32
"1, 1, 4, 20, and 75 mg/kg in a 21-d dose-response study."( Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat.
Evans, GL; Green, SJ; Lotinun, S; Pribluda, VS; Sibonga, JD; Turner, RT, 2003
)
0.32
" In order to understand better the molecular events associated with the activation of the estrogen receptor (ER), we have used microarray technology to determine the transcriptional program and dose-response characteristics of exposure to a potent synthetic estrogen, 17 alpha-ethynyl estradiol (EE), during prepubertal development."( Gene expression profile induced by 17 alpha-ethynyl estradiol in the prepubertal female reproductive system of the rat.
Carr, GJ; Daston, GP; Naciff, JM; Overmann, GJ; Richardson, BD; Tiesman, JP; Torontali, SM, 2003
)
0.32
"Toxicity of 17alpha-ethynylestradiol (EE2) and norethindrone (NOR), constituents of low dosage oral contraceptives, was assessed for the freshwater cladoceran Daphnia magna."( Toxicity of 17alpha-ethynylestradiol and norethindrone, constituents of an oral contraceptive pill to the swimming and reproduction of cladoceran Daphnia magna, with special reference to their synergetic effect.
Goto, T; Hiromi, J, 2003
)
0.32
" Kinetic and PAC dose-response experiments were conducted with the two best performing PACs."( HPLC-fluorescence detection and adsorption of bisphenol A, 17beta-estradiol, and 17alpha-ethynyl estradiol on powdered activated carbon.
Esparza, M; Snyder, SA; Westerhoff, P; Yoon, Y, 2003
)
0.32
"To compare the effects of the contraceptive patch to oral contraceptives (OCs) on follicular size and incidence of ovulation in normal cycles and after dosing errors."( Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.
Archer, DF; Creasy, GW; Fisher, AC; Moreau, M; Pierson, RA; Shangold, GA, 2003
)
0.32
"Follicular size and incidence of ovulation were significantly reduced among contraceptive patch users compared with women using OCs in normal cycles and after planned dosing errors."( Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.
Archer, DF; Creasy, GW; Fisher, AC; Moreau, M; Pierson, RA; Shangold, GA, 2003
)
0.32
" Results showed that the dosage regimen could damage the epididymal sperms and onset of antifertility within 6 weeks in male rats, and prevent the incidence of the side effect of irreversible azoospermia."( [A beam of dawn light of study on gossypol as a safe, effective, and reversible male antifertility contraceptive--evaluation of the studies by using low dose gossypol combined with steroid hormone for male contraception].
Xue, S, 2000
)
0.31
" Additional dose-response studies (semistatic, 3 weeks) with 4-nonylphenol (20, 100, and 500 microg/L), bisphenol A (40, 200, and 1000 microg/L), dibutylphthalate (40, 200, and 1000 microg/L DBP), and 17beta-estradiol (20 and 100 ng/L E2) were conducted."( Comparison of vitellogenin responses in zebrafish and rainbow trout following exposure to environmental estrogens.
Van den Belt, K; Verheyen, R; Witters, H, 2003
)
0.32
" Reduced frequency of dosing has the potential to improve patient compliance."( Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
Henzl, MR; Loomba, PK, 2003
)
0.32
" The current formulation offers an ultra-low steroidal dosage combined with a reduced pill-free interval to improve contraceptive efficacy."( The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg.
, 1999
)
0.3
" Different formulations of miconazole nitrate and single as well as multiple dosing were investigated during two separate randomized, open-label, crossover studies."( The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication.
Dieben, TO; Mulders, TM; van den Heuvel, MW; Verhoeven, CH, 2004
)
0.32
" This was prevented by ormeloxifene and the effect, though apparently more in females supplemented with higher dose of ormeloxifene, was not always significantly different and clear dose-response was not evident until BMD data was evaluated on T-/Z-score basis."( In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator.
Arshad, M; Ghosh, R; Sawlani, V; Sengupta, S; Sharma, S; Singh, MM, 2004
)
0.32
" Results demonstrated that the combined dosage regimen could damage epididymal sperm motility and density, and induce infertility within 8 weeks in rats; the infertility could be consistently sustained by giving single GA (12."( Combined administration of low-dose gossypol acetic acid with desogestrel/mini-dose ethinylestradiol/testosterone undecanoate as an oral contraceptive for men.
Cui, GH; Guo, Y; Xue, SP; Yang, ZJ; Ye, WS, 2004
)
0.32
" In this study, the influence of glucomannan in the oral bioavailability of ethinyl estradiol (EE), when administered to female rabbits in two different dosage forms (enteric capsules and dispersed in water), was established."( Effect of glucomannan and the dosage form on ethinylestradiol oral absorption in rabbits.
Castro, LJ; Diez, MJ; Fernández, N; García, JJ; González, A; Sahagún, A; Sierra, M, 2004
)
0.55
" The proposed normalization procedure is applied to a two-channel dose-response experiment."( Normalization of two-channel microarray experiments: a semiparametric approach.
Boverhof, DR; Burgoon, LD; Eckel, JE; Gennings, C; Therneau, TM; Zacharewski, TR, 2005
)
0.33
"250 mg per 7-day phase, respectively) for 5 days (days 17-21) concurrently with either 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21) or matching placebo during 2 consecutive 28-day OC dosing cycles."( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005
)
0.33
" For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.55
"In these healthy volunteers, steady-state zonisamide dosing had no clinically significant effect on the pharmacokinetics of EE or NOR."( Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Dai, Y; Griffith, SG, 2004
)
0.55
"]), for four days, dosing from postnatal day (PND) 20-23)."( Evaluation of the gene expression changes induced by 17-alpha-ethynyl estradiol in the immature uterus/ovaries of the rat using high density oligonucleotide arrays.
Carr, GJ; Daston, GP; Naciff, JM; Overmann, GI; Tiesman, JP; Torontali, SM, 2005
)
0.33
", a non-monotonic dose-response curve)."( Gene expression changes induced in the testis by transplacental exposure to high and low doses of 17{alpha}-ethynyl estradiol, genistein, or bisphenol A.
Carr, GJ; Daston, GP; Foertsch, LM; Hess, KA; Martinez, JE; Naciff, JM; Overmann, GJ; Richardson, BD; Tiesman, JP; Torontali, SM, 2005
)
0.33
" Regarding a potential for use in osteoporosis-prevention therapy, the dosage of a phytoestrogen, which is taken, will play an important role concerning a desired in vivo profile."( Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens.
Effenberger, KE; Johnsen, SA; Monroe, DG; Spelsberg, TC; Westendorf, JJ, 2005
)
0.33
"In women who are growth hormone (GH) deficient, exogenous estrogens increase the dosage of GH that is needed to normalize circulating levels of insulin-like growth factor (IGF-1)."( Influence of estrogen administration on the growth response to growth hormone (GH) in GH-deficient mice.
Alba, M; Fintini, D; Salvatori, R, 2005
)
0.33
" We believe that the observed reduction in the number of bleeding days by almost 50% compared to placebo in both the mifepristone combination group and the doxycycline group demonstrates a clinically significant improvement in bleeding patterns and that further trials are needed to compare different combinations of therapy as well as multiple dosing regimens in order to establish which is the most effective treatment option."( A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.
Findlay, JK; Fraser, IS; Hickey, M; O'Connor, V; Palmer, D; Salamonsen, LA; Weisberg, E, 2006
)
0.33
" With multiple regression analysis, a statistically significant effect was observed only in boys using a pharmacologic dosage (5."( Growth-reductive therapy in children with marfan syndrome.
Hennekam, RC; le Cessie, S; Rozendaal, L; Wit, JM, 2005
)
0.33
" This contraception has to be prescribed together with insulin dosage correction and demands on strict metabolic control of the diabetes and body weight."( [Contraception in women with diabetes mellitus].
Dimitrov, A; Kolarov, G; Mekhandzhiev, Ts; Nikolov, A; Todarova, K, 2005
)
0.33
" A dosage adjustment for lamotrigine may need to be considered when these agents are co-administered."( The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Job, S; Philipson, R; Sidhu, J; Singh, S, 2006
)
0.33
"To estimate whether progestin type or estrogen dose influences bleeding patterns, adverse effects, or satisfaction with combined oral contraceptives dosed continuously."( Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
Edelman, AB; Jensen, JT; Koontz, SL; Nichols, MD, 2006
)
0.33
" It is unclear whether the success was due to a higher dosage of finasteride (2."( Finasteride treatment of female pattern hair loss.
Iorizzo, M; Piraccini, BM; Tosti, A; Vincenzi, C; Voudouris, S, 2006
)
0.33
" The compounds were dosed (s."( Histopathology and histomorphometry of the urogenital tract in 15-month old male and female rats treated neonatally with SERMs and estrogens.
Karlsson, S, 2006
)
0.33
"The suspicion was that the graduated dosage of estrogen used for the donor-oocyte cycles suppressed the FSH allowing her to respond to endogenous gonadotropins."( Successful pregnancy with spontaneous ovulation in a woman with apparent premature ovarian failure who failed to conceive despite four transfers of embryos derived from donated oocytes.
Check, JH; Katsoff, B, 2006
)
0.33
" Mean t(1/2,z) of CMA was approximately 25 h after single dosing and 36-39 h at steady state."( Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Göhler, K; Kneip, C; Terlinden, R; Uragg, H, 2006
)
0.33
"The pharmacokinetics of CMA and EE is linear after multiple dosing and remains stable during long-term administration, once steady state is reached."( Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Göhler, K; Kneip, C; Terlinden, R; Uragg, H, 2006
)
0.33
" HO-1 expression was undetectable in hepatic parenchymal cells from rats receiving Methocel control or a single dose of ethinyl estradiol, however cytosolic HO-1 immunoreactivity in these cells after repeated dosing of ethinyl estradiol was pronounced."( Hepatic expression of heme oxygenase-1 and antioxidant response element-mediated genes following administration of ethinyl estradiol to rats.
Barron, AM; Leone, A; Lord, P; McMillian, MK; Morio, LA; Nie, AY; Parker, JB; Sawant, SP; Taggart, P, 2006
)
0.75
"Serial plasma and intracellular zidovudine pharmacokinetics following oral and intravenous dosing were determined in 18 men and 20 women treated with zidovudine."( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.
Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006
)
0.33
"Men exhibited higher area under the concentration versus time curve for intracellular zidovudine and zidovudine-monophosphate following oral and intravenous dosing and higher zidovudine triphosphate following oral dosing."( The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.
Aberg, J; Aweeka, FT; Bardeguez, A; Coombs, RW; Lizak, P; Rosenkranz, SL; Segal, Y; Thevanayagam, L; Watts, DH, 2006
)
0.33
" One means of improving user adherence with hormonal contraception is to minimize the dosing schedule."( A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch.
Graziottin, A, 2006
)
0.33
" Forty female Sprague-Dawley rats were divided into two groups: an experimental group received daily ethinylestradiol and levonorgestrel in a dosing model designed to simulate a typical oral contraception regime in humans, while a control group received daily oral placebo."( Reproductive hormone effects on strength of the rat anterior cruciate ligament.
Huber, P; Schmale, GA; Seidel, K; Simonian, P; Tencer, A; Woodhouse, E, 2007
)
0.34
"Adult, ovariectomized, female Macaca fascicularis, n = 3 per group, orally dosed for 12 weeks with vehicle; selective estrogen receptor modulator 393 (2, 4, or 8 mg/kg/day); selective estrogen receptor modulator 379 (4 mg/kg per day); raloxifene (3 mg/kg per day); tamoxifen (1 mg/kg per day); or ethinyl estradiol (3 microg/kg per day)."( Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Brown, KH; Cline, JM; Hutchison, J; Lees, CJ; Lundeen, S; Register, TC; Sikoski, P, 2007
)
0.74
"Administration of a 3 day dosing regimen of oral rifaximin was well tolerated and did not alter the pharmacokinetics of a commonly used combination OC containing EE and norgestimate."( Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
Bettenhausen, DK; Connolly, M; Forbes, WP; Pentikis, H; Trapnell, CB, 2007
)
0.58
"Film forming polymeric solutions may present an alternative to the common transdermal dosage forms such as patches or gels."( Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs.
Franke, P; Lehr, CM; Schaefer, UF; Zurdo Schroeder, I, 2007
)
0.34
" For EE2 a dose-response relationship was established with EC50 = 60."( Testing estrogenicity of known and novel (xeno-)estrogens in the MolDarT using developing zebrafish (Danio rerio).
Eggen, RI; Junghans, M; Muncke, J, 2007
)
0.34
" Zooplankton composition and physico-chemical variables were observed during 4 weeks of pre-application, 6 weeks of dosing via controlled release, and a 12 weeks post-treatment period."( Impact of 17alpha-ethinylestradiol on the plankton in freshwater microcosms--I: response of zooplankton and abiotic variables.
Hense, BA; Jaser, W; Pfister, G; Schramm, KW; Welzl, G; Wöhler-Moorhoff, GF, 2008
)
0.35
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" However, on the basis of the dose-response relationship between EE2 concentration and estrogenic activity in the yeast two-hybrid assay, it was surmised that the estrogenic activity in the culture medium of NAS may have been produced mostly by the remaining EE2 and not by its degradation intermediates and products."( Estrogenic activity removal of ethynylestradiol by nitrifying activated sludge and microorganisms involved in its degradation.
Fujisawa, S; Hosomi, M; Nakai, S; Nishikawa, M; Shi, J; Takada, M, 2007
)
0.34
" Several new contraceptive methods with alternate routes of delivery and less frequent dosing are available."( The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.
Arias, RD; Nucatola, DL; Wagner, MS, 2007
)
0.64
" The use of microarray technology to explore the molecular signals that underlie these dose-dependent processes has become increasingly common; however, the number of software tools for quantitatively analyzing and interpreting dose-response microarray data has been limited."( BMDExpress: a software tool for the benchmark dose analyses of genomic data.
Allen, BC; Thomas, RS; Yang, L, 2007
)
0.34
"We have developed BMDExpress, a Java application that combines traditional benchmark dose methods with gene ontology classification in the analysis of dose-response data from microarray experiments."( BMDExpress: a software tool for the benchmark dose analyses of genomic data.
Allen, BC; Thomas, RS; Yang, L, 2007
)
0.34
" The software allows users to efficiently analyze large dose-response microarray studies and identify reference doses at which particular cellular processes are altered."( BMDExpress: a software tool for the benchmark dose analyses of genomic data.
Allen, BC; Thomas, RS; Yang, L, 2007
)
0.34
" This review focuses on a unique oral contraceptive formulation containing levonogestrel 90 microg and ethinyl estradiol 20 microg, approved for use in a continuous dosing regimen designed to eliminate withdrawal bleeding throughout the entire year."( Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms.
Archer, DF; Jensen, JT, 2008
)
0.81
"Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing regimen the lowest dosage of ethinyl estradiol commonly used today with drospirenone, an innovative progestin."( Drospirenone/ethinyl estradiol.
Rapkin, AJ; Sorger, SN; Winer, SA, 2008
)
1.05
"This study was conducted to compare ovarian activity of an oral contraceptive containing drospirenone (drsp) 3 mg plus ethinylestradiol (EE) 20 mcg administered in 24/4 regimen compared with the conventional 21/7 regimen, during intended use and following predefined dosing errors."( Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Duijkers, I; Klipping, C; Marr, J; Trummer, D, 2008
)
0.35
"The drsp 3 mg/EE 20 mcg oral contraceptive in a 24/4 regimen was associated with greater ovarian suppression (despite intentional dosing error), which results in decreased hormonal fluctuations, and may increase contraceptive efficacy with the low-dose formulation."( Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Duijkers, I; Klipping, C; Marr, J; Trummer, D, 2008
)
0.35
" A reduction of the hormone-free interval of the pill to 5 or 4 days results in a complete suppression of the ovarian function, a reliable ovulation inhibition and an increase of the contraceptive efficacy in spite of a reduction of the EE dosage to 20 microg or 15 microg."( [Oral contraception - doses and way of administration].
Birkhäuser, M; Braendle, W; Keller, PJ; Kiesel, L; Kuhl, H; Mueck, A; Neulen, J; Thaler, C, 2009
)
0.35
" Ovariectomized C57BL6 mice were dosed with 20 micrograms/kg ethinylestradiol and the uterus was collected at 6, 24, and 72 h later to bracket the biphasic time course of estrogen action in the rodent uterus."( Estrogen modulates expression of putative housekeeping genes in the mouse uterus.
Nagel, SC; Pelch, KE; Schroder, AL, 2009
)
0.35
" The uniformity of dosage units test showed that the distribution of drugs in the matrix was homogeneous, which was further demonstrated by the polariscope result."( Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol.
Gao, Y; Liang, J; Liu, J; Xiao, Y, 2009
)
0.35
" The 20 microg dosage was preferred for women older than 35, those smoking more than 15 cigarettes per day, those with a family history of VTE, and those complaining of breast tenderness or headache."( Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: does it make a difference in the mind and the daily practise of gynaecologists and general practitioners?
Bitzer, J; Frey, B; Sabler, N; Tschudin, S; von Schönau, M, 2009
)
0.35
"Swiss gynaecologists and GPs do not preferentially prescribe the lowest possible dosage of EE."( Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: does it make a difference in the mind and the daily practise of gynaecologists and general practitioners?
Bitzer, J; Frey, B; Sabler, N; Tschudin, S; von Schönau, M, 2009
)
0.35
"Tenofovir DF and norgestimate-ethinyl estradiol are not involved in a clinically significant drug-drug interaction; tenofovir DF did not affect the steady-state pharmacokinetics of norgestimate or ethinyl estradiol, including the concentration at the end of the dosing interval."( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney, BP; Mathias, A, 2009
)
0.64
"This study compared the bleeding pattern, cycle control and safety of an oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG)."( Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
Ahrendt, HJ; Makalová, D; Mansour, D; Mellinger, U; Parke, S, 2009
)
0.73
" These results demonstrate that developmental exposure to pharmacologically relevant dosage levels of EE2 can permanently disrupt the reproductive morphology and function of the female rat."( In utero and lactational exposure to bisphenol A, in contrast to ethinyl estradiol, does not alter sexually dimorphic behavior, puberty, fertility, and anatomy of female LE rats.
Crofton, KM; Gray, LE; Hotchkiss, AK; Ryan, BC, 2010
)
0.6
" This might be an effect of the convenience of the weekly dosing schedule."( Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users.
Bodner, K; Bodner-Adler, B; Grünberger, W, 2011
)
0.37
"The contraceptive vaginal ring offers effective contraception that is self-administered, requires less frequent dosing than many other forms of contraception, and provides low doses of hormones."( The contraceptive vaginal ring.
Edwardson, J; Jamshidi, R, 2010
)
0.36
"In this study a zero crossing technique based on continuous wavelet transform (CWT) as well as classical derivative spectrophotometry (CDS) is presented for simultaneous determination of cyproterone acetate and ethinyl estradiol in binary mixtures and commercial dosage of drug, without using prior chemical pre-treatment."( Simultaneous spectrophotometric determination of cyproterone acetate and ethinyl estradiol in tablets using continuous wavelet and derivative transform.
Abdolmaleki, P; Esmaeili, EA; Sohrabi, MR, 2010
)
0.78
" EE/DRSP 24+4 (24 tablets containing hormones plus 4 containing placebo) features an innovative dosing regimen."( [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen].
Bruni Bresciani, V, 2010
)
0.36
" Oral contraceptives used were classified into those containing androgenic or antiandrogenic progestins and by ethinylestradiol (EE) dosage (20 mcg, 30 mcg and >30 mcg)."( Effects of sex hormones in oral contraceptives on the female sexual function score: a study in German female medical students.
Bitzer, J; Mueck, AO; Seeger, H; Wallwiener, CW; Wallwiener, LM; Wallwiener, M; Zipfel, S, 2010
)
0.36
"Although mounting evidence suggests exposure to estrogenic contaminants increases vitellogenin production in molluscs, demonstration of dose-response relationships and knowledge of the temporal nature of the vitellogenin response with continual exposure is currently lacking for biomarker utility."( Exposure to 17α-ethynylestradiol causes dose and temporally dependent changes in intersex, females and vitellogenin production in the Sydney rock oyster.
Andrew, MN; Dunstan, RH; Macfarlane, GR; O'Connor, WA, 2010
)
0.36
" This study investigated the impact of a transient exposure to ethinylestradiol (EE(2)) during early life (from 20-60 days post fertilization), including at a dosing level within the environmental range, on the subsequent reproductive behavior and success in both male and female zebrafish (Danio rerio) in competitive breeding scenarios."( Impacts of early life exposure to estrogen on subsequent breeding behavior and reproductive success in zebrafish.
Coe, TS; Filby, AL; Hodgson, D; Söffker, MK; Tyler, CR, 2010
)
0.36
" Pharmacokinetic parameters over the 24-h dosing period were similar at all time points measured after achieving steady-state plasma concentrations."( Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti, CE; Hendy, CH; Margolis, MB; O'Leary, CM; Waters, DH, 2011
)
0.37
" Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments."( Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Hindsberger, C; Jacobsen, LV; Vouis, J; Zdravkovic, M, 2011
)
0.92
" Dose-response LHR using patient basophils was observed for different hormones but after 3 months persisted only for 5β-pregnanediol."( A case of progesterone-induced anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis.
Bernstein, DI; Bernstein, IL; Bernstein, JA; Lummus, ZL, 2011
)
0.37
" The peak plasma concentration (C(max)), area under the concentration-time curve for a dosing interval (AUC([τ])), and lowest plasma concentration (C(min)) for EE and NGMN during cycles of treatment with Ortho Cyclen with and without coadministration of efavirenz were compared."( The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
Bertz, R; Eley, T; Garner, D; Krantz, K; Nettles, R; Persson, A; Sevinsky, H; Yones, C; Zhang, J, 2011
)
0.59
"ATV/RTV with dose-normalized EE/NGM resulted in geometric mean reductions of 16% in EE peak plasma concentration (C(max)), 19% in EE area under the concentration-time curve for a dosing interval (AUC([τ])) and 37% in EE lowest plasma concentration (C(min)), compared with EE 35 μg with NGM in the absence of ATV/RTV."( The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
Bertz, R; Chung, E; Eley, T; Mahnke, L; Persson, A; Xu, X; Yones, C; Zhang, J, 2011
)
0.59
" We excluded studies comparing monophasic with multiphasic pills, crossover trials, trials in which the difference in total content of ethinyl estradiol between preparations exceeded 105 µg per cycle and those comparing continuous dosing regimens."( Types of progestogens in combined oral contraception: effectiveness and side-effects.
Bloemenkamp, K; Gülmezoglu, AM; Helmerhorst, FM; Kulier, R; Lawrie, TA; Maitra, NK, 2011
)
0.57
" Therefore research focused on diminuition of the EE dosage and the development of a different estrogen component in oral contraceptives, specifically an estrogen occurring during physiological processes in the female body."( Pharmacological profile of estrogens in oral contraception.
Bitzer, J, 2011
)
0.37
" The pharmacokinetic parameters measured were maximum steady-state plasma concentration during a dosage interval (C(max,ss)), time to reach maximum plasma concentration following administration at steady state (t(max,ss)) and area under the plasma concentration-time curve during a dosage interval (τ) at steady state (AUC(τ,ss))."( Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich, C; Giessmann, T; Graefe-Mody, U; Iovino, M; Port, A; Ring, A; Woerle, HJ, 2011
)
0.37
"5 mg×kg(-1)×d(-1)) was given; group H, the same dosage of DSG/EE/TU as in group GH were administered; group C, rats were treated with vehicle (1% methyl cellulose) as control."( Drug synergistic antifertility effect of combined administration of low-dose gossypol with steroid hormones in rats.
Chang, Q; Hei, CC; Liu, Z; Ma, WZ; Qian, XJ; Shen, XS; Xu, ZL, 2011
)
0.37
" Blood samples were collected up to 24 hours after dosing on prespecified days."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
" Only treatments with stable dosing during a cycle were accepted."( Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide.
Düsterberg, B; Endrikat, J; Gerlinger, C; Richard, S; Rosenbaum, P, 2011
)
0.37
" We designed one example of a dose-response curve using the statistical model."( Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide.
Düsterberg, B; Endrikat, J; Gerlinger, C; Richard, S; Rosenbaum, P, 2011
)
0.37
" The bleeding patterns of two variants of a flexible dosing regimen designed to manage intracyclic bleeding problems during extended cycles were compared with that of a conventional OC regimen."( Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Elliesen, J; Garie, SG; Jensen, JT; Trummer, D, 2012
)
0.38
" The primary regimen [management of intracyclic bleeding (flexible(MIB)) regimen] was an extended dosing regimen that required subjects to initiate 4-day tablet-free intervals after 3 days of breakthrough bleeding/spotting."( Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Elliesen, J; Garie, SG; Jensen, JT; Trummer, D, 2012
)
0.38
"A flexible(MIB) dosing regimen of EE 20 mcg/drospirenone 3 mg is associated with good contraceptive efficacy and fewer bleeding/spotting days than the conventional 24/4 regimen."( Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Elliesen, J; Garie, SG; Jensen, JT; Trummer, D, 2012
)
0.38
" Interestingly, gene expression changes displayed a traditional dose-response relationship, with benchmark dose levels for the expression of Mt1, Mt2, p53, c-fos, and Mdm2 being 92."( Cadmium-induced effects on cellular signaling pathways in the liver of transgenic estrogen reporter mice.
Adamsson, A; Åkesson, A; Ali, I; Berglund, M; Damdimopoulou, P; Håkansson, H; Halldin, K; Mäkelä, SI; Stenius, U, 2012
)
0.38
" Healthy subjects were co-administered (1) single dose midazolam, a prototypical CYP3A4 substrate, followed by 14 days of lersivirine twice daily with single dose midazolam on the final day of lersivirine dosing or (2) 10 days of once-daily (QD) lersivirine and QD oral contraceptives (OCs; ethinylestradiol and levonorgestrel), substrates for CYP3A4, UGT2B7, and/or P-glycoprotein."( The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
Chong, CL; Davis, J; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.38
"We report a dose-response relationship between fertility in later life and estrogen dose used for the treatment of tall stature in adolescent girls; a higher estrogen dose is associated with increased infertility."( Fertility of tall girls treated with high-dose estrogen, a dose-response relationship.
Boot, AM; Drop, SL; Hendriks, AE; Laven, JS, 2012
)
0.38
"To determine whether extended-cycle dosing of an ultralow dose vaginal ring contraceptive decreases frequency of migraine aura and prevents menstrual related migraine (MRM)."( The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series.
Calhoun, A; Ford, S; Pruitt, A, 2012
)
0.38
" With the evolution of increasingly lower dosed combined hormonal contraceptives, we now have formulations that--provided that ovulation is inhibited--result in lower peak levels of estrogen than the concentrations attained during the native menstrual cycle."( The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series.
Calhoun, A; Ford, S; Pruitt, A, 2012
)
0.38
" The greater impact of PAC dosing on EE2 removal was due to its greater hydrophobic property."( Removal mechanisms of 17β-estradiol and 17α-ethinylestradiol in membrane bioreactors.
Cicek, N; Yang, W; Zhou, H, 2012
)
0.38
"Our finding showed that EE in tested dosage within MC3T3-E1 cells seem to affect the proliferation and differentiation; however, significant differences are achieved in ALP activity in early differentiation phase and further studies are needed to elucidate the mechanisms of EE on bone."( Effects of 17-α ethynyl estradiol on proliferation, differentiation & mineralization of osteoprecursor cells.
Park, JB, 2012
)
0.38
" No dose-response relation was found between the dose of ethinyloestradiol and AMH or AFC."( Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception.
Bentzen, JG; Forman, JL; Friis-Hansen, L; Johannsen, TH; Larsen, EC; Lidegaard, Ø; Nyboe Andersen, A; Pinborg, A, 2012
)
0.38
"The pharmacokinetics of EE and LNG at steady state based on the primary endpoints of area under the steady-state plasma concentration-time curve during a dosage interval τ (AUC(τ,ss)) and maximum steady-state plasma concentration during a dosage interval (C (max,ss)) were the main outcome measures."( Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ, 2013
)
0.39
" The hazard ratio (HR) from Cox proportional hazards models was used to assess the VTE relative risk (RR) with drospirenone compared with levonorgestrel, adjusted by a propensity score used to control for baseline co-morbidity and stratified by EE dosage and user-type (new/current)."( Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG, 2013
)
0.39
" An Arrhenius relationship of the zero-order release constants was established, indicating that temperature is a valid parameter to accelerate drug release from this dosage form and that the release mechanism is maintained under these accelerated test conditions."( Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring.
Clark, MR; Externbrink, A; Friend, DR; Klein, S, 2013
)
0.39
"The objective of this multicentre, randomised, double-blind study was to compare a combined oral contraceptive (COC) containing oestradiol valerate/dienogest (E2V/DNG) administered in a dynamic dosing regimen with a monophasic COC containing ethinyloestradiol/levonorgestrel (EE/LNG), with regard to their ability to reduce the frequency and intensity of headache and pelvic pain in women with hormone withdrawal-associated symptoms (HWAS)."( Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.
Macìas, G; Mellinger, U; Merki-Feld, GS; Parke, S; Serrani, M, 2013
)
0.39
"Co-administration of rilpivirine, at the therapeutic dosing regimen, with ethinylestradiol/norethindrone does not affect hormone pharmacokinetics, and is, therefore, unlikely to affect the efficacy or safety of this oral hormonal contraceptive."( Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Buelens, A; Crauwels, HM; Hoetelmans, RM; Stevens, M; van Heeswijk, RP, 2014
)
0.4
"5 μg/kg bw/day BPA (7-10nM), despite careful attention to potential BPA inputs (diet, drinking water, vehicle, cages, bedding, and dust) and rigorous dosing solution certification and delivery."( Comparison of life-stage-dependent internal dosimetry for bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of action in Sprague Dawley rats.
Camacho, L; Churchwell, MI; Delclos, KB; Doerge, DR; Fisher, JW; Sepehr, E; Twaddle, NC; Vanlandingham, MM, 2014
)
0.64
"Interventions comprised placebo or recombinant GH injections three times a week, with daily oral placebo or oral EE2 during childhood (25 ng/kg/d, ages 5-8 y; 50 ng/kg/d, ages >8-12 y); after age 12, all patients received escalating EE2 starting at a nominal dosage of 100 ng/kg/d."( Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial.
Cutler, GB; Garg, S; Kowal, K; Quigley, CA; Ross, JL; Wan, X, 2014
)
0.4
" Sometimes exogenous gonadotropins are needed as a boost but the dosage should be low so as not to down-regulate FSH receptors again."( Premature ovarian insufficiency - fertility challenge.
Check, JH, 2014
)
0.4
" Isotretinoin seems to provide the best chance at remission, but the number of reports is small, dosing schedules variable, and the long term follow up beyond a year is negligible; treatment failures have been reported."( Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppura
Scheinfeld, N, 2014
)
0.4
" High dosage of H2O2 and low pH were favorable for the degradation of EDCs."( Removal of phenolic endocrine disrupting compounds from waste activated sludge using UV, H2O2, and UV/H2O2 oxidation processes: effects of reaction conditions and sludge matrix.
Li, Y; Zhang, A, 2014
)
0.4
"Obese [body mass index (BMI)≥30 kg/m(2)], ovulatory, otherwise healthy, women received an OC containing 20 mcg ethinyl estradiol (EE)/100 mcg levonorgestrel (LNG) dosed cyclically (21 days active pills with 7-day placebo week) for two cycles and then were randomized for two additional cycles to the following: continuous cycling (CC, a dose neutral arm using the same OC with no hormone-free interval) or increased dose (ID, a dose escalation arm using an OC containing 30 mcg EE/150 mcg LNG cyclically)."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.61
"Both increasing the OC dose and continuous dosing appear to counteract the impact of obesity on key OC PK parameters."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.4
" Although the impact of these changes on OC efficacy is still under debate, PK parameters can be normalized in obese users by continuous dosing or increasing to a low-dose pill."( Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Cherala, G; Edelman, AB; Jensen, JT; McInnis, M; Munar, MY; Stanczyk, FZ, 2014
)
0.4
" Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleeding profiles during extended cycles through active management of bleeding symptoms."( Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive.
Han, L; Jensen, JT, 2014
)
0.87
"We examine the rationale for flexible extended dosing as well as review the dosing regimen."( Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive.
Han, L; Jensen, JT, 2014
)
0.64
"Flexible extended dosing of DRSP/EE (3 mg/20 μg) has similar pharmacokinetics and contraceptive efficacy of both conventional and fixed extended regimens."( Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive.
Han, L; Jensen, JT, 2014
)
0.64
" The primary outcome measure was the area under the concentration-time curve over a dosing interval of τ = 24 h (AUCτ) for EE and LNG plasma levels."( No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
Dienel, A; Heger-Mahn, D; Klipping, C; Pabst, G; Schläfke, S, 2014
)
0.62
" Effects of initial pH and CaO2 dosage were investigated."( Performance of calcium peroxide for removal of endocrine-disrupting compounds in waste activated sludge and promotion of sludge solubilization.
Li, Y; Wang, J; Zhang, A, 2015
)
0.42
"The remediation of four estrogenic endocrine-disrupting compounds (EDCs), estrone (E1), estradiol (E2), ethinylestradiol (EE2) and estriol (E3), was measured in saturated and unsaturated carbonate sand-filled columns dosed with wastewater from a sewage treatment plant."( Behaviour of estrogenic endocrine-disrupting chemicals in permeable carbonate sands.
Erler, DV; Eyre, BD; Kimber, S; Shepherd, BO; Tait, DR; van Zwieten, L, 2015
)
0.42
" FSFI scores for the three EE dosage categories and progestin components did not differ significantly."( Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland.
Bitzer, J; Brucker, SY; Mueck, AO; Schönfisch, B; Seeger, H; Taran, FA; Wallwiener, CW; Wallwiener, LM; Wallwiener, M; Zipfel, S, 2015
)
0.42
"25 mg once daily, n = 32) dosing was initiated on days 11 or 8, respectively, with evening (arm 1) or morning (arm 2) dosing; at steady state (days 15 or 22), a single lomitapide dose was administered; CYP3A inhibitor dosing continued for 6 days."( Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Dutta, S; Foulds, P; King, A; Korb, S; Patel, G; Sumeray, M; Wade, JR, 2016
)
0.67
"Combined with a progestin, E4 adequately suppresses ovarian activity, particularly when given at a dosage above 10 mg/day."( Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Appels, N; Coelingh Bennink, HJ; Duijkers, IJ; Foidart, JM; Jost, M; Klipping, C; Maillard, C; Mawet, M; Zimmerman, Y, 2015
)
0.42
" Pregnant NCTR Sprague-Dawley rats were orally dosed from gestational day 6 to parturition, and offspring were directly orally dosed until weaning (postnatal day 21)."( Effects of developmental exposure to bisphenol A on spatial navigational learning and memory in rats: A CLARITY-BPA study.
Camacho, L; Ellersieck, MR; Ferguson, SA; Javurek, AB; Johnson, SA; Lewis, SM; Painter, MS; Rosenfeld, CS; Vanlandingham, MM; Welsh, TH, 2016
)
0.43
" OCs have evolved over time, with decreasing estrogen doses, new progestins, and different dosing regimens."( Oral contraceptive use among women aged 15 to 49: Results from the Canadian Health Measures Survey.
Black, A; Dunn, S; Rotermann, M, 2015
)
0.42
"Ethinylestradiol (EE) as a highly active and low dosed compound is prone to oxidative degradation."( Influence of in line monitored fluid bed granulation process parameters on the stability of Ethinylestradiol.
Fricke, S; Hacker, MC; Roßteuscher-Carl, K; Schulz-Siegmund, M, 2015
)
0.42
" Determination of serum EE level 24 hr after the initial dosing and 6 and 24 hr after the final dosing of 2 μg/kg indicated that the administered EE entered the circulation and cleared after every administration."( Dose-dependent acceleration in the delayed effects of neonatal oral exposure to low-dose 17α-ethynylestradiol on reproductive functions in female Sprague-Dawley rats.
Kamiie, J; Kawashima, J; Nakamura, T; Shirota, K; Shirota, M; Yoshida, M, 2015
)
0.42
" The flexible extended dosing regimen, containing drospirenone and ethinylestradiol, may be particularly useful in patients suffering severe dysmenorrhea and improving the adherence and compliance with treatment."( Advances in pharmacotherapy for treating endometriosis.
Alessandri, F; Bogliolo, S; Ferrero, S; Gardella, B; Grillo, F; Leone Roberti Maggiore, U; Mastracci, L; Tafi, E; Vellone, VG, 2015
)
0.42
" The Ishikawa cell was determined to be fit for the purpose of recapitulating in vivo uterine response by verifying fidelity of the biological pathway components and the dose-response predictions to women of child-bearing age."( Editor's Highlight: Development of an In vitro Assay Measuring Uterine-Specific Estrogenic Responses for Use in Chemical Safety Assessment.
Alyea, RA; Andersen, MA; Balbuena, P; Childs, KM; Clewell, RA; Doheny, DL; Dong, J; LeSommer, C; Miller, MM; Ross, SM; Rowley, SM; Sun, B, 2016
)
0.43
" Confusing in some of the literature is that a few studies have reported erroneously calculated pharmacokinetic parameters after multiple dosing of oral contraceptives."( Clarification of contraceptive drug pharmacokinetics in obesity.
Jusko, WJ, 2017
)
0.46
"Ormeloxifene with its convenient twice-weekly dosage schedule was effective in treating AUB-L, with 72% of patients responding to 6-month treatment compared with 8% with COC, even though leiomyoma volume increased insignificantly with both ormeloxifene and COCs."( Efficacy of ormeloxifene versus oral contraceptive in the management of abnormal uterine bleeding due to uterine leiomyoma.
Agarwal, N; Bhatla, N; Hari, S; Kachhawa, G; Kriplani, A; Kulshrestha, V; Srivastava, A, 2016
)
0.43
" Forty-two healthy women, with regular intake of either high or low EE dosage over at least one year and up to 15 years participated in this study."( Contraceptive Use Affects Overall Olfactory Performance: Investigation of Estradiol Dosage and Duration of Intake.
Kollndorfer, K; Ohrenberger, I; Schöpf, V, 2016
)
0.43
"Although traditionally dosed combined oral contraceptives (COCs) (21 days of active pills, 7 days of inactive pills) have not been demonstrated as superior to placebo for the treatment of premenstrual dysphoria (PMD), some randomized controlled trials (RCTs) indicate that oral contraceptives administered with a shortened or eliminated hormone-free interval are superior to placebo."( Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.
Eisenlohr-Moul, TA; Girdler, SS; Johnson, JL; Rubinow, DR; Schmidt, PJ, 2017
)
0.46
"Fifty-five women with prospectively confirmed PMD completed a three-arm, RCT in which they were randomized to 3 months of placebo (n = 22), intermittent drospirenone/ethinyl estradiol dosed on a 21-7 schedule (n = 17), or continuous drospirenone/estradiol (n = 16) following a baseline assessment month."( Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.
Eisenlohr-Moul, TA; Girdler, SS; Johnson, JL; Rubinow, DR; Schmidt, PJ, 2017
)
0.65
" In general, the coexistence of RL-F1 and EE2 enhanced EE2 sorption in a wider monorhamnolipidic dosage range when freshly treated sorbate was used."( Sorption and desorption of 17α-ethinylestradiol onto sediments affected by rhamnolipidic biosurfactants.
Guo, YP; Hu, YY; Lin, H; Ou, XL, 2018
)
0.48
" Modeling results suggest that for E1, E2 and EE2, AOB-linked biodegradation is dominant over biodegradation by HB at all investigated COD dosing levels."( Model-based assessment of estrogen removal by nitrifying activated sludge.
Dai, X; Liu, Y; Ni, BJ; Peng, L; Song, S; Sun, J, 2018
)
0.48
"The in vivo relevance of ursodeoxycholate (UDCA) treatment (100 mg/kg/day, per oral tid for 5 days before cholestasis induction followed by the same dosing for 5 days) on hepatic function was investigated in rats with 17α-ethinylestradiol (EE, 10 mg/kg, subcutaneous for 5 days)-induced experimental cholestasis."( Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.
Chi, HY; Choi, MK; Choi, YA; Kang, YJ; Kim, MJ; Kwon, M; Shim, CK; Song, IS; Yoo, HH, 2018
)
0.71
" We also included data from 2 subjects who experienced rupture prior to COC dosing in the analysis."( Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study.
Edelman, AB; Hennebold, JD; Jensen, JT; McCrimmon, S; Messerle-Forbes, M; O'Donnell, A, 2018
)
0.48
"Laquinimod is an orally dosed immuno-modulator currently under development for Huntington's disease (HD)."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.51
" The ability of a progestin to inhibit ovulation depends on the type of compound and on its dosage and a difference of more than 20-fold in activity exists between compounds utilized today in COCs."( Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation.
Bastianelli, C; Benagiano, G; Brosens, I; Farris, M; Rosato, E, 2018
)
0.48
" Timed-pregnant National Center for Toxicological Research Sprague-Dawley rats (strain code 23) were dosed by gavage with vehicle control (0."( CLARITY-BPA: Bisphenol A or Propylthiouracil on Thyroid Function and Effects in the Developing Male and Female Rat Brain.
Bansal, R; Zoeller, RT, 2019
)
0.51
"Background Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type."( Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.
Adeyanju, OA; Olatunji, LA, 2019
)
0.51
" PBK models were developed using a generic approach and in vitro concentration-response data from the MCF-7 proliferation assay and the yeast estrogen screening assay were translated into in vivo dose-response data."( Development of a Generic Physiologically Based Kinetic Model to Predict In Vivo Uterotrophic Responses Induced by Estrogenic Chemicals in Rats Based on In Vitro Bioassays.
Rietjens, IMCM; van Ravenzwaay, B; Zhang, M, 2020
)
0.56
"Sprague-Dawley rats were exposed to BPA, vehicle, or positive control [ethinyl estradiol (EE2)] by oral gavage beginning on gestational day (GD)6 and continuing with direct dosing of the pups after birth."( A Combined Morphometric and Statistical Approach to Assess Nonmonotonicity in the Developing Mammary Gland of Rats in the CLARITY-BPA Study.
Acevedo, N; Bharadwaj, M; Fenton, SE; Montévil, M; Schaeberle, CM; Soto, AM, 2020
)
0.79
"Combined contraceptive vaginal rings (CVR) are increasingly appreciated due to several beneficial properties like avoidance of the hepatic first-pass effect, a comparatively low dosage of hormones and comfortable use."( Safety, efficacy and quality of life of the novel vaginal contraceptive ring containing etonogestrel/ethinylestradiol 11.0/3.474 mg after 3 years of "real life" experience.
Colli, E; Müller, A; Regidor, PA; Sailer, M, 2020
)
0.56
" Our aim was to describe the effectiveness and safety of both dosing strategies in our clinic cohort to help guide future management."( Double-Dose Desogestrel: Is it Effective in Adolescent Menstrual Dysfunction?
Burton, RC; Williams, CE, 2021
)
0.62
"Prevalence of amenorrhea and light spotting, side effects, and discontinuation rates of both dosing regimens."( Double-Dose Desogestrel: Is it Effective in Adolescent Menstrual Dysfunction?
Burton, RC; Williams, CE, 2021
)
0.62
" We then compared patients who received combined oral ethinyl estradiol with progestin (EE/P) in standard dosing (EE ≤35 mcg/day) vs taper dosing (EE >35mcg/day in any step-down regimen)."( A Retrospective Comparison of Time to Cessation of Acute Heavy Menstrual Bleeding in Adolescents Following Two Dose Regimens of Combined Oral Hormonal Therapy.
Baldwin, MK; Haley, KM; Roth, LP, 2022
)
0.97
"This study employed population pharmacokinetic (popPK) models to predict levonorgestrel (LNG) and ethinyl estradiol (EE) exposure after dosing with the transdermal contraceptive TWIRLA® (LNG/EE TDS) as a 12-week extended regimen in a healthy female population."( Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model.
Archer, DF; Korner, P; Lohmer, LRL; Pirone, J; Previtera, M; Stanczyk, FZ, 2022
)
1.21
" A transdermal patch of Ethinyl Estradiol (EE) nanoparticles was aimed to provide sustained release of the drug and lower dosage frequency."( Formulation and characterization of nanoparticle-based ethinyl estradiol transdermal drug delivery system for contraception and menopausal disorders.
Afzal, A; Bibi, S; Hussain, T; Javaid, Z; Kainat, -; Tabassum, M; Zaman, K, 2023
)
1.46
" While associations with endogenous sex hormones remain unclear, we showed that EE dosage in current users had a greater influence on brain anatomy compared to salivary EE levels and progestin androgenicity, with lower doses being associated with smaller cortical GMVs."( Morphologic alterations of the fear circuitry: the role of sex hormones and oral contraceptives.
Brouillard, A; Davignon, LM; Marin, MF; Turcotte, AM, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
xenoestrogenA synthetic or semi-synthetic compound that has oestrogenic activity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
17-hydroxy steroidA hydroxy steroid carrying a hydroxy group at position 17.
terminal acetylenic compoundAn acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Renin-angiotensin pathway (COVID-19 Disease Map)116
Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4)02
Estrogen receptor pathway01
Melatonin metabolism and effects016
Breast cancer pathway03

Protein Targets (113)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency31.66830.007215.758889.3584AID1224835; AID588342; AID624030
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
pregnane X receptorRattus norvegicus (Norway rat)Potency57.73150.025127.9203501.1870AID651751
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency15.08903.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency32.08670.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency22.38720.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
PPM1D proteinHomo sapiens (human)Potency32.99930.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency18.20300.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency9.14450.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency28.18380.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency8.61090.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency22.93610.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.51190.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency29.43180.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency11.11320.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency18.25120.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency5.49500.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.29790.000214.376460.0339AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency31.18820.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.36730.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.44760.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency28.70110.375827.485161.6524AID588526; AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency24.39610.005428.02631,258.9301AID1346982; AID1346985; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.79480.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588514; AID743069; AID743075; AID743077; AID743080; AID743091
GVesicular stomatitis virusPotency3.89020.01238.964839.8107AID1645842
polyproteinZika virusPotency22.38720.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency22.01630.00018.4406100.0000AID720579; AID720580
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency43.88640.001019.414170.9645AID588537; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency7.98340.023723.228263.5986AID588543; AID743223
caspase-3Homo sapiens (human)Potency22.93610.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency9.20000.005210.865235.4813AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.09510.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.44000.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency61.21520.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.558119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.42530.057821.109761.2679AID1159526
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency12.58930.036619.637650.1187AID1466; AID2242
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency12.58930.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency15.38050.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency53.12380.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.38810.000627.21521,122.0200AID651741; AID743202
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency23.13080.004611.374133.4983AID624296; AID624297
VprHuman immunodeficiency virus 1Potency39.81071.584919.626463.0957AID651644
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.81780.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency18.86770.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency43.64950.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency25.72200.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency8.66040.002319.595674.0614AID651631; AID720552
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58933.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58933.548118.039535.4813AID1466
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency43.64950.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency33.49150.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency15.84890.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)2.20000.40003.10009.7000AID721751
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)12.00000.11007.190310.0000AID1449628; AID1473738
Cytochrome P450 2B1Rattus norvegicus (Norway rat)Ki11.00000.08002.31005.8000AID589177
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.00350.00000.723732.7000AID264999; AID478658; AID625258
Estrogen receptorHomo sapiens (human)Ki0.00010.00000.42297.9070AID625258
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)1.71000.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki0.77700.00010.38637.0010AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)1.71000.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.77700.00070.76537.0010AID625263
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.95900.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.95100.00322.28879.3160AID625207
Cytochrome P450 3A4Homo sapiens (human)Ki18.00000.00011.41629.9000AID589137
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)32.92500.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki18.61000.00000.930610.0000AID625196
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)5.67800.11003.26419.0330AID625146
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)4.88120.00101.979414.1600AID255211; AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki1.09000.00031.21858.9270AID625228
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)32.92500.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki18.61000.00010.949010.0000AID625196
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)1.71000.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki0.77700.00070.78467.0010AID625263
Cytochrome P450 2B6Homo sapiens (human)Ki0.85000.00041.416010.0000AID589235; AID589236
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)IC50 (µMol)32.50000.30003.25807.3000AID1222388; AID1222389
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)1.71000.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.77700.00070.78467.0010AID625263
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.95900.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.95100.00031.465610.0000AID625207
3-oxo-5-alpha-steroid 4-dehydrogenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)960.00000.00427.468021.1000AID1180290
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)1.71000.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.77700.00070.78467.0010AID625263
Adenosine receptor A2aHomo sapiens (human)IC50 (µMol)20.93100.00071.559410.0000AID625195
Adenosine receptor A2aHomo sapiens (human)Ki11.75100.00001.06099.7920AID625195
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.05400.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.02900.00000.70488.1930AID625222
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)26.76900.00010.813310.0000AID625163
Mu-type opioid receptorHomo sapiens (human)Ki10.86700.00000.419710.0000AID625163
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)25.89400.00001.201110.0000AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki10.35800.00000.362410.0000AID625162
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)32.92500.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki18.61000.00000.965010.0000AID625196
Sulfotransferase 1A1Homo sapiens (human)IC50 (µMol)0.02000.02000.02000.0200AID1222386
Sulfotransferase 1A1Homo sapiens (human)Ki0.01430.00510.01200.0190AID1222383; AID1222384; AID1222385
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)0.55900.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.44400.00021.11158.0280AID625256
Aldehyde oxidaseHomo sapiens (human)IC50 (µMol)0.57000.00230.63203.3000AID547838
Nuclear receptor subfamily 1 group I member 3 Homo sapiens (human)IC50 (µMol)3.00000.08001.38974.0780AID1276955
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)20.20000.16003.95718.6000AID721752
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.01290.00010.529432.7000AID265000; AID478659
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)21.10000.01002.765610.0000AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)EC50 (µMol)0.02520.00000.53054.4000AID1724578; AID1724579
Sex hormone-binding globulinHomo sapiens (human)Kd0.15490.00020.34964.7863AID318680
Sulfotransferase 1A1Homo sapiens (human)Kd0.25220.00430.25220.5000AID1222381; AID1222382
Estrogen receptor betaHomo sapiens (human)EC50 (µMol)0.00350.00000.47954.8900AID1724577; AID1724580; AID1724581
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)Km14.50004.49006.51339.0000AID624630
Sulfotransferase 1A1Homo sapiens (human)Km0.57000.17001.83436.6200AID1222379; AID1222380
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (476)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2B6Homo sapiens (human)
steroid metabolic processCytochrome P450 2B6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2B6Homo sapiens (human)
cellular ketone metabolic processCytochrome P450 2B6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2B6Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
sulfationSulfotransferase 1A1Homo sapiens (human)
ethanol catabolic processSulfotransferase 1A1Homo sapiens (human)
catecholamine metabolic processSulfotransferase 1A1Homo sapiens (human)
xenobiotic metabolic processSulfotransferase 1A1Homo sapiens (human)
estrogen metabolic processSulfotransferase 1A1Homo sapiens (human)
amine metabolic processSulfotransferase 1A1Homo sapiens (human)
flavonoid metabolic processSulfotransferase 1A1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate metabolic processSulfotransferase 1A1Homo sapiens (human)
sulfationSulfotransferase 1A1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
lipid metabolic processAldehyde oxidaseHomo sapiens (human)
xenobiotic metabolic processAldehyde oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
osteoblast differentiationNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (191)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
monooxygenase activityCytochrome P450 2B6Homo sapiens (human)
iron ion bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-alpha-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
heme bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-beta-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2B6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2B6Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
aryl sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
protein bindingSulfotransferase 1A1Homo sapiens (human)
sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
flavonol 3-sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
steroid sulfotransferase activitySulfotransferase 1A1Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate bindingSulfotransferase 1A1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
aldehyde oxidase activityAldehyde oxidaseHomo sapiens (human)
iron ion bindingAldehyde oxidaseHomo sapiens (human)
identical protein bindingAldehyde oxidaseHomo sapiens (human)
protein homodimerization activityAldehyde oxidaseHomo sapiens (human)
molybdopterin cofactor bindingAldehyde oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingAldehyde oxidaseHomo sapiens (human)
NAD bindingAldehyde oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingAldehyde oxidaseHomo sapiens (human)
FAD bindingAldehyde oxidaseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription factor activityNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (85)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
endoplasmic reticulum membraneCytochrome P450 2B6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2B6Homo sapiens (human)
cytoplasmCytochrome P450 2B6Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
cytosolSulfotransferase 1A1Homo sapiens (human)
cytoplasmSulfotransferase 1A1Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
cytosolAldehyde oxidaseHomo sapiens (human)
extracellular exosomeAldehyde oxidaseHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytoplasmNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytosolNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytoskeletonNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (346)

Assay IDTitleYearJournalArticle
AID1724581Agonist activity at full length human ERbeta receptor assessed as transcriptional activity incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID69375Displacement of [3H]-estradiol from estrogen receptor in mature rat1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID345619Decrease in nuclear co-repressor receptor binding to mouse CAR L212A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID624630Drug glucuronidation reaction catalyzed by human recombinant UGT1A12005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID70670Relative binding affinity(RBA) for Estrogen receptor1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
C-nor-9,11-secoestranes as modified estrogens and fertility regulation.
AID345634Decrease in nuclear co-repressor receptor binding to mouse CAR S251L mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345623Enhancement of steroid receptor co-activator 1 binding to mouse CAR L212A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1724578Agonist activity at full length human ERalpha receptor assessed as transcriptional activity incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1724582Selectivity index, ratio of EC50 for agonist activity at full length human ERalpha to EC50 for agonist activity at full length human ERbeta incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID1768210Invivo agonist activity at estrogen receptor in CRL:CD(SD) rat assessed as appearance of low cuboidal phenotype of epithelium at 0.1 mg/kg, po administered for 4 days and measured at 4 hr post last dose on day 4 by hematoxylin and eosin staining based ass
AID249815Effect on uterine weight of immature rats at 0.06 ug/rat/day dose after 3 days2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
AID249803Weight of rat uterine when treated with compound at 0.06 ug/rat dose was determined2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
AID471549Decrease in tail skin temperature rise in morphine-addicted Sprague-Dawley rat hot flush model at 0.3 mg/kg, po administered daily measured for 60 mins after naloxone-induced morphine withdrawal2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID345641Enhancement of steroid receptor coactivator 1 binding to mouse CAR I252L mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID203785Binding affinity against Sex steroid binding protein(SBP) of human serum1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity.
AID35536Binding affinity against Alphafetoprotein (AFP), in rodents.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1906898Anti-hyperplasia activity in human MCF7 cells xenografted in Sprague-Dawley rat assessed as appearance of tall columnar phenotype in epithelial cells at 0.1 mg/kg, po once daily for 3 days by hematoxylin and eosin staining based assay2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Discovery of Thieno[2,3-
AID171778Uterotrophic activity in rats; ND means not determined1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
C-nor-9,11-secoestranes as modified estrogens and fertility regulation.
AID345560Activation of mouse CAR L212A mutant expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1724580Antagonist activity at full length human ERbeta receptor assessed as inhibition of estradiol-induced activation incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID345631Effect on steroid receptor coactivator 1 binding to mouse CAR H213A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345549Activation of mouse CAR F171A mutant expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1222381Binding affinity to human SULT1A1 expressed in Escherichia coli assessed as change in intrinsic fluorescence2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID345601Effect on nuclear co-repressor receptor binding to mouse CAR F171L mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID589235Mechanism based inhibition of human cytochrome P450 2B6 measured by 7-EFC O-deethylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID319383Effect on bone metabolism in po dosed ovariectomized Sprague-Dawley rat assessed as bone formation rate of proximal tibia cancellous bone2007Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.
AID188525Bone density at proximal metaphysis of excised femur in ovariectomized (OVX) rats at 0.01 mg/kg dose2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID173734Estrogenic potency as minimum protective oral dose for prevention of pregnancy in rats1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
11 beta-nitrate estrane analogues: potent estrogens.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID679354TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, 17alpha-Ethynyl-17beta-Estradiol: 100 uM) in membrane vesicles from MRP7-expressing HEK293 cells2003Molecular pharmacology, Feb, Volume: 63, Issue:2
Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
AID188024Oral estrogenic potency (E) relative to ethynylestradiol (EE) in rats1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Analogues of [(triethylsilyl)ethynyl]estradiol as potential antifertility agents.
AID1217708Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID345535Inhibition of human CAR2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1144583Uterotrophic activity in ovariectomized Sprague-Dawley rat assessed as uterine weight administered for 3 days (Rvb = 100 +/- 27%)1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Hypocholesterolemic activity of 1,3-bis(substituted phenoxy)-2-propanones.
AID184493Antiimplantation activity as minimum effective dose after oral administration1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
C-nor-9,11-secoestranes as modified estrogens and fertility regulation.
AID345655Decrease in nuclear co-repressor receptor binding to mouse CAR Y336A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1557024Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Steroidal N-Sulfonylimidates: Synthesis and biological evaluation in breast cancer cells.
AID345576Activation of mouse CAR L253F mutant expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1217704Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID180224Evaluation of oral estrogenic activity by using immature female rats ovariectomized at 21 days of age.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Steroidal silicon side-chain analogues as potential antifertility agents.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID471530Decrease in bone resorption in ovariectomized rat assessed as decrease in urine deoxypyridinoline level at 0.1 mg/kg, po administered daily measured after 6 weeks2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID345541Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID69062Relative binding affinity of Estrogen receptor measured by using [3H]17-beta-estradiol1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID69511Relative binding affinity (RBA) towards estrogen receptor.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Quantitative structure-activity relationships/comparative molecular field analysis (QSAR/CoMFA) for receptor-binding properties of halogenated estradiol derivatives.
AID172990Antifertility activity measured as minimum protective dose for prevention of pregnancy in rats1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Steroidal silicon side-chain analogues as potential antifertility agents.
AID69374Displacement of [3H]-estradiol from estrogen receptor in immature rat1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID173700Percent decrease in serum cholesterol relative to OVX controls, at 1.0 mg/Kg compound dose1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID264999Binding affinity to ERalpha2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1737234Inhibition of human CYP1B1 at 5 uM using 7-ethyl-O-resorufin as substrate incubated for 30 mins in presence of NADPH by EROD assay2020European journal of medicinal chemistry, May-01, Volume: 193Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
AID247463Estrogenic activity as percent gain in rat uterine weight at 0.02 mg/kg/day2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Amide derivatives of 9,11-seco-estra-1,3,5(10)-trien-11-oic acid as modified orally active estrogen agonists with moderate antagonistic activity.
AID184852Minimally effective dose(MED) (mg/kg body weight) at which a significant increase in EPO activity was observed in rats1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID345648Decrease in nuclear co-repressor receptor binding to mouse CAR L253F mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1217711Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID191706In vivo uterotrophic effect in rats relative to ethynylestradiol1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID589237Mechanism based inhibition of human cytochrome P450 2B6 measured by 7-EFC O-deethylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1210793Ratio of Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase to Ki for competitive inhibition of human liver cytosolic aldehyde oxidase2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID345663Decrease in nuclear co-repressor receptor binding to mouse CAR T350A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID471543Increase in vaginal fluidity in ovariectomized rat at 0.1 mg/kg, po administered daily measured after 6 weeks by cytology analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
AID1217730Time dependent inhibition of CYP2B6 (unknown origin) at 30 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID624647Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID227715Binding selectivity index (BSI) as the relative affinity for estrogen receptor at 25 degree C and no-specific binding1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID69396Binding affinity against estrogen receptor at 25 degree C1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity.
AID478660Ratio of 17-beta-estradiol IC50 to compound IC50 for ERalpha2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Synthesis and evaluation of 17alpha-arylestradiols as ligands for estrogen receptor alpha and beta.
AID69541Relative binding affinity against Estrogen receptor as inhibition of [3H]estradiol binding in rat uterus1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Selenium labeling in nuclear medicine. 2. D ring substituted estrogens.
AID345599Effect on steroid receptor co-activator 1 binding to mouse CAR F171A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345542Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID71138Ratio of displacement of 17-beta-[3H]-estradiol from calf uterine estrogen receptor compared to 17-beta-estradiol after 20 hr incubation in 7%DMF1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers.
AID1217721Time dependent inhibition of CYP2C19 in human liver microsomes at 10 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID191703In vivo uterotrophic effect in immature rats1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID1210792Uncompetitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as enzyme-substrate complex by Lineweaver-Burk plot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID1222383Inhibition of human SULT1A1 expressed in Escherichia coli assessed as 17beta-estradiol sulfation at 100 nM by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1906873In vivo agonist activity at ERalpha in immature Sprague-Dawley rat assessed as fold increase in uterine wet weight to body weight ratio at 0.1 mg/kg, po once daily for 3 days2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Discovery of Thieno[2,3-
AID1215845Effect on ER-mediated Mrp3 mRNA level in Wistar rat hepatocytes at 1 uM after 5 hrs by qRT-PCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID69394Binding affinity against estrogen receptor at 0C1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity.
AID1222382Binding affinity to human SULT1A1 expressed in Escherichia coli assessed as change in intrinsic fluorescence in presence of 3',5'-phosphoadenosine2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID182164In vivo anti-infertility activity in rats1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID302158Inhibition of NFkB mediated VCAM gene expression in C57BL/6 mouse at 5 mg/kg/day, po after 5 weeks2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthriti
AID35537Relative binding affinity for Alphafetoprotein1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID1210949Ratio of Kinact to Ki for CYP3A4 (unknown origin)2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.
AID589201Mechanism based inhibition of rat cytochrome P450 2B1, partition ratio2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID188021Oral antifertility potency (A) relative to ethynylestradiol (EE) in rats1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Analogues of [(triethylsilyl)ethynyl]estradiol as potential antifertility agents.
AID1124650Displacement of 17beta-[3H]estradiol from rabbit uterine estrogen receptor after 16 to 18 hrs by liquid scintillation counting1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Synthesis and estrogenic properties of 17-epi-ethynylestradiol and its ether derivatives epimestranol and epiquinestrol.
AID1215852Increase in ER-mediated c-Jun protein level in Wistar rat at 10 uM after 60 mins by Western blot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID1217725Time dependent inhibition of CYP3A4 (unknown origin) at 50 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID302157Inhibition of NFkB mediated RANTES gene expression in C57BL/6 mouse at 5 mg/kg/day, po after 5 weeks2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthriti
AID1768206Invivo agonist activity at estrogen receptor in CRL:CD(SD) rat assessed as increase in uterine wet weight to body weight ratio at 0.1 mg/kg, po administered for 4 days and measured at 4 hr post last dose on day 4 relative to control
AID478658Binding affinity to ERalpha by fluorescence polarization-based competitive binding assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Synthesis and evaluation of 17alpha-arylestradiols as ligands for estrogen receptor alpha and beta.
AID1210796Selectivity ratio Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate to Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase using phthalazine as substrate2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID302161Increase in uterine wet weight in C57BL/6 mouse at 5 mg/kg/day, po after 5 days relative to control2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthriti
AID1215843Toxicity in Wistar rat assessed as increase in Mrp3 mRNA level at 5 mg/kg, sc administered as single dose after 5 hrs by qRT-PCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID681735TP_TRANSPORTER: Western in vivo SD rat, liver2000Gastroenterology, Jan, Volume: 118, Issue:1
Expression of the bile salt export pump is maintained after chronic cholestasis in the rat.
AID345669Decrease in nuclear co-repressor receptor binding to mouse CAR T350M mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID183935Uterotrophic activity in ovariectomized (OVX) rats as uterine weight/body weight after 4 days therapy at 0.10 mg/kg dose2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens.
AID1724579Antagonist activity at full length human ERalpha receptor assessed as inhibition of estradiol-induced activation incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID589137Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID681729TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 1uM, Ethinyl estradiol: 25 uM) in membrane vesicles from Bsep-expressing Sf9 cells2000Hepatology (Baltimore, Md.), Jul, Volume: 32, Issue:1
Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats.
AID345565Decrease in mouse CAR H213A mutant activation expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID173687Percent decrease in serum cholesterol in ovariectomized (OVX) rats at 0.10 mg/kg dose2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID1144572Uterotrophic activity in ovariectomized weaned Sprague-Dawley rat assessed as uterine weight at 10 ug/kg/day measured after 3 days (Rvb = 100 +/- 15%)1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Cycloalkanones. 8. Hypocholesterolemic activity of long-chain ketones related to pentadecanone.
AID1215849Increase in ER-phosphorylation at Ser118 residue in Wistar rat hepatocytes nuclear extract at 10 uM after 30 mins by Western blot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID1215841Toxicity in Wistar rat assessed as biliary excretion of total glutathione per gm of liver at 5 mg/kg, sc administered as single dose after 5 hrs (Rvb = 2 +/- 0.79 nmol/min)2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID69676Relative binding affinity for estrogen receptor at 0C1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID302159Inhibition of NFkB mediated MHC gene expression in C57BL/6 mouse at 5 mg/kg/day, po after 5 weeks2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthriti
AID265000Binding affinity to ERbeta2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID1222388Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID345611Decrease in nuclear co-repressor receptor binding to mouse CAR N175A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1210791Competitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as free enzyme by Lineweaver-Burk plot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.
AID345666Effect on steroid receptor coactivator 1 binding to mouse CAR T350A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345660Effect on steroid receptor coactivator 1 binding to mouse CAR Y336A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID589177Mechanism based inhibition of rat cytochrome P450 2B1 measured by 7-EFC O-deethylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1215851Effect on ER-phosphorylation at Ser118 residue in Wistar rat hepatocytes nuclear extract at 10 uM after 30 to 120 mins pretreated with 1 uM ER antagonist ICI 182/780 for 30 mins before compound addition by Western blot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID759301Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID345572Decrease in mouse CAR I252L mutant activation expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID250791Effect of compound (15 mg/kg) on rat vasomotor instability in terms of tail skin temperature change 15 min after naloxone injection2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1215853Effect on ER-mediated c-Jun protein level in Wistar rat at 10 uM in presence of ER antagonist ICI182/780 by Western blot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID345614Enhancement of steroid receptor co-activator 1 binding to mouse CAR N175A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1215847Effect on ER-mediated Mrp3 mRNA level in Wistar rat hepatocytes at 10 uM after 5 hrs pretreated with 5 ug/ml RNA polymerase2 inhibitor actinomycin D for 30 mins before compound addition by qRT-PCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID1215842Toxicity in Wistar rat assessed as serum ALP activity at 5 mg/kg, sc administered as single dose after 5 hrs (Rvb = 256 +/- 10 U/l)2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID1222386Inhibition of SULT1A1 in human MCF7 cells assessed as 17beta-estradiol sulfation2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID265001Inhibition of estrogen receptor in Ishikawa cells2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID759309Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID345587Decrease in mouse CAR T350M mutant activation expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1464236Estrogenic effect in ovariectomized adult female Wistar rat assessed as uterine weight level at 10 ug, po dosed from day 1 to 3 and measured on day 4 relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
A prodrug design for improved oral absorption and reduced hepatic interaction.
AID1217729Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID759300Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID345672Effect on steroid receptor coactivator 1 binding to mouse CAR T350M mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1222396Activation of human recombinant UGT1A1 expressed in HEK293 cells assessed as increase in estradiol 3-glucuronidation using 15 uM estradiol by LC-MS/MS method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID345645Effect on steroid receptor coactivator 1 binding to mouse CAR I252L mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1464243Toxicity in ovariectomized adult female Wistar rat assessed as increase in angiotensin level at 10 ug, po dosed from day 1 to 3 and measured on day 4 relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
A prodrug design for improved oral absorption and reduced hepatic interaction.
AID759311Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID589194Mechanism based inhibition of human cytochrome P450 3A4, partition ratio2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID200434Relative binding affinity against sex steroid binding protein (SBP)1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1724577Displacement of fluormone from GST-tagged ERbeta receptor LBD (unknown origin) measured after 60 mins by TR-FRET competitive binding assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID69677Relative binding affinity for estrogen receptor at 25 degree C1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID1215850Effect on ER-phosphorylation at Ser118 residue in Wistar rat hepatocytes nuclear extract at 10 uM after 60 to 120 mins by Western blot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID290762Increase in uterine wet weight in Sprague-Dawley rat at 0.1 mg/kg2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID265004Agonist activity at estrogen receptor in MCF7 cells at 10 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID24236Partition coefficient (logP)1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID276695Agonist activity at ER receptor assessed as increase in uterine weight of Sprague-Dawley rat at 0.02 mg/kg/day, po relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Rapid synthesis of 4-benzylidene and 4-[bis-(4-methoxyphenyl)-methylene-2-substituted phenyl-benzopyrans as potential selective estrogen receptor modulators (SERMs) using McMurry coupling reaction.
AID478661Ratio of 17-beta-estradiol IC50 to compound IC50 for ERbeta2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Synthesis and evaluation of 17alpha-arylestradiols as ligands for estrogen receptor alpha and beta.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1557025Agonist activity at ERalpha (unknown origin) expressed in MCF7 cells assessed as transcriptional activity after 24 hrs by luciferase/beta-galactosidase reporter gene assay relative to 17beta-estradiol2019European journal of medicinal chemistry, Oct-01, Volume: 179Steroidal N-Sulfonylimidates: Synthesis and biological evaluation in breast cancer cells.
AID345651Effect on steroid receptor coactivator 1 binding to mouse CAR L253F mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID679820TP_TRANSPORTER: Northern blot from H4IIE rat hepatoma cells1998Biochemical and biophysical research communications, Apr-17, Volume: 245, Issue:2
Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene.
AID547838Inhibition of human aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID319380Effect on bone turnover in po dosed ovariectomized Sprague-Dawley rat assessed as mineral apposition rate of proximal tibia cancellous bone2007Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.
AID302160Inhibition of NFkB mediated TNFalpha gene expression in C57BL/6 mouse at 5 mg/kg/day, po after 5 weeks2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthriti
AID1215840Toxicity in Wistar rat assessed as biliary excretion of total bile salts per gm of liver at 5 mg/kg, sc administered as single dose after 5 hrs (Rvb = 50 +/- 6 nmol/min)2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID319377Effect on bone turnover in po dosed ovariectomized Sprague-Dawley rat assessed as mineralizing surface of proximal tibia cancellous bone2007Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.
AID69389Nonspecific binding affinity (NSB) for estrogen receptor1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID345591Decrease in mouse CAR L353A mutant activation expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1215846Effect on Mrp2 mRNA level in Wistar rat hepatocytes at 1 to 10 uM after 5 hrs by qRT-PCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID1133849Uterotrophic activity in spayed Wistar rat assessed as autopsies by measuring uterus weight at 0.1 umol, po after 2 weeks (Rvb = 15.9 +/- 0.50 mg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Disteroidyl ethers. 1. Synthesis and oral long-lasting uterotrophic activity of 1,3,5(10)-estratrien-17-yl enol ethers of 3-keto steroids.
AID1222397Activation of human recombinant UGT1A1 expressed in HEK293 cells assessed as increase in estradiol 3-glucuronidation using 7.5 uM estradiol by LC-MS/MS method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID197230Oral estrogenic activity in uterotropic assay in rats at 100-1000 ng dose1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and biological activity of some 15-oxaestranes.
AID345546Increase in nuclear co-repressor receptor binding to wild type mouse CAR expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345678Effect on nuclear co-repressor receptor binding to mouse CAR L353A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID178720Dose required to reduce serum cholesterol by 50% relative to ovariectomized (OVX) controls1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID1464242Toxicity in ovariectomized adult female Wistar rat assessed as reduction in plasma HDL level at 10 ug, po dosed from day 1 to 3 and measured on day 4 relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
A prodrug design for improved oral absorption and reduced hepatic interaction.
AID1222380Activity of human SULT1A1 expressed in Escherichia coli at 6 uM by Michaelis-Menten equation analysis in presence of PAPS2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID679818TP_TRANSPORTER: Western blot, H4IIE rat hepatoma cells1998Biochemical and biophysical research communications, Apr-17, Volume: 245, Issue:2
Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene.
AID69841Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
11 beta-Substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: a structure-affinity relationship study.
AID681612TP_TRANSPORTER: transepithelial transport in MDR1-expressing MDCK cells2004Pharmaceutical research, Jul, Volume: 21, Issue:7
P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
AID345637Decrease in steroid receptor coactivator 1 binding to mouse CAR S251L mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID102594Inhibition of estrogen-stimulated MCF-7 cell proliferation; not active1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID345568Decrease in mouse CAR S251L mutant activation expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1222385Inhibition of human SULT1A1 expressed in Escherichia coli assessed as beta-naphthol sulfation at 100 nM by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID1215844Induction of ER-mediated Mrp3 mRNA level in Wistar rat hepatocytes at 10 uM after 5 hrs by qRT-PCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID1217717Time dependent inhibition of CYP2C9 (unknown origin) at 30 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID345682Decrease in steroid receptor coactivator 1 binding to mouse CAR L353A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID70981Displacement of [3H]estradiol from estrogen receptor in squirrel monkey1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID1217716Time dependent inhibition of CYP2C8 (unknown origin) at 10 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217728Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID170224Percent decrease in serum cholesterol in ovariectomized (OVX) rats at 0.10 mg/kg dose2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID265003Inhibition of estrogen receptor in MCF7 cells2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID71139Ratio of displacement of 17-beta-[3H]-estradiol from calf uterine estrogen receptor compared to 17-beta-estradiol after 2 hr incubation1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers.
AID589236Mechanism based inhibition of human cytochrome P450 2B6 measured by 7-EFC O-deethylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID540235Phospholipidosis-negative literature compound
AID184255Percent increase in uterine weight in ovariectomized (OVX) rats at 0.10 mg/kg dose2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens.
AID276680Antagonist activity at ER receptor assessed as increase in uterine weight in Sprague-Dawley rat at 0.02 mg/kg/day, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Rapid synthesis of 4-benzylidene and 4-[bis-(4-methoxyphenyl)-methylene-2-substituted phenyl-benzopyrans as potential selective estrogen receptor modulators (SERMs) using McMurry coupling reaction.
AID276681Agonist activity at ER receptor assessed as increase in uterine weight in Sprague-Dawley rat at 0.02 mg/kg/day, po2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Rapid synthesis of 4-benzylidene and 4-[bis-(4-methoxyphenyl)-methylene-2-substituted phenyl-benzopyrans as potential selective estrogen receptor modulators (SERMs) using McMurry coupling reaction.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1217727Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1215839Toxicity in Wistar rat assessed as bile flow per gm of liver at 5 mg/kg, sc administered as single dose after 5 hrs (Rvb = 1.40 +/- 0.14 ul/min)2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID1222384Inhibition of human SULT1A1 expressed in Escherichia coli assessed as p-nitrophenol sulfation at 100 nM by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID1180290Inhibition of Sprague-Dawley rat liver steroid 5-alpha-reductase assessed as inhibition of testosterone conversion to dihydrotestosterone incubated for 30 mins by HPLC method2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Conformational analysis of an anti-androgenic, (E,E)-8-hydroxygermacrene B, using NOESY and dynamic NMR spectroscopy.
AID1222379Activity of human SULT1A1 expressed in Escherichia coli at 6 uM by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.
AID345596Effect on nuclear co-repressor receptor binding to mouse CAR F171A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID345579Decrease in mouse CAR Y336A mutant activation expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1222389Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID249807Estrogenic activity in rat uterine weight assay2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Amide derivatives of 9,11-seco-estra-1,3,5(10)-trien-11-oic acid as modified orally active estrogen agonists with moderate antagonistic activity.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID126489Estrogenic effect in rhesus monkey relative to ethynylestradiol1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID71141Ratio of RBA values obtained a with and without DMF at 20h incubation1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1215854Effect on total ER level in Wistar rat hepatocytes nuclear extract at 10 uM after 30 to 120 mins by Western blot analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID319386Prevention of bone loss in po dosed ovariectomized Sprague-Dawley rat assessed as osteoclast surface of proximal tibia cancellous bone2007Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID249809Anti-estrogenic activity in rat uterine weight assay2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Amide derivatives of 9,11-seco-estra-1,3,5(10)-trien-11-oic acid as modified orally active estrogen agonists with moderate antagonistic activity.
AID345554Effect on mouse CAR F171L mutant expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID69381Compound was evaluated in vivo for estrogenic receptor potency relative to ethynylestradiol in rat. 1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID759307Agonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells at 10 uM after 40 hrs by luciferase reporter gene assay relative to control2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID173698Percent decrease in serum cholesterol relative to OVX controls, at 0.01 mg/Kg compound dose1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID69840Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
11 beta-Substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: a structure-affinity relationship study.
AID184853Minimally effective dose(MED) (mg/kg body weight) at which a statistically significant (p<= 0.05) increase in uterine weight/body weight was observed1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
AID1222395Activation of human recombinant UGT1A1 expressed in HEK293 cells assessed as increase in estradiol 3-glucuronidation by LC-MS/MS method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID681555TP_TRANSPORTER: Northern blot in vivo SD rat, liver2000Gastroenterology, Jan, Volume: 118, Issue:1
Expression of the bile salt export pump is maintained after chronic cholestasis in the rat.
AID1217710Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID345628Decrease in nuclear co-repressor receptor binding to mouse CAR H213A mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID345584Decrease in mouse CAR T350A mutant activation expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1215848Effect on ER-mediated Mrp3 mRNA level in Wistar rat hepatocytes at 10 uM after 5 hrs pretreated with 1 uM ER antagonist ICI 182/780 for 30 mins before compound addition by qRT-PCR analysis2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID679054TP_TRANSPORTER: Western in vivo, liver of SD rat1997Gastroenterology, Jul, Volume: 113, Issue:1
The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis.
AID345543Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1124644Induction of vaginal cornification in ovariectomized mature rat at 0.025 to 0.1 mg/kg, po administered with sesame oil by Allen-Doisy method relative to control1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Synthesis and estrogenic properties of 17-epi-ethynylestradiol and its ether derivatives epimestranol and epiquinestrol.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID589187Mechanism based inhibition of human cytochrome P450 2B6, partition ratio2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID250810Effect of compound (0.3 mg/kg) on rat vasomotor instability in terms of tail skin temperature change 15 min after naloxone injection2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID345607Effect on steroid receptor co-activator 1 binding to mouse CAR F171L mutant expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID172991In vivo for antifertility potency in rat at 200 ug/Kg/day1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID69238Displacement of [3H]estradiol from estrogen receptor in immature rabbit1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID721752Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID551632Estrogenic activity in ovariectomized Sprague-Dawley rat assessed as effect on uterine weight at 0.01 mg/kg, po qd for 3 days (Rvb = 35.0 +/- 0.6)2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Synthetic analogs of daidzein, having more potent osteoblast stimulating effect.
AID1276955Inverse agonist activity at GAL4 fused-human CAR-LBD transfected HEK293 cells after 24 hrs by luciferase reporter gene assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor.
AID1768207Invivo agonist activity at estrogen receptor in CRL:CD(SD) rat assessed as increase in uterine wet weight to body weight ratio at 60 mg/kg, po administered for 4 days and measured at 4 hr post last dose on day 4 relative to control
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID173924Postcoital antifertility potency is determined as minimum protective dose for prevention of pregnancy in rats1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
11 beta-nitrate estrane analogues: potent estrogens.
AID265002Agonist activity at estrogen receptor in Ishikawa cells at 10 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID589128Mechanism based inhibition of human cytochrome P450 3A4 measured by midazolam hydroxylation in vivo2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID478659Binding affinity to ERbeta by fluorescence polarization-based competitive binding assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Synthesis and evaluation of 17alpha-arylestradiols as ligands for estrogen receptor alpha and beta.
AID1133848Uterotrophic activity in spayed Wistar rat assessed as autopsies by measuring uterus weight at 0.1 umol, po after 1 week (Rvb = 15.1 +/- 0.51 mg)1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Disteroidyl ethers. 1. Synthesis and oral long-lasting uterotrophic activity of 1,3,5(10)-estratrien-17-yl enol ethers of 3-keto steroids.
AID345683Cytotoxicity against HEK293 cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8,556)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903898 (45.56)18.7374
1990's1168 (13.65)18.2507
2000's1550 (18.12)29.6817
2010's1594 (18.63)24.3611
2020's346 (4.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 93.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index93.74 (24.57)
Research Supply Index9.27 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index184.95 (26.88)
Search Engine Supply Index2.10 (0.95)

This Compound (93.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,566 (17.27%)5.53%
Reviews426 (4.70%)6.00%
Case Studies463 (5.10%)4.05%
Observational18 (0.20%)0.25%
Other6,597 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (245)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinyle [NCT03091595]Phase 282 participants (Actual)Interventional2017-02-07Completed
Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri [NCT03890042]100 participants (Actual)Interventional2019-03-01Completed
A Phase 1, Open-Label, Parallel, Sequential, Multi-part Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of an Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers [NCT03856970]Phase 187 participants (Actual)Interventional2019-03-11Completed
A Phase 1, Randomized, Open Label, 2-Way Crossover Study To Assess The Effect Of Multiple Dose CP-690,550 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids In Healthy Female Subjects [NCT01137708]Phase 120 participants (Actual)Interventional2010-06-30Completed
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT05282940]Phase 136 participants (Actual)Interventional2022-02-26Completed
Oral Contraceptive Pill Pretreatment in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Using the Gonadotrophin Releasing Hormone Antagonist Protocol (A Randomized Controlled Trial) [NCT03881904]Phase 1/Phase 2740 participants (Anticipated)Interventional2017-06-01Recruiting
Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme [NCT01174524]Phase 4100 participants (Actual)Interventional2008-01-31Completed
A Multicenter, Open Label, Randomized, Two-period Crossover Study on the Insertion of MK-8342A (NuvaRing®) Placebo With and Without the Use of NuvaRing Applicator in Healthy Female Subjects [NCT02275546]Phase 3164 participants (Actual)Interventional2014-12-11Completed
A Double-blind Two-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics (PK) of an Ethinyl Estradiol and Levonorgestrel Containing Combined Oral Contraceptive (COC) [NCT01297179]Phase 130 participants (Actual)Interventional2008-10-31Completed
A Phase III, Randomized, Open-label, Active-controlled, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate - 17ß-estradiol) in Healthy, Sexually-active Women Aged 18-50 [NCT01656434]Phase 33,173 participants (Actual)Interventional2012-11-02Terminated(stopped due to Business reasons)
A Pilot, Randomized, Placebo-Controlled Trial Evaluating the Treatment of Premenstrual Dysphoric Disorder With Oral Contraceptives in Bipolar Disorder. [NCT05098574]Phase 260 participants (Anticipated)Interventional2022-11-30Recruiting
A Phase 3, Randomized, Active-Comparator Controlled Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring and the Levonorgestrel-Ethinyl Estradiol (LNG-EE) 150/30 μg Combined Oral Contrac [NCT02616146]Phase 32,016 participants (Actual)Interventional2015-12-01Terminated(stopped due to Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.)
Doppler Analysis of Ovarian Stromal Blood Flow Changes After Treatment With Metformin Versus Ethinylestradiol-cyproterone Acetate in Women With Polycystic Ovarian Syndrome [NCT03236740]Phase 4101 participants (Actual)Interventional2017-08-01Completed
An Open-label, Randomized, Parallel Group Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) [NCT01044056]Phase 424 participants (Actual)Interventional2004-03-31Completed
Drug Use Investigation of MARVELON [NCT01005056]3,838 participants (Actual)Observational2005-05-31Completed
A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-04965842 ON THE PHARMACOKINETICS OF SINGLE-DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE SUBJECTS [NCT03662516]Phase 117 participants (Actual)Interventional2018-09-26Completed
[NCT01569945]371 participants (Actual)Interventional2004-09-30Completed
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of EDP 305 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Adult Female Subjects [NCT03783897]Phase 143 participants (Actual)Interventional2018-11-27Completed
Clomiphine Citrate and Estradiol Versus Clomiphine Citrate and Sildenafil in Comparison With Clomiphine Citrate Alone for Induction of Ovulation in Unexplained Infertility: Double Blind Randomised Trial [NCT03755037]Phase 1150 participants (Actual)Interventional2017-01-31Completed
An Open-Label Drug Interaction Study in Healthy Subjects to Evaluate the Effects of Multiple Doses of JNJ55308942 on the Cytochrome P450 CYP3A4, CYP2D6 and CYP2C19 Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol [NCT03547024]Phase 114 participants (Actual)Interventional2018-06-08Completed
Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females [NCT04964193]24 participants (Actual)Interventional2019-03-12Completed
Validation of 24-hour Trough Concentration as a Surrogate for Intensive Pharmacokinetic Measurements for a Combined Oral Contraceptive Pill Containing Desogestrel [NCT05002738]Phase 422 participants (Actual)Interventional2021-09-10Completed
Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease [NCT02144246]Phase 15 participants (Actual)Interventional2014-05-31Terminated
A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo. [NCT01569113]Phase 476 participants (Actual)Interventional2012-03-31Completed
The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of Polycystic Ovary Syndrome. [NCT03843736]Phase 3200 participants (Anticipated)Interventional2019-02-21Recruiting
A Multi-centre, Randomized, Double-blind, Active Control, Parallel-group, 2-arm Study to Investigate the Effect of Ethinylestradiol / Drospirenone (0.02 mg/3 mg) Oral Contraception in a 24/4 Regimen Compared to Ethinylestradiol / Desogestrel (0.02 mg/0.15 [NCT01076582]Phase 3592 participants (Actual)Interventional2010-04-30Completed
Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS: an Open-label, Non-randomized Controlled Clinical Study [NCT05872425]120 participants (Anticipated)Interventional2023-02-01Recruiting
AFTER: Application for the Etonogestrel/Ethinyl Estradiol Ring--potential for Emergency Contraception [NCT03120728]Phase 436 participants (Anticipated)Interventional2017-07-10Recruiting
The Influence of Oral Contraceptives on Mood, Sexuality and Economic Behavior [NCT02257671]400 participants (Anticipated)Interventional2012-02-29Recruiting
Open-Label Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of ELPIDA® in Co-Administration With Other Drugs in Healthy Volunteers [NCT03709355]Phase 156 participants (Actual)Interventional2018-11-14Completed
An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 After a Single Subcutaneous Dose in Healthy Female Volunteers Whose Pituitary Function is Suppressed by Lyndiol®. [NCT00647933]Phase 124 participants (Actual)Interventional2000-06-30Completed
Multicenter, Open-Label, Uncontrolled Study to Investigate the Impact of Weight and BMI on Inhibition of Ovulation of a Transdermal Patch Formulation Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene in Young Female Volunteers Stratified by BMI Ove [NCT00873483]Phase 2173 participants (Actual)Interventional2009-04-30Completed
Low Dose of Aspirin for the Management of Endometriosis-associated Pelvic Pain: a Randomized, Open, Controlled Trial [NCT05156879]Phase 4220 participants (Anticipated)Interventional2021-12-23Recruiting
A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150µg of Nestorone® and 15µg of Ethinyl Estradiol (150/15 NES/EE CVR) [NCT00455156]Phase 31,143 participants (Actual)Interventional2006-12-31Completed
A Study to Evaluate the Relative Bioavailability of Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva Pharmaceuticals, USA) Compared to FEMCON® Fe (Norethindrone/Ethinyl Estradiol) 0.4 mg/0.035 mg Chewable Tablets (Warner Chilcott) in [NCT01344369]Phase 136 participants (Actual)Interventional2008-08-31Completed
A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE SUBJECTS [NCT03608241]Phase 112 participants (Actual)Interventional2018-09-21Completed
A Multicenter, Open-Label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins [NCT01291004]Phase 1206 participants (Actual)Interventional2011-01-31Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]1,578 participants (Actual)Observational2003-06-09Completed
A Study in Healthy Female Participants to Investigate the Effect of JNJ-64530440 on the Single-dose of Ethinylestradiol and Drospirenone (Oral Contraceptive), and Midazolam, and the Effect of a High-fat Meal on the Single-dose of JNJ-64530440 [NCT03890341]Phase 10 participants (Actual)Interventional2021-06-01Withdrawn(stopped due to Stopped due to a strategic decision.)
Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris [NCT00752635]Phase 448 participants (Actual)Interventional2004-09-30Completed
A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of YAZ Compared With Placebo In The Treatment Of Hidradenitis Suppurativa [NCT00722800]Phase 24 participants (Actual)Interventional2008-10-31Terminated(stopped due to Poor recruitment)
A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06700841 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS [NCT04267250]Phase 118 participants (Actual)Interventional2020-08-24Completed
A Multicenter, Open-Label, Randomized, Controlled Study to Compare the Effects on Bone Mineral Density of DR-105 and a 28-Day Cycle Oral Contraceptive Regimen in Healthy, Postmenarchal, Adolescent Females [NCT00924560]Phase 21,361 participants (Actual)Interventional2009-06-30Completed
A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150 ug of Nestorone® and 15 ug of Ethinyl Estradiol [NCT00263341]Phase 31,135 participants (Actual)Interventional2005-12-31Completed
A Study to Evaluate the Effects of Annovera™ and Tampon Co-Usage on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol [NCT04272008]Phase 121 participants (Actual)Interventional2020-03-06Completed
Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol [NCT02485821]Phase 2/Phase 3200 participants (Actual)Interventional2015-06-30Completed
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424 (Dienogest 2 mg / Ethinyl Estradiol 0.02 mg) During 13 Cycles [NCT03945513]Phase 31,034 participants (Actual)Interventional2019-12-03Completed
Gender Disparity and Hormones in Cystic Fibrosis [NCT02036879]Early Phase 155 participants (Actual)Interventional2014-02-28Completed
Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects [NCT02103569]Phase 120 participants (Actual)Interventional2014-04-30Completed
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of NGM/EE Tablets Manufactured at 2 Different Facilities [NCT02127593]Phase 1101 participants (Actual)Interventional2013-06-30Completed
Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Effects of an Estrogen-progestin Combination as add-on to Inpatient Psychotherapy in Adult Female Patients Suffering From Anorexia Nervosa [NCT03172533]Phase 211 participants (Actual)Interventional2016-03-15Terminated(stopped due to Difficulties in recruitment)
[NCT02400801]166 participants (Anticipated)Interventional2013-06-30Active, not recruiting
A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies [NCT03557619]Phase 112 participants (Anticipated)Interventional2019-07-30Recruiting
The Impact of Different Administration Routes of Hormonal Contraceptives on Androgen Synthesis, Glucose Metabolism and Inflammation. A Prospective Randomized Trial. [NCT01087879]45 participants (Anticipated)Interventional2007-10-31Completed
Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin [NCT01103518]Phase 4100 participants (Anticipated)Interventional2009-12-31Active, not recruiting
Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol and Either 1.05 or 2.1 mg Gestodene in Healthy Young Female Volunteers Over a Period of 3 Treatment Cyc [NCT00915915]Phase 2108 participants (Actual)Interventional2009-06-30Completed
A Multi-center, Double-blind, Double-dummy, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of SH T00658ID Compared to SH D593B in the Treatment of Primary Dysmenorrhea [NCT00909857]Phase 3507 participants (Actual)Interventional2009-04-30Completed
An Open Label Multicentre Study to Evaluate Patient Satisfaction and Preference for the EVRA Transdermal Contraceptive System Compared to Previously Used Contraceptive Method. [NCT00653016]Phase 4405 participants (Actual)Interventional2002-10-31Completed
Oral Contraceptive Efficacy and Body Weight: Does Obesity Affect the Risk of Contraceptive Failure? [NCT00662454]Phase 4120 participants (Actual)Interventional2006-01-31Completed
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone [NCT02652650]Phase 118 participants (Actual)Interventional2015-12-31Completed
Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills [NCT00829114]Phase 4370 participants (Anticipated)Interventional2009-03-31Completed
An Open-label Pharmacokinetic Drug Interaction Study of Folic Acid and 250 Mcg NGM/35 Mcg E E (ORTHO-CYCLEN) in Healthy Women. [NCT00709332]Phase 147 participants (Actual)Interventional2005-01-31Completed
Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy F [NCT00914693]Phase 31,694 participants (Actual)Interventional2009-04-30Completed
Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone [NCT00468481]Phase 3385 participants (Actual)Interventional2007-04-30Completed
Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters [NCT00732693]Phase 442 participants (Actual)Interventional2002-02-28Completed
Drospirenone and Ethinyl Estradiol Combinations (Yasmin) as Infertility Treatments for Premature Ovarian Failure: a Perspective Follow-up Study. [NCT02757469]20 participants (Anticipated)Interventional2016-05-31Not yet recruiting
A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to [NCT01209143]Phase 152 participants (Actual)Interventional2010-11-30Completed
Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison t [NCT03074045]Phase 3145 participants (Actual)Interventional2017-03-13Completed
An Open-label Pharmacokinetic Drug Interaction Study of Folic Acid and 250 Mcg NGM/35 Mcg EE (ORTHO-CYCLEN) in Healthy Women.. [NCT00709982]Phase 147 participants (Actual)Interventional2005-05-31Completed
A Pivotal Bioequivalence Study of 250 Mcg NGM/25 Mcg EE With or Without Folic Acid in Healthy Female Subjects [NCT00709644]Phase 154 participants (Actual)Interventional2005-04-30Completed
A PHASE 1, OPEN LABEL, FIXED SEQUENCE STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE PF-06650833 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS [NCT05064332]Phase 110 participants (Actual)Interventional2021-10-08Completed
Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles [NCT00729404]Phase 217 participants (Actual)Interventional2008-08-31Terminated
Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing® [NCT00710606]40 participants (Actual)Interventional2008-06-30Completed
The Effects of Oral vs. Intravaginal Hormonal Contraception on Vaginal Health [NCT00612508]14 participants (Actual)Interventional2007-05-31Completed
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04230070]Phase 130 participants (Actual)Interventional2020-10-24Completed
A Prospective, Multicenter, Double-Blinded, Randomized Study to Evaluate Bleeding Patterns in Women Using One of Three Different Doses of DR-1031 Oral Contraceptive Compared to Seasonale Oral Contraceptive Regimen [NCT00394771]Phase 2567 participants (Actual)Interventional2006-10-31Completed
Open-Label Study of the Safety and Efficacy of a Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol [NCT00391807]Phase 31,683 participants (Actual)Interventional2006-11-30Completed
A Phase 1, Open-label Study to Assess the Effect of CTP-543 on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Subjects [NCT04309643]Phase 121 participants (Actual)Interventional2020-06-09Completed
A PHASE 1, RANDOMIZED, OPEN LABEL, 2 WAY CROSSOVER STUDY TO DEMONSTRATE A LACK OF AN EFFECT OF MULTIPLE DOSE PF 06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS [NCT04018274]Phase 129 participants (Actual)Interventional2019-08-09Completed
Single-center,Open-label, Uncontrolled Study to Investigate the Effects of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene on the Endometrium in a 21-day Regimen for 13 Cycles in 80 Healthy Women [NCT00896571]Phase 292 participants (Actual)Interventional2009-07-31Completed
A Prospective, Multicenter, Randomized, Double-Blind Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With the Oral Contraceptive Regimen DR-1021 [NCT00544882]Phase 361 participants (Actual)Interventional2007-10-31Completed
A Definitive Bioequivalence Study of ORTHO EVRA Exhibiting Faster Equilibration Profile and Currently Marketed ORTHO EVRA in Healthy Female Volunteers [NCT00775086]Phase 142 participants (Actual)Interventional2004-05-31Completed
Humatrope Treatment to Final Height in Turner's Syndrome [NCT00191113]Phase 3154 participants (Actual)Interventional1989-02-28Completed
A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers [NCT00685906]Phase 124 participants (Anticipated)Interventional2008-04-30Completed
Contraceptive Hormone and Reward Measurement (CHARM Study) [NCT05058872]Phase 4144 participants (Anticipated)Interventional2021-10-01Recruiting
Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives [NCT00640224]Phase 465 participants (Actual)Interventional2005-03-31Completed
A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy Of YAZ Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris [NCT00722761]Phase 330 participants (Actual)Interventional2009-04-30Completed
An Open Label Study to Evaluate Cycle Control With Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) and Yaz (Drospirenone/Ethinyl Estradiol) in Healthy Sexually Active Females [NCT00745901]Phase 4355 participants (Actual)Interventional2008-05-31Completed
Transdermal Contraception Patch: EU Cycle Control Study Versus EVRA [NCT00984789]Phase 3393 participants (Actual)Interventional2009-05-31Completed
Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation [NCT00999479]0 participants (Actual)Interventional2009-10-31Withdrawn(stopped due to Poor enrollment)
A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehyperten [NCT00420342]Phase 292 participants (Actual)Interventional2007-01-31Completed
[NCT01581814]Phase 399 participants (Actual)Interventional2008-10-31Completed
"Effect of Cyproterone Acetate / Ethinyl Estradiol Combination on Periodontal Tissue and High Sensitivity C- Reactive Protein Levels in Women With Polycystic Ovary Syndrome Having Gingivitis." [NCT05657171]50 participants (Anticipated)Observational2022-12-12Not yet recruiting
Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. [NCT01056042]Phase 4112 participants (Anticipated)Interventional2007-06-30Completed
A Three-Part Phase 1 Study to Evaluate the Potential Drug-Drug Interactions Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel-Ethinyl Estradiol-Containing Oral Contraceptives, and Carbamazepine in Healthy Adult Participants [NCT06071442]Phase 160 participants (Anticipated)Interventional2023-10-09Recruiting
A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate the Effects on Hemostasis, Lipids and Carbohydrate Metabolism, and on Adrenal and Thyroid Function of a Monophasic COC Containing 2.5 mg NOMAC and 1.5 mg E2 Compared to a Monophasic CO [NCT00511355]Phase 3121 participants (Actual)Interventional2006-10-31Completed
Hormonal Cycles in Women: Effects on TMD Pain & Symptoms [NCT00237042]252 participants (Actual)Interventional2005-10-31Completed
Impact of Gastric Bypass Surgery on the Pharmacokinetics of Oral Contraceptive Hormones [NCT01941134]Phase 40 participants (Actual)Interventional2013-04-30Withdrawn(stopped due to Recruitment trouble)
Levonorgestrel Intrauterine System Versus Oral Contraceptives for Heavy Menses [NCT02002260]59 participants (Anticipated)Interventional2013-02-28Active, not recruiting
A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Non-Fasting Conditions. [NCT01182207]Phase 133 participants (Actual)Interventional2006-07-31Completed
A Multicenter, Randomized, Open-labe, Controlled Study to Evaluate the Efficacy and Safety of the Combined Levonorgestrel(LNG) 100mcg and Ethinyl Estradiol(EE) 20mcg for Oral Contraception [NCT02021097]Phase 31,008 participants (Anticipated)Interventional2012-02-29Recruiting
The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants [NCT02027337]Phase 4200 participants (Anticipated)Interventional2013-12-31Recruiting
Hormonal Contraception and the Risk of HIV Acquisition [NCT00006324]6,360 participants Interventional1999-12-31Completed
[NCT00006133]970 participants Interventional2000-06-30Completed
Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills [NCT00570440]Phase 4362 participants (Anticipated)Interventional2007-08-31Completed
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose, Combination Oral Contraceptive, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle [NCT00196326]Phase 32,235 participants (Actual)Interventional2005-06-30Completed
An Open Label Study of the Contraceptive Efficacy of Norethindrone and Ethinyl Estradiol. [NCT00477633]Phase 31,700 participants (Actual)Interventional2007-06-30Completed
Phase 1, Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication (Miconazole Nitrate) on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring Releasing a Daily Do [NCT02215395]Phase 145 participants (Actual)Interventional2014-03-31Completed
Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS [NCT04257500]Phase 440 participants (Anticipated)Interventional2020-06-24Recruiting
A Relative Bioavailability Study of 0.4 mg/35 Mcg Norethindrone and Ethinyl Estradiol Chewable Tablets Under Fasting Conditions [NCT01340625]Phase 136 participants (Actual)Interventional2006-12-31Completed
Characterisation of Relative Bioavailability and Assessment of Bioequivalence of a Newly Developed Ethinylestradiol/Dienogest IR Formulation in Comparison With a Marketed Reference Product (Valette®) [NCT01600274]20 participants (Actual)Interventional2010-01-31Completed
A Comparison of Body Weight Changing and Side Effects Between Treatment With 30 mcg Ethinylestradiol/2 mg Chlormadinone Acetate (Belara®) and 30 mcg Ethinylestradiol/3 mg Drospirenone (Yasmin®): A Randomized Control Trial [NCT01608698]Phase 4100 participants (Anticipated)Interventional2012-06-30Enrolling by invitation
Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women [NCT00593294]Phase 4150 participants (Actual)Interventional2006-01-31Completed
An Open-label Study of the Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel in Healthy Volunteers [NCT04972396]Phase 140 participants (Actual)Interventional2021-10-05Completed
Reduction of Premature Discontinuation of Contraceptive Implants by Advance Provision of an OCP-based Participant Intervention: Randomized Clinical Trial [NCT04828824]Phase 4600 participants (Anticipated)Interventional2021-06-18Recruiting
Comparison of E/P Therapy in Continuous Regimen Versus Combination of LNG-IUS Plus E/P [NCT02556411]50 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Comparing the Safety and Efficacy in the Use of Dienogest, Leuprolide Acetate, DMPA and Combined Oral Contraceptive Pills (Microgynon) on Endometriosis Patients After Conservative Surgery [NCT06145438]Phase 3100 participants (Anticipated)Interventional2023-09-04Recruiting
A Phase I, Open Label, Fixed Sequence, Single-Center Study to Evaluate the Effect of Multiple Dose Administration of VI-0521 on the Pharmacokinetics of a Single Dose of Oral Contraceptive in Healthy Female Subjects [NCT00821496]Phase 120 participants (Actual)Interventional2009-01-31Completed
The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30®) in Healthy Women [NCT02697851]Phase 113 participants (Actual)Interventional2016-07-31Terminated(stopped due to "Insufficient enrolment and business reasons")
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effects of Odalasvir and AL-335 at Steady-state, Given as Single Agents and in Combination With Simeprevir, on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone [NCT02885454]Phase 124 participants (Actual)Interventional2016-08-31Completed
A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions. [NCT01182194]Phase 132 participants (Actual)Interventional2006-06-30Completed
The Effects of Treatment With Oral Contraceptive Pill Containing Ethinyl Estradiol-Cyproterone Acetate and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in Polycystic Ovarian Syndrome [NCT02866786]Phase 4101 participants (Actual)Interventional2016-08-15Completed
A Drug-Drug Interaction Study to Evaluate the Effects of Strong CYP3A Induction and Inhibition on the Pharmacokinetics of Segesterone Acetate and Ethinyl Estradiol From the Annovera™ Contraceptive Vaginal System [NCT04290390]Phase 167 participants (Actual)Interventional2020-02-12Completed
Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes [NCT00946192]Phase 3121 participants (Actual)Interventional2009-05-31Completed
A Study of Continuous Oral Contraceptives and Doxycycline [NCT00480532]131 participants (Actual)Interventional2007-05-31Completed
A Single-center, Randomized, Placebo-Controlled Phase I Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers [NCT02846142]Phase 194 participants (Actual)Interventional2016-06-30Completed
Follicular Profiles After Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle [NCT00204438]45 participants Interventional2002-02-28Completed
The Effects of Oral Contraceptive Pills vs Hormonal Patch on Coagulation Parameters [NCT00554632]24 participants (Actual)Interventional2003-04-30Completed
Monocenter, Open-label, Randomized Study to Determine the Ovulation Inhibitory Effect of the Combined Oral Contraceptive SH T04769G and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), Applied for Two Treatment Cycles to 60 Healthy Female Volu [NCT00471991]Phase 260 participants (Actual)Interventional2007-04-30Completed
Phase3,Open-label,Long-term,NSAID-Add-on,Clinical Trial of Mono-phase Low-dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis. [NCT00212277]Phase 30 participants Interventional2005-02-28Completed
A Randomized, Open-Label Study Comparing the Effect of a Contraceptive Vaginal Ring Delivering Daily Doses of 150 Micrograms Nestorone and 15 Micrograms Ethinyl Estradiol to an Oral Contraceptive Containing 150 Micrograms of Levonorgestrel and 30 Microgra [NCT00213096]Phase 250 participants Interventional2003-03-31Completed
An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study to Compare Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg in 2 Dosage Forms With Different Dissolution Characteristics in Healthy, Cycling Women [NCT00447863]Phase 10 participants (Actual)Interventional2007-08-31Withdrawn
A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors [NCT02705963]Phase 119 participants (Actual)Interventional2016-10-20Completed
Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency [NCT02922348]Phase 30 participants (Actual)Interventional2016-03-01Withdrawn
A PHASE 1, OPEN-LABEL, TWO-PART STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ATORVASTATIN AND MIDAZOLAM IN HEALTHY ADULTS AND AN ORAL CONTRACEPTIVE IN HEALTHY POST-MENOPAUSAL F [NCT05093205]Phase 135 participants (Actual)Interventional2021-10-25Completed
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 0.1 mg/0.02 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04194905]Phase 110 participants (Actual)Interventional2020-11-21Completed
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17dNorgestimate and Ethinyl Estradiol With the Oral Contraceptive Mercilon. [NCT00236782]Phase 31,517 participants (Actual)Interventional1997-10-31Completed
The Effect of Exenatide on Single and Multiple Doses Oral Contraceptive Pharmacokinetics in Healthy Female Subjects [NCT00254800]Phase 138 participants (Actual)Interventional2005-11-30Completed
A Multicenter, Double-blind, Randomized, Placebo-controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-estradiol 1 mg, Drospirenone 2 mg /17ß-estradiol 1 mg, Drospirenone 1 mg /17ß-estradiol 1 mg) Combinations and 17ß-estradiol (1 mg [NCT00102141]Phase 3750 participants (Actual)Interventional2004-04-30Completed
An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra [NCT00269620]Phase 4500 participants (Actual)Interventional2005-06-30Completed
An Open-label, Non-randomized Study to Investigate the Effects of Twice-Daily Milvexian Administration on the Pharmacokinetics of Single Doses of Midazolam, Ethinylestradiol and Drospirenone in Healthy Adult Females [NCT05706753]Phase 120 participants (Actual)Interventional2023-01-25Completed
Research on Risk Factors and Comprehensive Intervention Measures of Polycystic Ovary Syndrome Complicated With Mental Diseases Such as Depression and Anxiety [NCT04984070]100 participants (Anticipated)Interventional2021-01-01Recruiting
Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents [NCT00326404]Phase 3130 participants (Anticipated)Interventional2006-05-31Recruiting
An Open-Label Study Evaluating the Bleeding Profile of Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) Administered as an Extended Regimen [NCT00344383]Phase 261 participants (Actual)Interventional2003-11-30Completed
The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives [NCT00428311]Phase 450 participants Interventional2004-04-30Completed
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a 91-Day Extended-Cycle Combination Oral Contraceptive (Seasonale) for the Treatment of Low Bone Mineral Density in Adolescent Females With Secondary Amenorrhea an [NCT00117260]Phase 30 participants (Actual)Interventional2005-07-31Withdrawn(stopped due to Sponsor decision)
A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills [NCT00117273]Phase 336 participants (Anticipated)Interventional2005-06-30Completed
Improving Contraceptive Effectiveness in Obese Women [NCT01170390]Phase 432 participants (Actual)Interventional2009-09-30Completed
An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers [NCT01328184]Phase 118 participants (Actual)Interventional2011-04-30Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Levonorgestrel 90 Mcg and Ethinyl Estradiol 20 Mcg in a Continuous Daily Regimen on Menstrual Cycle-Related Symptoms [NCT00161681]Phase 3200 participants Interventional2005-07-31Completed
Phase 3,Placebo Controlled,Randomized,Double-Blinded,NSAID-Add-on,Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis. [NCT00212342]Phase 3100 participants (Actual)Interventional2004-12-31Completed
A Comparative Pharmacokinetic Study of EVRA and CILEST in Healthy Female Volunteers [NCT00254865]Phase 134 participants (Actual)Interventional2002-08-31Completed
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women [NCT00996580]Phase 33,597 participants (Actual)Interventional2009-10-31Completed
A Single Center, Randomized,Open-label,Controlled, Three-arm Study to Evaluate the Effect of a New Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of Two Reference COCs Containing Either 30 mcg Ethinylestr [NCT02957630]Phase 1/Phase 2101 participants (Actual)Interventional2016-09-30Completed
The Frequency and Management of Breakthrough Bleeding During Extended Therapy With the Transvaginal Contraceptive Ring [NCT00475553]75 participants (Actual)Interventional2006-05-31Completed
[NCT01511822]Phase 40 participants InterventionalCompleted
Clinical Efficacy and Metabolic Impact of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Normal-weight Women With Polycystic Ovary Syndrome: a Randomized Study. [NCT01519401]50 participants (Actual)Interventional2010-02-28Completed
A Phase 1, Single-center, Open-label, Single-sequence Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 With Oral Contraceptives in Healthy Female Participants [NCT05891262]Phase 115 participants (Actual)Interventional2023-06-06Completed
The Treatment of Menstrually-Related Mood Disorders With Extended Versus Interrupted Oral Contraceptives [NCT00089414]Phase 25 participants (Actual)Interventional2004-07-31Terminated(stopped due to Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of protocol.)
A Pharmacokinetic Study to Evaluate the Effect of Colchicine on the Pharmacokinetic Profile of an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone in Healthy Women [NCT01040845]Phase 130 participants (Actual)Interventional2007-08-31Completed
A Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide [NCT01508858]Phase 121 participants (Actual)Interventional2006-11-30Completed
Modulation Of Putative Surrogate Endpoint Biomarkers In Endometrial Biopsies From Women With HNPCC [NCT00033358]Phase 252 participants (Actual)Interventional2002-02-28Completed
Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality [NCT01805817]Phase 40 participants (Actual)Interventional2012-12-31Withdrawn
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder [NCT00128934]Phase 3744 participants (Anticipated)Interventional2005-08-31Completed
Human Ovarian Follicular Dynamics and Emergency Contraception [NCT00204451]Phase 440 participants Interventional2005-07-31Completed
Estrogen Priming to Increase the Efficacy of Standard Adjuvant Chemotherapy in Operable Breast Cancer. [NCT00193726]Phase 3273 participants (Actual)Interventional2005-07-31Terminated(stopped due to The accrual was very slow and there were many competing studies ongoing/initiated .)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder [NCT00195559]Phase 3526 participants (Anticipated)Interventional2005-09-30Completed
An Open-label, Randomized, 2-Period, Crossover Study to Assess the Comparative Pharmacokinetics of LSP-5415 and NuvaRing® in Healthy Adult Females [NCT05360576]Phase 240 participants (Actual)Interventional2022-02-24Completed
Bioavailability of a Formulation of Dienogest and Ethinyl Estradiol 2.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT04193852]Phase 110 participants (Actual)Interventional2019-11-09Completed
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate CYP3A4-Mediated, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adult Subjects [NCT04142762]Phase 180 participants (Actual)Interventional2019-10-18Completed
Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation. [NCT02352090]Phase 459 participants (Actual)Interventional2015-04-01Completed
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17deacetyl-norgestimate and Ethinyl Estradiol. [NCT00236769]Phase 31,751 participants (Actual)Interventional1997-11-30Completed
Open-Label, Randomized, Partially Balanced, Incomplete Block Design Study to Evaluate the Hormone Exposure From Commercial EVRA (Manufactured by LOHMANN Therapie-Systeme) and an Oral Contraceptive [NCT00258063]Phase 160 participants (Actual)Interventional2004-05-31Completed
A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Warfarin, Bupropion, and Ethinyl Estradiol and Norethindrone (Oral Contraceptive) in Healthy Adult Subjects [NCT04709094]Phase 152 participants (Actual)Interventional2019-07-28Completed
An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil. [NCT00236795]Phase 31,494 participants (Actual)Interventional1997-01-31Completed
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception [NCT00245921]Phase 32,000 participants Interventional2003-02-28Completed
A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 Mg and Ethinyl Estradiol 20 Mg in a Continuous 28-Day Regimen for Oral Contraception Versus a Cyclic 21-Day Regimen Oral Contraceptive [NCT00248963]Phase 3600 participants InterventionalCompleted
A Single Center, Open-Label Study to Evaluate the Effects on Ovulation of Levonorgestrel 90mg and Ethinyl Estradiol 20mg in a Daily, Continuous, Oral Regimen. [NCT00254189]Phase 260 participants Interventional2002-12-31Completed
An Open Label, Multicentre Study of the EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch in Europe: Evaluation of Women's Experience With EVRA� and Comparison With Previously Used Methods of Contraception. [NCT00261482]Phase 4778 participants (Actual)Interventional2003-07-31Completed
A Randomized, Double-Blind, Two-Part, Parallel-Group, Comparative Study to Evaluate Blood Folate Levels in Women Taking an Oral Contraceptive With and Without Folic Acid [NCT00301587]Phase 30 participants (Actual)InterventionalWithdrawn(stopped due to Company decision to not fund further development of women's health new drug development programs.)
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol [NCT00307632]Phase 4580 participants (Actual)Interventional2003-02-28Completed
A Randomized, Open-Label, Multicenter Study Comparing the Bleeding Profile of Ortho Evra (Norelgestromin/Ethinyl Estradiol) Continuous Regimen vs. Ortho Evra Cyclic Regimen [NCT00320580]Phase 2239 participants (Actual)InterventionalCompleted
Open-Label Study of Cycle Control With Extended Administration of Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 Mcg Oral Tablets [NCT00338052]Phase 2207 participants (Actual)Interventional2006-06-30Completed
[NCT01501448]Phase 4118 participants (Actual)Interventional2012-01-31Completed
[NCT00004763]Phase 245 participants Interventional1993-01-31Completed
Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration [NCT01250210]Phase 2123 participants (Actual)Interventional2007-09-30Completed
Identification of the Menstrual Cycle-Associated Factors That Modulate Circulating Lipid Levels in Premenopausal Women [NCT01546454]5 participants (Actual)Interventional2012-02-29Completed
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment [NCT05316935]Phase 2/Phase 3118 participants (Anticipated)Interventional2022-07-13Recruiting
The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers [NCT01448291]Phase 430 participants (Anticipated)Interventional2011-10-31Recruiting
Metformin Plus EE30µg-drospirenone and Weight Loss- Impact on Endothelial Function and hsCRP Levels in PCOS [NCT01459445]26 participants (Anticipated)Interventional2011-02-28Active, not recruiting
Open Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate (NA) and Ethinyl Estradiol (EE) [NCT00932321]Phase 3938 participants (Actual)Interventional2004-01-31Completed
Bioavailability of Formulation Clormadinone/Ethinyl Estradiol Coated Tablets 2 mg/0.02 mg With Regards to the Marketed Reference Product [NCT04713904]Phase 138 participants (Actual)Interventional2021-01-16Completed
Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception Containing Estradiol Hemihydrate Compared to Ethinyl Estradiol [NCT03077555]Phase 469 participants (Actual)Interventional2017-01-21Completed
A Single Dose Pharmacokinetics Study of NPC-01 (1mg Norethisterone and 0.02mg Ethynyl Estradiol) in Healthy Female Volunteers [NCT01246791]Phase 312 participants (Actual)Interventional2010-11-30Completed
Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome [NCT02460445]37 participants (Actual)Interventional2015-01-31Completed
Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel (Ethinyl Estradiol + Levonorgestrel + Folic Acid - Coated Tablet - 0.02 mg + 0.10 mg + 0.4 mg; Biolab Sanus Farmaceutica Ltda) in Female Volunt [NCT03359057]Phase 336 participants (Actual)Interventional2013-02-26Completed
Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri [NCT03037944]Early Phase 132 participants (Anticipated)Interventional2016-03-01Recruiting
A Mechanistic Examination of Continuous Cycle Oral Contractive Administration in Binge Eating [NCT04278755]Phase 28 participants (Actual)Interventional2020-09-24Terminated(stopped due to Halted prematurely due to COVID-19-related enrollment challenges.)
Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial [NCT01573377]40 participants (Actual)Interventional2012-02-29Completed
A Phase 1, Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone [NCT01597986]Phase 124 participants (Actual)Interventional2012-04-30Completed
Ovulation Incidence in Oral Contraceptive Users [NCT03106454]Phase 358 participants (Anticipated)Interventional2014-08-31Suspended(stopped due to Investigator leave of absence)
The Oral Contraceptive Pill for Premenstrual Worsening of Depression. [NCT00633360]32 participants (Actual)Interventional2008-02-29Completed
An Open-label, Single-dose, Randomized, 2-period, Crossover, Bioequivalence Study to Compare Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women [NCT00319163]Phase 126 participants Interventional2006-05-31Completed
The Effect of Ortho Tri-Cyclen on Bone Mineral Density in Pediatric Subjects With Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study [NCT00320567]Phase 2123 participants (Actual)InterventionalCompleted
Pharmacodynamics of NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol) and IKH-01( 1mg Norethisterone and 0.035mg Ethinyl Estradiol); Effect of NPC-01 and IKH-01 on Serum Concentrations of Estradiol, Progesterone, FSH and LH. [NCT01253824]Phase 314 participants (Actual)Interventional2011-01-31Completed
Postmarketing Study Of Lybrel In Relation To Venous Thromboembolism [NCT01297348]598,682 participants (Actual)Observational2007-07-31Completed
Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales [NCT02210702]Phase 433 participants (Anticipated)Interventional2014-07-31Recruiting
Effects of Protease Inhibitor Use on Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics in HIV-positive Women [NCT02531321]Phase 417 participants (Actual)Interventional2015-08-31Terminated(stopped due to Difficulty recruiting)
A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol [NCT02533427]Phase 115 participants (Actual)Interventional2015-10-29Completed
Determining the Impact of Combined Hormonal Contraceptives on Ulipristal Acetate [NCT02577601]Phase 436 participants (Actual)Interventional2015-09-08Completed
Estrogen Therapy in Non-severe COVID-19 Patients: Proposed Treatment Scheme in a Tertiary Hospital [NCT04539626]44 participants (Actual)Interventional2020-10-01Active, not recruiting
Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa [NCT00310791]Phase 2/Phase 380 participants (Actual)Interventional2004-04-30Completed
Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy [NCT01796613]Phase 2/Phase 3120 participants (Actual)Interventional2013-06-30Completed
Metabolic Syndrome in PCOS: Precursors and Interventions [NCT00442689]97 participants (Actual)Interventional2006-07-31Completed
The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects [NCT03262727]Phase 149 participants (Actual)Interventional2017-09-01Completed
Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 and Its Generics in Europe: An Observational Post-Authorisation Safety Study [NCT02410031]759 participants (Actual)Observational2015-06-26Completed
Evaluation of Periodontal Status and High Sensitivity C Reactive Protein Levels in Female Patients Diagnosed With Polycystic Ovary Syndrome on Cyproterone Acetate/Ethinyl Estradiol Combination Regimen: a Cross Sectional Study [NCT05021861]150 participants (Anticipated)Observational2021-11-30Not yet recruiting
A Single-center, Double-blind for Cenerimod, Open-label for Moxifloxacin, Placebo-controlled, Parallel-group, Randomized Study in Healthy Male and Female Subjects to Investigate I: the Effect of Cenerimod on the QTc Interval II: the Effect of Cenerimod on [NCT04255277]Phase 197 participants (Actual)Interventional2020-01-31Completed
Phase3, Placebo Controlled, Randomized, Double-blinded, Long-Term, NSAID-Add-on, Clinical Trial of NPC-16 for Treatment of Dysmenorrhea [NCT02362711]Phase 3248 participants (Actual)Interventional2015-02-28Completed
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midaz [NCT03111511]Phase 118 participants (Actual)Interventional2017-03-27Completed
An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of 240 mg BI 201335 QD on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Voluntee [NCT01570244]Phase 116 participants (Actual)Interventional2012-04-30Completed
Functional Study of the Hypothalamus in High-resolution Magnetic Resonance Imaging (MRI) in Women With Polycystic Ovary Syndrome (PCOS): a Comparative Study [NCT03043924]52 participants (Anticipated)Interventional2017-09-26Active, not recruiting
Comparative Study of the Effect on Acne With Norgestimate Containing Triphasic Oral Contraceptive and Biphasic Preparation Containing Desogestrel [NCT01466673]Phase 4201 participants (Actual)Interventional2008-12-31Completed
Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea? [NCT03124524]Phase 499 participants (Actual)Interventional2015-01-15Completed
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of Multiple Doses of BMS-986278 on the Pharmacokinetics of Combined Oral Contraceptives (Drospirenone/Ethinyl Estradiol) in Healthy Female Participants [NCT05985590]Phase 136 participants (Anticipated)Interventional2023-08-18Recruiting
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART) [NCT01903031]Phase 284 participants (Actual)Interventional2014-12-30Completed
A Multicenter, Randomized, Partially-blinded, Phase IIb Dose-finding Study on Ovarian Function, Vaginal Bleeding Pattern, and Pharmacokinetics Associated With the Use of Combined Vaginal Rings Releasing 17β-estradiol Plus Three Different Doses of Either N [NCT01709318]Phase 2666 participants (Actual)Interventional2012-12-12Completed
A Single Centre, Open-label, Randomized, Parallel Group, Multiple Dose Comparison of the Effect of TPV 750 mg and RTV 200 mg or TPV 500 mg and RTV 100 mg, Administered Twice Daily, on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol [NCT02245438]Phase 152 participants (Actual)Interventional2002-05-31Terminated
A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants [NCT06039826]Phase 147 participants (Anticipated)Interventional2023-09-12Active, not recruiting
Open-label Randomized Controlled Trial for the Effects of Continuous Ethinylestradiol/Levonorgestrel (30/150 μg/Day) Compared With Vitamin E (400 IU/Day) in the Treatment of Menstrually-related Migraine and Migraine During Perimenopause [NCT04007874]Phase 3360 participants (Anticipated)Interventional2019-09-10Recruiting
Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects [NCT03506399]Phase 10 participants (Actual)Interventional2018-06-30Withdrawn(stopped due to Stopped for futility. Phase 3 studies not likely to meet primary endpoints.)
The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects [NCT03262740]Phase 158 participants (Actual)Interventional2017-09-11Completed
Contraceptive Vaginal Ring Releasing Etonogestrel and Ethinylestradiol (NuvaRing): Cycle Control, Acceptability and Tolerability Study in Indian Women [NCT01490190]Phase 4252 participants (Actual)Interventional2011-12-26Completed
Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases [NCT02349399]26,065 participants (Actual)Observational2015-05-01Completed
A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemosatic Parameters in Healthy Women [NCT01388491]Phase 2293 participants (Actual)Interventional2011-10-31Completed
Comparison of Coagulation Profiles in Oral Contraceptive Pills Users Between 1.5 mg Estradiol/2.5 mg Nomegestrol Acetate (Zoely) and 15 mcg Ethinylestradiol/60 mcg Gestodene (Minidoz): A Randomized Control Trial [NCT03531437]Phase 4112 participants (Actual)Interventional2016-03-31Terminated(stopped due to problem with recruiting participants)
An Open-label Drug-drug Interaction Study in Healthy Female Adult Subjects to Investigate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel [NCT03249402]Phase 124 participants (Actual)Interventional2017-08-14Completed
Control of Bleeding on Nexplanon in Latinx Patients [NCT05116371]144 participants (Anticipated)Observational2021-12-01Not yet recruiting
A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Drug-drug Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone [NCT03126097]Phase 118 participants (Actual)Interventional2017-04-13Terminated(stopped due to Study stopping rules were met.)
Open-label, Randomized, Fixed Sequence Cross-over Study With Five Parallel Treatment Arms and Three Treatment Periods to Quantify the Drug-drug Interactions of Two Rifampicin Dose Strengths on Four Progestins and a Fixed Progestin-ethinylestradiol Combina [NCT03353857]Phase 168 participants (Actual)Interventional2017-11-29Completed
The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study [NCT05135013]200 participants (Anticipated)Observational2021-11-16Not yet recruiting
The Efficacy and Safety Study of Tung's Acupuncture for Improving Ovarian Function of Polycystic Ovarian Syndrome: a Randomised Controlled Trial [NCT02729545]Phase 260 participants (Actual)Interventional2016-04-30Completed
A Phase 1 Study to Evaluate the Pharmacokinetic Interaction Potential Between BIIB074 and an Oral Contraceptive Regimen in Healthy Female Subjects [NCT03324685]Phase 136 participants (Actual)Interventional2017-11-11Completed
A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy [NCT03301207]Phase 125 participants (Actual)Interventional2017-10-20Completed
The Effect of the Co-administration of Atazanavir (ATV) and Ritonavir (RTV) on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects [NCT00357604]Phase 122 participants Interventional2006-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]Plasma Concentration for Contraceptives
NCT00191113 (18) [back to overview]Number of Participants With Any Abnormal Fasting Glucose/Insulin Ratio Value
NCT00191113 (18) [back to overview]Number of Participants With Any Abnormal Fasting Glucose Value
NCT00191113 (18) [back to overview]Glycosylated Hemoglobin, Change From Baseline
NCT00191113 (18) [back to overview]Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population
NCT00191113 (18) [back to overview]Number of Participants With an Abnormal Pure Tone Audiometry, Audiologist Assessment
NCT00191113 (18) [back to overview]Number of Participants With Abnormal Speech Audiometry, Audiologist Assessment
NCT00191113 (18) [back to overview]Number of Participants With Abnormal Impedance Tympanometry, Audiologist Assessment
NCT00191113 (18) [back to overview]Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline, As-Treated Population
NCT00191113 (18) [back to overview]Minimum Fasting Glucose/Insulin Ratio Values
NCT00191113 (18) [back to overview]Maximum Glycosylated Hemoglobin
NCT00191113 (18) [back to overview]Maximum Fasting Insulin Values
NCT00191113 (18) [back to overview]Maximum Fasting Glucose Value
NCT00191113 (18) [back to overview]Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Last Measurement After Attainment of Final Height
NCT00191113 (18) [back to overview]Height (Centimeters [cm])
NCT00191113 (18) [back to overview]Number of Participants With Hearing Loss, Audiologist Assessment
NCT00191113 (18) [back to overview]Number of Participants With Any Abnormal Glycosylated Hemoglobin (HbA1c) Value
NCT00191113 (18) [back to overview]Number of Participants With Any Abnormal Fasting Insulin Value
NCT00191113 (18) [back to overview]Fasting Glucose, Change From Baseline
NCT00196326 (3) [back to overview]"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining On Drug Pregnancy"
NCT00196326 (3) [back to overview]"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining On Drug Pregnancy"
NCT00196326 (3) [back to overview]Participants With Treatment-Emergent Adverse Events
NCT00237042 (4) [back to overview]Number of Participants With Pain-Related Activity Interference
NCT00237042 (4) [back to overview]Number of Participants With Pain-Related Activity Interference
NCT00237042 (4) [back to overview]Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)
NCT00237042 (4) [back to overview]Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)
NCT00310791 (1) [back to overview]Areal Bone Density by DXA
NCT00391807 (17) [back to overview]Percentage of Subjects With Amenorrhea, Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Median Duration of Withdrawal Bleeding, Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Median Duration of Withdrawal Bleeding, Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Median Duration of Withdrawal Bleeding, Cycle 12, MITT Population
NCT00391807 (17) [back to overview]Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Amenorrhea, Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Total Number of Bleeding Days Per Cycle, Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Total Number of Bleeding Days Per Cycle, Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45, MITT Population
NCT00391807 (17) [back to overview]Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,
NCT00391807 (17) [back to overview]Percentage of Subjects With Withdrawal Bleeding (%), Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Withdrawal Bleeding (%), Cycle 2, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Withdrawal Bleeding (%), Cycle 13, MITT Population
NCT00391807 (17) [back to overview]Percentage of Subjects With Amenorrhea, Cycle 6, MITT Population
NCT00391807 (17) [back to overview]Total Number of Bleeding Days Per Cycle, Cycle 6, MITT Population
NCT00394771 (12) [back to overview]Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]Days With Bleeding During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)
NCT00394771 (12) [back to overview]Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)
NCT00394771 (12) [back to overview]Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)
NCT00394771 (12) [back to overview]Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)
NCT00394771 (12) [back to overview]Days With Bleeding During Active Cycle 2 (Day 92-176)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)
NCT00442689 (7) [back to overview]Change in High-density Lipoprotein (HDL) Levels During Study Period
NCT00442689 (7) [back to overview]Change in Low-density Lipoprotein (LDL) Levels Over the Study Period
NCT00442689 (7) [back to overview]Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period
NCT00442689 (7) [back to overview]Change in Resting Energy Expenditure (REE) Over the Study Period
NCT00442689 (7) [back to overview]Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI
NCT00442689 (7) [back to overview]Change in Disposition Index
NCT00442689 (7) [back to overview]Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 24
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8
NCT00468481 (47) [back to overview]Mean Neural Tube Defect (NTD) Risk Reduction at Week 24
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Red Blood Cell (RBC) Folate Level at 24 Weeks
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 4
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 8
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 12
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 12
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8
NCT00468481 (47) [back to overview]Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12
NCT00468481 (47) [back to overview]Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 20
NCT00468481 (47) [back to overview]Plasma Folate Level at 24 Weeks
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 4
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 8
NCT00468481 (47) [back to overview]Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Homocysteine Levels at Week 16
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 16
NCT00468481 (47) [back to overview]Mean Change From Baseline in Plasma Folate Levels at Week 20
NCT00477633 (3) [back to overview]Pearl Index, 18-35 Years, MITT Population
NCT00477633 (3) [back to overview]Mean Number of Days of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population
NCT00477633 (3) [back to overview]Mean Median Duration (Days) of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population
NCT00480532 (3) [back to overview]Differences in Bleeding Patterns Between Study Groups.
NCT00480532 (3) [back to overview]Subject Compliance
NCT00480532 (3) [back to overview]Subject Satisfaction.
NCT00511355 (47) [back to overview]Serum Concentration of HDL2-cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Free Thyroxine (T4)
NCT00511355 (47) [back to overview]Serum Concentration of Free Testosterone
NCT00511355 (47) [back to overview]Serum Concentration of Dihydrotestosterone (DHT)
NCT00511355 (47) [back to overview]Serum Concentration of Dehydroepiandrosterone Sulphate (DHEAS)
NCT00511355 (47) [back to overview]Serum Concentration of D-Dimer
NCT00511355 (47) [back to overview]Serum Concentration of Corticosteroid Binding Globulin (CBG)
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor VIII
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor VIIc
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor VIIa
NCT00511355 (47) [back to overview]Serum Concentration of Sex Hormone Binding Globulin (SHBG)
NCT00511355 (47) [back to overview]Serum Concentration of C-Reactive Protein (CRP)
NCT00511355 (47) [back to overview]Serum Concentration of Apolipoprotein B
NCT00511355 (47) [back to overview]Serum Concentration of Apolipoprotein A-1
NCT00511355 (47) [back to overview]Serum Concentration of Antithrombin III
NCT00511355 (47) [back to overview]Serum Concentration of Androstenedione
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Early Withdrawal Bleeding
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Continued Withdrawal Bleeding
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only)
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Breakthrough Bleeding
NCT00511355 (47) [back to overview]Number of Participants With an Occurrence of Absence of Withdrawal Bleeding
NCT00511355 (47) [back to overview]Incremental AUC3 for Insulin (OGTT)
NCT00511355 (47) [back to overview]Incremental AUC3 for Glucose (OGTT)
NCT00511355 (47) [back to overview]Serum Concentration of Clotting Factor II
NCT00511355 (47) [back to overview]Average Number of Withdrawal Bleeding/Spotting Days
NCT00511355 (47) [back to overview]Average Number of Breakthrough Bleeding/Spotting Days
NCT00511355 (47) [back to overview]AUC3 for Insulin (OGTT)
NCT00511355 (47) [back to overview]Area Under the Curve Over 3 Hours (AUC3) for Glucose (Oral Glucose Tolerance Test [OGTT])
NCT00511355 (47) [back to overview]APC Resistance Ratio (Activated Partial Thromboplastin Time [APTT]-Based)
NCT00511355 (47) [back to overview]Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)
NCT00511355 (47) [back to overview]Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)
NCT00511355 (47) [back to overview]Serum Concentration of Thyroid Stimulating Hormone (TSH)
NCT00511355 (47) [back to overview]Serum Concentration of Thyroxin Binding Globulin (TBG)
NCT00511355 (47) [back to overview]Serum Concentration of Total Cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Total Cortisol
NCT00511355 (47) [back to overview]Serum Concentration of Total Testosterone
NCT00511355 (47) [back to overview]Serum Concentration of Total Triglycerides
NCT00511355 (47) [back to overview]Serum Concentration of Prothrombin Fragments 1 + 2
NCT00511355 (47) [back to overview]Serum Concentration of Protein S (Total)
NCT00511355 (47) [back to overview]Serum Concentration of Protein S (Free)
NCT00511355 (47) [back to overview]Serum Concentration of Protein C
NCT00511355 (47) [back to overview]Serum Concentration of Low Density Lipoprotein (LDL)-Cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Lipoprotein(a)
NCT00511355 (47) [back to overview]Serum Concentration of High Density Lipoprotein (HDL)-Cholesterol
NCT00511355 (47) [back to overview]Serum Concentration of Hemoglobin Type A1c (HbA1c)
NCT00511355 (47) [back to overview]Serum Concentration of HDL3-cholesterol
NCT00544882 (9) [back to overview]Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day
NCT00544882 (9) [back to overview]Serum Inhibin-B Levels by Cycle Day
NCT00544882 (9) [back to overview]Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size
NCT00544882 (9) [back to overview]Number of Days of Bleeding During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]Serum Estradiol Levels by Cycle Day
NCT00544882 (9) [back to overview]Percentage of Follicles Greater Than 5 mm in Diameter
NCT00544882 (9) [back to overview]Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods
NCT00612508 (2) [back to overview]Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.
NCT00612508 (2) [back to overview]Adverse Events
NCT00633360 (2) [back to overview]Percent Change in Daily Record of Severity of Problems (DRSP)
NCT00633360 (2) [back to overview]Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS)
NCT00640224 (23) [back to overview]Peripheral Insulin Sensitivity at Baseline and 6 Months.
NCT00640224 (23) [back to overview]Hs-CRP at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta Androstenedione at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta 17-OHProg at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta 17-OHPreg at Baseline and 6 Months
NCT00640224 (23) [back to overview]Adiponectin at Baseline and 6 Months
NCT00640224 (23) [back to overview]Delta DHEA at Baseline and 6 Months
NCT00640224 (23) [back to overview]Hepatic Insulin Sensitivity at Baseline and 6 Months.
NCT00640224 (23) [back to overview]Triglycerides at Baseline and 6 Months
NCT00640224 (23) [back to overview]Total Testosterone at Baseline and 6 Months
NCT00640224 (23) [back to overview]Total Fat Mass at Baseline and 6 Months
NCT00640224 (23) [back to overview]SHBG at Baseline and 6 Months
NCT00640224 (23) [back to overview]Percent Body Fat at Baseline and 6 Months
NCT00640224 (23) [back to overview]Non-HDL Cholesterol at Baseline and 6 Months
NCT00640224 (23) [back to overview]Night Blood Pressure at Baseline and 6 Months
NCT00640224 (23) [back to overview]Morning Blood Pressure at Baseline and 6 Months
NCT00640224 (23) [back to overview]Leptin at Baseline and 6 Months
NCT00640224 (23) [back to overview]LDL at Baseline and 6 Months
NCT00640224 (23) [back to overview]HDL at Baseline and 6 Months
NCT00640224 (23) [back to overview]Cholesterol at Baseline and 6 Months
NCT00640224 (23) [back to overview]Glucose Tolerance Status at Baseline and 6 Months.
NCT00640224 (23) [back to overview]Free Testosterone at Baseline and 6 Months
NCT00640224 (23) [back to overview]DHEAS at Baseline and 6 Months
NCT00710606 (3) [back to overview]Mean Endometrial Proliferation
NCT00710606 (3) [back to overview]Number of Participants Achieving a Maximum Follicle Diameter > 13mm During the 3 Weeks of Follow-up
NCT00710606 (3) [back to overview]Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol
NCT00722761 (2) [back to overview]Percent Change in Truncal Lesion Counts
NCT00722761 (2) [back to overview]Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination
NCT00722800 (3) [back to overview]Mean Improvement in the Sartorius Severity Score at Month 6.
NCT00722800 (3) [back to overview]Change From Baseline in VAS Pain Scale at Month 6.
NCT00722800 (3) [back to overview]Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Month 6.
NCT00745901 (20) [back to overview]Number of Days of Unscheduled Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]Number of Days of Unscheduled Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]Number of Days of Unscheduled Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]Number of Days of Total Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]Number of Days of Total Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]Number of Days of Total Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]Patient Satisfaction - Overall
NCT00745901 (20) [back to overview]Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes
NCT00745901 (20) [back to overview]Overall Number of Days of Unscheduled Blood Loss
NCT00745901 (20) [back to overview]Overall Number of Days of Total Blood Loss
NCT00745901 (20) [back to overview]Overall Number of Days of Scheduled Blood Loss
NCT00745901 (20) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting Cycle 1
NCT00745901 (20) [back to overview]Number of Participants With Unscheduled Bleeding Cycle 3
NCT00745901 (20) [back to overview]Number of Days of Scheduled Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]Number of Days of Scheduled Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]Number of Participants With Unscheduled Bleeding Cycle 2
NCT00745901 (20) [back to overview]Number of Participants With Unscheduled Bleeding Cycle 1
NCT00745901 (20) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting Cycle 3
NCT00745901 (20) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting Cycle 2
NCT00745901 (20) [back to overview]Number of Days of Scheduled Blood Loss - Cycle 2
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Onset of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Onset of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]Percentage of Participants With Intracyclic Bleeding at Cycle 1
NCT00909857 (68) [back to overview]Percentage of Participants With Intracyclic Bleeding at Cycle 3
NCT00909857 (68) [back to overview]Percentage of Participants With Withdrawal Bleeding at Cycle 1
NCT00909857 (68) [back to overview]Percentage of Participants With Withdrawal Bleeding at Cycle 3
NCT00909857 (68) [back to overview]Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Participants With Improvement in Participants' Assessment in the Clinical Global Impression
NCT00909857 (68) [back to overview]Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination
NCT00909857 (68) [back to overview]Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening
NCT00909857 (68) [back to overview]Percentage of Participants Satisfied With Study Treatment
NCT00909857 (68) [back to overview]Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)
NCT00909857 (68) [back to overview]Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)
NCT00909857 (68) [back to overview]Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain
NCT00909857 (68) [back to overview]Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain
NCT00909857 (68) [back to overview]Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode
NCT00909857 (68) [back to overview]Difference in Duration Between Longest and Shortest Spotting Only Episode
NCT00909857 (68) [back to overview]General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Length of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Length of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Maximum Length of Bleeding or Spotting Episodes
NCT00909857 (68) [back to overview]Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]Maximum Length of Spotting Only Episodes
NCT00909857 (68) [back to overview]Mean Length of Bleeding or Spotting Episodes
NCT00909857 (68) [back to overview]Mean Length of Spotting Only Episodes
NCT00909857 (68) [back to overview]Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]Number of Days With Bleeding or Spotting
NCT00909857 (68) [back to overview]Number of Days With Spotting-only
NCT00909857 (68) [back to overview]Number of Episodes With Bleeding or Spotting
NCT00909857 (68) [back to overview]Number of Episodes With Spotting-only
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Days at Cycle 1
NCT00909857 (68) [back to overview]Number of Intracyclic Bleeding Days at Cycle 3
NCT00924560 (13) [back to overview]Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]Change From Baseline in Serum Deoxypyridinoline
NCT00924560 (13) [back to overview]Change From Baseline in Serum Osteocalcin
NCT00924560 (13) [back to overview]Change From Baseline in Serum Procollagen 1 N-terminal Propeptide
NCT00924560 (13) [back to overview]Change From Baseline in Proximal Femur Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]Change From Baseline in Serum Type I Collagen N-telopeptide
NCT00924560 (13) [back to overview]Change From Baseline in Bone-specific Alkaline Phosphatase
NCT00924560 (13) [back to overview]Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)
NCT00924560 (13) [back to overview]Change From Baseline in Proximal Femur Bone Mineral Density
NCT00924560 (13) [back to overview]Change From Baseline in Total Body Bone Mineral Density
NCT00924560 (13) [back to overview]Change From Baseline in Total Body Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]Number of Participants With Adverse Events (AEs)
NCT00924560 (13) [back to overview]Change From Baseline in Lumbar Spine Bone Mineral Density
NCT00932321 (2) [back to overview]Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population
NCT00932321 (2) [back to overview]Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population
NCT00946192 (2) [back to overview]Change in Total Volumetric Bone Mineral Density (Tibia)
NCT00946192 (2) [back to overview]Change in Lumbar Bone Mineral Density
NCT00996580 (9) [back to overview]All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]All Users Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight
NCT00996580 (9) [back to overview]Summary of Participants With Treatment-emergent Adverse Events
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Colchicine With Norethindrone/Ethinyl Estradiol at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Colchicine
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Placebo
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Ethinyl Estradiol With Placebo
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Colchicine With Norethindrone/Ethinyl Estradiol
NCT01040845 (10) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] Ethinyl Estradiol With Colchicine
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Norethindrone With Placebo at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Norethindrone With Colchicine at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Ethinyl Estradiol With Placebo at Steady State (Cmax, ss)
NCT01040845 (10) [back to overview]Maximum Plasma Concentration of Ethinyl Estradiol With Colchicine at Steady State (Cmax, ss)
NCT01044056 (4) [back to overview]AUC 0-infinity (PK Parameter) for the ASPE Group.
NCT01044056 (4) [back to overview]Area Under the Curve (AUC) 0-21 Days (PK Parameter) Measured for the ASPE Group
NCT01044056 (4) [back to overview]AUC 0-tlast (PK Parameter) for the ASPE Group.
NCT01044056 (4) [back to overview]Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) Group
NCT01170390 (5) [back to overview]LNG Steady State at Baseline and Then Post-randomization
NCT01170390 (5) [back to overview]LNG AUC
NCT01170390 (5) [back to overview]LNG AUC
NCT01170390 (5) [back to overview]EE Steady State After Randomization
NCT01170390 (5) [back to overview]EE Steady State Baseline
NCT01182194 (6) [back to overview]AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182194 (6) [back to overview]AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182194 (6) [back to overview]Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182194 (6) [back to overview]AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182194 (6) [back to overview]AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182194 (6) [back to overview]Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182207 (6) [back to overview]AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182207 (6) [back to overview]AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182207 (6) [back to overview]AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182207 (6) [back to overview]Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182207 (6) [back to overview]Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182207 (6) [back to overview]AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Rosiglitazone
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethindrone
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Norethindrone
NCT01209143 (4) [back to overview]Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone
NCT01246791 (12) [back to overview]Elimination Rate Constant (Kel) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Plasma Half Life (t1/2) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Peak Plasma Concentration (Cmax) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Peak Plasma Concentration (Cmax) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Mean Residence Time (MRT) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Mean Residence Time (MRT) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Elimination Rate Constant (Kel) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Time to Peak Plasma Concentration (Tmax) on Norethisterone of NPC-01
NCT01246791 (12) [back to overview]Time to Peak Plasma Concentration (Tmax) on Ethinyl Estradiol of NPC-01
NCT01246791 (12) [back to overview]Plasma Half Life (t1/2) on Norethisterone of NPC-01
NCT01250210 (2) [back to overview]Ovulation Suppression in Three Treatment Groups Over 3 Cycles
NCT01250210 (2) [back to overview]Cycle Control
NCT01253824 (4) [back to overview]Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01297348 (2) [back to overview]Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls
NCT01297348 (2) [back to overview]Incidence Rate of Idiopathic Venous Thromboembolism (VTE)
NCT01328184 (18) [back to overview]Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.
NCT01328184 (18) [back to overview]Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]Assessment of Tolerability
NCT01328184 (18) [back to overview]Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)
NCT01340625 (6) [back to overview]Cmax of Norethindrone
NCT01340625 (6) [back to overview]Cmax of Ethinyl Estradiol
NCT01340625 (6) [back to overview]AUC0-inf of Ethinyl Estradiol
NCT01340625 (6) [back to overview]AUC0-inf of Norethindrone
NCT01340625 (6) [back to overview]AUC0-t of Ethinyl Estradiol
NCT01340625 (6) [back to overview]AUC0-t of Norethindrone
NCT01344369 (6) [back to overview]Cmax of Ethinyl Estradiol
NCT01344369 (6) [back to overview]Cmax of Norethindrone
NCT01344369 (6) [back to overview]AUC0-t of Norethindrone
NCT01344369 (6) [back to overview]AUC0-inf of Ethinyl Estradiol
NCT01344369 (6) [back to overview]AUC0-inf of Norethindrone
NCT01344369 (6) [back to overview]AUC0-t of Ethinyl Estradiol
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)
NCT01388491 (14) [back to overview]Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin
NCT01466673 (10) [back to overview]Number of Participants With Abnormal Vaginal Blood Loss at Month 1, 3 and 6
NCT01466673 (10) [back to overview]Number of Participants With Treatment Response at the End-of-Therapy by Participant's Self-Assessment at Month 6
NCT01466673 (10) [back to overview]Percentage of Participants Showing Treatment Response on the Investigator's Global Assessment at Month 6
NCT01466673 (10) [back to overview]Percentage of Participants With Categorical Score for Sebum Assessment at Month 1, 3 and 6
NCT01466673 (10) [back to overview]Change From Baseline in Blood Pressure (BP) at Month 6
NCT01466673 (10) [back to overview]Change From Baseline in Body Weight at Month 6
NCT01466673 (10) [back to overview]Change From Baseline in Total and Each Type of Acne Lesions Count at Month 1
NCT01466673 (10) [back to overview]Change From Baseline in Total and Each Type of Acne Lesions Count at Month 3
NCT01466673 (10) [back to overview]Change From Baseline in Total and Each Type of Acne Lesions Count at Month 6
NCT01466673 (10) [back to overview]Number of Participants Non-Compliant With Therapy
NCT01490190 (18) [back to overview]Participants' Assessment of Feeling Vaginal Ring at Any Time
NCT01490190 (18) [back to overview]Participants' Assessment of Feeling Vaginal Ring During Intercourse
NCT01490190 (18) [back to overview]Participants' Overall Satisfaction With Vaginal Ring
NCT01490190 (18) [back to overview]Number of Participants With Intermenstrual Bleeding/Spotting
NCT01490190 (18) [back to overview]Number of Bleeding Days Per Cycle
NCT01490190 (18) [back to overview]Frequency of Partner Feeling Vaginal Ring During Intercourse
NCT01490190 (18) [back to overview]Participants' Assessment of Ease of Insertion of Vaginal Ring
NCT01490190 (18) [back to overview]Number of Participants Who Reported a Serious Adverse Event During the Study
NCT01490190 (18) [back to overview]Number of Participants Who Reported at Least One Adverse Event During the Study
NCT01490190 (18) [back to overview]Average Number of Bleeding Days Per Cycle
NCT01490190 (18) [back to overview]Average Number of Pads Used Per Day, Per Cycle, During Menstruation While Using Ring
NCT01490190 (18) [back to overview]Frequency of Partner Objecting to Vaginal Ring Use
NCT01490190 (18) [back to overview]Number of Participants Who Plan to Continue Using Vaginal Ring
NCT01490190 (18) [back to overview]Number of Participants Who Would Recommend Vaginal Ring to Others
NCT01490190 (18) [back to overview]Number of Participants With Regular Menstrual Cycles
NCT01490190 (18) [back to overview]Number of Pregnancies Due to Contraceptive Method Failure During the Study
NCT01490190 (18) [back to overview]Number of Spotting Days Per Cycle
NCT01490190 (18) [back to overview]Participants' Assessment of Ease of Removal of Vaginal Ring
NCT01546454 (1) [back to overview]Total to HDL Cholesterol Ratio
NCT01570244 (8) [back to overview]AUCt,ss of Ethinylestradiol
NCT01570244 (8) [back to overview]AUCτ,ss of Levonorgestrel
NCT01570244 (8) [back to overview]C24,ss of Ethinylestradiol
NCT01570244 (8) [back to overview]C24,ss of Levonorgestrel
NCT01570244 (8) [back to overview]Number of Participants With Drug Related Adverse Events
NCT01570244 (8) [back to overview]Cmax,ss of Levonorgestrel
NCT01570244 (8) [back to overview]Cmax,ss of Ethinylestradiol
NCT01570244 (8) [back to overview]Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG.
NCT01656434 (3) [back to overview]Number of Participants Who Experience at Least One Venous or Arterial Thrombotic/Thromboembolic Event
NCT01656434 (3) [back to overview]Percentage of Participants Who Experienced At Least One Adverse Event
NCT01656434 (3) [back to overview]Change From Baseline in Body Weight
NCT01709318 (12) [back to overview]Percentage of Participants With Any Drug-Related Serious Adverse Event
NCT01709318 (12) [back to overview]Percentage of Participants Who Experienced At Least One Drug-Related Adverse Event
NCT01709318 (12) [back to overview]Percentage of Participants With Breakthrough Bleeding and/or Spotting During Cycle 3
NCT01709318 (12) [back to overview]Percentage of Participants With Ovulation Incidence, by Cycle
NCT01709318 (12) [back to overview]Percentage of Participants Who Experienced At Least One Serious Adverse Event
NCT01709318 (12) [back to overview]Percentage of Participants With Progesterone Concentrations >16 Nmol/L, by Cycle
NCT01709318 (12) [back to overview]Percentage of Participants Who Experienced At Least One Adverse Event
NCT01709318 (12) [back to overview]Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01709318 (12) [back to overview]Number of Participants With Venous or Arterial Thrombotic/Thromboembolic Events
NCT01709318 (12) [back to overview]Intensity of Withdrawal Bleeding During Cycle 2
NCT01709318 (12) [back to overview]Intensity of Breakthrough Bleeding and/or Spotting During Cycle 3
NCT01709318 (12) [back to overview]Percentage of Participants With Absence of Withdrawal Bleeding and/or Spotting During Cycle 2
NCT01903031 (21) [back to overview]RTV PK Parameter Tmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]ATV PK Parameter Cmax Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]Ethinyl Estradiol Concentrations at Study Day 21
NCT01903031 (21) [back to overview]Etonogestrel Concentrations at Study Day 21
NCT01903031 (21) [back to overview]Percentage of Participants With Signs and Symptoms of Grade 2 or Higher Deemed Possibly, Probably or Definitely Related to Study Treatment
NCT01903031 (21) [back to overview]ATV PK Parameter AUC(0-24h) Calculated Based on Intensive Atazanavir (ATV) PK Samples Obtained From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]ATV PK Parameter CLss/F Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]ATV PK Parameter Cmin Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]ATV PK Parameter Time to Cmax (Tmax) Determined Based on ATV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]EFV PK Parameter Area Under the Concentration-Time Curve (AUC0-24hours) Calculated Based on Intensive EFV PK Samples Obtained From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]EFV PK Parameter Clearance (CLss/F) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]EFV PK Parameter Maximum Plasma Concentration (Cmax) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]EFV PK Parameter Minimum Plasma Concentration (Cmin) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B
NCT01903031 (21) [back to overview]Ethinyl Estradiol Concentrations Obtained on Study Days 7 and 14.
NCT01903031 (21) [back to overview]Etonogestrel Concentrations Obtained on Study Days 7 and 14
NCT01903031 (21) [back to overview]Proportion of Participants With Plasma HIV-1 RNA Levels <40 Copies/mL
NCT01903031 (21) [back to overview]Proportion of Participants With Progesterone Levels Greater Than 5 ng/mL.
NCT01903031 (21) [back to overview]Ritonavir (RTV) PK Parameter AUC(0-24h) Calculated Based on Intensive RTV PK Samples Obtained From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]RTV PK Parameter CLss/F Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]RTV PK Parameter Cmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT01903031 (21) [back to overview]RTV PK Parameter Cmin Determined Based on RTV Levels From Individual Participants Enrolled in Arm C
NCT02275546 (2) [back to overview]Percentage of Participants With Successful Ring Insertion
NCT02275546 (2) [back to overview]Percentage of Participants With Vaginal Ring Expulsion Within 48 Hours of Insertion
NCT02352090 (11) [back to overview]Anti Mullerian Hormone (AMH)
NCT02352090 (11) [back to overview]D-dimer
NCT02352090 (11) [back to overview]F1+2
NCT02352090 (11) [back to overview]High-Density Lipoprotein (HDL)
NCT02352090 (11) [back to overview]High-sensitivity C Reactive Protein
NCT02352090 (11) [back to overview]Low-Density Lipoprotein (LDL)
NCT02352090 (11) [back to overview]Thrombin Generation, ETP Endogenous Thrombin Potential
NCT02352090 (11) [back to overview]Matsuda Index- Whole Body Insulin Sensitivity Index
NCT02352090 (11) [back to overview]Total Cholesterol
NCT02352090 (11) [back to overview]Triglyceride
NCT02352090 (11) [back to overview]Fasting Insulin
NCT02531321 (2) [back to overview]Levonorgestrel Area Under the Curve
NCT02531321 (2) [back to overview]Ethinyl Estradiol Area Under the Curve
NCT02533427 (27) [back to overview]Pharmacokinetic (PK) Parameter: AUCtau of Norelgestromin
NCT02533427 (27) [back to overview]Pharmacokinetic (PK) Parameter: AUCtau of Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: AUCtau of Ethinyl Estradiol
NCT02533427 (27) [back to overview]PK Parameter: AUCtau of Norgestrel
NCT02533427 (27) [back to overview]PK Parameter: Cmax of Ethinyl Estradiol
NCT02533427 (27) [back to overview]PK Parameter: Cmax of Norelgestromin
NCT02533427 (27) [back to overview]PK Parameter: Cmax of Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: Ctau of Ethinyl Estradiol
NCT02533427 (27) [back to overview]PK Parameter: Ctau of Norelgestromin
NCT02533427 (27) [back to overview]PK Parameter: Ctau of Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: Ctau of Norgestrel
NCT02533427 (27) [back to overview]Percentage of Participants Who Experienced Laboratory Abnormalities
NCT02533427 (27) [back to overview]PK Parameter: AUCtau of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
NCT02533427 (27) [back to overview]PK Parameter: CLss/F Ethinyl Estradiol, and Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: Cmax of Sofosbuvir (SOF), SOF Metabolites (GS-566500 and GS-331007), Velpatasvir (VEL), and Voxilaprevir (VOX)
NCT02533427 (27) [back to overview]PK Parameter: Ctau of SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
NCT02533427 (27) [back to overview]PK Parameter: t1/2 of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: t1/2 of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
NCT02533427 (27) [back to overview]PK Parameter: Tlast of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: Tlast of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
NCT02533427 (27) [back to overview]PK Parameter: Tmax of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: Tmax of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
NCT02533427 (27) [back to overview]PK Parameter: CLss/F of SOF, VEL, and VOX
NCT02533427 (27) [back to overview]PK Parameter: λz of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX
NCT02533427 (27) [back to overview]PK Parameter: λz of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate
NCT02533427 (27) [back to overview]PK Parameter: Cmax of Norgestrel
NCT02533427 (27) [back to overview]Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
NCT02577601 (1) [back to overview]Number of Participants With Follicle Rupture
NCT02616146 (5) [back to overview]Number of Participants With Absence of Withdrawal Bleeding (AWB), by Cycle
NCT02616146 (5) [back to overview]Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle
NCT02616146 (5) [back to overview]Number of Participants Who Experienced an Adverse Event (AE)
NCT02616146 (5) [back to overview]Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)
NCT02616146 (5) [back to overview]Number of Participants Who Discontinued Treatment Due to an AE
NCT02729545 (9) [back to overview]Changes in Total Testosterone (TT) From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Change in LH/FSH Ratio From Baseline to the 24th Week
NCT02729545 (9) [back to overview]Change in LH/FSH Ratio From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Body Mass Index (BMI) From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in FSH From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in LH From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Ovarian Volume From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Polycystic Ovary Number From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in the Number of Bleeding Events From Baseline to the End of Treatment
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Behavioral Inhibition Subscale Score
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Delay Discounting Parameter k
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Nucleus Accumbens Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Prefrontal Cortex Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Self-reported Reward Sensitivity Subscale Score
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Weekly Average Binge-eating Frequency
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Dorsal Striatum Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)
NCT04278755 (8) [back to overview]Change From Pre-intervention to Intervention Endpoint in Binge Eating Sum Score
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter
NCT05064332 (8) [back to overview]Number of Participants With Treatment Emergent Adverse Events by Severity
NCT05064332 (8) [back to overview]Number of Participants With Treatment Emergent Treatment-Related Adverse Events
NCT05064332 (8) [back to overview]Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Ethinyl Estradiol
NCT05064332 (8) [back to overview]Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration for Levonorgestrel
NCT05064332 (8) [back to overview]Maximum Plasma Concentration for Levonorgestrel
NCT05064332 (8) [back to overview]Number of Participants With Categorical Vital Signs Data of Potential Clinical Concern
NCT05064332 (8) [back to overview]Number of Participants With Laboratory Abnormalities of Potential Clinical Concern
NCT05064332 (8) [back to overview]Maximum Plasma Concentration (Cmax) for Ethinyl Estradiol

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.4.58.35.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)14.916.127.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.7296133
RAL 400mg b.i.d.6.65.411.6

[back to top]

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.

Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG115.97100.20

[back to top]

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.

,
Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG53.9655.25
EFV 600mg q.d. With ENG53.6456.65

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,
InterventionParticipants (Count of Participants)
3rd TrimesterPostpartum
EFV 600mg q.d.2021
MVC 150 or 300mg b.i.d.87

[back to top]

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,,,,,,,,,,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
2nd Trimester3rd TrimesterPostpartum
ATV/RTV Arm 1: 300/100mg q.d.11212
DRV/COBI 800/150 mg q.d.3414
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.71622
DRV/RTV 600/100mg b.i.d.71922
DRV/RTV 800/100mg q.d.91922
DTG 50mg q.d.92023
EFV 600 mg q.d. (Outside THA)123334
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.82927
ETR 200mg b.i.d.5137
EVG/COBI 150/150mg q.d.81018
FPV/RTV 700/100mg b.i.d.82622
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)101926
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.93027
ATV/COBI 300/150 mg q.d.125
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA1514
RAL 400mg b.i.d.113330
RPV 25mg q.d.142625
TAF 10mg q.d. w/COBI152322
TAF 25mg q.d.132324
TAF 25mg q.d. w/COBI or RTV Boosting102418
TFV 300mg q.d.22727
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.11112
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.72332

[back to top]

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

,,,
Interventionmcg/mL (Median)
2-10 hours after birth18-28 hours after birth36-72 hours after birth5-9 days after birth
DRV/COBI 800/150 mg q.d.0.351.431.871.72
DTG 50mg q.d.1.731.531.000.06
EFV 600 mg q.d. (Outside THA)1.11.00.90.4
EVG/COBI 150/150mg q.d.0.1320.0320.0050.005

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

Interventionng*hour/mL (Geometric Mean)
2nd Trimester3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.NA27173645

[back to top]

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.55.151.879.6
DRV/RTV 600/100mg b.i.d.45.845.961.7
FPV/RTV 700/100mg b.i.d.43.5032.1551.60
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA34.233.5

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.0.0630.0560.081

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

,,,,,,,,,,,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.25.3318.8536.20
ATV/RTV Arm 1: 300/100mg q.d.88.241.957.9
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.30.645.748.8
DRV/COBI 800/150 mg q.d.50.0042.0595.55
DRV/RTV 800/100mg q.d.64.663.5103.9
DTG 50mg q.d.47.649.265.0
EFV 600 mg q.d. (Outside THA)47.3060.0262.70
EVG/COBI 150/150mg q.d.15.314.021.0
TAF 10mg q.d. w/COBI0.1970.2060.216
TAF 25mg q.d.0.1710.2120.271
TAF 25mg q.d. w/COBI or RTV Boosting0.1810.2570.283
TFV 300mg q.d.1.92.43.0
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.14.528.839.6
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.26.237.758.7

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.55.458.3

[back to top]

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

Interventionhour (Median)
DTG 50mg q.d.32.8
EVG/COBI 150/150mg q.d.7.6
DRV/COBI 800/150 mg q.d.NA
EFV 600 mg q.d. (Outside THA)65.6

[back to top]

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.1.9691.6692.387

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.5.445.10

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.2.822.203.90
ATV/RTV Arm 1: 300/100mg q.d.NA3.64.1
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.3.114.514.52
DRV/COBI 800/150 mg q.d.4.593.677.04
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.6.226.558.96
DRV/RTV 600/100mg b.i.d.5.645.537.78
DRV/RTV 800/100mg q.d.6.775.788.11
DTG 50mg q.d.3.623.544.85
EFV 600 mg q.d. (Outside THA)3.875.134.41
FPV/RTV 700/100mg b.i.d.5.615.126.75
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)3.893.625.37
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA5.15.0
TFV 300mg q.d.0.2500.2450.298
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.1.22.54.1
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.2.733.565.43

[back to top]

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.701.010.63
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.8.410.714.6
RAL 400mg b.i.d.2.2501.7703.035
RPV 25mg q.d.0.1450.1340.134

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionng/mL (Median)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.448647

[back to top]

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionng/mL (Median)
2nd Trimester3rd TrimesterPostpartum
EVG/COBI 150/150mg q.d.1447.11432.81713.1
TAF 10mg q.d. w/COBI80.491.298.2
TAF 25mg q.d.69.796133
TAF 25mg q.d. w/COBI or RTV Boosting87.8107141

[back to top]

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

Interventionng/mL (Geometric Mean)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.108128

[back to top]

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.2.842.524.51
DRV/RTV 600/100mg b.i.d.2.122.222.51
FPV/RTV 700/100mg b.i.d.2.121.642.87
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA0.470.52

[back to top]

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.360.480.38
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.130.130.28
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.3.75.17.2
RAL 400mg b.i.d.0.06210.0640.0797

[back to top]

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.0.210.210.61
ATV/RTV Arm 1: 300/100mg q.d.2.00.71.2
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.490.710.90
DRV/COBI 800/150 mg q.d.0.330.271.43
DRV/RTV 800/100mg q.d.0.991.172.78
DTG 50mg q.d.0.730.931.28
EFV 600 mg q.d. (Outside THA)1.491.481.94
EVG/COBI 150/150mg q.d.0.02580.04870.3771
TAF 10mg q.d. w/COBI0.001950.001950.00195
TAF 25mg q.d.0.001950.001950.00195
TAF 25mg q.d. w/COBI or RTV Boosting0.001950.001950.00195
TFV 300mg q.d.0.0390.0540.061
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.0.30.50.8
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.440.571.26

[back to top]

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.1.602.05

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.0.15
DTG 50mg q.d.1.25
EVG/COBI 150/150mg q.d.0.91
DRV/COBI 800/150 mg q.d.0.07
ATV/COBI 300/150 mg q.d.0.07
TFV 300mg q.d.0.88

[back to top]

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
TAF 10mg q.d. w/COBI0.97
EFV 600 mg q.d. (Outside THA)0.67
EFV 600mg q.d.0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.0.2
RAL 400mg b.i.d.1.5
ETR 200mg b.i.d.0.52
MVC 150 or 300mg b.i.d.0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.12
RPV 25mg q.d.0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.0.18

[back to top]

Plasma Concentration for Contraceptives

Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum

Interventionpg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG604
LPV/RTV 400/100 b.i.d. With ENG428
EFV 600mg q.d. With ENG125

[back to top]

Number of Participants With Any Abnormal Fasting Glucose/Insulin Ratio Value

Indicates if patient had any measured value below threshold of normality at any visit during addendum. Abnormal Fasting Glucose/Insulin Ratio = Fasting Glucose/Insulin Ratio <=4.5 milligrams per 10^-4 Units (mg/10^-4U). (NCT00191113)
Timeframe: At start and through end of 4-year addendum

Interventionparticipants (Number)
As-Treated No Growth Hormone1
As-Treated Growth Hormone3

[back to top]

Number of Participants With Any Abnormal Fasting Glucose Value

Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Fasting Glucose=Fasting Glucose >=100 milligrams per deciliter (mg/dL). (NCT00191113)
Timeframe: At start and through end of 4-year addendum

Interventionparticipants (Number)
As-Treated No Growth Hormone0
As-Treated Growth Humatrope3

[back to top]

Glycosylated Hemoglobin, Change From Baseline

Change from core study baseline to addendum 2 maximum. (NCT00191113)
Timeframe: At core study baseline, and at end of 4-year addendum

Interventionpercent (%) (Least Squares Mean)
Treated-As-Randomized Control0.215
Treated-As-Randomized Humatrope0.208

[back to top]

Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population

Value analyzed is change from baseline to the most mature height measurement available. The terms Standard Deviation Score (SDS) and National Center for Health Statistics (NCHS) were defined in baseline characteristics. Greater height SDS values indicate greater height; positive values of change from baseline indicate increased height. (NCT00191113)
Timeframe: Baseline, and end of 4-year addendum

InterventionStandard Deviation Score (SDS) [NCHS] (Least Squares Mean)
As-Randomized Control0.09
As-Randomized Humatrope0.97

[back to top]

Number of Participants With an Abnormal Pure Tone Audiometry, Audiologist Assessment

(NCT00191113)
Timeframe: at completion of core study or beginning of addendum

Interventionparticipants (Number)
As-Treated No Growth Hormone10
As-Treated Growth Hormone29

[back to top]

Number of Participants With Abnormal Speech Audiometry, Audiologist Assessment

(NCT00191113)
Timeframe: at completion of core study or beginning of addendum

Interventionparticipants (Number)
As-Treated No Growth Hormone3
As-Treated Growth Hormone12

[back to top]

Number of Participants With Abnormal Impedance Tympanometry, Audiologist Assessment

(NCT00191113)
Timeframe: at completion of core study or beginning of addendum

Interventionparticipants (Number)
As-Treated No Growth Hormone2
As-Treated Growth Hormone18

[back to top]

Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline, As-Treated Population

Value analyzed is change from baseline to the most mature height measurement available. The terms Standard Deviation Score (SDS) and National Center for Health Statistics (NCHS) were defined in baseline characteristics. Greater height SDS values indicate greater height; positive values of change from baseline indicate increased height. (NCT00191113)
Timeframe: every 3 months during core study, and at start and end of 4-year addendum

InterventionStandard Deviation Score (SDS) [NCHS] (Least Squares Mean)
As-Treated No Growth Hormone-0.09
As-Treated Growth Humatrope0.99

[back to top]

Minimum Fasting Glucose/Insulin Ratio Values

Minimum measured value over addendum. In special cases an additional measurement is taken at 2 years. (NCT00191113)
Timeframe: At start and through end of 4-year addendum (up to an additional 2 years)

Interventionmilligrams per 10^-4 Units (mg/[10^-4]U) (Mean)
As-Treated No Growth Hormone12.5
As-Treated Growth Hormone12.2

[back to top]

Maximum Glycosylated Hemoglobin

Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years. (NCT00191113)
Timeframe: At start and through end of 4-year addendum (up to an additional 2 years)

Interventionpercent (%) (Mean)
As-Treated No Growth Hormone5.0
As-Treated Growth Hormone5.0

[back to top]

Maximum Fasting Insulin Values

Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years. (NCT00191113)
Timeframe: At start and through end of 4-year addendum (up to an additional 2 years)

Interventionmicro International Units per milliliter (Mean)
As-Treated No Growth Hormone9.5
As-Treated Growth Hormone9.7

[back to top]

Maximum Fasting Glucose Value

Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years. (NCT00191113)
Timeframe: At start and through end of 4-year addendum (up to an additional 2 years)

Interventionmilligrams per deciliter (mg/dL) (Mean)
As-Treated No Growth Hormone85.2
As-Treated Growth Hormone85.2

[back to top]

Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Last Measurement After Attainment of Final Height

SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS [NCHS] uses the NCHS US general female population reference height values for age (Kuczmarski RJ et al. 2000) as the population mean and standard deviation. Calculation of Height SDS is provided in Height SDS [Lyon] description (Baseline). Since data reported by Kuczmarski RJ et al provides US general female population standards, values of Height SDS [NCHS] for untreated patients with Turner syndrome tend to be below zero e.g, -2.0 to -4.0 SDS. (NCT00191113)
Timeframe: at completion of core study, or at end of 4-year addendum

InterventionStandard Deviation Score (SDS) [NCHS] (Least Squares Mean)
As-Treated No Growth Hormone-3.30
As-Treated Growth Hormone-2.25

[back to top]

Height (Centimeters [cm])

Most mature measurement available, at or after attainment of Final Height. (NCT00191113)
Timeframe: every 3 months during core study, and at start and end of 4-year addendum

Interventioncentimeters (cm) (Least Squares Mean)
As-Treated No Growth Hormone141.63
As-Treated Growth Humatrope148.52

[back to top]

Number of Participants With Hearing Loss, Audiologist Assessment

Sensorineural Hearing Loss (SNHL)=air conduction threshold >20 dB HL and air-bone gap ≤10 dB HL; Conductive Hearing Loss (CHL)= air conduction threshold >20 dB HL, bone conduction threshold ≤20 dB HL and air-bone gap >10 dB HL; Mixed Hearing Loss (MHL) = evidence of SNHL as defined above and CHL as defined above, in the same ear; Unspecified Hearing Loss (UHL)= abnormal hearing with none of SNHL, CHL, or MHL present. (NCT00191113)
Timeframe: at completion of core study or beginning of addendum

,
Interventionparticipants (Number)
Conductive Hearing LossSensorineural Hearing LossMixed Hearing LossUnspecified Hearing Loss
As-Treated Growth Hormone71591
As-Treated No Growth Hormone1821

[back to top]

Number of Participants With Any Abnormal Glycosylated Hemoglobin (HbA1c) Value

Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Glycosylated Hemoglobin = HbA1c ≥6.8% (up until 11-May-1998); and then HbA1c ≥6.1% (from 19-May-1998 onwards). (NCT00191113)
Timeframe: At start and through end of 4-year addendum

Interventionparticipants (Number)
As-Treated No Growth Hormone0
As-Treated Growth Hormone0

[back to top]

Number of Participants With Any Abnormal Fasting Insulin Value

Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Fasting Insulin = Fasting Insulin >=35 micro International Units per milliliter (uIU/mL). (NCT00191113)
Timeframe: At start and through end of 4-year addendum

Interventionparticipants (Number)
As-Treated No Growth Hormone1
As-Treated Growth Humatrope2

[back to top]

Fasting Glucose, Change From Baseline

Change from core study baseline to addendum 2 maximum. (NCT00191113)
Timeframe: At core study baseline, and at end of 4-year addendum

Interventionmg / dL (Least Squares Mean)
Treated-As-Randomized Control5.495
Treated-As-Randomized Humatrope3.003

[back to top]

"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining On Drug Pregnancy"

"Pearl Index= ((100)*(number of pregnancies)*(4 cycles/year))/number of 91-day cycles completed.~The pregnancy rate included on-drug pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 14 days after the date of last combination dose of study medication.~Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 14 days after the date of last combination dose of study medication.~Three denominators are reported;~excluding cycles where other birth control methods (BCMs) was used~all complete cycles~compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)" (NCT00196326)
Timeframe: up to one year

Interventionpregnancies per 100 woman years exposure (Number)
Excluding other BCMs (n=1732)All complete cycles (n=1735)Compliant-Use (n=1685)
DR-10112.442.421.77

[back to top]

"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining On Drug Pregnancy"

"Pearl Index= ((100)*(number of pregnancies)*(4 cycles/year))/number of 91-day cycles completed.~The pregnancy rate included on-drug pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 7 days after the date of last combination dose of study medication.~Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 7 days after the date of last combination dose of study medication.~Three denominators are reported;~excluding cycles where other birth control methods (BCMs) was used~all complete cycles~compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)" (NCT00196326)
Timeframe: up to one year

Interventionpregnancies per 100 woman years exposure (Number)
Excluding other BCMs (n=1732)All complete cycles (n=1735)Compliant-Use (n=1685)
DR-10112.152.121.77

[back to top]

Participants With Treatment-Emergent Adverse Events

Safety was assessed by summarizing adverse events recorded in the patient's daily diary and reported by subjects at each study visit, and by summarizing results of examination, vital signs and clinical laboratory values. (NCT00196326)
Timeframe: Day 1 up to one year

Interventionparticipants (Number)
DR-10111742

[back to top] [back to top] [back to top]

Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)

Average of 0-10 ratings of current facial pain, average facial pain in the last month and worst facial pain in the last month, where 0 is no pain and 10 is pain as bad as could be. For the combined outcome, the minimum score is 0 and maximum is 10, with 0 being better (no pain) and 10 being the worst outcome. (NCT00237042)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Self Management3.1
Targeted Self Management2.9
Continuous Oral Contraceptives3.6

[back to top]

Characteristic Pain Intensity (Characteristic Intensity of Facial Pain)

Average of 0-10 ratings of current facial pain, average facial pain in the last month and worst facial pain in the last month, where 0 is no pain and 10 is pain as bad as could be. For the combined outcome, the minimum score is 0 and maximum is 10, with 0 being better (no pain) and 10 being the worst outcome. (NCT00237042)
Timeframe: 12 months

InterventionUnits on a scale (Mean)
Self Management2.8
Targeted Self Management2.8
Continuous Oral Contraceptives3.9

[back to top]

Areal Bone Density by DXA

(NCT00310791)
Timeframe: 18-Months

Interventiong/cm2 (Mean)
Placebo0.88
Active0.89

[back to top]

Percentage of Subjects With Amenorrhea, Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol49.1

[back to top]

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 2, MITT Population

MITT Population (NCT00391807)
Timeframe: 2 Cycles, 28 days each (56 days)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol3.21

[back to top]

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 13, MITT Population

MITT Population (NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol1.81

[back to top]

Median Duration of Withdrawal Bleeding, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.99

[back to top]

Median Duration of Withdrawal Bleeding, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.93

[back to top]

Median Duration of Withdrawal Bleeding, Cycle 12, MITT Population

(NCT00391807)
Timeframe: 12 cycles, 28 days each (336 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.85

[back to top]

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 6, MITT Population

MITT Population (NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol2.00

[back to top]

Percentage of Subjects With Amenorrhea, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol30.7

[back to top]

Total Number of Bleeding Days Per Cycle, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol4.57

[back to top]

Total Number of Bleeding Days Per Cycle, Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol3.36

[back to top]

Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45, MITT Population

(NCT00391807)
Timeframe: 13 Cycles, 28 days each (1 year)

InterventionPregnancy Rate (Number)
Norethindrone/Ethinyl Estradiol2.167

[back to top]

Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPregnancy Rate (Number)
Norethindrone/Ethinyl Estradiol2.554

[back to top]

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol25.0

[back to top]

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol34.8

[back to top]

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol22.4

[back to top]

Percentage of Subjects With Amenorrhea, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol42.9

[back to top]

Total Number of Bleeding Days Per Cycle, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol3.00

[back to top]

Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection. (NCT00394771)
Timeframe: Day 1-84

Interventiondays (Median)
Low Dose DR-103113
Midrange Dose DR-103113.5
High Dose DR-103115
Seasonale15

[back to top]

Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection. (NCT00394771)
Timeframe: Day 92-176

Interventiondays (Median)
Low Dose DR-10316
Midrange Dose DR-10317
High Dose DR-10315
Seasonale6

[back to top]

Days With Bleeding During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. (NCT00394771)
Timeframe: Day 1-84

Interventiondays (Median)
Low Dose DR-10313.5
Midrange Dose DR-10312.5
High Dose DR-10314
Seasonale2

[back to top]

Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)

Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. (NCT00394771)
Timeframe: Day 1-84

Interventiondays (Median)
Low Dose DR-10310
Midrange Dose DR-10310
High Dose DR-10310
Seasonale0

[back to top]

Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy. (NCT00394771)
Timeframe: Day 92-176

Interventiondays (Median)
Low Dose DR-10310
Midrange Dose DR-10310
High Dose DR-10310
Seasonale0

[back to top] [back to top] [back to top] [back to top] [back to top]

Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)

Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1. (NCT00394771)
Timeframe: Day 85-91

,,,
Interventionparticipants (Number)
0 day1-3 days4-7 days
High Dose DR-1031252754
Low Dose DR-1031143659
Midrange Dose DR-1031281763
Seasonale271875

[back to top]

Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)

Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2. (NCT00394771)
Timeframe: Day 177-183

,,,
Interventionparticipants (Number)
0 day1-3 days4-7 days
High Dose DR-1031232645
Low Dose DR-1031153250
Midrange Dose DR-1031203244
Seasonale212460

[back to top]

Days With Bleeding During Active Cycle 2 (Day 92-176)

Bleeding is defined as a flow heavy enough to require sanitary protection. (NCT00394771)
Timeframe: Day 92-176

Interventiondays (Median)
Low Dose DR-10311
Midrange Dose DR-10312
High Dose DR-10311
Seasonale2

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-3.4
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-4.4
1.5 mg MPA / 0.3 mg CEE (Prempro)1.1

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.4
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.2
1.5 mg MPA / 0.3 mg CEE (Prempro)2.0

[back to top]

Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8

Sodium sensitivity was defined as ≥ 10 mmHg drop in mean arterial pressure, calculated from the office cuff BP values from Day 1 to Day 3. The number of subjects shifting from sodium sensitive at Baseline to sodium resistant at Week 8 or sodium resistant at Baseline to sodium sensitive at Week 8 by treatment group was reported. (NCT00420342)
Timeframe: 8 weeks plus 3 days

,,
Interventionparticipants (Number)
BaselineWeek 8
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)41
1.5 mg MPA / 0.3 mg CEE (Prempro)42
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)32

[back to top]

Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements

The mean change in 24-hr Diastolic Blood Pressure (DBP) from Baseline to Week 8 was calculated for the full analysis set. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.19
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-0.91
1.5 mg MPA / 0.3 mg CEE (Prempro)0.57

[back to top]

Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population

The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the per protocol (PP) population. The change from baseline means was adjusted for center and baseline SBP. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.08
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)0.06
1.5 mg MPA / 0.3 mg CEE (Prempro)2.82

[back to top]

Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population

The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the full analysis set. The change from baseline means was adjusted for center and baseline SBP. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.03
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-0.27
1.5 mg MPA / 0.3 mg CEE (Prempro)2.18

[back to top]

Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements

Systolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle) (NCT00420342)
Timeframe: Baseline to Week 8

,,
InterventionmmHg (Mean)
mean daytimemean nighttimemean trough
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.081.57-1.91
1.5 mg MPA / 0.3 mg CEE (Prempro)1.533.97-1.51
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.061.64-1.48

[back to top]

Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements

Diastolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle) (NCT00420342)
Timeframe: Baseline to Week 8

,,
InterventionmmHg (Median)
mean daytimemean nighttimemean trough
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.950.20-1.04
1.5 mg MPA / 0.3 mg CEE (Prempro)0.171.75-0.30
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.560.67-1.13

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.9
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-1.9
1.5 mg MPA / 0.3 mg CEE (Prempro)1.4

[back to top]

Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough

Seated systolic and diastolic office cuff blood pressures were taken at each visit; the mean of three readings were used at each timepoint. (NCT00420342)
Timeframe: Baseline to Week 8

,,
InterventionmmHg (Mean)
Systolic Blood Pressure (SBP)Diastolic Blood Pressure (DBP)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-5.25-1.34
1.5 mg MPA / 0.3 mg CEE (Prempro)-4.200.33
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-6.02-0.36

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-2.6
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-3.7
1.5 mg MPA / 0.3 mg CEE (Prempro)1.1

[back to top]

Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)

Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM >112 mmHg, >116 mmHg, >120 mmHg, >124 mmHg, and >130 mmHg. (NCT00420342)
Timeframe: Baseline to Week 8

InterventionmmHg (Mean)
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-5.2
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)-4.0
1.5 mg MPA / 0.3 mg CEE (Prempro)1.0

[back to top]

Change in High-density Lipoprotein (HDL) Levels During Study Period

Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months

Interventionmg/dL (Mean)
Oral Contraceptive - 16
Flutamide - 2-5
Placebo - 3-2

[back to top]

Change in Low-density Lipoprotein (LDL) Levels Over the Study Period

Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months

Interventionmg/dL (Mean)
Oral Contraceptive - 1-6
Flutamide - 2-9
Placebo - 3-7

[back to top]

Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period

Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months

InterventionL/min (Mean)
Oral Contraceptive - 1-0.5
Flutamide - 2-1.6
Placebo - 31.1

[back to top]

Change in Resting Energy Expenditure (REE) Over the Study Period

Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months

InterventionKcal/day (Mean)
Oral Contraceptive - 17
Flutamide - 2-79
Placebo - 3-88

[back to top]

Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI

Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months

InterventionL (Mean)
Oral Contraceptive - 1-0.1
Flutamide - 2-0.1
Placebo - 30.1

[back to top]

Change in Disposition Index

Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months

Interventionmin^-1 (Mean)
Oral Contraceptive - 11653
Flutamide - 2194
Placebo - 3-184

[back to top]

Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period

Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months

Interventionpercentage of body mass (Mean)
Oral Contraceptive - 10.4
Flutamide - 2-1.9
Placebo - 3-1.9

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 24

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 24

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)0.1

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)448.9
Drospirenone (DRSP)/Ethinylestradiol (EE)68.0

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)452.7
Drospirenone (DRSP)/Ethinylestradiol (EE)64.6

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)110.9
Drospirenone (DRSP)/Ethinylestradiol (EE)-37.6

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)310.3
Drospirenone (DRSP)/Ethinylestradiol (EE)68.2

[back to top]

Mean Neural Tube Defect (NTD) Risk Reduction at Week 24

The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline (NCT00468481)
Timeframe: Baseline and week 24

Interventionper 1000 birth (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.51
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.03

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)50.3
Drospirenone (DRSP)/Ethinylestradiol (EE)47.1

[back to top]

Red Blood Cell (RBC) Folate Level at 24 Weeks

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: Week 24

Interventionnmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1406.91
Drospirenone (DRSP)/Ethinylestradiol (EE)1022.21

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)67.5
Drospirenone (DRSP)/Ethinylestradiol (EE)51.8

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)61.5
Drospirenone (DRSP)/Ethinylestradiol (EE)45.9

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)64.0
Drospirenone (DRSP)/Ethinylestradiol (EE)43.7

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.4
Drospirenone (DRSP)/Ethinylestradiol (EE)45.9

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)68.1
Drospirenone (DRSP)/Ethinylestradiol (EE)54.1

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)41.7
Drospirenone (DRSP)/Ethinylestradiol (EE)41.5

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.5
Drospirenone (DRSP)/Ethinylestradiol (EE)42.3

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.4
Drospirenone (DRSP)/Ethinylestradiol (EE)43.2

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.8
Drospirenone (DRSP)/Ethinylestradiol (EE)39.7

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)58.7
Drospirenone (DRSP)/Ethinylestradiol (EE)39.8

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.6
Drospirenone (DRSP)/Ethinylestradiol (EE)43.1

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.8
Drospirenone (DRSP)/Ethinylestradiol (EE)41.8

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1122.8
Drospirenone (DRSP)/Ethinylestradiol (EE)1345.0

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)15.2
Drospirenone (DRSP)/Ethinylestradiol (EE)0.6

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 8

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)18.4
Drospirenone (DRSP)/Ethinylestradiol (EE)2.2

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 12

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 12

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)0

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1469.8
Drospirenone (DRSP)/Ethinylestradiol (EE)1378.4

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)0.3

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1486.6
Drospirenone (DRSP)/Ethinylestradiol (EE)1435.9

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1500.3
Drospirenone (DRSP)/Ethinylestradiol (EE)1316.1

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1175.7
Drospirenone (DRSP)/Ethinylestradiol (EE)1256.1

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1412.7
Drospirenone (DRSP)/Ethinylestradiol (EE)1407.6

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)910.9
Drospirenone (DRSP)/Ethinylestradiol (EE)915.1

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1308.9
Drospirenone (DRSP)/Ethinylestradiol (EE)1025.2

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1365.2
Drospirenone (DRSP)/Ethinylestradiol (EE)967.6

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1419.8
Drospirenone (DRSP)/Ethinylestradiol (EE)981.3

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1355.3
Drospirenone (DRSP)/Ethinylestradiol (EE)949.2

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1007.1
Drospirenone (DRSP)/Ethinylestradiol (EE)889.5

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1184.8
Drospirenone (DRSP)/Ethinylestradiol (EE)970.4

[back to top]

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)67.4
Drospirenone (DRSP)/Ethinylestradiol (EE)46.4

[back to top]

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1460.5
Drospirenone (DRSP)/Ethinylestradiol (EE)1454.7

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 20

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 20

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.2

[back to top]

Plasma Folate Level at 24 Weeks

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: Week 24

Interventionnmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.55
Drospirenone (DRSP)/Ethinylestradiol (EE)41.67

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 4

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 4

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)0
Drospirenone (DRSP)/Ethinylestradiol (EE)0

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 8

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 8

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)0

[back to top]

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)405.8
Drospirenone (DRSP)/Ethinylestradiol (EE)86.5

[back to top]

Mean Change From Baseline in Plasma Homocysteine Levels at Week 16

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 16

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.1

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)2.4

[back to top]

Mean Change From Baseline in Plasma Folate Levels at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)15.1
Drospirenone (DRSP)/Ethinylestradiol (EE)-1.6

[back to top]

Pearl Index, 18-35 Years, MITT Population

Pregnancy rate in women 18-35 years old, Pearl Index - number of pregnancies per 100 women-years of treatment (NCT00477633)
Timeframe: 13 cycles (28 days each), approximately 364 days

InterventionPearl Index (Number)
Norethindrone/Ethinyl Estradiol Tablets1.903

[back to top]

Mean Number of Days of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population

(NCT00477633)
Timeframe: 12 cycles (28 days each), approximately 336 days

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol Tablets1.19

[back to top]

Mean Median Duration (Days) of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population

"Each IB episode has a unique duration, with 0, 1, 2, 3 or more episodes per cycle. To obtain mean median duration of episodes during a cycle, take the median duration of all episodes in each cycle. If there are no episodes in the cycle, then median duration is undefined/missing for that cycle. 1 episode - median duration = duration of that episode, 2 episodes - median duration = average of 2 durations, more than 2 episodes, calculated in usual way for median of an ordered set of numbers. Once median determined for each cycle/subject, the mean & SD of those quantities calculated." (NCT00477633)
Timeframe: 12 cycles (28 days each), approximately 336 days

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol Tablets3.52

[back to top]

Differences in Bleeding Patterns Between Study Groups.

number of days of bleeding and spotting, self reported on calendar (NCT00480532)
Timeframe: The outcome was also assessed for day 1 to 84

Interventiondays (Mean)
Placebo (Treatment)26.72
Doxy (7 Day Treatment Arm)31.86
Placebo (Prevention)25.69
Subantibmicrobial Dose Doxy18.84

[back to top]

Subject Compliance

measured by self report of pill intake on daily diary (yes/no), and reported as percentage with no missed pills over entire study (NCT00480532)
Timeframe: Assessed on day 112 of the study (the end of the study period). The outcome reflects the number of subjects who did not miss pills during the entire 112 day study. It does not represent a change from baseline.

Interventionnumber of participants with no missed pi (Number)
Placebo (Treatment)25
Doxy (7 Day Treatment Arm)21
Placebo (Prevention)19
Subantibmicrobial Dose Doxy20

[back to top]

Subject Satisfaction.

"measured using 100 mm visual analog scale. anchors of not at all satisfied (0mm) extremely satisfied (100mm)" (NCT00480532)
Timeframe: Assessed on day 112 of the study (the end of the study period). This outcome does not represent a change from baseline. It was assessed at the end of the study period.

Interventionmm (Mean)
Placebo (Treatment)63.9
Doxy (7 Day Treatment Arm)64.2
Placebo (Prevention)72.0
Subantibmicrobial Dose Doxy67.0

[back to top]

Serum Concentration of HDL2-cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=58 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.690.40
NOMAC-E20.630.55

[back to top]

Serum Concentration of Free Thyroxine (T4)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionpmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE14.115.7
NOMAC-E214.015.9

[back to top]

Serum Concentration of Free Testosterone

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionpmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE26.39.9
NOMAC-E224.512.8

[back to top]

Serum Concentration of Dihydrotestosterone (DHT)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE0.620.36
NOMAC-E20.590.53

[back to top]

Serum Concentration of Dehydroepiandrosterone Sulphate (DHEAS)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionumol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE5.194.00
NOMAC-E24.944.32

[back to top]

Serum Concentration of D-Dimer

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmg/L Fibrinogen Equivalent Units (FEU) (Mean)
Baseline (n=60; NOMAC-E2; n=58)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.190.26
NOMAC-E20.210.18

[back to top]

Serum Concentration of Corticosteroid Binding Globulin (CBG)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline to Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9321980
NOMAC-E29101116

[back to top]

Serum Concentration of Clotting Factor VIII

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9598
NOMAC-E29389

[back to top]

Serum Concentration of Clotting Factor VIIc

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE10596
NOMAC-E2105109

[back to top]

Serum Concentration of Clotting Factor VIIa

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionU/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE8598
NOMAC-E284118

[back to top]

Serum Concentration of Sex Hormone Binding Globulin (SHBG)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE77100
NOMAC-E274108

[back to top]

Serum Concentration of C-Reactive Protein (CRP)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmg/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.984.43
NOMAC-E20.821.32

[back to top]

Serum Concentration of Apolipoprotein B

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventiong/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.640.80
NOMAC-E20.640.68

[back to top]

Serum Concentration of Apolipoprotein A-1

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventiong/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE1.601.67
NOMAC-E21.581.78

[back to top]

Serum Concentration of Antithrombin III

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9996
NOMAC-E2100102

[back to top]

Serum Concentration of Androstenedione

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE10.276.96
NOMAC-E29.608.23

[back to top]

Number of Participants With an Occurrence of Early Withdrawal Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Early withdrawal bleeding was defined as any withdrawal bleeding that started before the current expected bleeding period. Expected bleeding period: NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle; LNG-EE: 7-day period starting on Day 22 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE411002
NOMAC-E2543212

[back to top]

Number of Participants With an Occurrence of Continued Withdrawal Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Continued withdrawal bleeding was defined as any withdrawal bleeding that continued into the expected non-bleeding period of the next cycle. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 5 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=54 NOMAC-E2; n=50 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=53 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)
LNG-EE2528262729
NOMAC-E21511131113

[back to top]

Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only)

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough spotting was defined as any spotting episode that occurred during the expected non-bleeding period that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE1695243
NOMAC-E217104744

[back to top]

Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE1695243
NOMAC-E218115866

[back to top]

Number of Participants With an Occurrence of Breakthrough Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding was defined as any bleeding episode that occurred during the expected non-bleeding period that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE100000
NOMAC-E2311123

[back to top]

Number of Participants With an Occurrence of Absence of Withdrawal Bleeding

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Absence of withdrawal bleeding was defined as no bleeding/spotting episode that began during or continued into the expected bleeding period. Expected bleeding period: NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle; LNG-EE: 7-day period starting on Day 22 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionParticipants (Number)
Cycle 1 (n=56 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=55 NOMAC-E2; n=51 LNG-EE)Cycle 3 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 4 (n=54 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=52 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE010001
NOMAC-E26858510

[back to top]

Incremental AUC3 for Insulin (OGTT)

Blood insulin levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Incremental area under the curve was defined as incremental AUC3 = AUC3 - 3*fasting concentration. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*pmol/L (Mean)
Baseline (n=51 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=46 NOMAC-E2; n=47 LNG-EE)
LNG-EE451603
NOMAC-E2517534

[back to top]

Incremental AUC3 for Glucose (OGTT)

Blood glucose levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Incremental area under the curve was defined as incremental AUC3 = AUC3 - 3*fasting concentration. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*mmol/L (Mean)
Baseline (n=59 NOMAC-E2; n=55 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE1.063.19
NOMAC-E21.581.76

[back to top]

Serum Concentration of Clotting Factor II

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE9497
NOMAC-E29495

[back to top]

Average Number of Withdrawal Bleeding/Spotting Days

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Withdrawal bleeding/spotting was defined as any episode that occurred during the expected bleeding period. Expected bleeding period: NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle; LNG-EE: 7-day period starting on Day 22 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionDays (Mean)
Cycle 1 (n=50 NOMAC-E2; n=53 LNG-EE)Cycle 2 (n=47 NOMAC-E2; n=50 LNG-EE)Cycle 3 (n=49 NOMAC-E2); n=52 LNG-EE)Cycle 4 (n=46 NOMAC-E2; n=52 LNG-EE)Cycle 5 (n=47 NOMAC-E2; n=51 LNG-EE)Cycle 6 (n=42 NOMAC-E2; n=49 LNG-EE)
LNG-EE5.84.94.95.04.94.2
NOMAC-E24.84.73.94.03.83.5

[back to top]

Average Number of Breakthrough Bleeding/Spotting Days

"Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: NOMAC-E2: 21-day period starting on Day 4 of the cycle; LNG-EE: 21-day period starting on Day 1 of the cycle." (NCT00511355)
Timeframe: Every 28-day cycle for 6 cycles

,
InterventionDays (Mean)
Cycle 1 (n=18 NOMAC-E2; n=16 LNG-EE)Cycle 2 (n=11 NOMAC-E2; n=9 LNG-EE)Cycle 3 (n=5 NOMAC-E2; n=5 LNG-EE)Cycle 4 (n=8 NOMAC-E2; n=2 LNG-EE)Cycle 5 (n=6 NOMAC-E2; n=4 LNG-EE)Cycle 6 (n=6 NOMAC-E2; n=3 LNG-EE)
LNG-EE4.63.33.24.02.03.0
NOMAC-E23.54.34.63.83.34.7

[back to top]

AUC3 for Insulin (OGTT)

Blood insulin levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*pmol/L (Mean)
Baseline (n=51 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=46 NOMAC-E2; n=47 LNG-EE)
LNG-EE558721
NOMAC-E2650658

[back to top]

Area Under the Curve Over 3 Hours (AUC3) for Glucose (Oral Glucose Tolerance Test [OGTT])

Blood glucose levels were determined as fasting values just before oral glucose intake and each half hour thereafter for 2 hours and again after 3 hours. Oral glucose tolerance was analysed using the (unadjusted) area under the curve over the 3 hours (AUC3). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionhrs*mmol/L (Mean)
Baseline (n=59 NOMAC-E2; n=55 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=50 LNG-EE)
LNG-EE14.4416.69
NOMAC-E215.8216.09

[back to top]

APC Resistance Ratio (Activated Partial Thromboplastin Time [APTT]-Based)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). APC resistance ratio (APTT-based) measures the anticoagulation response of plasma to APC after activation of the intrinsic coagulation pathway. An increase in the ratio indicates a increased responsiveness to APC. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionRatio (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE1.001.03
NOMAC-E21.011.05

[back to top]

Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). APC resistance ratio (ETP-based) measures the anticoagulation response of plasma to APC after activation of the extrinsic coagulation pathway. An increase in the ratio indicates a reduced responsiveness to APC. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionRatio (Mean)
Baseline (n=59 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.831.99
NOMAC-E20.801.14

[back to top]

Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)

In-treatment pregnancies were pregnancies with an estimated date of conception from the day of first intake of trial medication up to and including the day of last (active or placebo) intake of trial medication extended with a maximum of 2 days. Each 13 cycles (28 days per cycle) constitutes a woman year. The Pearl Index was obtained by dividing the number of in-treatment pregnancies that occurred by the time (in 100 women years) that the women were under risk of becoming pregnant. (NCT00511355)
Timeframe: 6 cycles

InterventionPregnancies per 100 woman years (Number)
NOMAC-E20
LNG-EE0

[back to top]

Serum Concentration of Thyroid Stimulating Hormone (TSH)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionmU/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE2.202.75
NOMAC-E22.692.96

[back to top]

Serum Concentration of Thyroxin Binding Globulin (TBG)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmg/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE20.328.4
NOMAC-E220.324.2

[back to top]

Serum Concentration of Total Cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE4.534.48
NOMAC-E24.484.51

[back to top]

Serum Concentration of Total Cortisol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE502944
NOMAC-E2482608

[back to top]

Serum Concentration of Total Testosterone

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60, NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53, NOMAC-E2; n=52 LNG-EE)
LNG-EE1.900.91
NOMAC-E21.681.23

[back to top]

Serum Concentration of Total Triglycerides

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.821.02
NOMAC-E20.941.00

[back to top]

Serum Concentration of Prothrombin Fragments 1 + 2

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionnmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE0.190.42
NOMAC-E20.180.31

[back to top]

Serum Concentration of Protein S (Total)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE7976
NOMAC-E27883

[back to top]

Serum Concentration of Protein S (Free)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE8699
NOMAC-E28599

[back to top]

Serum Concentration of Protein C

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of normal (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=52 LNG-EE)
LNG-EE103113
NOMAC-E2107108

[back to top]

Serum Concentration of Low Density Lipoprotein (LDL)-Cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE2.472.61
NOMAC-E22.412.40

[back to top]

Serum Concentration of Lipoprotein(a)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventiong/L (Mean)
Baseline (n=60 NOMAC-E2; n=57 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE0.150.12
NOMAC-E20.150.17

[back to top]

Serum Concentration of High Density Lipoprotein (HDL)-Cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE1.681.41
NOMAC-E21.631.65

[back to top]

Serum Concentration of Hemoglobin Type A1c (HbA1c)

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). HbA1c was determined before glucose loading. Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
InterventionPercent of glycosylated hemoglobin (Mean)
Baseline (n=60 NOMAC-E2; n=58 LNG-EE)Cycle 6 (n=53 NOMAC-E2; n=51 LNG-EE)
LNG-EE5.35.4
NOMAC-E25.35.3

[back to top]

Serum Concentration of HDL3-cholesterol

Serum samples were obtained under fasting conditions (no food or alcoholic beverages within 12 hours of serum sampling). Each cycle consists of 28 days. (NCT00511355)
Timeframe: Baseline and Cycle 6 (between Days 15 and 21 of the cycle)

,
Interventionmmol/L (Mean)
Baseline (n=58 NOMAC-E2; n=50 LNG-EE)Cycle 6 (n=52 NOMAC-E2; n=51 LNG-EE)
LNG-EE1.141.10
NOMAC-E21.101.16

[back to top]

Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods

The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventiondays (Mean)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-10212.193.191.96
Mircette1.413.671.64

[back to top]

Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods

The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventionpercentage of participants (Number)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-102148.177.855.6
Mircette59.392.653.6

[back to top]

Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day

Levels of follicle stimulating hormone were measured throughout the study from blood samples. (NCT00544882)
Timeframe: Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.

,
InterventionmIU/mL (Median)
Cycle 2 - Day 2 (n=28, 28)Cycle 2 - Day 4 (n=28, 28)Cycle 2 - Day 6 (n=28, 27)Cycle 2 - Days 19-20 (n=26, 28)Cycle 2 - Day 23 (n=27, 28)Cycle 2 - Day 24 (n=25, 28)Cycle 2 - Day 25 (n=27, 28)Cycle 2 - Day 27 (n=25, 28)Cycle 2 - Day 28 (n=26, 28)Cycle 3 - Day 2 (n=27, 28)Cycle 3 - Day 4 (n=27, 28)Cycle 3 - Day 6 (n=24, 26)
DR-10214.003.553.701.452.702.802.903.705.054.903.702.50
Mircette4.003.703.501.552.353.703.903.904.704.053.602.50

[back to top]

Serum Inhibin-B Levels by Cycle Day

Levels of inhibin-B were measured throughout the study from blood samples. (NCT00544882)
Timeframe: Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.

,
Interventionpg/mL (Median)
Cycle 2 - Day 2 (n=28, 28)Cycle 2 - Day 4 (n=28, 28)Cycle 2 - Day 6 (n=28, 27)Cycle 2 - Days 19-20 (n=26, 28)Cycle 2 - Day 23 (n=27, 28)Cycle 2 - Day 24 (n=25, 28)Cycle 2 - Day 25 (n=27, 28)Cycle 2 - Day 27 (n=25, 28)Cycle 2 - Day 28 (n=26, 28)Cycle 3 - Day 2 (n=27, 28)Cycle 3 - Day 4 (n=27, 28)Cycle 3 - Day 6 (n=24, 26)
DR-102192.3042.8046.3523.1528.1036.8035.2039.6041.9554.7051.1036.15
Mircette99.0064.4541.2028.8532.1555.0062.3049.2055.0557.9552.2529.55

[back to top]

Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size

The change in the size of the largest documented follicle during combination therapy (Days 1 to 21) and during monotherapy/placebo (Days 21-28) measured by trans-vaginal ultrasound. (NCT00544882)
Timeframe: Cycle 2, Days 1-20 and Cycle 2, Days 21-28

Interventionmm (Mean)
DR-1021-2.02
Mircette-1.79

[back to top]

Number of Days of Bleeding During Unscheduled and Scheduled Study Periods

The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventiondays (Mean)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-10210.702.300.70
Mircette0.522.630.71

[back to top]

Serum Estradiol Levels by Cycle Day

Levels of estradiol were measured throughout the study from blood samples. (NCT00544882)
Timeframe: Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.

,
Interventionpg/mL (Median)
Cycle 2 - Day 2 (n=28, 28)Cycle 2 - Day 4 (n=28, 28)Cycle 2 - Day 6 (n=27, 27)Cycle 2 - Days 19-20 (n=26, 28)Cycle 2 - Day 23 (n=27, 28)Cycle 2 - Day 24 (n=25, 28)Cycle 2 - Day 25 (n=27, 28)Cycle 2 - Day 27 (n=25, 28)Cycle 2 - Day 28 (n=26, 28)Cycle 3 - Day 2 (n=27, 28)Cycle 3 - Day 4 (n=27, 27)Cycle 3 - Day 6 (n=24, 26)
DR-102147.0062.5043.0019.0024.0025.0024.0030.0036.0034.0066.0028.50
Mircette51.5034.5029.0020.5019.0026.5026.0020.0027.5043.0027.0032.00

[back to top]

Percentage of Follicles Greater Than 5 mm in Diameter

Ovarian follicles were measured by trans-vaginal ultrasound. The size of the 3 largest follicles was documented for each participant, and the percentage of follicles greater than 5 mm in diameter was calculated based on the total number follicles present (indicated by n for each time point). (NCT00544882)
Timeframe: Cycle 1, Days 11, 19-20, 23, 25, 27, Cycle 2, Days 4, 11, 19-20, 23, 25, 27, Cycle 3, Day 4.

,
Interventionpercentage of follicles (Number)
Cycle 1 - Day 11 (n=63, 48)Cycle 1 - Day 19-20 (n= 47, 94)Cycle 1 - Day 23 (n= 30, 76)Cycle 1 - Day 25 (n= 85, 106)Cycle 1 - Day 27 (n=135, 145)Cycle 2 - Day 4 (n=154, 156)Cycle 2 - Day 11 (n=76, 54)Cycle 2 - Days 19-20 (n=143, 148)Cycle 2 - Day 23 (n=91, 62)Cycle 2 - Day 25 (n=69, 80)Cycle 2 - Day 27 (n=94, 132)Cycle 3 - Day 4 (n=138, 117)
DR-102130.229.850.032.929.635.127.617.524.230.423.425.4
Mircette29.227.726.331.135.231.431.518.924.218.820.527.4

[back to top]

Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods

The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries. (NCT00544882)
Timeframe: Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21

,
Interventionpercentage of participants (Number)
Cycle 2 - Unscheduled (Day 1-21)Cycle 2 - Scheduled (Day 22-28)Cycle 3 - Unscheduled (Day 1-21)
DR-102118.577.829.6
Mircette33.377.825.0

[back to top]

Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.

Histologic evalation of vaginal sections was performed to measured and record the absolute thickness of the vaginal epithelium. Baseline findings were compared to biopsies after three and six cycles of treatment. Mean values were compared using T-test for paired data for baseline and 84 days, and baseline and 168 days (NCT00612508)
Timeframe: baseline, 84 days, 168 days

,
Interventionmm (Mean)
mean difference at 84 daysmean difference at 168 days
Desogen0.01-0.02
NuvaRing-0.005.007

[back to top]

Adverse Events

Self-reported treatment-related and serious adverse events (NCT00612508)
Timeframe: over 168 days

Interventionparticipants (Number)
Oral Contraceptive1
Intravaginal Ring Contraceptive0

[back to top]

Percent Change in Daily Record of Severity of Problems (DRSP)

The DRSP is a 24-item self-administered daily dairy that assesses the severity of mood and physical symptoms which occur as part of the premenstrual syndrome and PMDD. Each question is rated on a scale of 1-6 with a total score range from 24-144. A higher score indicates greater symptom burden. (NCT00633360)
Timeframe: Baseline and 2 months

Interventionpercent change (Median)
Drospirenone and Ethinyl Estradiol-23.5
Placebo-20.9

[back to top]

Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS)

The Montgomery-Åsberg Depression Rating Scale is a widely used 10-item clinician-rated scale that describes the severity of depressive symptoms. It has a range of 0-60 with higher scores indicating greater symptom burden. Participants were assessed at baseline and during 2nd treatment month in order to calculate the change in MADRS score. (NCT00633360)
Timeframe: Baseline and 2 months

Interventionpercent change (Median)
Drospirenone and Ethinyl Estradiol-43.6
Placebo-38.9

[back to top]

Peripheral Insulin Sensitivity at Baseline and 6 Months.

Peripheral insulin sensitivity was evaluated during the hyperinsulinemic-euglycemic clamp. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/kg/min per uU/mL (Mean)
Peripheral insulin sensitivity, BaselinePeripheral insulin sensitivity, 6 months
Drospirenone/Ethinyl Estradiol2.12.0
Rosiglitazone2.23.2

[back to top]

Hs-CRP at Baseline and 6 Months

hs-CRP(high-sensitivity C-reactive protein) was measured by COAG-Nephelometry. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/L (Mean)
hs-CRP, Baselinehs-CRP, 6 months
Drospirenone/Ethinyl Estradiol1.73.8
Rosiglitazone2.12.2

[back to top]

Delta Androstenedione at Baseline and 6 Months

Delta Androstenedione was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Delta Androstenedione, BaselineDelta Androstenedione, 6 months
Drospirenone/Ethinyl Estradiol82.6117.0
Rosiglitazone79.258.4

[back to top]

Delta 17-OHProg at Baseline and 6 Months

Delta 17-OHProg (17-hydroxyprogesterone) was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Delta 17-OHProg, BaselineDelta 17-OHProg, 6 months
Drospirenone/Ethinyl Estradiol169.8175.4
Rosiglitazone207.0178.0

[back to top]

Delta 17-OHPreg at Baseline and 6 Months

Delta 17-OHPreg (17-hydroxypregnenolone) was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Delta 17-OHPreg, BaselineDelta 17-OHPreg, 6 months
Drospirenone/Ethinyl Estradiol1024.31088.9
Rosiglitazone912.8914.7

[back to top]

Adiponectin at Baseline and 6 Months

Adiponectin was measured by radioimmunoassay. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionug/mL (Mean)
Adiponectin, BaselineAdiponectin, 6 months
Drospirenone/Ethinyl Estradiol5.96.7
Rosiglitazone6.511.6

[back to top]

Delta DHEA at Baseline and 6 Months

Delta DHEA was measured by HPLC-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionug/dL (Mean)
Delta DHEA, BaselineDelta DHEA, 6 months
Drospirenone/Ethinyl Estradiol1001.61092.1
Rosiglitazone817.4643.4

[back to top]

Hepatic Insulin Sensitivity at Baseline and 6 Months.

Hepatic insulin sensitivity was evaluated prior to the hyperinsulinemic-euglycemic clamp. (NCT00640224)
Timeframe: Baseline and 6 months

,
Intervention(mg/kg/min x uU/mL)-1 (Mean)
Hepatic insulin sensitivity, BaselineHepatic insulin sensitivity, 6 months
Drospirenone/Ethinyl Estradiol17.416.8
Rosiglitazone17.324.1

[back to top]

Triglycerides at Baseline and 6 Months

Triglycerides were measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
Triglycerides, BaselineTriglycerides, 6 months
Drospirenone/Ethinyl Estradiol148.4163.5
Rosiglitazone106.779.2

[back to top]

Total Testosterone at Baseline and 6 Months

Total testosterone was measured by HPLC(high-performance liquid chromatography)-tandem mass spectroscopy. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/dL (Mean)
Total Testosterone, BaselineTotal Testosterone, 6 months
Drospirenone/Ethinyl Estradiol34.530.6
Rosiglitazone45.736.9

[back to top]

Total Fat Mass at Baseline and 6 Months

DXA (dual-energy x-ray absorptiometry) scans were done to measure total fat mass. (NCT00640224)
Timeframe: Baseline and 6 months

,
InterventionKg (Mean)
Fat mass, BaselineFat mass, 6 months
Drospirenone/Ethinyl Estradiol48.049.1
Rosiglitazone44.545.4

[back to top]

SHBG at Baseline and 6 Months

SHBG (sex hormone-binding globulin) was measured by immunoradiometric assay. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionnmol/L (Mean)
SHBG, BaselineSHBG, 6 months
Drospirenone/Ethinyl Estradiol22.7154.5
Rosiglitazone28.137.0

[back to top]

Percent Body Fat at Baseline and 6 Months

DXA scans were done to measure the percentage of body fat. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionpercentage of body fat (Mean)
Percent body fat, BaselinePercent body fat, 6 months
Drospirenone/Ethinyl Estradiol47.348.2
Rosiglitazone46.246.6

[back to top]

Non-HDL Cholesterol at Baseline and 6 Months

Non-HDL cholesterol was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
Non-HDL cholesterol, BaselineNon-HDL cholesterol, 6 months
Drospirenone/Ethinyl Estradiol70.687.6
Rosiglitazone65.362.3

[back to top]

Night Blood Pressure at Baseline and 6 Months

Night blood pressure was measured with an automated sphygmomanometer. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmm Hg (Mean)
Night Systolic BP, BaselineNight Diastolic BP, BaselineNight Systolic BP, 6 monthsNight Diastolic BP, 6 months
Drospirenone/Ethinyl Estradiol112.958.6116.962.6
Rosiglitazone117.563.0115.261.7

[back to top]

Morning Blood Pressure at Baseline and 6 Months

Morning blood pressure was measured with an automated sphygmomanometer. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmm Hg (Mean)
Morning Systolic BP, BaselineMorning Diasytolic BP, BaselineMorning Systolic BP, 6 monthsMorning Diastolic BP, 6 months
Drospirenone/Ethinyl Estradiol108.558.1112.259.5
Rosiglitazone108.258.1107.558.7

[back to top]

Leptin at Baseline and 6 Months

Leptin was measured by radioimmunoassay. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionng/mL (Mean)
Leptin, BaselineLeptin, 6 months
Drospirenone/Ethinyl Estradiol40.646.8
Rosiglitazone43.842.7

[back to top]

LDL at Baseline and 6 Months

LDL (low-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
LDL, BaselineLDL, 6 months
Drospirenone/Ethinyl Estradiol85.997.7
Rosiglitazone85.484.3

[back to top]

HDL at Baseline and 6 Months

HDL (high-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
HDL, BaselineHDL, 6 months
Drospirenone/Ethinyl Estradiol40.955.0
Rosiglitazone42.746.1

[back to top]

Cholesterol at Baseline and 6 Months

Cholesterol was measured using the standards of the Centers for Disease Control and Prevention. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionmg/dL (Mean)
Cholesterol, BaselineCholesterol, 6 months
Drospirenone/Ethinyl Estradiol156.5185.2
Rosiglitazone149.5146.2

[back to top]

Glucose Tolerance Status at Baseline and 6 Months.

Glucose tolerance status was classified according to the ADA (American Diabetes Association) criteria. (NCT00640224)
Timeframe: Baseline and 6 months

,
InterventionParticipants (Count of Participants)
Normal glucose tolerance, baselineImpaired glucose tolerance, baselineNormal glucose tolerance, 6 monthsImpaired glucose tolerance, 6 months
Drospirenone/Ethinyl Estradiol128137
Rosiglitazone152152

[back to top]

Free Testosterone at Baseline and 6 Months

Free testosterone was measured by equilibrium dialysis. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionpg/mL (Mean)
Free Testosterone, BaselineFree Testosterone, 6 months
Drospirenone/Ethinyl Estradiol7.51.9
Rosiglitazone10.77.7

[back to top]

DHEAS at Baseline and 6 Months

DHEAS (dehydroepiandrosterone sulfate) was measured by radioimmunoassay in dilute serum after hydrolysis. (NCT00640224)
Timeframe: Baseline and 6 months

,
Interventionug/dL (Mean)
DHEAS, BaselineDHEAS, 6 months
Drospirenone/Ethinyl Estradiol212.2197.5
Rosiglitazone165.4160.9

[back to top]

Mean Endometrial Proliferation

The mean endometrial proliferation from week 1, week 2 and week3 (NCT00710606)
Timeframe: Transvaginal ultrasound measurements of endometrial proliferation will be completed over continuous ring use, an average of 3 weeks

Interventionmillimeters (Mean)
Obese Subjects4.7
Normal Weight Subjects3.9

[back to top]

Number of Participants Achieving a Maximum Follicle Diameter > 13mm During the 3 Weeks of Follow-up

Follicular development was minimal in both groups, with only five women achieving a maximum follicle diameter > 13mm at any time during the 3 weeks of follow-up (3 normal weight and 2 obese women). (NCT00710606)
Timeframe: continuous ring use, an average of 3 weeks

InterventionParticipant w/follicular diameter >=13mm (Number)
Obese Subjects2
Normal Weight Subjects3

[back to top]

Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol

Serum concentrations were obtained from thirty-seven women completed follow-up. (NCT00710606)
Timeframe: Measurements at Week 3 and Week 6 continuous ring use

,
Interventionng/L (Geometric Mean)
Etonogesterel (ENG) Week 3Ethinyl Estradiol (EE) Week 3Etonogesterel (ENG) Week 6Ethinyl Estradiol (EE) Week 6
Normal Weight127521.9106316.2
Obese124014.8109612.5

[back to top]

Percent Change in Truncal Lesion Counts

Acne lesion count (noninflammatory, inflammatory and total lesions) difference between week 0 (baseline) and week 24 is divided by the acne lesion count at week 0 and multiplied by 100. A positive change indicates a decrease in truncal acne lesions. (NCT00722761)
Timeframe: 0-24 weeks

,
Interventionpercentage change of lesions (Mean)
Noninflammatory lesionsInflammatory lesionsTotal acne lesions
Drosperinone and Ethinyl Estradiol52.153.251.8
Placebo Tablet-9.218.217

[back to top]

Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination

Percentage of subjects rated Clear (score 0) or Almost Clear (score 1) on the Investigator's Global Assessment (IGA) of truncal acne at Week 24 as well as Subject's Assessment of Acne at Week 24/Early Termination were taken. It was computed by: number of successes (those scored 0 or 1)divided by the number of participants multiplied by 100. (NCT00722761)
Timeframe: 24 weeks

,
Interventionpercentage of participants (Number)
Investigator Global Assessment IGASubject Assessment SGA
Drosperinone and Ethinyl Estradiol53.360
Placebo Tablet2080

[back to top]

Mean Improvement in the Sartorius Severity Score at Month 6.

The Sartorius Severity score reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease. (NCT00722800)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Drospirenone and Ethinyl Estradiol (YAZ)-3.5
Placebo Tablets12

[back to top]

Change From Baseline in VAS Pain Scale at Month 6.

"For this pain assessment, the participant indicated the level of average pain experienced over the past 24 hours on a horizontal line, 10 cm in length. A score of 0 indicated no pain and a score of 10 indicated worst pain. The value indicates the change from the baseline participant assessment on the 0 to 10 scale. A negative value indicates a reduction in pain intensity." (NCT00722800)
Timeframe: 6 months from Baseline

Interventionunits on a scale (Mean)
Drospirenone and Ethinyl Estradiol (YAZ)-2.25
Placebo Tablets2

[back to top]

Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Month 6.

Dermatology Life Quality Index (DLQI) Score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. The DLQI score ranges from 0 (best) to 30 (worst). (NCT00722800)
Timeframe: 6 months

Interventionpoints (Mean)
Drospirenone and Ethinyl Estradiol (YAZ)3
Placebo Tablets8.5

[back to top]

Number of Days of Unscheduled Blood Loss - Cycle 3

Number of Days of Unscheduled Blood Loss - Cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE1.4
DRSP/20mcg EE2.4

[back to top]

Number of Days of Unscheduled Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE1.3
DRSP/20mcg EE1.9

[back to top]

Number of Days of Unscheduled Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE1.9
DRSP/20mcg EE2.0

[back to top]

Number of Days of Total Blood Loss - Cycle 3

cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to Day 84)

InterventionDays (Mean)
NGM/25mcg EE4.6
DRSP/20mcg EE3.6

[back to top]

Number of Days of Total Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 2 (day 29 to Day 56)

InterventionDays (Mean)
NGM/25mcg EE5.3
DRSP/20mcg EE4.6

[back to top]

Number of Days of Total Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to Day 28)

InterventionDays (Mean)
NGM/25mcg EE6.2
DRSP/20mcg EE5.2

[back to top]

Patient Satisfaction - Overall

patient satisfaction based on 5 questions during three 28-day cycles - Question 1 (Overall Satisfaction). On a scale of 1 to 5 where 1=Very satisfied and 5=Very dissatisfied. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3

,
InterventionParticipants (Number)
Number of responses1. Very Satisfied2. Somewhat satisfied3. Neither satisfied or dissatisfied4. Dissatisfied5. Very dissatisfied
DRSP/20mcg EE16211532681
NGM/25mcg EE159993512112

[back to top]

Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes

Unscheduled blood loss episodes are bounded on both sides by at least 1 non- bleeding day. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3 (Day 8 to Day 80)

,
InterventionParticipants (Number)
0 Episode1 Episode2 Episodes3 Episodes4 Episodes5 Episodes6 Episodes8 Episodes9 Episodes
DRSP/20mcg EE29415022118231
NGM/25mcg EE55462321137000

[back to top]

Overall Number of Days of Unscheduled Blood Loss

cycle control between treatment groups, for three 28-day cycles. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3 (Day 8 to Day 80)

InterventionDays (Mean)
NGM/25mcg EE4.6
DRSP/20mcg EE6.1

[back to top]

Overall Number of Days of Total Blood Loss

cycle control between treatment groups, overall. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. (NCT00745901)
Timeframe: Cycle 1 to 3 (Day 8 to Day 84)

InterventionDays (Mean)
NGM/25mcg EE15.8
DRSP/20mcg EE13.2

[back to top]

Overall Number of Days of Scheduled Blood Loss

summary of the overall number of days of scheduled blood loss. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 1 to Cycle 3 (Day 8 to Day 84)

InterventionDays (Mean)
NGM/25mcg EE11.2
DRSP/20mcg EE7.0

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting Cycle 1

Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE53
DRSP/20mcg EE56

[back to top]

Number of Participants With Unscheduled Bleeding Cycle 3

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE65
DRSP/20mcg EE94

[back to top]

Number of Days of Scheduled Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 1 (Day 22 to 32 for NGM/25mcg EE and day 25 to 32 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE4.3
DRSP/20mcg EE3.2

[back to top]

Number of Days of Scheduled Blood Loss - Cycle 3

cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 3 (Day 78 to 84 for NGM/25mcg EE and day 81 to 84 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE3.1
DRSP/20mcg EE1.2

[back to top]

Number of Participants With Unscheduled Bleeding Cycle 2

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE57
DRSP/20mcg EE87

[back to top]

Number of Participants With Unscheduled Bleeding Cycle 1

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE72
DRSP/20mcg EE74

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting Cycle 3

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle. (NCT00745901)
Timeframe: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE47
DRSP/20mcg EE74

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting Cycle 2

Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding. (NCT00745901)
Timeframe: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

InterventionParticipants (Number)
NGM/25mcg EE39
DRSP/20mcg EE62

[back to top]

Number of Days of Scheduled Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen. (NCT00745901)
Timeframe: Cycle 2 (Day 50 to 60 for NGM/25mcg EE and day 53 to 60 for DRSP/20mcg EE)

InterventionDays (Mean)
NGM/25mcg EE4.0
DRSP/20mcg EE2.8

[back to top]

Number of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.2
Ethinyl Estradiol, Levonorgestrel (Miranova)0.2

[back to top]

Number of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.1
Ethinyl Estradiol, Levonorgestrel (Miranova)0.1

[back to top]

Onset of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)4.8
Ethinyl Estradiol, Levonorgestrel (Miranova)4.9

[back to top]

Onset of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.1
Ethinyl Estradiol, Levonorgestrel (Miranova)4.3

[back to top]

Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their other own costs per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of acupuncture per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of alternative medicine per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of herbs/teas per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of massages per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of medical counseling per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of pain medication per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.46
Ethinyl Estradiol, Levonorgestrel (Miranova)5.04

[back to top]

Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of physiotherapy per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of vitamins per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars. (NCT00909857)
Timeframe: At screening (average over 3 months before screening)

InterventionDollars (Median)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.00
Ethinyl Estradiol, Levonorgestrel (Miranova)0.00

[back to top]

Percentage of Participants With Intracyclic Bleeding at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)19.0
Ethinyl Estradiol, Levonorgestrel (Miranova)16.7

[back to top]

Percentage of Participants With Intracyclic Bleeding at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)10.8
Ethinyl Estradiol, Levonorgestrel (Miranova)11.6

[back to top]

Percentage of Participants With Withdrawal Bleeding at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)91.2
Ethinyl Estradiol, Levonorgestrel (Miranova)93.2

[back to top]

Percentage of Participants With Withdrawal Bleeding at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionPercentage of Participants (Number)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)68.1
Ethinyl Estradiol, Levonorgestrel (Miranova)79.3

[back to top]

Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)90.2
Ethinyl Estradiol, Levonorgestrel (Miranova)89.6

[back to top]

Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: at final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)93.7
Ethinyl Estradiol, Levonorgestrel (Miranova)92.5

[back to top]

Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)81.91
Ethinyl Estradiol, Levonorgestrel (Miranova)79.18

[back to top]

Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)88.64
Ethinyl Estradiol, Levonorgestrel (Miranova)83.87

[back to top]

Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.8
Ethinyl Estradiol, Levonorgestrel (Miranova)79.4

[back to top]

Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)89.6
Ethinyl Estradiol, Levonorgestrel (Miranova)87.9

[back to top]

Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)78.85
Ethinyl Estradiol, Levonorgestrel (Miranova)77.35

[back to top]

Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)85.95
Ethinyl Estradiol, Levonorgestrel (Miranova)84.79

[back to top]

Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)62.6
Ethinyl Estradiol, Levonorgestrel (Miranova)62.2

[back to top]

Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)68.2
Ethinyl Estradiol, Levonorgestrel (Miranova)67.2

[back to top]

Participants With Improvement in Participants' Assessment in the Clinical Global Impression

The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Participants were asked to rate their improvement during the course of the study. (NCT00909857)
Timeframe: At cycle 2 (28 days per cycle)

,
InterventionParticipants (Number)
MissingNot assessedVery much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worse
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)116091471850
Ethinyl Estradiol, Levonorgestrel (Miranova)014675572443

[back to top]

Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression

The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Investigators were asked to rate the participants' improvement during the course of the study. (NCT00909857)
Timeframe: At cycle 2 (28 days per cycle)

,
InterventionParticipants (Number)
MissingNot assessedVery much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worse
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)016387491760
Ethinyl Estradiol, Levonorgestrel (Miranova)014284542336

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At Baseline (28 days per cycle)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.047.913.220.917.9
Ethinyl Estradiol, Levonorgestrel (Miranova)0.051.711.723.912.2

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At cycle 2 (28 days per cycle)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.078.68.56.42.1
Ethinyl Estradiol, Levonorgestrel (Miranova)0.072.66.58.74.3

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At final examination (28 days)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.485.95.63.01.7
Ethinyl Estradiol, Levonorgestrel (Miranova)0.085.22.64.81.7

[back to top]

Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle. (NCT00909857)
Timeframe: At screening (28 days)

,
InterventionPercentage of Participants (Number)
MissingNever4 working hours1 working day>= 2 working days
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.438.016.226.518.8
Ethinyl Estradiol, Levonorgestrel (Miranova)0.040.416.129.613.9

[back to top]

Percentage of Participants Satisfied With Study Treatment

Participants were asked to express the degree of their satisfaction with study treatment. (NCT00909857)
Timeframe: From cycle 1 to cycle 3 (28 days per cycle)

,
InterventionPercentage of participants (Number)
MissingVery satisfiedSaatisfiedNeither satisfied nor dissatisfiedDissatisfiedVery dissatisfied
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.953.432.17.32.10.4
Ethinyl Estradiol, Levonorgestrel (Miranova)1.350.430.08.33.50.4

[back to top]

Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)

Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

,
InterventionPercentage of Participants (Number)
Baseline period-daily activities impairedBaseline period- leisure activities impairedTreatment period-daily activities impairedTreatment period- leisure activities impaired
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)93.292.354.752.6
Ethinyl Estradiol, Levonorgestrel (Miranova)92.290.060.061.3

[back to top]

Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)

Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

,
InterventionPercentage of participants (Number)
Baseline period-daily activities impairedBaseline period- leisure activities impairedTreatment period-daily activities impairedTreatment period- leisure activities impaired
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)92.390.651.747.9
Ethinyl Estradiol, Levonorgestrel (Miranova)91.389.656.556.5

[back to top]

Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

,
InterventionPercentage of participants (Number)
SpottingLightNormalHeavy
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)53.530.29.37.0
Ethinyl Estradiol, Levonorgestrel (Miranova)62.210.813.513.5

[back to top]

Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

,
InterventionPercentage of participants (Number)
SpottingLightNormalHeavy
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)45.527.313.613.6
Ethinyl Estradiol, Levonorgestrel (Miranova)30.421.730.417.4

[back to top]

General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.2
Ethinyl Estradiol, Levonorgestrel (Miranova)76.5

[back to top]

Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)50.7
Ethinyl Estradiol, Levonorgestrel (Miranova)51.8

[back to top]

Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.0
Ethinyl Estradiol, Levonorgestrel (Miranova)74.0

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding

Evaluated was the number of days with bleeding-associated pelvic pain, excluding days during withdrawal bleeding (WB) and the 2 days preceding such WB, and during administration deviation bleeding and the 2 days preceding such bleeding (normalized to a standard 56-day period). Baseline period: 2 days before first menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of the 1st treatment cycle until 3rd day before the WB of the cycle after the 2nd treatment cycle (normalized to standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.3
Ethinyl Estradiol, Levonorgestrel (Miranova)0.1

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding

Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-4.0
Ethinyl Estradiol, Levonorgestrel (Miranova)-3.7

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)

Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionTablets (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-4.5
Ethinyl Estradiol, Levonorgestrel (Miranova)-5.6

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)

Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionTablets (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-6.2
Ethinyl Estradiol, Levonorgestrel (Miranova)-6.6

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain

Dysmenorrheic pain was defined as pelvic pain during the menstrual/withdrawal bleeding episode and the 2 days before this episode. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period). (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-4.6
Ethinyl Estradiol, Levonorgestrel (Miranova)-4.2

[back to top]

Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain

Dysmenorrheic pain: pelvic pain during menstrual/withdrawal bleeding (WB) episode and 2 days before. Scores per day: 0 No pain; 1 Mild pain with no need for painkiller; 2 Moderate pain with need for painkiller; 3 Severe pain with need for painkiller. Baseline period: 2 days before 1st menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of 1st treatment cycle until 3rd day before WB of the cycle after 2nd treatment cycle (normalized to standard 56-day period). Score difference min -168 (best), max 168 (worst) (NCT00909857)
Timeframe: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)-10.6
Ethinyl Estradiol, Levonorgestrel (Miranova)-10.0

[back to top]

Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.6
Ethinyl Estradiol, Levonorgestrel (Miranova)4.6

[back to top]

Difference in Duration Between Longest and Shortest Spotting Only Episode

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)1.2
Ethinyl Estradiol, Levonorgestrel (Miranova)0.7

[back to top]

General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)75.8
Ethinyl Estradiol, Levonorgestrel (Miranova)72.7

[back to top]

Length of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.2
Ethinyl Estradiol, Levonorgestrel (Miranova)5.4

[back to top]

Length of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)4.5
Ethinyl Estradiol, Levonorgestrel (Miranova)5.2

[back to top]

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.7
Ethinyl Estradiol, Levonorgestrel (Miranova)4.0

[back to top]

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.7
Ethinyl Estradiol, Levonorgestrel (Miranova)4.1

[back to top]

Maximum Length of Bleeding or Spotting Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)7.1
Ethinyl Estradiol, Levonorgestrel (Miranova)8.4

[back to top]

Maximum Length of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)6.0
Ethinyl Estradiol, Levonorgestrel (Miranova)6.2

[back to top]

Maximum Length of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.5
Ethinyl Estradiol, Levonorgestrel (Miranova)4.9

[back to top]

Maximum Length of Spotting Only Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.9
Ethinyl Estradiol, Levonorgestrel (Miranova)3.6

[back to top]

Mean Length of Bleeding or Spotting Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)5.17
Ethinyl Estradiol, Levonorgestrel (Miranova)5.83

[back to top]

Mean Length of Spotting Only Episodes

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.29
Ethinyl Estradiol, Levonorgestrel (Miranova)3.26

[back to top]

Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At baseline cycle (28 days per cycle)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)73.6
Ethinyl Estradiol, Levonorgestrel (Miranova)72.6

[back to top]

Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome) (NCT00909857)
Timeframe: At final examination (28 days)

InterventionScores on a scale (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)77.3
Ethinyl Estradiol, Levonorgestrel (Miranova)76.4

[back to top]

Number of Days With Bleeding or Spotting

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)20.0
Ethinyl Estradiol, Levonorgestrel (Miranova)23.6

[back to top]

Number of Days With Spotting-only

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)7.3
Ethinyl Estradiol, Levonorgestrel (Miranova)7.6

[back to top]

Number of Episodes With Bleeding or Spotting

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)3.9
Ethinyl Estradiol, Levonorgestrel (Miranova)4.1

[back to top]

Number of Episodes With Spotting-only

Bleeding/spotting episodes (day[s] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting. (NCT00909857)
Timeframe: From day 1 to day 90

InterventionEpisodes (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.5
Ethinyl Estradiol, Levonorgestrel (Miranova)0.4

[back to top]

Number of Intracyclic Bleeding Days at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted. (NCT00909857)
Timeframe: At cycle 1 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)1.2
Ethinyl Estradiol, Levonorgestrel (Miranova)1.0

[back to top]

Number of Intracyclic Bleeding Days at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted. (NCT00909857)
Timeframe: At cycle 3 (28 days per cycle)

InterventionDays (Mean)
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)0.6
Ethinyl Estradiol, Levonorgestrel (Miranova)0.6

[back to top]

Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong (Least Squares Mean)
Change from Baseline to Month 6Change from Baseline to Month 12
28-day Levonorgestrel OC0.691.20
91-day Levonorgestrel OC1.291.86
Untreated Control1.121.94

[back to top]

Change From Baseline in Serum Deoxypyridinoline

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionnmol/L (Mean)
Change from Baseline to Month 6 (n=234, 224, 349)Change from Baseline to Month 12 (n=233, 226, 348)
28-day Levonorgestrel OC-0.10.1
91-day Levonorgestrel OC-0.1-0.1
Untreated Control0.1-0.1

[back to top]

Change From Baseline in Serum Osteocalcin

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionnmol/L (Mean)
Change from Baseline to Month 6 (n=236, 224, 354)Change from Baseline to Month 12 (n=235, 225, 348)
28-day Levonorgestrel OC-3.9-3.7
91-day Levonorgestrel OC-4.8-4.5
Untreated Control-5.1-7.1

[back to top]

Change From Baseline in Serum Procollagen 1 N-terminal Propeptide

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionµg/L (Mean)
Change from Baseline to Month 6 (n=237, 225, 355)Change from Baseline to Month 12 (n=235, 226, 349)
28-day Levonorgestrel OC-38.7-39.8
91-day Levonorgestrel OC-49.9-50.4
Untreated Control-57.8-86.0

[back to top]

Change From Baseline in Proximal Femur Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong (Least Squares Mean)
Change from Baseline to Month 6 (n=238, 227, 358)Change from Baseline to Month 12 (n=238, 224, 359)
28-day Levonorgestrel OC0.090.28
91-day Levonorgestrel OC0.260.59
Untreated Control0.130.43

[back to top]

Change From Baseline in Serum Type I Collagen N-telopeptide

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
InterventionnM bone collagen equivalents (BCE) (Mean)
Change from Baseline to Month 6 (n=235, 224, 356)Change from Baseline to Month 12 (n=236, 225, 350)
28-day Levonorgestrel OC-3.9-4.3
91-day Levonorgestrel OC-4.8-4.5
Untreated Control-0.7-3.1

[back to top]

Change From Baseline in Bone-specific Alkaline Phosphatase

(NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventionµg/L (Mean)
Change from Baseline to Month 6 (n=236, 224, 353)Change from Baseline to Month 12 (n=235, 225, 347)
28-day Levonorgestrel OC-5.9-6.6
91-day Levonorgestrel OC-6.8-6.9
Untreated Control-6.2-10.3

[back to top]

Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)

"Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.~Percent change from Baseline was calculated as (BMD at Month 12 - BMD at Baseline)/BMD at Baseline * 100%." (NCT00924560)
Timeframe: Baseline and Month 12

Interventionpercent change (Least Squares Mean)
91-day Levonorgestrel OC2.26
28-day Levonorgestrel OC1.45
Untreated Control2.50

[back to top]

Change From Baseline in Proximal Femur Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong/cm^2 (Least Squares Mean)
Change from Baseline to Month 6 (n=238, 227, 358)Change from Baseline to Month 12 (n=238, 224, 359)
28-day Levonorgestrel OC0.000.01
91-day Levonorgestrel OC0.010.02
Untreated Control0.010.01

[back to top]

Change From Baseline in Total Body Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong/cm^2 (Least Squares Mean)
Change from Baseline to Month 6 (n=130, 126, 149)Change from Baseline to Month 12 (n=130, 126, 150)
28-day Levonorgestrel OC0.010.01
91-day Levonorgestrel OC0.010.01
Untreated Control0.010.02

[back to top]

Change From Baseline in Total Body Bone Mineral Content (BMC)

Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong (Least Squares Mean)
Change from Baseline to Month 6 (n=130, 126, 149)Change from Baseline to Month 12 (n=130, 126, 150)
28-day Levonorgestrel OC38.7063.78
91-day Levonorgestrel OC40.7772.86
Untreated Control46.2684.95

[back to top]

Number of Participants With Adverse Events (AEs)

"An adverse event was any untoward medical occurrence in a clinical investigation subject participating in the clinical study, and did not necessarily need to have a causal relationship with treatment or the clinical study. The relationship of each adverse event to study treatment or procedures, and the severity and seriousness of each adverse event was judged by the investigator, as described below.~A severe AE is defined as incapacitating, with inability to perform usual activities.~A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions:~fatal or life-threatening;~required or prolonged inpatient hospitalization;~resulted in persistent or significant disability/incapacity;~congenital anomaly or birth defect;~important medical event." (NCT00924560)
Timeframe: 12 months

,,
Interventionparticipants (Number)
Any adverse eventSevere adverse eventTreat-related adverse eventDeathsOther serious adverse eventsWithdrawn from study due to adverse events
28-day Levonorgestrel OC258209501233
91-day Levonorgestrel OC252141000934
Untreated Control274107001

[back to top]

Change From Baseline in Lumbar Spine Bone Mineral Density

Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. (NCT00924560)
Timeframe: Baseline, Month 6 and Month 12

,,
Interventiong/cm^2 (Least Squares Mean)
Change from Baseline to Month 6Change from Baseline to Month 12
28-day Levonorgestrel OC0.010.01
91-day Levonorgestrel OC0.020.02
Untreated Control0.010.03

[back to top]

Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population

Pearl Index = 1300 * number of pregnancies/number of women-cycles of treatment (NCT00932321)
Timeframe: 5.6 months (6 - 28 day cycles)

InterventionPearl Index (Number)
24 Day NA/EE1.823
21 Day NA/EE2.978

[back to top]

Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population

Self-reported via patient completed diary (none - no vaginal bleeding, light - less than normal menstruation, normal - like normal menstruation, heavy - more than normal menstruation) along with daily use of sanitary protection (other than panty liners). Light bleeding requiring no more than single pad or tampon will be spotting. (NCT00932321)
Timeframe: 5.6 months (6 - 28 day cycles)

InterventionDays (Mean)
24 Day NA/EE6.31
21 Day NA/EE7.31

[back to top]

Change in Total Volumetric Bone Mineral Density (Tibia)

Change in total volumetric bone density at the tibia with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes (NCT00946192)
Timeframe: 12 months

Interventionmg HA/cm^3 (Mean)
Estrogen Patch7.01
Estrogen Pill1.17
Control3.71

[back to top]

Change in Lumbar Bone Mineral Density

Change in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes (NCT00946192)
Timeframe: 12 months

Interventiong/cm^2 (Mean)
Estrogen Patch0.025
Estrogen Pill0.008
Control0.012

[back to top]

All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~In order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(13)/(total number of 28-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total2.74
DR-103: <90 kg Subpopulation2.40
DR-103: >=90kg Subpopulation4.42

[back to top]

Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight

A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the four 91-day treatment cycles. (NCT00996580)
Timeframe: Day 1 up to year 1

,,
Interventionpregnancies / cumulative exposure (Number)
Cycle 1Cycle 2Cycle 3Cycle 4
DR-103: <90 kg Subpopulation0.00620.01160.02030.0256
DR-103: >=90kg Subpopulation0.01640.02150.03920.0457
DR-103: Total0.00800.01340.02360.0291

[back to top]

All Users Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight

A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the four 91-day treatment cycles. (NCT00996580)
Timeframe: Day 1 up to year 1

,,
Interventionpregnancies / cumulative exposure (Number)
Cycle 1Cycle 2Cycle 3Cycle 4
DR-103: <90 kg Subpopulation0.00600.01140.01850.0239
DR-103: >=90kg Subpopulation0.01390.02310.03390.0429
DR-103: Total0.00740.01340.02120.0272

[back to top]

Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(4)/(total number of 91-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total3.25
DR-103: <90 kg Subpopulation2.83
DR-103: >=90kg Subpopulation5.32

[back to top]

Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~In order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(13)/(total number of 28-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total2.92
DR-103: <90 kg Subpopulation2.55
DR-103: >=90kg Subpopulation4.72

[back to top]

Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(4)/(total number of 91-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total3.71
DR-103: <90 kg Subpopulation3.23
DR-103: >=90kg Subpopulation6.04

[back to top]

All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(4)/(total number of 91-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total2.82
DR-103: <90 kg Subpopulation2.46
DR-103: >=90kg Subpopulation4.54

[back to top]

Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight

"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or > 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.~In order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.~The PI is defined as number of contraceptive failures per 100 women-years of exposure:~(100)*(total number of pregnancies)*(13)/(total number of 28-day cycles)" (NCT00996580)
Timeframe: Day 1 up to year 1

Interventionpregnancies / 100 woman years exposure (Number)
DR-103: Total3.07
DR-103: <90 kg Subpopulation2.68
DR-103: >=90kg Subpopulation4.94

[back to top]

Summary of Participants With Treatment-emergent Adverse Events

"The on-treatment time frame spanned the time during which study drug was administered until 3 weeks beyond the last study drug date.~Relationship to study drug was assessed by the investigator.~Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention." (NCT00996580)
Timeframe: Day 1 up to 13 months

Interventionparticipants (Number)
Treatment-emergent AEs (TEAEs)Treatment-related AEsSerious AEsTEAEs leading to discontinuation
DR-1032605108658463

[back to top]

Maximum Plasma Concentration of Colchicine With Norethindrone/Ethinyl Estradiol at Steady State (Cmax, ss)

The maximum or peak concentration that Colchicine with Norethindrone/Ethinyl Estradiol reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose

Interventionng/mL (Mean)
Colchicine With Norethindrone/Ethinyl Estradiol3.11

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Colchicine

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng-hr/mL (Mean)
Norethindrone With Colchicine175.57

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Norethindrone With Placebo

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Norethindrone With Placebo178.08

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Ethinyl Estradiol With Placebo

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Ethinyl Estradiol With Placebo1.29

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Colchicine With Norethindrone/Ethinyl Estradiol

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose

Interventionng/mL (Mean)
Colchicine With Norethindrone/Ethinyl Estradiol18.40

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] Ethinyl Estradiol With Colchicine

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule. (NCT01040845)
Timeframe: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.33, 3.67, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 14, 18, 24, 36, and 48 hours after drug administration.

Interventionng/mL (Mean)
Ethinyl Estradiol With Colchicine1.24

[back to top]

Maximum Plasma Concentration of Norethindrone With Placebo at Steady State (Cmax, ss)

The maximum or peak concentration that Norethindrone with Placebo reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Norethindrone With Placebo24.42

[back to top]

Maximum Plasma Concentration of Norethindrone With Colchicine at Steady State (Cmax, ss)

The maximum or peak concentration that Norethindrone with Colchicine reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Norethindrone With Colchicine24.17

[back to top]

Maximum Plasma Concentration of Ethinyl Estradiol With Placebo at Steady State (Cmax, ss)

The maximum or peak concentration that Ethinyl Estradiol with Placebo reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Ethinyl Estradiol With Placebo0.15

[back to top]

Maximum Plasma Concentration of Ethinyl Estradiol With Colchicine at Steady State (Cmax, ss)

The maximum or peak concentration that Ethinyl Estradiol with Colchicine reaches in the plasma at steady state. Steady state refers to the point that constant concentration of drug is achieved subsequent to administration of constant doses of that drug given at constant intervals. (NCT01040845)
Timeframe: Day 21 of each cycle - plasma concentrations were drawn prior to the morning dose (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 (prior to pm colchicine/placebo dose), and 24 hours post-dose.

Interventionng/mL (Mean)
Ethinyl Estradiol With Colchicine0.14

[back to top]

AUC 0-infinity (PK Parameter) for the ASPE Group.

AUC 0-infinity was measured using ethinylestradiol serum concentration using a radio-immune assay at several time points during the 21 days of active treatment and the washout period thereafter. AUC 0-infinity was calculated as AUC 0-tlast extrapolated to infinity using the regression line from which t 1/2 was calculated. (NCT01044056)
Timeframe: 21 days of active treatment and the washout period thereafter

Interventionng.h/mL (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill22.7
Norelgestrominum and Ethinylestradiol Contraceptive Patch37.7
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring11.2

[back to top]

Area Under the Curve (AUC) 0-21 Days (PK Parameter) Measured for the ASPE Group

AUC 0-21 days was measured using ethinylestradiol serum concentration using a radio-immune assay at several time points during the 21 days of active treatment (NCT01044056)
Timeframe: 21 days

Interventionnh.h/mL (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill21.9
Norelgestrominum and Ethinylestradiol Contraceptive Patch35.8
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring10.6

[back to top]

AUC 0-tlast (PK Parameter) for the ASPE Group.

AUC 0-tlast was measured using ethinylestradiol serum concentrations using a radio-immune assay at several time points during the 21 days of active treatment and the washout period thereafter. (NCT01044056)
Timeframe: 21 days of active treatment and washout period thereafter

Interventionng.h/mL (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill22.5
Norelgestrominum and Ethinylestradiol Contraceptive Patch37.5
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring11.1

[back to top]

Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) Group

Cmax was measured using ethinylstradiol serum concentration at several time points during the 21 days of active treatment and the washout thereafter. (NCT01044056)
Timeframe: 21 days of active treatment and washout period thereafter

Interventionpg/ml (Mean)
Levonorgestrel/Ethinylestradiol Oral Contraceptive Pill168
Norelgestrominum and Ethinylestradiol Contraceptive Patch105
Etonogestrel and Ethinylestradiol Contraceptive Vaginal Ring37.1

[back to top]

LNG Steady State at Baseline and Then Post-randomization

The main goal is to test whether key pharmacokinetic parameters of levonordestrel (LNG) differ between obese women taking traditionally dosed OCs versus the interventional arms (i.e. using each obese subject as their own control). (NCT01170390)
Timeframe: baseline (2 months) and post-randomization (4 months)

,
Interventionng/mL (Mean)
LNG steady state levels at baselineAfter randomization (4 months)
Aviane & Aviane3.823.01
Aviane and Portia3.133.58

[back to top]

LNG AUC

Area under the curve post-randomization for levonorgestrel. AUC was calculated and extrapolated using post randomization in single daily samples drawn during Cycle 4 days 20-26. Serial repeat sampling to obtain a detailed PK curve was not performed to obtain this AUC. Subjects could provide samples during these days at times convenient to them and PK software accounted for the time between when the drug was dosed versus when the sample was drawn. (NCT01170390)
Timeframe: post-randomization (4 months)

Interventionhr*ng/mL (Mean)
Aviane & Aviane412
Aviane and Portia283

[back to top]

LNG AUC

Baseline measurements of levonorgestrel AUC (on Aviane). Area under the curve at baseline for levonorgestrel. AUC was calculated from time zero to 168 hours and extrapolated to infinity from serial repeat sampling (0,0.5,1.1.5,2,3,4,6,8,12 hours and then single samples daily for 4 days between Cycles 1 and 2. (NCT01170390)
Timeframe: baseline (2 months)

Interventionhr*ng/mL (Mean)
Aviane and Aviane267
Aviane and Portia199

[back to top]

EE Steady State After Randomization

Steady state levels of ethinyl estradiol (EE) post- randomization (NCT01170390)
Timeframe: Post-randomiziation 4 months

Interventionng/mL (Mean)
Aviane & Aviane0.08
Aviane and Portia0.11

[back to top]

EE Steady State Baseline

Steady state levels of ethinyl estradiol (EE) at baseline (2 months) (NCT01170390)
Timeframe: Baseline (2 months)

Interventionng/mL (Mean)
Aviane & Aviane0.12
Aviane and Portia0.1

[back to top]

AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Ethinyl Estradiol AUC0-inf. (NCT01182194)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1236.96
YAZ® (Reference)1235.91

[back to top]

AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Drospirenone AUC0-inf. (NCT01182194)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)866.91
YAZ® (Reference)884.24

[back to top]

Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Ethinyl Estradiol Cmax. (NCT01182194)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)128.87
YAZ® (Reference)126.03

[back to top]

AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Ethinyl Estradiol AUC0-t. (NCT01182194)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1145.90
YAZ® (Reference)1155.31

[back to top]

AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Drospirenone AUC0-t. (NCT01182194)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)814.32
YAZ® (Reference)824.41

[back to top]

Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Drospirenone Cmax. (NCT01182194)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)67.69
YAZ® (Reference)74.33

[back to top]

AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Ethinyl Estradiol AUC0-inf. (NCT01182207)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1155.69
YAZ® (Reference)1175.76

[back to top]

AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Drospirenone AUC0-t. (NCT01182207)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)889.67
YAZ® (Reference)867.10

[back to top]

AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Ethinyl Estradiol AUC0-t. (NCT01182207)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)1066.24
YAZ® (Reference)1079.54

[back to top]

Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Drospirenone Cmax. (NCT01182207)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)52.77
YAZ® (Reference)53.65

[back to top]

Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Ethinyl Estradiol Cmax. (NCT01182207)
Timeframe: Blood samples collected over a 72 hour period.

Interventionpg/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)87.95
YAZ® (Reference)91.23

[back to top]

AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Drospirenone AUC0-inf. (NCT01182207)
Timeframe: Blood samples collected over a 120 hour period.

Interventionng*h/mL (Mean)
Drospirenone/Ethinyl Estradiol (Test)951.18
YAZ® (Reference)930.38

[back to top]

Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Rosiglitazone

On Days 1 and 8, blood samples were taken prior to the administration of rosiglitazone and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of rosiglitazone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma rosiglitazone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratio of Cmax of rosiglitazone was defined as the Cmax of rosiglitazone on Day 8/ Cmax of rosiglitazone on Day 1. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL (Number)
Vismodegib + Rosiglitazone93.1

[back to top]

Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethindrone

On Days 1 and 8, blood samples were taken prior to the administration of the contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of ethinyl estradiol and norethindrone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma ethinyl estradiol and norethindrone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratios of Cmax of ethinyl estradiol and norethindrone were defined as the ratios of Cmax of ethinyl estradiol and norethindrone on Day 8 divided by Cmax of ethinyl estradiol and norethindrone on Day 1, respectively. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL (Number)
Ethinyl estradiolNorethindrone
Vismodegib + Oral Contraceptive105112

[back to top]

Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Norethindrone

On Days 1 and 8, blood samples were taken prior to the administration of the contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of ethinyl estradiol and norethindrone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma ethinyl estradiol and norethindrone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratios of AUC(0-inf) of ethinyl estradiol and norethindrone were defined as the ratios of AUC(0-inf) of ethinyl estradiol and norethindrone on Day 8 divided by AUC(0-inf) of ethinyl estradiol and norethindrone on Day 1, respectively. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL*hr (Number)
Ethinyl estradiolNorethindrone
Vismodegib + Oral Contraceptive99.6123

[back to top]

Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone

On Days 1 and 8, blood samples were taken prior to the administration of rosiglitazone and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose. Plasma concentrations of rosiglitazone were determined using a validated liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) assay. Individual and mean plasma rosiglitazone concentration versus time data were tabulated and plotted by analyte. The pharmacokinetic parameters of each analyte were calculated using standard non-compartmental methods (WinNonlin version 5.2.1, Pharsight Corp., Mountain View, CA). The geometric mean ratio of AUC(0-inf) of rosiglitazone was defined as the AUC(0-inf) of rosiglitazone on Day 8/AUC(0-inf) of rosiglitazone on Day 1. (NCT01209143)
Timeframe: Pre-dose and 30 minutes, and 1, 2, 3, 4, and 6 hours, between 8 and 12 hours, and 24 hours post-dose

Interventionng/mL*hr (Number)
Vismodegib + Rosiglitazone92.0

[back to top]

Elimination Rate Constant (Kel) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of elimination rate constant (kel) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhr^-1 (Mean)
NPC-010.141

[back to top]

Plasma Half Life (t1/2) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of plasma Half life (t1/2) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-015.499

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of area under the plasma concentration versus time curve (AUC) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionng・hr/mL (Mean)
NPC-0169.183

[back to top]

Peak Plasma Concentration (Cmax) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of peak plasma concentration (Cmax) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionng/mL (Mean)
NPC-0112.481

[back to top]

Peak Plasma Concentration (Cmax) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of peak plasma concentration (Cmax) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionpg/mL (Mean)
NPC-0155.783

[back to top]

Mean Residence Time (MRT) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of mean residence time (MRT) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-016.340

[back to top]

Mean Residence Time (MRT) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of mean residence time (MRT) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-015.161

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of area under the plasma concentration versus time curve (AUC) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionpg・hr/mL (Mean)
NPC-01368.123

[back to top]

Elimination Rate Constant (Kel) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of elimination rate constant (kel) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhr^-1 (Mean)
NPC-010.101

[back to top]

Time to Peak Plasma Concentration (Tmax) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of time to peak plasma concentration (Tmax) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-011.81

[back to top]

Time to Peak Plasma Concentration (Tmax) on Ethinyl Estradiol of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of time to peak plasma concentration (Tmax) of ethinyl estradiol that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-011.50

[back to top]

Plasma Half Life (t1/2) on Norethisterone of NPC-01

Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of plasma Half life (t1/2) of norethisterone that are active substances of NPC-01. (NCT01246791)
Timeframe: 0, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0, 24.0 hours after single dosing of NPC-01

Interventionhours (Mean)
NPC-017.357

[back to top]

Ovulation Suppression in Three Treatment Groups Over 3 Cycles

"Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are:~Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points.~Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points.~Perfect compliance: If no patch has been off >1 day and no more than 1 day has elapsed between patch changes.~Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit." (NCT01250210)
Timeframe: 3 months

,,
Intervention%of cycles with possible ovulation (Number)
ITT, perfect complianceComplete progesterone, perfect complianceITT, verifiable complianceComplete progesterone, verifiable compliance
AG20020.720.714.914.9
AG200-1511.511.712.012.0
AG200LE36.536.932.532.5

[back to top]

Cycle Control

The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days. (NCT01250210)
Timeframe: 3 months

Interventionnumber of episodes (Mean)
AG200LE0.29
AG2000.29
AG200-150.15

[back to top]

Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

Progesterone was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
Interventionng・day/mL (Mean)
Difference of progesterone(BL-SDA)Difference of progesterone(FU-SDA)
IKH-0193.14859.344
NPC-0154.17189.711

[back to top]

Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

LH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
InterventionmIU・day/mL (Mean)
Difference of LH(BL-SDA)Difference of LH(FU-SDA)
IKH-0157.12459.837
NPC-0160.87461.571

[back to top]

Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

FSH was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
InterventionmIU・day/mL (Mean)
Differnce of FSH (BL-SDA)Difference of FSH(FP-SDA)
IKH-01-4.3800.538
NPC-01-9.609-4.404

[back to top]

Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))

Estradiol was measured on day 3, 6, 9, 12, 15, 18, 21, 24 on 3 consecutive menstrual period (pre administration/Baseline(BL), study drug administration(SDA), post administration/follow up(FU)) and calculated AUC from these data (NCT01253824)
Timeframe: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles

,
Interventionpg・day/mL, (Mean)
Difference of estradiol AUC (BL-SDA)Difference of estradiol AUC(FU-SDA)
IKH-012478.02434.9
NPC-011654.71872.6

[back to top]

Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls

Idiopathic VTE cases=new DVT, PE or CVST occurring in absence of known risk factors. Matched Control was defined as participants with no diagnosis of VTE matched for age, calendar time, exposure status and database. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control. (NCT01297348)
Timeframe: Index date (date of VTE diagnosis for case and corresponding date for matched control)

,,
Interventionparticipants (Number)
Current user: CaseCurrent user: Matched ControlPast user: CasePast user: Matched Control
Lybrel174711
Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)27611441439
Other OCs: Levonorgestrel, Ethinyl Estradiol 20 Mcg (Levo-20)53254410

[back to top]

Incidence Rate of Idiopathic Venous Thromboembolism (VTE)

Idiopathic VTE=deep vein thrombosis (DVT), pulmonary embolism (PE), or cerebral venous sinus thrombosis (CVST) occurring in absence of known risk factors. Incidence rate reported for current, past users. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control. (NCT01297348)
Timeframe: Index date (date of VTE diagnosis for case and corresponding date for matched control)

,,
Interventionincidence rate per 100000 person-years (Number)
Current usersPast users
Lybrel176.254.1
Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)87.518.0
Other OCs: Levonorgestrel, Ethinyl Estradiol 20 Mcg (Levo-20)50.517.6

[back to top]

Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)

Apparent clearance of ethinylestradiol in the plasma at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionmL/min (Geometric Mean)
Microgynon552
Microgynon Plus Empa536

[back to top]

Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)

Apparent volume of distribution during the terminal phase at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionL (Geometric Mean)
Microgynon729
Microgynon Plus Empa757

[back to top]

Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

Area under the concentration-time curve of ethinylestradiol in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionpg*h/mL (Geometric Mean)
Microgynon907
Microgynon Plus Empa932

[back to top]

Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)

Maximum measured concentration of ethinylestradiol in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionpg/mL (Geometric Mean)
Microgynon97.6
Microgynon Plus Empa96.8

[back to top]

Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)

Mean residence time of ethinylestradiol in the body at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon18.6
Microgynon Plus Empa19.5

[back to top]

Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)

Terminal half-life of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon15.3
Microgynon Plus Empa16.3

[back to top]

Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)

Time from last dosing to the maximum measured concentration of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Median)
Microgynon1.26
Microgynon Plus Empa1.50

[back to top]

Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.

Number of participants with clinically relevant abnormalities in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as adverse events. (NCT01328184)
Timeframe: Day 1 to day 17

Interventionparticipants (Number)
Microgynon0
Microgynon Plus Empa0

[back to top]

Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)

Time from last dosing to the maximum measured concentration of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Median)
Microgynon1.00
Microgynon Plus Empa1.00

[back to top]

Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)

Terminal rate constant of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Intervention1/h (Geometric Mean)
Microgynon0.0189
Microgynon Plus Empa0.0184

[back to top]

Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)

Terminal half-life of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon36.7
Microgynon Plus Empa37.6

[back to top]

Levonorgestrel: Maximum Measured Concentration (Cmax,ss)

Maximum measured concentration of levonorgestrel in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionng/mL (Geometric Mean)
Microgynon7.98
Microgynon Plus Empa8.44

[back to top]

Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

Area under the concentration-time curve of levonorgestrel in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionng*h/mL (Geometric Mean)
Microgynon94.0
Microgynon Plus Empa95.9

[back to top]

Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)

Apparent volume of distribution during the terminal phase at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionL (Geometric Mean)
Microgynon84.6
Microgynon Plus Empa85.0

[back to top]

Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)

Apparent clearance of levonorgestrel in the plasma at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionmL/min (Geometric Mean)
Microgynon26.6
Microgynon Plus Empa26.1

[back to top]

Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)

Terminal rate constant of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Intervention1/h (Geometric Mean)
Microgynon0.0454
Microgynon Plus Empa0.0425

[back to top]

Assessment of Tolerability

Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory, bad and not assessable. (NCT01328184)
Timeframe: Within Day 24 to Day 31

,
Interventionpercentage of participants (Number)
GoodSatisfactoryNot satisfactoryBadNot assessable
Microgynon94.45.60.00.00.0
Microgynon Plus Empa94.45.60.00.00.0

[back to top]

Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)

Mean residence time of levonorgestrel in the body at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon48.8
Microgynon Plus Empa49.6

[back to top]

Cmax of Norethindrone

Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)10.94
Ovcon® 35 Fe (Reference)10.00

[back to top]

Cmax of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)230.56
Ovcon® 35 Fe (Reference)237.00

[back to top]

AUC0-inf of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)2129.43
Ovcon® 35 Fe (Reference)2131.84

[back to top]

AUC0-inf of Norethindrone

Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)48.67
Ovcon® 35 Fe (Reference)45.43

[back to top]

AUC0-t of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)1976.72
Ovcon® 35 Fe (Reference)1989.82

[back to top]

AUC0-t of Norethindrone

Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01340625)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)43.83
Ovcon® 35 Fe (Reference)40.73

[back to top]

Cmax of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)137.6758
FEMCON® Fe (Reference)137.8485

[back to top]

Cmax of Norethindrone

Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)4.3306
FEMCON® Fe (Reference)4.2282

[back to top]

AUC0-t of Norethindrone

Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)37.8065
FEMCON® Fe (Reference)37.3991

[back to top]

AUC0-inf of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)2072.5423
FEMCON® Fe (Reference)2152.3775

[back to top]

AUC0-inf of Norethindrone

Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionng*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)43.9982
FEMCON® Fe (Reference)43.8819

[back to top]

AUC0-t of Ethinyl Estradiol

Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01344369)
Timeframe: Blood samples collected over a 60 hour period.

Interventionpg*h/mL (Mean)
Norethindrone/Ethinyl Estradiol (Test)1916.2311
FEMCON® Fe (Reference)1987.6311

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin

Normal range for this hemostatic parameter was 75% to 130%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)-1.6
Treatment II-3.2

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance

This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 2.00 to 3.36. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionratio (Least Squares Mean)
Treatment I: (DR-102)-0.3
Treatment II-0.4

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen

The normal range for this hemostatic parameter was 50% to 147%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal 50% to 147% (Least Squares Mean)
Treatment I: (DR-102)-11.4
Treatment II-6.6

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer

Normal range for this hemostatic parameter was 0 to 729 mcg/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionmcg/L (Least Squares Mean)
Treatment I: (DR-102)16.4
Treatment II13.4

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin

Normal range for this parameter was 28 to 146 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionnmol/L (Least Squares Mean)
Treatment I: (DR-102)163.4
Treatment II149.1

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol

Normal range for this adrenal parameter was 85.6 to 618.2 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionnmol/L (Least Squares Mean)
Treatment I: (DR-102)239.0
Treatment II230.8

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels

Normal range for this hemostatic parameter was 41 to 372 pmol/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpmol/L (Least Squares Mean)
Treatment I: (DR-102)45.0
Treatment II56.8

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity

The normal range for this hemostatic parameter was 70% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)16.3
Treatment II13.0

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII

Normal range for this hemostatic parameter was 50% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)11.1
Treatment II10.6

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII

Normal range for this hemostatic parameter was 60% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)17.9
Treatment II15.1

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity

Normal range for this hemostatic parameter was 70% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionpercentage of normal (Least Squares Mean)
Treatment I: (DR-102)3.3
Treatment II3.0

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance

This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 0.32 to 1.79. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionratio (Least Squares Mean)
Treatment I: (DR-102)0.8
Treatment II0.7

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)

Normal range for this parameter was 0.35 to 5.5 mIU/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

InterventionmIU/L (Least Squares Mean)
Treatment I: (DR-102)0.2
Treatment II0.3

[back to top]

Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin

Normal range for this adrenal parameter was 1906.448 to 4520.504 mg/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction. (NCT01388491)
Timeframe: Baseline through Month 6

Interventionmg/L (Least Squares Mean)
Treatment I: (DR-102)4083.3
Treatment II3721.8

[back to top]

Number of Participants With Abnormal Vaginal Blood Loss at Month 1, 3 and 6

Vaginal blood loss encompasses spotting and bleeding. Spotting is defined as a bleeding requiring no or at most one sanitary pad per day; however, bleeding requires two or more sanitary pads per day. (NCT01466673)
Timeframe: Month 1, 3 and 6

,
InterventionParticipants (Number)
Spotting at Month 1 (n=100,101)Spotting at Month 3 (n=93, 96)Spotting at Month 6 (n=93, 95)Bleeding at Month 1 (n=100,101)Bleeding at Month 3 (n=93, 96)Bleeding at Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)243473
Ethinyl Estradiol/Norgestimate (EE/NGM)5641346

[back to top]

Number of Participants With Treatment Response at the End-of-Therapy by Participant's Self-Assessment at Month 6

Participant's self-assessment at end-of-therapy was measured by using the self-assessment questionnaire which included 3 questions, about the rating of acne improvement since start of study; comparison of this acne treatment with the one used in past and the continuity of treatment on physician's prescription to evaluate efficacy and acceptability of the study medication. The score was graded at 4 parameters as excellent, better, no change and worse. (NCT01466673)
Timeframe: Month 6

,
InterventionParticipants (Number)
ExcellentBetterNo ChangeWorse
Ethinyl Estradiol/Desogestrel (EE/DSG)355831
Ethinyl Estradiol/Norgestimate (EE/NGM)474534

[back to top]

Percentage of Participants Showing Treatment Response on the Investigator's Global Assessment at Month 6

Percentage of participants showing treatment response on the Investigator's global assessment was graded on a 5-point scale as 0=worse, 1=no change, 2=fair, 3=good, and 4=excellent. (NCT01466673)
Timeframe: Month 6

,
InterventionPercentage of participants (Number)
0 (Worse)1 (No Change)2 (Fair)3 (Good)4 (Excellent)
Ethinyl Estradiol/Desogestrel (EE/DSG)1.031.0323.7152.5821.65
Ethinyl Estradiol/Norgestimate (EE/NGM)5.054.044.0443.4343.43

[back to top]

Percentage of Participants With Categorical Score for Sebum Assessment at Month 1, 3 and 6

Sebum assessment that is facial seborrhea (very oily skin) was assessed using sebutape strip on the forehead. Percentage of participants with facial seborrhea were assessed using categorical scores ranging from level 1 (lowest) to level 5 (highest). Highest level indicates worsening. (NCT01466673)
Timeframe: Baseline and Month 1, 3 and 6

,
InterventionPercentage of Participants (Number)
Level 1: Baseline (n=100,101)Level 2: Baseline (n=100,101)Level 3: Baseline (n=100,101)Level 4: Baseline (n=100,101)Level 5: Baseline (n=100,101)Level 1: Month 1 (n=100,101)Level 2: Month 1 (n=100,101)Level 3: Month 1 (n=100,101)Level 4: Month 1 (n=100,101)Level 5: Month 1 (n=100,101)Level 1: Month 3 (n=93, 96)Level 2: Month 3 (n=93, 96)Level 3: Month 3 (n=93, 96)Level 4: Month 3 (n=93, 96)Level 5: Month 3 (n=93, 96)Level 1: Month 6 (n=93, 95)Level 2: Month 6 (n=93, 95)Level 3: Month 6 (n=93, 95)Level 4: Month 6 (n=93, 95)Level 5: Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)3.9612.8744.5534.653.968.9111.8845.5432.670.9910.4214.5859.3814.581.0422.1143.1629.475.260.00
Ethinyl Estradiol/Norgestimate (EE/NGM)3.0010.0043.0031.0013.007.0013.0047.0030.003.006.4534.4145.1611.832.1544.0927.9620.436.451.08

[back to top]

Change From Baseline in Blood Pressure (BP) at Month 6

Blood pressure is the pressure of blood flowing through blood vessels. Change from Baseline in blood pressure is the value at Month 6 minus value at Baseline. (NCT01466673)
Timeframe: Baseline and Month 6

,
InterventionMillimeters of Mercury (Mean)
Systolic BP: Baseline (n=100/101)Diastolic BP: Baseline (n=100/101)Systolic BP: Change at Month 6 (n=93, 95)Diastolic BP: Change at Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)110.269.47-0.24-0.48
Ethinyl Estradiol/Norgestimate (EE/NGM)110.670.230.33-0.80

[back to top]

Change From Baseline in Body Weight at Month 6

Change from Baseline in body weight is the value at Month 6 minus value at Baseline. (NCT01466673)
Timeframe: Baseline and Month 6

,
InterventionKilograms (Mean)
Baseline (n=100,101)Change at Month 6 (n=93,95)
Ethinyl Estradiol/Desogestrel (EE/DSG)54.24-0.20
Ethinyl Estradiol/Norgestimate (EE/NGM)55.62-0.08

[back to top]

Change From Baseline in Total and Each Type of Acne Lesions Count at Month 1

Total acne (pimples) lesion (abnormal area of tissue, such as a wound, sore, rash, or boil) count is summation of all lesions which includes all comedones (open and closed), papules, pustules, and nodules. Change from Baseline means lesions at Baseline minus lesions at Month 1. Positive value indicates decrease in lesion count while negative value indicates increase in lesion count. (NCT01466673)
Timeframe: Baseline and Month 1

,
InterventionLesions (Mean)
Comedones Counts: BaselinePapules Counts: BaselinePustules Counts: BaselineNodules Counts: BaselineTotal Counts: BaselineComedones Counts: Change at Month 1Papules Counts: Change at Month 1Pustules Counts: Change at Month 1Nodules Counts: Change at Month 1Total Counts: Change at Month 1
Ethinyl Estradiol/Desogestrel (EE/DSG)11.434.461.120.0017.003.440.620.18-0.024.22
Ethinyl Estradiol/Norgestimate (EE/NGM)10.974.320.900.1216.313.430.200.350.124.10

[back to top]

Change From Baseline in Total and Each Type of Acne Lesions Count at Month 3

Total acne (pimples) lesion (abnormal area of tissue, such as a wound, sore, rash, or boil) count is summation of all lesions which includes all comedones (open and closed), papules, pustules, and nodules. Change from Baseline means lesions at Baseline minus lesions at Month 3. Positive value indicates decrease in lesion count while negative value indicates increase in lesion count. (NCT01466673)
Timeframe: Baseline and Month 3

,
InterventionLesions (Mean)
Comedones Counts: Change at Month 3 (n=93, 96)Papules Counts: Change at Month 3 (n=93, 96)Pustules Counts: Change at Month 3 (n=93, 96)Nodules Counts: Change at Month 3 (n=93, 96)Total Counts: Change at Month 3 (n=93, 96)
Ethinyl Estradiol/Desogestrel (EE/DSG)5.601.890.700.008.19
Ethinyl Estradiol/Norgestimate (EE/NGM)5.712.830.630.128.84

[back to top]

Change From Baseline in Total and Each Type of Acne Lesions Count at Month 6

Total acne (pimples) lesion (abnormal area of tissue, such as a wound, sore, rash, or boil) count is summation of all lesions which includes all comedones (open and closed), papules, pustules, and nodules. Change from Baseline means lesions at Baseline minus lesions at Month 6. Positive value indicates decrease in lesion count while negative value indicates increase in lesion count. (NCT01466673)
Timeframe: Baseline and Month 6

,
InterventionLesions (Mean)
Comedones Counts: Change at Month 6 (n=93, 95)Papules Counts: Change at Month 6 (n=93, 95)Pustules Counts: Change at Month 6 (n=93, 95)Nodules Counts: Change at Month 6 (n=93, 95)Total Counts: Change at Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)8.212.770.960.0011.94
Ethinyl Estradiol/Norgestimate (EE/NGM)9.023.520.770.1313.44

[back to top]

Number of Participants Non-Compliant With Therapy

Compliance was assessed by transforming the data of forgotten tablets listed in the diary cards. Number of participants who forgot to take the drug was reported. (NCT01466673)
Timeframe: Month 1, 3 and 6

,
InterventionParticipants (Number)
At Month 1 (n=100, 101)At Month 3 (n=93, 96)At Month 6 (n=93, 95)
Ethinyl Estradiol/Desogestrel (EE/DSG)5106
Ethinyl Estradiol/Norgestimate (EE/NGM)71310

[back to top]

Participants' Assessment of Feeling Vaginal Ring at Any Time

Participants were asked to assess whether they could feel the NuvaRing at any time and to characterize how often as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: NeverFirst cycle: RarelyFirst cycle: OccasionallyFirst cycle: MostlyFirst cycle: AlwaysSecond cycle: NeverSecond cycle: RarelySecond cycle: OccasionallySecond cycle: MostlySecond cycle: AlwaysThird cycle: NeverThird cycle: RarelyThird cycle: OccasionallyThird cycle: MostlyThird cycle: Always
NuvaRing878925121078682111779530

[back to top]

Participants' Assessment of Feeling Vaginal Ring During Intercourse

Participants were asked to assess whether they could feel the NuvaRing during intercourse and to characterize how often as one the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: NeverFirst cycle: RarelyFirst cycle: OccasionallyFirst cycle: MostlyFirst cycle: AlwaysSecond cycle: NeverSecond cycle: RarelySecond cycle: OccasionallySecond cycle: MostlySecond cycle: AlwaysThird cycle: NeverThird cycle: RarelyThird cycle: OccasionallyThird cycle: MostlyThird cycle: Always
NuvaRing8581333210082210112569901

[back to top]

Participants' Overall Satisfaction With Vaginal Ring

Participants were asked to characterize their overall satisfaction with the NuvaRing as one of the following: very satisfied, satisfied, neutral, unsatisfied, or very unsatisfied. The number of participants who responded to each category was reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle (N = 252): Very satisfiedFirst cycle (N = 252): SatisfiedFirst cycle (N = 252): NeutralFirst cycle (N = 252): UnsatisfiedFirst cycle (N = 252): Very unsatisfiedFirst cycle (N = 252): Missing dataSecond cycle (N = 213): Very satisfiedSecond cycle (N = 213): SatisfiedSecond cycle(N = 213): NeutralSecond cycle (N = 213): UnsatisfiedSecond cycle (N = 213): Very unsatisfiedSecond cycle (N = 213): Missing dataThird cycle (N = 207): Very satisfiedThird cycle (N = 207): SatisfiedThird cycle (N = 207): NeutralThird cycle (N = 207): UnsatisfiedThird cycle (N = 207): Very unsatisfiedThird cycle (N = 207): Missing data
NuvaRing681192891278211215103881079111

[back to top]

Number of Participants With Intermenstrual Bleeding/Spotting

Number of participants who experienced vaginal bleeding, which includes BLEEDING or SPOTTING, at any time during a cycle other than normal menstruation while in the study. Vaginal bleeding that required >=2 pads per day was classified as BLEEDING. Vaginal bleeding that required <=1 pad per day was classified as SPOTTING. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: Total bleeding/spottingFirst cycle: BleedingFirst cycle: SpottingSecond cycle: Total bleeding/spottingSecond cycle: BleedingSecond cycle: SpottingThird cycle: Total bleeding/spottingThird cycle: BleedingThird cycle: Spotting
NuvaRing514000101

[back to top]

Number of Bleeding Days Per Cycle

Intermenstrual vaginal bleeding that required >=2 pads per day was classified as BLEEDING. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionDays (Mean)
First cycleSecond cycleThird cycle
NuvaRing400

[back to top]

Frequency of Partner Feeling Vaginal Ring During Intercourse

Participants were asked if their partners could feel the NuvaRing during intercourse and to characterize their partners' experience as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: NeverFirst cycle: RarelyFirst cycle: OccasionallyFirst cycle: MostlyFirst cycle: AlwaysSecond cycle: NeverSecond cycle: RarelySecond cycle: OccasionallySecond cycle: MostlySecond cycle: AlwaysThird cycle: NeverThird cycle: RarelyThird cycle: OccasionallyThird cycle: MostlyThird cycle: Always
NuvaRing88753452112652331121691031

[back to top]

Participants' Assessment of Ease of Insertion of Vaginal Ring

Participants were asked to classify their ability to insert the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: Very easyFirst cycle: EasyFirst cycle: NeutralFirst cycle: DifficultFirst cycle: Very difficultFirst cycle: FailedSecond cycle: Very easySecond cycle: EasySecond cycle: NeutralSecond cycle: DifficultSecond cycle: Very difficultSecond cycle: FailedThird cycle: Very easyThird cycle: EasyThird cycle: NeutralThird cycle: DifficultThird cycle: Very difficultThird cycle: Failed
NuvaRing59825940073105206007811312100

[back to top]

Number of Participants Who Reported a Serious Adverse Event During the Study

A serious adverse event is any adverse drug or biologic or device experience that results in death, a life-threatening adverse event, persistent or significant disability or incapacity; requires in-patient hospitalization, or prolonged hospitalization; or causes a congenital anomaly or birth defect. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
NuvaRing0

[back to top]

Number of Participants Who Reported at Least One Adverse Event During the Study

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic, or medical device, which does not necessarily have a causal relationship with the treatment. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
NuvaRing47

[back to top]

Average Number of Bleeding Days Per Cycle

Mean duration of menstruation, per day, per cycle, during the study period. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionDays (Mean)
First cycle (N = 201)Second cycle (N = 203)Third cycle (N = 203)
NuvaRing3.83.73.6

[back to top]

Average Number of Pads Used Per Day, Per Cycle, During Menstruation While Using Ring

Intensity of menstruation, as indicated by the median number of pads used per day by participants during each cycle of NuvaRing use. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionPads (Median)
First cycle (N = 201)Second cycle (N = 203)Third cycle (N = 203)
NuvaRing222

[back to top]

Frequency of Partner Objecting to Vaginal Ring Use

Participants were asked if their partners objected to their using the NuvaRing during intercourse and to characterize the frequency of their partners' objections as one of the following: never, rarely, occasionally, mostly, or always. The number of participants who responded to each category was reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: NeverFirst cycle: RarelyFirst cycle: OccasionallyFirst cycle: MostlyFirst cycle: AlwaysSecond cycle: NeverSecond cycle: RarelySecond cycle: OccasionallySecond cycle: MostlySecond cycle: AlwaysThird cycle: NeverThird cycle: RarelyThird cycle: OccasionallyThird cycle: MostlyThird cycle: Always
NuvaRing129704101435551015345330

[back to top]

Number of Participants Who Plan to Continue Using Vaginal Ring

Participants were asked at follow-up visits after every cycle whether they planned to continue using NuvaRing, and their answers were recorded. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle (N = 252): YesFirst cycle (N = 252): NoFirst cycle (N = 252): Missing dataSecond cycle (N = 213): YesSecond cycle (N = 213): NoSecond cycle (N = 213): Missing dataThird cycle (N = 207): YesThird cycle (N = 207): NoThird cycle (N = 207): Missing data
NuvaRing21692720553159471

[back to top]

Number of Participants Who Would Recommend Vaginal Ring to Others

Participants were asked at follow-up visits after every cycle whether they would recommend NuvaRing to other women, and their answers were reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle (N = 252): YesFirst cycle (N = 252): NoFirst cycle (N = 252): Missing dataSecond cycle (N = 213): YesSecond cycle (N = 213): NoSecond cycle (N = 213): Missing dataThird cycle (N = 207): YesThird cycle (N = 207): NoThird cycle (N = 207): Missing data
NuvaRing2081628197133193131

[back to top]

Number of Participants With Regular Menstrual Cycles

The number of participants who experienced regular menstrual bleeding patterns throughout the period of NuvaRing use. Bleeding patterns were to be characterized by particpants as regular or irregular. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: RegularFirst cycle: IrregularFirst cycle: Missing dataSecond cycle: RegularSecond cycle: IrregularSecond cycle: Missing dataThird cycle: RegularThird cycle: IrregularThird cycle: Missing data
NuvaRing192931994120031

[back to top]

Number of Pregnancies Due to Contraceptive Method Failure During the Study

For participants with suspected pregnancy during in-treatment period, pregnancy was to be confirmed by hCG qualitative analysis using strip and/or other test(s) at the discretion of the treating physician. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionPregnancies (Number)
First cycle (N = 252): YesFirst cycle (N = 252): NoFirst cycle (N = 252): Missing dataSecond cycle (N = 213): YesSecond cycle (N = 213): NoSecond cycle (N = 213): Missing dataThird cycle (N = 207): YesThird cycle (N = 207): NoThird cycle (N = 207): Missing data
NuvaRing0226260210302070

[back to top]

Number of Spotting Days Per Cycle

Intermenstrual vaginal bleeding that required <=1 pad per day was classified as SPOTTING. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionDays (Mean)
First cycle (N = 4)Second cycle (N = 0)Third cycle (N = 1)
NuvaRing5.503

[back to top]

Participants' Assessment of Ease of Removal of Vaginal Ring

Participants were asked to classify their ability to remove the NuvaRing as very easy, easy, neutral, difficult, very difficult, or failed. The number of participants who responded to each category was reported. (NCT01490190)
Timeframe: Up to 84 days (three 28-day cycles)

InterventionParticipants (Number)
First cycle: Very easyFirst cycle: EasyFirst cycle: NeutralFirst cycle: DifficultFirst cycle: Very difficultFirst cycle: FailedSecond cycle: Very easySecond cycle: EasySecond cycle: NeutralSecond cycle: DifficultSecond cycle: Very difficultSecond cycle: FailedThird cycle: Very easyThird cycle: EasyThird cycle: NeutralThird cycle: DifficultThird cycle: Very differentThird cycle: Failed
NuvaRing701286000811194000881132100

[back to top]

Total to HDL Cholesterol Ratio

(NCT01546454)
Timeframe: Entire Study

InterventionTotal to HDL Cholesterol Ratio (Mean)
Non-steroidal Effects0.146
Contraceptive Effects0.148
Steroid Effects-0.89

[back to top]

AUCt,ss of Ethinylestradiol

Area under the curve over the dosing interval t under steady state conditions of ethinylestradiol (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 hours (h) after drug administration

Interventionpg*h/mL (Geometric Mean)
Microgynon1010
Microgynon + Faldaprevir1450

[back to top]

AUCτ,ss of Levonorgestrel

Area under the curve over the dosing interval τ under steady state conditions of levonorgestrel (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionng*h/mL (Geometric Mean)
Microgynon83.3
Microgynon + Faldaprevir120

[back to top]

C24,ss of Ethinylestradiol

measured concentration of the analyte at the end of dosing interval under steady state conditions of ethinylestradiol (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionpg/mL (Geometric Mean)
Microgynon19.1
Microgynon + Faldaprevir33.2

[back to top]

C24,ss of Levonorgestrel

measured concentration of the analyte at the end of dosing interval under steady state conditions of levonorgestrel (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionng/mL (Geometric Mean)
Microgynon2.43
Microgynon + Faldaprevir3.85

[back to top] [back to top]

Cmax,ss of Levonorgestrel

maximum measured concentration over the uniform dosing interval under steady state conditions of levonorgestrel (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionng/mL (Geometric Mean)
Microgynon7.57
Microgynon + Faldaprevir8.95

[back to top]

Cmax,ss of Ethinylestradiol

maximum measured concentration over the uniform dosing interval under steady state conditions of ethinylestradiol (NCT01570244)
Timeframe: on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration

Interventionpg/mL (Geometric Mean)
Microgynon108
Microgynon + Faldaprevir127

[back to top]

Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG.

Clinical relevant abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. (NCT01570244)
Timeframe: from drug administration up to 14 days

Interventionparticipants (Number)
Microgynon0
Microgynon + Faldaprevir0

[back to top]

Number of Participants Who Experience at Least One Venous or Arterial Thrombotic/Thromboembolic Event

(NCT01656434)
Timeframe: Up to 54 weeks

InterventionParticipants (Number)
NOMAC-E20
NETA-EE1

[back to top]

Percentage of Participants Who Experienced At Least One Adverse Event

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug. (NCT01656434)
Timeframe: Up to 54 weeks

InterventionPercentage of Participants (Number)
NOMAC-E241.2
NETA-EE45.2

[back to top]

Change From Baseline in Body Weight

Participants' body weights were measured in a consistent manner throughout the trial, using standardized equirpment. Last In-Treatment Measurement refers to a participant's end of trial visit, the timing of which differed among participants. (NCT01656434)
Timeframe: Baseline and Week 52

,
Interventionkilograms (Mean)
After Cycle 3 (n=2135; n=527)After Cycle 6 (n=1809; n=459)After Cycle 9 (n=1468; n=391)After Cycle 13 (n=462; n=145)Last In-Treatment Measurement (n=2231; n=549)
NETA-EE0.410.290.320.900.75
NOMAC-E20.140.641.211.571.39

[back to top] [back to top] [back to top]

Percentage of Participants With Breakthrough Bleeding and/or Spotting During Cycle 3

Breakthrough bleeding and/or spotting (BTB-S) is defined as any bleeding or spotting episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Bleeding = any bloody vaginal discharge that required one or more sanitary pads or tampons per day; Spotting = any bloody vaginal discharge that required no sanitary pads or tampons per day. (NCT01709318)
Timeframe: Day 1 Cycle 3 through Day 28 Cycle 3 (Up to ~28 days)

InterventionPercentage of Participants (Number)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day14.6
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day13.3
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day17.5
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day13.6
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day16.3
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day6.4
NuvaRing®6.2

[back to top]

Percentage of Participants With Ovulation Incidence, by Cycle

Ovulation was defined as having 2 or more consecutive progesterone concentrations >16 nmol/L within 5 days, confirmed by ultrasound evidence of ovulation (follicular rupture or preceding presence of a follicle-like structure >15 mm in size). (NCT01709318)
Timeframe: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)

,,,,,,
InterventionPercentage of Participants (Number)
Cycle 1Cycle 2Cycle 3
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day000
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day000
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day000
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day000
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day000
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day000
NuvaRing®000

[back to top]

Percentage of Participants Who Experienced At Least One Serious Adverse Event

A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose; or is another important medical event deemed such by medical or scientific judgment. (NCT01709318)
Timeframe: Up to ~92 days

InterventionPercentage of Participants (Number)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day0.0
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day0.0
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day0.0
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day0.0
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day0.0
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day0.0
NuvaRing®0.0

[back to top]

Percentage of Participants With Progesterone Concentrations >16 Nmol/L, by Cycle

Maximum progesterone (Max P) was defined as the maximum progesterone value. Ovulation was defined as 2 or more consecutive progesterone concentrations >16 nmol/L within 5 days during the 3 treatment cycles, supported by ultrasound evidence of ovulation. The Max P values greater than 16 nmol/L are presented by vaginal ring group and cycle. (NCT01709318)
Timeframe: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)

,,,,,,
InterventionPercentage of Participants (Number)
Cycle 1 Max P > 16 nmol/LCycle 2 Max P > 16 nmol/LCycle 3 Max P > 16 nmol/L
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day000
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day000
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day000
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day000
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day000
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day000
NuvaRing®000

[back to top]

Percentage of Participants Who Experienced At Least One Adverse Event

An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug. (NCT01709318)
Timeframe: Up to ~92 days

InterventionPercentage of Participants (Number)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day43.0
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day40.0
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day43.6
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day37.7
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day39.0
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day46.5
NuvaRing®39.3

[back to top]

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug. (NCT01709318)
Timeframe: Up to ~92 days

InterventionPercentage of Participants (Number)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day3.8
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day4.7
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day2.6
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day2.6
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day0
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day1.2
NuvaRing®1.1

[back to top]

Number of Participants With Venous or Arterial Thrombotic/Thromboembolic Events

Venous or arterial thrombotic/thrombo-embolic events, (VTEs or ATEs) (e.g., deep venous thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident) were assessed. (NCT01709318)
Timeframe: From Cycle 1 Day 1 up to 8 days after Day 28 of Cycle 3 (Up to ~92 days)

InterventionParticipants (Count of Participants)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day0.0
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day0.0
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day0.0
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day0.0
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day0.0
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day0.0
NuvaRing®0.0

[back to top]

Intensity of Withdrawal Bleeding During Cycle 2

Intensity of withdrawal bleeding during Cycle 2 was defined as the ratio of the number of withdrawal bleeding days divided by the number of withdrawal bleeding and/or spotting days. Withdrawal bleeding and/or spotting is considered any bleeding or spotting episode that starts during or continues into the expected bleeding period (i.e., when the ring has been removed the last week of the cycle). Absence of withdrawal bleeding is no withdrawal bleeding and/or spotting episodes during an expected bleeding period when the ring has been removed. (NCT01709318)
Timeframe: Day 1 Cycle 2 through Day 28 Cycle 2 (Up to ~28 days)

InterventionRatio (Mean)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day0.87
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day0.92
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day0.86
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day0.90
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day0.92
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day0.93
NuvaRing®0.95

[back to top]

Intensity of Breakthrough Bleeding and/or Spotting During Cycle 3

Intensity of breakthrough bleeding and/or spotting (BTB-S) during Cycle 3 was defined as the ratio of the number of breakthrough bleeding days divided by the number of breakthrough bleeding and/or spotting days. Breakthrough bleeding and/or spotting (BTB-S) is defined as any bleeding or spotting episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Bleeding = any bloody vaginal discharge that required one or more sanitary pads or tampons per day; Spotting = any bloody vaginal discharge that required no sanitary pads or tampons per day. (NCT01709318)
Timeframe: Day 1 Cycle 3 through Day 28 Cycle 3 (Up to ~ 28 days)

InterventionRatio (Mean)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day0.42
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day0.80
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day0.68
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day0.73
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day0.67
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day0.33
NuvaRing®0.67

[back to top]

Percentage of Participants With Absence of Withdrawal Bleeding and/or Spotting During Cycle 2

Withdrawal bleeding and/or spotting is considered any bleeding or spotting episode that starts during or continues into the expected bleeding period (i.e., when the ring has been removed the last week of the cycle). Absence of withdrawal bleeding is no withdrawal bleeding and/or spotting episodes during an expected bleeding period when the ring has been removed. (NCT01709318)
Timeframe: Day 1 Cycle 2 through Day 28 Cycle 2 (Up to ~28 days)

InterventionPercentage of Participants (Number)
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/Day5.5
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/Day1.9
Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/Day4.4
Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/Day7.8
Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/Day3.7
Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/Day1.9
NuvaRing®1.8

[back to top]

RTV PK Parameter Tmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the PK parameter Tmax of RTV before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Tmax defines time to maximum concentration since dose is initiated. (NCT01903031)
Timeframe: Intensive RTV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement)

Interventionhour (Median)
Tmax day 0Tmax day 21
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs3.03.0

[back to top]

ATV PK Parameter Cmax Determined Based on ATV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the ATV PK parameter Cmax obtained from both sampling periods, before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Cmax defines maximum concentration observed within the first 8 hours of the 24 hour dosing interval. (NCT01903031)
Timeframe: Intensive ATV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

Interventionng/mL (Median)
Cmax day 0Cmax day 21
NuvaRing With ATV/r Plus TDF ≥1 NRTIs4291.03583.0

[back to top]

Ethinyl Estradiol Concentrations at Study Day 21

This evaluates the effect of EFV and ATV/r on ethinyl estradiol by measuring ethinyl estradiol concentrations on all three study arms 21 days after NuvaRing administration. The PK blood sample for measurement of ethinyl estradiol on study day 21 was taken before the NuvaRing was removed. The assay lower limit of quantification for ethinyl estradiol was 5 pg/mL ; values < 5 were assigned a value of half the lower limit (ie, 2.5 pg/mL). (NCT01903031)
Timeframe: Day 21

Interventionpg/mL (Median)
NuvaRing and no ART21.30
NuvaRing With EFV Plus ≥2 NRTIs11.40
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs16.05

[back to top]

Etonogestrel Concentrations at Study Day 21

This evaluates the effect of EFV and ATV/r on etonogestrel by measuring etonogestrel concentrations on all three study arms 21 days after NuvaRing administration. The pharmacokinetic (PK) blood sample for measurement of etonogestrel on study day 21 was taken before the NuvaRing was removed. The assay lower limit of quantification for etonogestrel was 250 pg/mL; values < 250 were assigned a value of half the lower limit (ie, 125 pg/mL). (NCT01903031)
Timeframe: Day 21

Interventionpg/mL (Median)
NuvaRing and no ART1860.00
NuvaRing With EFV Plus ≥2 NRTIs429.00
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs3290.00

[back to top] [back to top]

ATV PK Parameter AUC(0-24h) Calculated Based on Intensive Atazanavir (ATV) PK Samples Obtained From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the PK parameter AUC(0-24h) of ATV before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. AUC(0-24h) defines area under the concentration-time curve over the period of 24 hours (pre-dose concentration was used to impute concentration at 24h). (NCT01903031)
Timeframe: Intensive ATV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement)

Interventionh*ng/mL (Median)
AUC0-24h day 0AUC0-24h day 21
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs44313.736764.7

[back to top]

ATV PK Parameter CLss/F Determined Based on ATV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the ATV PK parameter CLss/F obtained from both sampling periods, before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. CLss/f defines apparent oral clearance. (NCT01903031)
Timeframe: Intensive ATV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

InterventionL/h (Median)
CLss/F day 0CLss/F day 21
NuvaRing With ATV/r Plus TDF ≥1 NRTIs6.88.2

[back to top]

ATV PK Parameter Cmin Determined Based on ATV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the ATV PK parameter Cmin obtained from both sampling periods, before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Cmin defines minimum concentration observed within the first 8 hours of the 24 hour dosing interval. (NCT01903031)
Timeframe: Intensive ATV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

Interventionng/mL (Median)
Cmin day 0Cmin day 21
NuvaRing With ATV/r Plus TDF ≥1 NRTIs796.7599.4

[back to top]

ATV PK Parameter Time to Cmax (Tmax) Determined Based on ATV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the ATV PK parameter Tmax obtained from both sampling periods, before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Tmax defines time to maximum concentration since dose is initiated. (NCT01903031)
Timeframe: Intensive ATV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

Interventionhour (Median)
Tmax day 0Tmax day 21
NuvaRing With ATV/r Plus TDF ≥1 NRTIs2.93.0

[back to top]

EFV PK Parameter Area Under the Concentration-Time Curve (AUC0-24hours) Calculated Based on Intensive EFV PK Samples Obtained From Individual Participants Enrolled in Arm B

This evaluates the effect of NuvaRing on the PK parameter AUC(0-24h) of EFV before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. AUC(0-24h) defines area under the concentration-time curve over the period of 24 hours (pre-dose concentration was used to impute concentration at 24h). (NCT01903031)
Timeframe: Intensive EFV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

Interventionh*ng/mL (Median)
AUC0-24h day 0AUC0-24h day 21
NuvaRing With EFV Plus ≥2 NRTIs68949.157795.9

[back to top]

EFV PK Parameter Clearance (CLss/F) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B

This evaluates the effect of NuvaRing on the EFV PK parameter CLss/F obtained from both sampling periods, before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. CLss/F defines apparent oral clearance (NCT01903031)
Timeframe: Intensive EFV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

InterventionL/h (Median)
CLss/F day 0CLss/F day 21
NuvaRing With EFV Plus ≥2 NRTIs8.710.4

[back to top]

EFV PK Parameter Maximum Plasma Concentration (Cmax) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B

This evaluates the effect of NuvaRing on the EFV PK parameter Cmax obtained from both sampling periods, before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Cmax defines maximum concentration observed within the first 8 hours of the 24 hour dosing interval. (NCT01903031)
Timeframe: Intensive EFV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

Interventionng/mL (Median)
Cmax day 0Cmax day 21
NuvaRing With EFV Plus ≥2 NRTIs4541.03786.0

[back to top]

EFV PK Parameter Minimum Plasma Concentration (Cmin) Determined Based on EFV Levels From Individual Participants Enrolled in Arm B

This evaluates the effect of NuvaRing on the EFV PK parameter Cmin obtained from both sampling periods, before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Cmin defines minimum concentration observed within the first 8 hours of the 24 hour dosing interval. (NCT01903031)
Timeframe: Intensive EFV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement).

Interventionng/mL (Median)
Cmin day 0Cmin day 21
NuvaRing With EFV Plus ≥2 NRTIs2121.51766.0

[back to top]

Ethinyl Estradiol Concentrations Obtained on Study Days 7 and 14.

This evaluates the effect of EFV and ATV/r on ethinyl estradiol by measuring ethinyl estradiol concentrations on all three study arms 7 and 14 days after NuvaRing administration. The assay lower limit of quantification for ethinyl estradiol was 5 pg/mL; values < 5 were assigned a value of half the lower limit (ie, 2.5 pg/mL). (NCT01903031)
Timeframe: Study days 7 and 14

,,
Interventionpg/mL (Median)
Concentration at Day 7Concentration at Day 14
NuvaRing and no ART18.0519.70
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs15.7016.55
NuvaRing With EFV Plus ≥2 NRTIs9.9810.50

[back to top]

Etonogestrel Concentrations Obtained on Study Days 7 and 14

This evaluates the effect of EFV and ATV/r on etonogestrel by measuring etonogestrel concentrations on all three study arms 7 and 14 days after NuvaRing administration. The assay lower limit of quantification for etonogestrel was 250 pg/mL; values < 250 were assigned a value of half the lower limit (ie, 125 pg/mL). (NCT01903031)
Timeframe: Study days 7 and 14

,,
Interventionpg/mL (Median)
Concentration at Day 7Concentration at Day 14
NuvaRing and no ART1970.002070.00
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs3250.003530.00
NuvaRing With EFV Plus ≥2 NRTIs427.00437.00

[back to top]

Proportion of Participants With Plasma HIV-1 RNA Levels <40 Copies/mL

This evaluates the short-term impact of Nuvaring on virologic suppression in participants who have been administered Nuvaring alone or together with EFV or ATV/r by measuring proportion of participants with plasma HIV-1 RNA levels <40 copies/mL at study day 0 (before vaginal ring placement) and study day 21 (three weeks after vaginal ring placement). An FDA-approved HIV-1 RNA assay was required. (NCT01903031)
Timeframe: Study day 0 and study day 21

,,
Interventionproportion of participants (Number)
Proportion with HIV-1 RNA <40 copies/mL at day 0Proportion with HIV-1 RNA <40 copies/mL at day 21
NuvaRing and no ART0.220.17
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs0.890.85
NuvaRing With EFV Plus ≥2 NRTIs0.930.85

[back to top]

Proportion of Participants With Progesterone Levels Greater Than 5 ng/mL.

This evaluates alterations in progesterone levels due to the potential PK interaction between NuvaRing and the ARVs EFV and ATV/r by examining progesterone levels at study days 0 (before vaginal ring placement), 7, 14, and 21 (before vaginal ring removal), and study day 28, without regard to menstrual cycle status at study entry. (NCT01903031)
Timeframe: Study days 0, 7, 14, 21 and 28

,,
Interventionproportion of participants (Number)
Proportion with progesterone >5 at day 0Proportion with progesterone >5 at day 7Proportion with progesterone >5 at day 14Proportion with progesterone >5 at day 21Proportion with progesterone >5 at day 28
NuvaRing and no ART0.080.080.000.000.00
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs0.250.080.000.000.00
NuvaRing With EFV Plus ≥2 NRTIs0.040.240.040.000.00

[back to top]

Ritonavir (RTV) PK Parameter AUC(0-24h) Calculated Based on Intensive RTV PK Samples Obtained From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the PK parameter AUC(0-24h) of RTV before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. AUC(0-24h) defines area under the concentration-time curve over the period of 24 hours (pre-dose concentration was used to impute concentration at 24h). (NCT01903031)
Timeframe: Intensive RTV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement)

Interventionh*ng/mL (Median)
AUC0-24h day 0AUC0-24h day 21
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs10740.07210.7

[back to top]

RTV PK Parameter CLss/F Determined Based on RTV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the PK parameter CLss/F of RTV before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. CLss/F defines apparent oral clearance. (NCT01903031)
Timeframe: Intensive RTV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement)

Interventionhour (Median)
CLss/F day 0CLss/F day 21
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs9.313.9

[back to top]

RTV PK Parameter Cmax Determined Based on RTV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the PK parameter Cmax of RTV before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Cmax defines maximum concentration observed within the first 8 hours of the 24 hour dosing interval. (NCT01903031)
Timeframe: Intensive RTV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement)

Interventionng/mL (Median)
Cmax day 0Cmax day 21
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs1437.01063.0

[back to top]

RTV PK Parameter Cmin Determined Based on RTV Levels From Individual Participants Enrolled in Arm C

This evaluates the effect of NuvaRing on the PK parameter Cmin of RTV before NuvaRing placement (at study day 0) and three weeks later (on study day 21), prior to NuvaRing removal. Cmin defines minimum concentration observed within the first 8 hours of the 24 hour dosing interval. (NCT01903031)
Timeframe: Intensive RTV PK samples at pre-dose, 1, 3, 4, 5, and 8 hours post-dose on study day 0 (before vaginal ring placement) and on study day 21 (3 weeks after vaginal ring placement)

Interventionng/mL (Median)
Cmin day 0Cmin day 21
NuvaRing With ATV/r Plus TDF and ≥1 NRTIs70.051.9

[back to top]

Percentage of Participants With Successful Ring Insertion

Participants completed a Post-Insertion Questionnaire in which they were asked about their experience inserting the vaginal ring. Their answers were recorded and evaluated. (NCT02275546)
Timeframe: Day 1 (immediately after vaginal ring insertion)

InterventionPercentage of participants (Number)
Applicator100
No Applicator (Manual)100

[back to top]

Percentage of Participants With Vaginal Ring Expulsion Within 48 Hours of Insertion

Participants completed a Follow-Up Questionnaire in which they asked if they experienced vaginal ring expulsion. Their answers were recorded and evaluated. (NCT02275546)
Timeframe: Up to 48 hours after vaginal ring insertion

InterventionPercentage of participants (Number)
Applicator0
No Applicator (Manual)0

[back to top]

Anti Mullerian Hormone (AMH)

Change in Serum concentrations of anti-mullerian hormone reflecting ovarian reserve from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionng/mL (Mean)
Synthetic Estrogen + Progestin-0.8
Natural Estrogen + Progestin-0.4
Progestin-Only0.07

[back to top]

D-dimer

Markers of coagulation activation (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionpercentage change from baseline (Mean)
Synthetic Estrogen + Progestin12.6
Natural Estrogen + Progestin2.4
Progestin-Only-1.6

[back to top]

F1+2

Change in plasma concentrations of F1+2 a marker of coagulation activation (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionpercentage change from baseline (Mean)
Synthetic Estrogen + Progestin24.1
Natural Estrogen + Progestin-5.5
Progestin-Only-8.5

[back to top]

High-Density Lipoprotein (HDL)

Change in concentration of High-Density Lipoprotein HDL from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin0.20
Natural Estrogen + Progestin-0.02
Progestin-Only-0.02

[back to top]

High-sensitivity C Reactive Protein

Change in plasma concentrations of acute phase protein 'C reactive protein' (CRP), a marker of chronic inflammation. (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmg/L (Mean)
Synthetic Estrogen + Progestin1.10
Natural Estrogen + Progestin-0.06
Progestin-Only0.13

[back to top]

Low-Density Lipoprotein (LDL)

Change in concentration of Low-Density Lipoprotein LDL from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin-0.16
Natural Estrogen + Progestin-0.14
Progestin-Only0.01

[back to top]

Thrombin Generation, ETP Endogenous Thrombin Potential

Change from baseline in thrombin generation, measured by thrombin generation assay-Calibrated automated thrombogram (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionpercentage change from baseline (Mean)
Synthetic Estrogen + Progestin63.9
Natural Estrogen + Progestin26.4
Progestin-Only7.1

[back to top]

Matsuda Index- Whole Body Insulin Sensitivity Index

"Matsuda index is calculated from the standard 2h Oral Glucose Tolerance Test and corresponding insulin values.~Matsuda index = 10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]) The Matsuda index is correlated (r = 0.73) with the rate of whole-body glucose disposal during the euglycemic insulin clamp.~Matsuda index <2.5 is considered insulin resistant, higher values indicate less insulin resistance. A decrease in matsuda index over the study period would indicate decreased insulin sensitivity." (NCT02352090)
Timeframe: We calculated the change in Matsuda index from baseline to 9 weeks.

Interventionunits on a scale (Mean)
Synthetic Estrogen + Progestin-1.02
Natural Estrogen + Progestin-0.10
Progestin-Only-1.45

[back to top]

Total Cholesterol

Change in concentrations of total cholesterol from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin0.10
Natural Estrogen + Progestin-0.16
Progestin-Only0.11

[back to top]

Triglyceride

Change in triglyceride concentrations from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

Interventionmmol/L (Mean)
Synthetic Estrogen + Progestin0.45
Natural Estrogen + Progestin0.18
Progestin-Only0.06

[back to top]

Fasting Insulin

Mean change in fasting serum insulin from baseline to nine weeks (NCT02352090)
Timeframe: baseline and 9 weeks

InterventionmU/l (Mean)
Synthetic Estrogen + Progestin1.4
Natural Estrogen + Progestin1.02
Progestin-Only1.99

[back to top]

Levonorgestrel Area Under the Curve

Levonorgestrel AUC from 0 to 72 hours (NCT02531321)
Timeframe: 24 days

Interventionng/mL*h (Mean)
Ritonavir321
Control243

[back to top]

Ethinyl Estradiol Area Under the Curve

Ethinyl estradiol area under the curve from 0 to 72 hours (NCT02531321)
Timeframe: 24 days

Interventionng/mL*h (Mean)
Ritonavir3867
Control3270

[back to top]

Pharmacokinetic (PK) Parameter: AUCtau of Norelgestromin

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionhours*picogram/milliliter (h*pg/mL) (Mean)
Part A: NGM/EE13757.4
Part B: NGM/EE + SOF/VEL/VOX + VOX14690.4

[back to top]

Pharmacokinetic (PK) Parameter: AUCtau of Norgestimate

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT02533427)
Timeframe: Cycle 1,Study Day 14:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionh*ng/mL (Mean)
Part A: NGM/EE0.2
Part B: NGM/EE + SOF/VEL/VOX + VOX0.5

[back to top]

PK Parameter: AUCtau of Ethinyl Estradiol

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionh*pg/mL (Mean)
Part A: NGM/EE835.2
Part B: NGM/EE + SOF/VEL/VOX + VOX871.4

[back to top]

PK Parameter: AUCtau of Norgestrel

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionhours*nanogram/milliliter (h*ng/mL) (Mean)
Part A: NGM/EE41.1
Part B: NGM/EE + SOF/VEL/VOX + VOX47.3

[back to top]

PK Parameter: Cmax of Ethinyl Estradiol

Cmax is defined as the maximum concentration of drug. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionpg/mL (Mean)
Part A: NGM/EE68.4
Part B: NGM/EE + SOF/VEL/VOX + VOX80.6

[back to top]

PK Parameter: Cmax of Norelgestromin

Cmax is defined as the maximum concentration of drug. (NCT02533427)
Timeframe: Cycle 1,Study Day 14:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionpg/mL (Mean)
Part A: NGM/EE1080.9
Part B: NGM/EE + SOF/VEL/VOX + VOX1162.2

[back to top]

PK Parameter: Cmax of Norgestimate

Cmax is defined as the maximum concentration of drug. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionng/mL (Mean)
Part A: NGM/EE0.0
Part B: NGM/EE + SOF/VEL/VOX + VOX0.1

[back to top]

PK Parameter: Ctau of Ethinyl Estradiol

Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionpg/mL (Mean)
Part A: NGM/EE19.7
Part B: NGM/EE + SOF/VEL/VOX + VOX18.2

[back to top]

PK Parameter: Ctau of Norelgestromin

Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT02533427)
Timeframe: Part A:Cycle 1,Study Day 14:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Part B:Cycle 2,Study Day 42:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionpicogram/milliliter (pg/mL) (Mean)
Part A: NGM/EE364.1
Part B: NGM/EE + SOF/VEL/VOX + VOX413.9

[back to top]

PK Parameter: Ctau of Norgestimate

Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose;Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionng/mL (Mean)
Part A: NGM/EE0.0
Part B: NGM/EE + SOF/VEL/VOX + VOX0.0

[back to top]

PK Parameter: Ctau of Norgestrel

Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionnanogram/milliliter (ng/mL) (Mean)
Part A: NGM/EE1.5
Part B: NGM/EE + SOF/VEL/VOX + VOX1.8

[back to top]

Percentage of Participants Who Experienced Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Grade 1: mild; Grade 2: moderate;Grade 3: severe or medically significant but not immediately life-threatening; Grade 4: life-threatening consequences. (NCT02533427)
Timeframe: First dose date up to the last dose date (maximum: 84 days) plus 10 days

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3Grade 4
Part A: NGM/EE60.013.313.30.0
Part B: NGM/EE + SOF/VEL/VOX + VOX53.36.70.00.0

[back to top]

PK Parameter: AUCtau of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionh*ng/mL (Mean)
SOFGS-566500GS-331007VELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX1997.22769.312098.98226.33857.9

[back to top]

PK Parameter: CLss/F Ethinyl Estradiol, and Norgestimate

CLss/F is defined as the apparent steady state oral clearance following administration of the drug. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

,
Interventionmilliliter/hour (mL/h) (Mean)
Ethinyl EstradiolNorgestimate
Part A: NGM/EE34226.81285855.5
Part B: NGM/EE + SOF/VEL/VOX + VOX32000.0617498.8

[back to top]

PK Parameter: Cmax of Sofosbuvir (SOF), SOF Metabolites (GS-566500 and GS-331007), Velpatasvir (VEL), and Voxilaprevir (VOX)

Cmax is defined as the maximum concentration of drug. (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionng/mL (Mean)
SOFGS-566500GS-331007VELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX967.6491.1979.4853.3512.4

[back to top]

PK Parameter: Ctau of SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX

Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionng/mL (Mean)
GS-566500GS-331007VELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX10.6323.1154.656.1

[back to top]

PK Parameter: t1/2 of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate

t1/2 is defined as the estimate of the terminal elimination half-life of the drug. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

,
Interventionhours (Median)
NorelgestrominNorgestrelEthinyl EstradiolNorgestimate
Part A: NGM/EE18.9133.7613.681.03
Part B: NGM/EE + SOF/VEL/VOX + VOX28.9557.4210.782.30

[back to top]

PK Parameter: t1/2 of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX

t1/2 is defined as the estimate of the terminal elimination half-life of the drug. (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionhours (Median)
SOFGS-566500GS-331007VELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX0.682.7030.0619.758.51

[back to top]

PK Parameter: Tlast of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate

Tlast is defined as the time (observed time point) of Clast. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

,
Interventionhours (Median)
NorelgestrominNorgestrelEthinyl EstradiolNorgestimate
Part A: NGM/EE24.0024.0024.001.50
Part B: NGM/EE + SOF/VEL/VOX + VOX24.0024.0024.002.75

[back to top]

PK Parameter: Tlast of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX

Tlast is defined as the time (observed time point) of Clast. (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionhours (Median)
SOFGS-566500GS-331007VELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX6.0016.0024.0024.0024.00

[back to top]

PK Parameter: Tmax of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate

Tmax is defined as the time (observed time point) of Cmax. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

,
Interventionhours (Median)
NorelgestrominNorgestrelEthinyl EstradiolNorgestimate
Part A: NGM/EE3.004.003.001.50
Part B: NGM/EE + SOF/VEL/VOX + VOX3.004.002.001.50

[back to top]

PK Parameter: Tmax of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX

Tmax is defined as the time (observed time point) of Cmax. (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionhours (Median)
SOFGS-566500GS-331007VELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX2.504.004.004.006.00

[back to top]

PK Parameter: CLss/F of SOF, VEL, and VOX

CLss/F is defined as the apparent steady state oral clearance following administration of the drug. (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

InterventionmL/h (Mean)
SOFVELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX218383.112757.356071.5

[back to top]

PK Parameter: λz of SOF, SOF Metabolites (GS-566500 and GS-331007), VEL, and VOX

λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. (NCT02533427)
Timeframe: Cycle 2, Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Intervention1/h (Mean)
SOFGS-566500GS-331007VELVOX
Part B: NGM/EE + SOF/VEL/VOX + VOX1.1600.2470.0200.0370.077

[back to top]

PK Parameter: λz of Norelgestromin, Norgestrel, Ethinyl Estradiol, and Norgestimate

λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42:Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

,
Intervention1/hours (1/h) (Mean)
NorelgestrominNorgestrelEthinyl EstradiolNorgestimate
Part A: NGM/EE0.0350.0160.0530.674
Part B: NGM/EE + SOF/VEL/VOX + VOX0.0250.0120.0590.392

[back to top]

PK Parameter: Cmax of Norgestrel

Cmax is defined as the maximum concentration of drug. (NCT02533427)
Timeframe: Cycle 1,Study Day 14: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose; Cycle 2,Study Day 42: Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours postdose

Interventionng/mL (Mean)
Part A: NGM/EE2.0
Part B: NGM/EE + SOF/VEL/VOX + VOX2.3

[back to top]

Percentage of Participants Who Experienced Treatment-Emergent Adverse Events

(NCT02533427)
Timeframe: First dose date up to the last dose date (maximum: 84 days) plus 10 days

Interventionpercentage of participants (Number)
Part A: NGM/EE66.7
Part B: NGM/EE + SOF/VEL/VOX + VOX93.3

[back to top]

Number of Participants With Follicle Rupture

Following dosing with UPA, subjects underwent daily visits with ultrasound monitoring until evidence of follicle rupture (complete disappearance or >50% reduction of the mean size of the leading follicle). (NCT02577601)
Timeframe: within 5 days of taking the study drug

InterventionParticipants (Count of Participants)
UPA Only1
UPA + COC9

[back to top]

Number of Participants With Absence of Withdrawal Bleeding (AWB), by Cycle

Participants were asked to keep a daily diary to record vaginal bleeding events. AWB was defined as no bleeding/spotting during the expected bleeding period. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

,
InterventionParticipants (Count of Participants)
Cycle 1Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9
ENG-E2 125 μg/300 μg7634261733000
LNG-EE 150 μg/30 μg151010601210

[back to top]

Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle

BTB-S was considered any bleeding/spotting that occurred during expected non-bleeding interval that was neither early nor continued withdrawal bleeding. BTB-S was classified as follows: Bleeding = any bloody vaginal discharge that required one or more sanitary pads or tampons per day; Spotting = any bloody vaginal discharge that required no sanitary pads or tampons per day. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

,
InterventionParticipants (Count of Participants)
Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7Cycle 8Cycle 9
ENG-E2 125 μg/300 μg1661127942291381
LNG-EE 150 μg/30 μg543620138720

[back to top]

Number of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
ENG-E2 125 μg/300 μg530
LNG-EE 150 μg/30 μg140

[back to top]

Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)

The Primary Efficacy Outcome Measure for this study was contraceptive efficacy, or the prevention of in-treatment pregnancy. The total incidence of in-treatment pregnancies was expressed as the Pearl Index, which is defined as the number of in-treatment pregnancies per 100 woman-years of exposure (one woman-year defined as a period of 365.25 days). NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year (13 28-day cycles)

InterventionPregnancies per 100 woman years (Number)
ENG-E2 125 μg/300 μg1.54
LNG-EE 150 μg/30 μg2.93

[back to top]

Number of Participants Who Discontinued Treatment Due to an AE

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. NOTE: Due to early termination of this study, the ENG-E2 reporting group received only up to 10 cycles of treatment, and the LNG-EE reporting group received only up to 9 cycles of treatment. (NCT02616146)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
ENG-E2 125 μg/300 μg61
LNG-EE 150 μg/30 μg23

[back to top]

Changes in Total Testosterone (TT) From Baseline to the End of Treatment

changes in total testosterone (TT) , values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionnmol/L (Mean)
Tung's Acupuncture-0.67
CPA/EE-0.33

[back to top]

Change in LH/FSH Ratio From Baseline to the 24th Week

the change in LH/FSH ratio, values at the 24th week minus the values at baseline (NCT02729545)
Timeframe: baseline to the 24th week

Interventionratio (Mean)
Tung's Acupuncture-0.39
CPA/EE-0.44

[back to top]

Change in LH/FSH Ratio From Baseline to the End of Treatment

the change in LH/FSH ratio, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionratio (Mean)
Tung's Acupuncture-0.66
CPA/EE-0.96

[back to top]

Changes in Body Mass Index (BMI) From Baseline to the End of Treatment

the changes in BMI, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionkg/m^2 (Mean)
Tung's Acupuncture-0.90
CPA/EE-0.44

[back to top]

Changes in FSH From Baseline to the End of Treatment

changes in follicle-stimulating hormone (FSH), values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

InterventionmIU/mL (Mean)
Tung's Acupuncture-0.49
CPA/EE-0.22

[back to top]

Changes in LH From Baseline to the End of Treatment

changes in luteinizing hormone(LH), values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

InterventionmIU/mL (Mean)
Tung's Acupuncture-3.92
CPA/EE-5.66

[back to top]

Changes in Ovarian Volume From Baseline to the End of Treatment

changes in ovarian volume, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventioncm^3 (Mean)
Tung's Acupuncture-1.70
CPA/EE-1.03

[back to top]

Changes in Polycystic Ovary Number From Baseline to the End of Treatment

the changes in polycystic ovary number, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionpolycystic ovaries (Mean)
Tung's Acupuncture0.00
CPA/EE0.00

[back to top]

Changes in the Number of Bleeding Events From Baseline to the End of Treatment

Changes in the number of bleeding events, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionbleeding events (Mean)
Tung's Acupuncture0.66
CPA/EE1.21

[back to top]

Change From Pre-intervention to Intervention Endpoint in Behavioral Inhibition Subscale Score

The Behavioral Inhibition/Behavioral Activation questionnaire will be used to assess behavioural inhibition (BI). The minimum score on the BI subscale is 7, maximum 28. Greater scores indicate greater BI. Change is defined as the average change in BI from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC1.43

[back to top]

Change From Pre-intervention to Intervention Endpoint in Delay Discounting Parameter k

The Monetary Choice Questionnaire will be used to measure delay discounting. Participants will be asked to make a series of hypothetical choices between small, sooner (impulsive) vs. larger, later (self controlled) hypothetical monetary outcomes. k is a hyperbolic function with larger k values indicating more valuation of a larger delayed reward and smaller values indicating preference for more immediate, smaller rewards (more impulsivity). k can range from 0 to .25 with scores of .25 indicating complete valuation of the immediate reward and 0 indicating complete valuation of the larger, delayed reward. Change is defined as the average change in k from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionk value (Mean)
Continuous OC.01

[back to top]

Change From Pre-intervention to Intervention Endpoint in Nucleus Accumbens Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Nucleus Accumbens (NAcc) reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
Continuous OC.0423

[back to top]

Change From Pre-intervention to Intervention Endpoint in Prefrontal Cortex Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Prefrontal cortex reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
Continuous OC.01

[back to top]

Change From Pre-intervention to Intervention Endpoint in Self-reported Reward Sensitivity Subscale Score

Sensitivity to Punishment/Sensitivity to Reward Questionnaire will be used to measure reward sensitivity. The reward sensitivity subscale will be used, which is rated on a true/false scale with scores ranging 0-24. Higher scores indicate more sensitivity to reward. Change is defined as the average change in reward sensitivity from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC1.60

[back to top]

Change From Pre-intervention to Intervention Endpoint in Weekly Average Binge-eating Frequency

Binge eating frequency is based on a weekly diary of self-reported binge eating frequency. Participants were asked how many times during the past week they had a binge eating episode. Scores can range from 0 to infinity as frequency is self-reported as the number of binge eating episodes in the previous week. Higher scores indicate more episodes of binge eating. Change is defined as the average change in self-reported binge eating frequency from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionepisodes/week (Mean)
Continuous OC-0.43

[back to top]

Change From Pre-intervention to Intervention Endpoint in Dorsal Striatum Signal Intensity in Response to Reward During the Monetary Incentive Delay Task (MIDT)

"Dorsal striatum reactivity (defined as caudate signal intensity and putamen signal intensity) to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionpercentage signal change (Mean)
CaudatePutamen
Continuous OC-.012.02

[back to top]

Change From Pre-intervention to Intervention Endpoint in Binge Eating Sum Score

"Binge eating will be measured using the 8-item binge eating subscale of the Eating Pathology Symptoms Inventory (EPSI), which measures features of binge eating (e.g., consumption of large quantities of food, mindless eating) on a 5-point Likert scale from never to very often. The EPSI scale is designed to assess behavior over the past 28 days. Items are summed for a scale score ranging from 0-32. Higher scores indicate more frequent experiences with binge eating behavior. Change is defined as the average change in the binge eating scale score from pre-intervention to intervention." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)

Interventionscore on a scale (Mean)
Continuous OC-6.60

[back to top]

Pharmacokinetics Parameter

Area Under Curve from 0 to 72 hours (AUCt) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg*hr/mL (Mean)
AUC0-t of Cyproterone AcetateAUC0-t of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet127.54842.56
Elzsa Film-coated Tablet132.56870.45

[back to top]

Pharmacokinetics Parameter

Maximum plasma concentration (Cmax) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg/mL (Mean)
Cmax of Cyproterone AcetateCmax of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet16.2093.61
Elzsa Film-coated Tablet17.39103.69

[back to top]

Number of Participants With Treatment Emergent Adverse Events by Severity

An AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. AEs are classified according to the severity in 3 categories. a) mild - AEs does not interfere with participant's usual function; b) moderate - AEs interferes to some extent with participant's usual function; c) severe - AEs interferes significantly with participant's usual function. Only those categories in which at least 1 participant had data were reported. (NCT05064332)
Timeframe: From the first dose up to 35 days after the last dose of study intervention

,,
InterventionParticipants (Count of Participants)
Nausea (mild)Toothache (mild)Headache (mild)Pruritus (mild)
Period 1: Oral Contraceptive0000
Period 2: PF-066508331012
Period 2: PF-06650833 + Oral Contraceptive0100

[back to top] [back to top]

Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Ethinyl Estradiol

AUClast was defined as area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for EE was determined using linear/Log trapezoidal method. (NCT05064332)
Timeframe: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36 and 48 hours post OC dose in Periods 1 and 2

Interventionpicogram*hour per milliliter (pg*hr/mL) (Geometric Mean)
Period 1: Oral Contraceptive812.3
Period 2: PF-06650833 + Oral Contraceptive823.9

[back to top]

Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration for Levonorgestrel

AUClast was defined as area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for LN was determined using linear/Log trapezoidal method. (NCT05064332)
Timeframe: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36 and 48 hours post OC dose in Periods 1 and 2

Interventionpg*hr/mL (Geometric Mean)
Period 1: Oral Contraceptive31510
Period 2: PF-06650833 + Oral Contraceptive34190

[back to top]

Maximum Plasma Concentration for Levonorgestrel

Cmas was defined as maximum plasma concentration. Cmax for LN was observed directly from data. (NCT05064332)
Timeframe: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36 and 48 hours post OC dose in Periods 1 and 2

Interventionpg/mL (Geometric Mean)
Period 1: Oral Contraceptive3468
Period 2: PF-06650833 + Oral Contraceptive4092

[back to top]

Number of Participants With Categorical Vital Signs Data of Potential Clinical Concern

Systolic blood pressure (BP), diastolic BP and supine pulse rate measurements meeting the criteria of potential clinical concern were summarized by treatment using categories as defined: Systolic BP min. <90 mmHg; Systolic BP max. decrease ≥30 or max. increase ≥30; Diastolic BP min. <50 mmHg; Diastolic BP max. decrease ≥20 or max. increase ≥20; Supine pulse rate min. <40 bpm or max. >120 bpm. (NCT05064332)
Timeframe: Day 1 for Period 1 and Day 1, Day 10, Day 12 for Period 2

InterventionParticipants (Count of Participants)
Period 1: Oral Contraceptive0
Period 2: PF-06650833 + Oral Contraceptive0

[back to top]

Number of Participants With Laboratory Abnormalities of Potential Clinical Concern

Hematology (hemoglobin, hematocrit, erythrocytes [Ery.], Ery.mean corpuscular volume, Ery.mean corpuscular hemoglobin, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes); clinical chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate, glucose, creatine kinase); and urinalysis (pH, glucose, ketones, protein, hemoglobin, urobilinogen, bilirubin, nitrite, leukocyte esterase, Ery., leukocytes, epithelial cells, casts and bacteria) tests were assessed. Only those categories, in which at least 1 participant had data were reported. (NCT05064332)
Timeframe: Day 10, Day 12 for Period 2

InterventionParticipants (Count of Participants)
Urine Hemoglobin ≥1Leukocyte Esterase ≥1
Period 2: PF-06650833 + Oral Contraceptive52

[back to top]

Maximum Plasma Concentration (Cmax) for Ethinyl Estradiol

Cmax was defined as maximum plasma concentration. Cmax for EE was observed directly from data. (NCT05064332)
Timeframe: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36 and 48 hours post OC dose in Periods 1 and 2

Interventionpicogram per milliliter (pg/mL) (Geometric Mean)
Period 1: Oral Contraceptive84.00
Period 2: PF-06650833 + Oral Contraceptive79.86

[back to top]